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The aim of this project was to investigate the transcriptome of human haematopoietic stem 
cells (HSCs), megakaryocytes and platelets to gain insights into steady state and accelerated 
thrombopoiesis that occurs in states of haemostatic demand and in thrombosis by applying 
these findings to the pathological setting of acute coronary thrombosis. 
 
To investigate transcriptional heterogeneity within the human HSC population, single cell RNA 
sequencing was performed in human bone marrow HSCs. Transcriptionally distinct 
subpopulations were identified including two megakaryocyte biased subsets with potentially 
differing functional relevance. Both populations expressed megakaryocyte specific transcripts, 
one of which also co-expressed common myeloid and megakaryocyte-erythroid progenitor 
transcripts while the other did not.  
 
This study represents the first interrogation of the human bone marrow megakaryocyte 
transcriptome. Cells were collected from healthy human bone marrow and analysed by low 
input and single cell RNA sequencing. To identify novel drivers of megakaryocyte maturation, 
the human bone marrow megakaryocyte transcriptome was compared to that of 
megakaryocytes cultured from human CD34+ cells, a process known to generate immature 
megakaryocytes. Transcriptional signatures associated with increasing megakaryocyte ploidy 
were then investigated. Increasing megakaryocyte ploidy level was found to be associated 
with an upregulation of transcripts involved in translation and protein processing as well as 
expression of a number of transmembrane receptors which might have functional relevance. 
 
Finally, the pathological setting of acute coronary thrombosis was used as a model for 
accelerated thrombopoiesis. Megakaryocyte and platelet transcriptomes were compared 
between patients with acute myocardial infarction (AMI) as well as severe coronary disease 
and a control group. The transcriptional signature relating to disease compared to control in 
megakaryocytes included upregulation of platelet activation related transcripts in 
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Hb Haemoglobin 
HGNC HUGO gene nomenclature committee 
HSA Human serum albumin 
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MegE Megakaryocyte-Erythroid lineage 
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MK  Megakaryocyte 
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MPP Multipotent progenitor 
MPV Mean platelet volume 
mRNA Messenger ribonucleic acid 
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NSTEMI Non ST-elevation myocardial infarction 
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PCA Principal component analysis 
PCT Plateletcrit 
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RNA Ribonucleic acid 
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RT-qPCR Real time quantitative polymerase chain reaction 
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Gene, transcript and protein nomenclature 
 
Where possible the HUGO Gene Nomenclature Committee (HGNC) gene symbols and 
guidelines have been used to describe genes and gene products. 
 
Human gene and transcript symbols are capitalised and italicised (e.g., ITGA2B) and proteins 
are represented in standard fonts (e.g., TPO).  
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CHAPTER 1  
Introduction 
 
Megakaryocytes are highly specialised haematopoietic progenitor cells with the primary 
function of producing and releasing platelets into the circulation, a process known as 
thrombopoiesis. Like all haemopoietic cells, megakaryocytes derive from the haematopoietic 
stem cell (HSC) and growing evidence suggests the existence of a direct differentiation route 
from the HSC, together with the classically described route through a number of progressively 
committed progenitors (Notta et al. 2016). Megakaryocytes comprise <0.01% of the total 
number of nucleated cells in the bone marrow (Harker and Finch 1969). They are unique 
among mammalian cells in that they are the largest cell in the bone marrow with diameters up 
to 150μm and undergo multiple genomic DNA replications without cell division, known as 
endomitosis, resulting in cells with an enlarged cytoplasm and ploidy levels that can reach 
128N (Odell and Jackson 1968; Tomer, Harker and Burstein 1988; Tomer et al. 1989). 
Platelet production can occur at any level of polyploidisation with each megakaryocyte 
releasing up to 6,000 platelets into the circulation (Harker and Finch 1969). 
 
Platelets are small circulating anucleate cytoplasmic units (2-5 μm) that play a pivotal role in 
haemostasis. Their primary function is to maintain vascular integrity by sensing and 
responding to endothelial damage by activation, aggregation and thrombus formation and as 
such are important contributors to atherothrombotic disease (Monaco, Mathur, and Martin 
2005).  
 
The highly complex megakaryocyte-platelet haemostatic system is unique to mammals, 
having no precedent in the lower orders where nucleated thrombocytes circulate and control 
haemostasis (Ratnoff 1987). The benefit and evolutionary advantage of such a complex 




1.1.1 Haematopoietic stem cells 
 
HSCs are an extremely rare cell population that resides within a highly regulated stem cell 
niche in the bone marrow; although HSCs can also be isolated from foetal liver, cord blood 
and adult peripheral blood (Bluteau et al. 2013). HSCs sit at the apex of a developmental 
hierarchy, whereby they undergo long-term self-renewal, as well as, generate ~1011 new cells 
every day of all blood cell types (Orkin and Zon 2008). Current knowledge of HSCs and 
haematopoiesis originates predominantly from mouse and is a direct result of distinguishing 
cells by their surface markers, coupled with either in vitro clonal assays or functional, 
transplant-based tracking of their repopulation activity (Osawa et al. 1996). The biology of 
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HSCs, particularly in humans, remains poorly understood because of their rarity and due to 
the difficulty in obtaining pure populations in high numbers for molecular analysis. While the 
HSC population in the mouse is thought to reside within the Lin-Sca-1+c-Kithi(LSK)CD34-Flt3-
(±CD48-CD150+) subset (Adolfsson et al. 2001; Kent et al. 2009; Weksberg et al. 2008), 
human HSCs are defined by surface marker expression of Lin-CD34+CD38-CD45RA-
CD90+CD49f+. However, only 1 in 10 of these cells will go on to give long term repopulation in 
serial transplantation experiments, which are considered the gold standard to prove self-
renewal and ability to form all blood lineages (Notta et al. 2011).  
 
HSCs were originally thought to be a homogeneous population, however heterogeneity of 
cellular states within the HSC compartment has in fact been demonstrated (Guo et al. 2013; 
Muller-Sieburg et al. 2012; Moignard et al. 2013). Recent studies have shown that individual 
HSCs exhibit different reconstitution patterns with distinct lineage bias and long term self-
renewal that are stably inherited by their HSC offspring (Muller-Sieburg et al. 2012; Sieburg et 
al. 2006; Dykstra et al. 2007). HSC compartments have been defined in terms of their self-
renewal ability into short term (more abundant) and long term (rarer) HSCs, ST-HSCs and LT-
HSCs respectively (Muller-Sieburg et al. 2004; Reya et al. 2001; Weissman, Anderson, and 
Gage 2001). Novel technologies have now been developed that use in situ inducible labelling 
techniques, to enable the study of physiological haematopoiesis in healthy bone marrow in 
physiological settings, rather than in the inflammatory environment of the transplantation 
setting. These have demonstrated that traditionally defined ST-HSCs and multipotent 
progenitors together make up a reservoir of thousands of multipotent progenitor clones that 
maintain steady-state haematopoiesis, with the rarer LT-HSCs having only a limited 
contribution (Busch et al. 2015; Sun et al. 2014). HSCs have also been distinguished by their 
lineage differentiation potential (Müller-Sieburg et al. 2002; Muller-Sieburg et al. 2004, 2012; 
Dykstra et al. 2007) into: myeloid-biased, lymphoid-biased or balanced (Muller-Sieburg et al. 
2004, 2012) or as lymphoid-deficient (α), myeloid-deficient (γ and δ) and balanced (β) 
(Dykstra et al. 2007). There is also support for myeloid-biased and lymphoid-biased HSC 
subsets in humans (W. W. Pang et al. 2011; Cavazzana-Calvo et al. 2011). Furthermore, 
there is evidence to show an increase in myeloid biased HSCs with age, which is thought to 
be epigenetically regulated (W. W. Pang, Schrier, and Weissman 2017). 
 
Therefore, the HSC population, pure in terms of expression of surface markers, and 
previously considered homogeneous, is in fact made up of functionally distinct sub 
populations. However, while the different subsets may be defined by their progeny in vivo; 
due to the retrospective nature of these assays, individual cells shown to possess HSC 
properties are no longer available for molecular analyses. An effective method to 
prospectively distinguish HSC subsets at molecular level is not yet available. Moreover, it is 
increasingly evident that the presence of cell surface markers does not directly reflect the 
transcriptional state of a cell (Schroeder 2010). A number of studies have assessed 
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transcriptional variation within the HSC population either using single cell RT-qPCR (Guo et 
al. 2013; Adolfsson et al. 2005; Forsberg et al. 2006; Månsson et al. 2007; Akashi et al. 2003; 
Hu et al. 1997; Miyamoto et al. 2002) and more recently 2 studies have performed single cell 
RNA-sequencing (RNA-seq) of mouse HSCs (Wilson et al. 2015; Grover et al. 2016) and 1 
study has used this technology to study the zebrafish haematopoietic system (Macaulay et al. 
2016). Single cell RNA-seq of HSCs in mouse in combination with index FACS analysis and 
transplantation has enabled identification of genetic programs associated with the true 
repopulating HSC (Wilson et al. 2015) as well as proportional changes in transcriptionally 
distinct HSC subpopulations with age (Grover et al. 2016). In the zebrafish model single cell 
RNA-seq in HSCs has uncovered several transcriptionally distinct differentiation states as 
cells undergo lineage commitment (Macaulay et al. 2016). 
 
1.1.2 Early megakaryocyte lineage commitment from the HSC 
 
In the classical model of haematopoiesis, hierarchical differentiation begins from HSCs and 
progresses through a cascade of increasingly committed and lineage restricted progenitors, 
regarded as transient intermediates that ultimately generate all mature circulating myeloid and 
lymphoid cell types (Figure 1.1a). In this model HSCs produce short-lived multipotent 
progenitors (MPPs) which, in turn generate the oligopotent common myeloid (Akashi et al. 
2000) and lymphoid progenitors (Kondo, Weissman, and Akashi 1997) (CMP, CLP 
respectively). In myeloid differentiation CMPs undergo further commitment to either the 
granulocyte-macrophage progenitor (GMP) or the megakaryocyte-erythroid progenitor (MEP) 
which ultimately produces megakaryocytes (and platelets) and erythrocytes. 
 
With improvement in cell purification and functional clonal assays several findings have 
challenged this conventional paradigm, as further resolution has been made possible. It is 
now becoming evident that commitment to the megakaryocyte lineage may occur early and 
from the HSC directly, therefore independent of the intermediate CMP and MEP progenitors 
(Notta et al. 2016).  
 
Importantly, the original model for thrombopoiesis proposed that ST-HSCs and MPPs 
maintain a full repertoire of lympho-myeloid lineage potential, comparable to the LT-HSC 
(Reya et al. 2001). However, the finding of an early loss of megakaryocyte/erythroid (MegE) 
potential upstream of the lympho-myeloid bifurcation has led to a key revision to this model. In 
mouse, LSKCD34+Flt3+ cells have been identified as lymphoid-primed multipotent 
progenitors (LMPPs) with combined granulocyte-macrophage and lymphoid potential but very 
limited MegE potential compared with LT-HSCs (LSKCD34-Flt3-) and ST-HSCs 
(LSKCD34+Flt3-) subsets both in in vitro clonal assays and in vivo transplantation (Adolfsson 
et al. 2005). This is supported by the finding that single HSCs were able to produce lineage 
committed bipotent MegE cells after just one cell division in vitro (Takano et al. 2004). The 
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concept of the LMPP and loss of MegE potential with progressive differentiation after the level 
of the HSC has been supported by a number of other studies (Forsberg et al. 2006; Lai and 
Kondo 2006; Yoshida et al. 2006; Luc et al. 2008; Arinobu et al. 2007) and following 
transplantation experiments, platelet reconstitution has been shown to be the first to be 
detected amongst all other terminally differentiated cells (Forsberg et al. 2006). More recently, 
paired daughter cell analysis has introduced the possibility of unipotent megakaryocyte 
progenitors arising directly from the LT-HSC independently of the erythroid lineage 
(Yamamoto et al. 2013; Haas et al. 2015) and in in vitro tracking experiments megakaryocyte 
colonies are the first to emerge from HSC cultures (Guo et al. 2013). 
 
While human hematopoiesis is generally thought to follow the same differentiation model as in 
mouse, there has been very little certainty regarding megakaryocyte development from the 
human HSC, as standard in vitro clonal assays cannot be reliably interpreted (Notta et al. 
2016). Recently, a new model for human haematopoiesis has been proposed based on 
improved cell sorting schemes, using additional cell surface markers and an optimised single 
cell clonal assay able to support simultaneous lineage commitment to myeloid, erythroid and 
megakaryocytic fates (Notta et al. 2016). Single cell clonal assays were performed on 11 
populations to determine cell fate: HSCs, MPPs, CMPs, MEPs and GMPs; the classically 
defined MPPs, CMPs and MEPs were further subdivided into 3 populations based on their 
surface expression of CD71 and the thrombopoietin (TPO) receptor: MPL. Interestingly, 
MEPs from adult bone marrow fate was predominantly restricted to erythroid and to a lesser 
extent myeloid lineage, with less than 3% of cells giving rise to bipotent MegE progenitors. 
Rather megakaryocyte lineage potential was independent of intermediate progenitors (CMP 
and MEP) and branched directly from the multipotent HSC compartment, becoming the first 
major lineage bifurcation (Figure 1.1b). The originally defined CMPs were found to be a highly 
heterogeneous population (Notta et al. 2016). 
 
1.1.3 Megakaryocyte-biased HSC population 
 
Single cell RT-qPCR and more recently single cell RNA-seq has provided the opportunity to 
assess transcriptional variation within the HSC and other progenitor cell compartments and 
has thereby been used to decipher the organisation of haematopoietic hierarchies. 
Transcriptional profiling also supports the revised model for haematopoiesis described above. 
Unlike committed progenitors, HSCs and MPPs are shown to express multiple lineage 
associated genetic programs(Akashi et al. 2003; Hu et al. 1997; Miyamoto et al. 2002). A 
number of studies in mouse, have demonstrated megakaryocyte specific gene expression in 
the HSC compartment, a gradual down regulation of MegE transcriptional priming from LT-
HSCs to LMPPs (Adolfsson et al. 2005; Månsson et al. 2007; Notta et al. 2016) and a lack of 
co-expression between MegE genes (e.g., GATA-1, VWF, MPL) and lymphoid specific genes 
in single HSCs suggesting a subset of LT-HSCs specifically primed towards a MegE lineage 
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(Månsson et al. 2007). Furthermore, when murine haematopoietic progenitor cell populations 
are clustered on the basis of single cell gene expression, the MegE lineage branch is found to 
be closely associated with LT-HSCs. This further substantiates previous evidence to show 
that the MegE lineage separates early from lympho-myeloid lineages. Indeed, a MegE genetic 
program has been demonstrated within the most primitive subset of mouse HSCs – the 
LSKCD34-Flt3-CD48-CD150+ HSC population (Guo et al. 2013).  
 
More recently expression of larger repertoires of genes has been simultaneously assessed at 
the single cell level using RT-qPCR or single cell RNA-seq. Single cell gene expression 
analysis has allowed a number of megakaryocyte specific genes (including VWF, GP1BA, 
ITGA2B and MPL to be detected in populations within the most primitive HSC subset in both 
mouse (Wilson et al. 2015) and zebrafish (Macaulay et al. 2016) models which could reflect a 
HSC population biased towards the megakaryocyte lineage.  
 
A platelet-primed HSC population has been prospectively identified on the basis of VWF gene 
expression which is the most highly expressed megakaryocytic gene in mouse HSCs 
(Sanjuan-Pla et al. 2013). Using a transgenic mouse model with a GFP (green fluorescent 
protein) reporter to the VWF gene, approximately 60% of HSCs (LSKCD34-CD48-CD150+) 
were shown to express VWF. This subpopulation was TPO dependent and demonstrated 
higher expression of other megakaryocyte specific genes using both microarrays and qPCR. 
When VWF expressing HSCs were serially transplanted in limiting numbers they led to both 
short and long-term reconstitution with a marked platelet bias, a contribution to the myeloid 
lineage and only limited lymphoid potential. While the VWF+ HSC population was able to give 
rise to VWF-ve HSCs, the opposite was not true hierarchically placing this platelet-biased 
HSC population at the apex of the haematopoietic tree. More recently, single cell RNA-seq of 
HSCs from young and aged mice has revealed that megakaryocyte specific genes are among 
the most upregulated in aged HSCs (Grover et al. 2016). Furthermore, single cell RNA-seq 
has made it possible to demonstrate that on a genome wide level both the number and level 
of expression of megakaryocyte and platelet specific genes increases with age. While this 
was true in both VWF+ and VWF- HSCs the VWF+ HSC population was seen to expand 
markedly in relation to the VWF- HSC population with age.  
 
Further evidence for a megakaryocyte/platelet biased HSC population that could be 
analogous to that expressing VWF has also been reported on the basis of differences in cell 
surface marker expression. The megakaryocyte/platelet cell surface marker and part of the 
glycoprotein IIb/IIIa fibrinogen receptor, CD41, had been known to be thought to only be 
expressed in embryonic HSCs being switched off after birth (Ferkowicz 2003; Debili et al. 
2001; Rhodes et al. 2008; Robin, Ottersbach and Boisset 2011). However, its surface 
expression has now been demonstrated on a subset of adult mouse HSCs (LSKCD34-CD48- 
CD150+) which show a platelet-bias on serial transplantation with the knock out of CD41 
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resulting in reduced levels of all mature blood cell lineages; again, a population that expands 
with age (Gekas and Graf 2013). Another platelet-biased subset within the mouse (LSKCD34-
CD150+) HSC population has been proposed on the basis of expression of c-Kit (Grinenko et 
al. 2014; Shin et al. 2014). Early platelet production was shown to be restricted to the highest 
c-Kit expressing HSCs both transplantation and in vitro clonal assays and this was also 
correlated with megakaryocyte specific gene expression. 
 
1.1.4 Similarities between HSCs and megakaryocytes and interaction within the stem 
cell niche 
 
It has become increasingly clear that HSCs and megakaryocytes have a more complex 
relationship than previously appreciated. As described above, improved cell purification 
techniques and single cell transcriptional resolution have demonstrated expression of 
megakaryocyte lineage specific genes in murine and human HSCs (Wilson et al. 2015; 
Macaulay et al. 2016; Notta et al. 2016). Furthermore, in unsupervised clustering human 
HSCs and megakaryocyte progenitors have been shown to cluster and display more similarity 
than any other progenitor pairs in the haematopoietic tree using either single cell methods 
(Wilson et al. 2015) or bulk RNA-seq (Novershtern et al. 2011). Megakaryocytes and HSCs 
share dependence on a number of transcription factors including RUNX1 (Sun and Downing 
2004; Growney et al. 2005; Gilliland et al. 1999), GATA2 (Rodrigues et al. 2005; Chang et al. 
2002), the Ets family of transcription factors (Hock et al. 2004) and MEIS1 (Azcoitia et al. 
2005; Hisa et al. 2004).  
 
HSCs and megakaryocytes also share cell surface markers the most notable being the TPO 
receptor MPL. TPO was first cloned in 1994 and is known to be the major regulator of 
megakaryopoiesis and megakaryocyte maturation (Gurney et al. 1994). MPL expression is 
critical for HSC expansion with HSCs from MPL deficient mice being ineffective in long term 
mature blood cell reconstitution of irradiated recipients (Kimura et al. 1998). TPO signalling 
has also been shown to play an important regulatory role in maintaining HSC quiescence 
(Qian et al. 2007; Yoshihara et al. 2007). Other shared cell surface markers include CD150 
(Kiel et al. 2005; Pronk et al. 2007), the fibrinogen receptor CD41 (Gekas and Graf 2013) and 
the CXCL12 receptor, CXCR4, which plays a role in homing both megakaryocytes and HSCs 
to the vascular sinusoidal space and in their retention within the bone marrow (Möhle et al. 
1998; Z. Wang et al. 2008). 
 
Regulation of HSC proliferation, quiescence and long-term repopulating potential occurs in 
the vascular sinusoidal space, at the endosteal surface of trabecular bone marrow, termed 
the stem cell niche (Morrison and Scadden 2014). The importance of this microenvironment in 
regulation of HSC function has been widely reported. A number of cell types within the niche, 
all of non-haematopoietic origin, have been implicated in HSC maintenance. These include 
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endothelial cells, osteoblasts, mesenchymal stromal cells, Schwann cells and sympathetic 
nerves either directly or via the production of factors such as CXCL12 (Ding and Morrison 
2013; Greenbaum et al. 2013), angiopoietin (Arai et al. 2004), kit ligand (Thorén et al. 2008), 
and TGFB (Yamazaki et al. 2011). Megakaryocytes reside in direct contact with the sinusoidal 
endothelium, where platelet production occurs and are therefore in close proximity with HSCs 
in the stem cell niche (Morrison and Scadden 2014). A role for megakaryocytes in the 
regulation of HSC function has been proposed (Morrison and Scadden 2014; Heazlewood et 
al. 2013; Olson et al. 2013) suggesting a regulatory feedback mechanism between 
megakaryocytes and the HSC compartment. Recent reports demonstrate a critical role for 
megakaryocytes in maintaining HSC quiescence, whereby in mouse, acute depletion of 
megakaryocytes lead to HSC expansion and proliferation, with no effect on other cell types 
(Bruns et al. 2014; Zhao et al. 2014). It has also been suggested that this effect may be 
mediated through release of CXCL4 (PF4 or platelet factor 4) (Bruns et al. 2014) as injection 
of PF4 into megakaryocyte depleted mice has been shown to cause partial HSC quiescence. 
By contrast PF4 knockout mice showed increased HSC cell cycle activity and proliferation. 
TGFβ release from megakaryocytes has also been implicated (Zhao et al. 2014), whereby 
injection of TGFB in megakaryocyte depleted mice restored HSC quiescence and in mice with 
conditional deletion of TGFB an expansion in the HSC population is observed. Taken together 
these observations suggest that megakaryocytes serve as HSC-derived niche cells to 
dynamically regulate HSC function. It is of course possible that due to the HSC heterogeneity 
described above, specific molecular cues within the niche may instruct HSC fate at different 
levels depending on the targeted subpopulation. Moreover, platelets may also regulate HSC 
quiescence through effects on circulating TPO concentrations as described in Section 1.3 (de 





Figure 1.1 Classical and redefined blood cell differentiation pathways. 
A. Classical haematopoietic tree with megakaryocyte differentiation occuring through a 
number of progressively committed progenitors; B. Redefined haematopoietic tree with direct 
differentiation from HSC to megakaryocyte independent of intermediate precursors. LT-HSC: 
long term HSC; ST-HSC: short term HSC; CMP: common myeloid progenitor; MEP: 
megakaryocyte-erythroid progenitor; MkP: megakaryocyte progenitor, EryP: erythroid 
progenitor, LMPP: lymphoid-primed multipotent progenitor; GMP: granulocyte-macrophage 






1.1.5 Terminal megakaryopoiesis 
 
Despite recent evidence presented above to support an early lineage commitment to the 
megakaryocyte lineage from the HSC, our current understanding of the terminal stages of 
megakaryopoiesis is based on the classical model of haematopoietic differentiation where 
there is an established evidence base to support the common origin of the megakaryocyte 
and the erythroblast from the bi-potent MEP. Although much of these evidence to support an 
MEP population is from cell cultures (Debili et al. 1996), the MEP has been observed in 
murine bone marrow (Vannucchi et al. 2000) and there is an overlap in the transcription 
factors that regulate both megakaryocyte and erythroblast differentiation including GATA-1 
(Lemarchandel et al. 1993), GATA-2 (Orkin 1992), NFE-2 (Romeo et al. 1990) and FOG-1 
(Chang et al. 2002) and therefore similarities in gene expression (L. Chen et al. 2014). 
However, recent work using transcriptional profiling at the single cell level has shown that 
conventionally defined MEPs are a mixed population with the majority of cells transcriptionally 
primed to generate exclusively either megakaryocytes or erythroblasts (Psaila et al. 2016; 
Notta et al. 2016).  
 
MEPs have traditionally been described to give rise to the burst forming unit megakaryocyte 
(BFU-MK) with high proliferation capacity with the ability to develop into 50-500 
megakaryocytes in a week which in turn gives rise to the more mature colony forming 
megakaryocytes (CFU-MK) which can only give rise to 3-50 megakaryocytes (Briddell et al. 
1989). Both of these early progenitors express the surface antigens CD34, CD33, surface 
glycoproteins IIb (GPIIb/CD41) and IIIa (GPIIIa/CD61), leukocyte-associated immunoglobulin-
like receptor 1 (LAIR-1) and MPL. The promegakaryoblast is the most primitive 
morphologically distinct megakaryocyte precursor which gives rise to the megakaryoblast. 
The megakaryoblast (15-50um) has a high nuclear to cytoplasmic ratio, with elevated RNA 
levels and synthesis of alpha and dense granules. The pro-megakaryocyte is larger (20-
80um) with a more mature cytoplasm, with developed granules and a complex demarcation 
membrane system, but not yet polyploid (Italiano and Shivdasani 2003).  
 
1.1.6 Polyploidisation by endomitosis 
 
While megakaryocyte progenitors proliferate through 2N-4N stages (mitosis), during which 
their progression through the cell cycle is indistinguishable from any other haematopoietic 
cell, the mature megakaryocyte is an obligate polyploid cell (Odell and Jackson 1968). 
Megakaryocytes maturation is accompanied by successive rounds of DNA replication without 
cytokinesis, known as endomitosis. This process results in large polyploid cells containing 2 
(4N) to 64 (128N) times the DNA content of a cell that replicates by mitosis, within a lobulated 
nucleus. Although the endomitotic process can stop at any ploidy level, during steady state 
platelet production the mean ploidy of mammalian megakaryocytes in the bone marrow is 
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16N (Nagl 1978; Tomer, Harker, and Burstein 1988) (Figure 1.2).  
 
It was initially thought that endomitosis corresponded to a failure of mitosis in anaphase, as 
the late stages of mitosis were not observed (Nagata, Muro, and Todokoro 1997). However, 
studies using time-lapse microscopy have shown that megakaryocytes complete anaphase, 
but there is regression of cleavage furrow formation leading to failure of the completion of 
cytokinesis (Lordier et al. 2008) (Figure 1.3). Although the mechanism of polyploidisation is 
still not well understood, altered expression of cyclins D and E, spindle checkpoint proteins 
and chromosome passenger proteins, such as Aurora A kinase (AURKA) and Aurora B 
kinase (AURKB), key regulators of cytokinesis, have been implicated (Wen et al. 2012; 
Lordier et al. 2010). AURKA is known to regulate microtubule-organising center localisation, 
chromosome dynamics and histone H3 phosphorylation in oocytes (Ding, Swain, and Smith 
2011) and is required for bipolar spindle development (Cowley et al. 2009). AURKB, although 
with a less well understood role in polyploidisation, is a component of the chromosome 
passenger complex that is known to control mitotic and endomitotic cells cycles (Lordier et al. 
2010). AURKA and AURKB inhibition has been found to lead to increased ploidy in cultured 
megakaryocytes as well as in vivo (Wen et al. 2012). It has recently been shown that 
polyploidy and thrombopoiesis may also occur via endoreplication which like endomitosis 
leads to uniform multiple genomic DNA replication rounds but achieves this by successive 
DNA synthesis and gap phases rather than aberrant mitotic cycles (Trakala et al. 2015). 
Endomitosis is certainly the predominant polyploidisation mechanism in vivo as evidenced by 
severe thrombocytopaenia caused by genetic ablation of Cdc20 (cell division cycle 20), which 
is known to lead to mitotic arrest (Trakala et al. 2015). However, this may be rescued by 
concomitant ablation of the main cell cycle kinases, Cdk1 and Cdk2, effectively facilitating 
polyploidisation via the unconventional route of endoreplication which is compatible with 
megakaryocyte function and thrombopoiesis (Trakala et al. 2015). This supports the 
hypothesis that the primary function of polyploidisation is to increase cell size for 
thrombopoiesis (Thon and Italiano 2012). 
 
While it is assumed that the role of polyploidisation is to increase cell volume and synthetic 
capacity while minimising the energy required for cytokinesis (Zimmet and Ravid 2000), the 
precise purpose of acquiring multiple functional chromosome complements is unclear. 
Polyploidisation has been shown to be associated with functional gene amplification, where 
there is an increase in the number of copies of a gene without a proportional increase in other 
genes, rather than epigenetic silencing (Raslova et al. 2003). The concept of gene 
amplification with increases in ploidy level and size is supported by the observation that 
megakaryocytes derived from adult blood have an increased capacity to produce platelets in 
culture conditions than megakaryocytes derived from cord blood which tend to have a 
relatively lower ploidy (Mattia et al. 2002). Furthermore, the extent to which ploidy level and 
platelet formation are linked is not well established; high levels of polyploidy are thought not to 
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be essential for platelet production (Mattia et al. 2002; Miyazaki et al. 2000). It has been 
shown that there is no difference in cytoplasmic extensions or platelet production in culture 
between megakaryocytes cultured from adult blood of low ploidy compared with cultured 
megakaryocytes driven to higher ploidy levels with nicotinamide  (vitamin B3) (Giammona et 
al. 2006). However, the authors note that it is not known to what extent the method used for 
measuring platelet production in culture recapitulates physiological platelet release. 
Furthermore, while nicotinamide increased cell ploidy it did not induce megakaryocyte 
cytoplasmic maturation (Giammona et al. 2009), emphasising the importance of cell 
maturation as an independent factor to megakaryocyte ploidy level in platelet production.  
 
1.1.7 Cytoplasmic maturation 
 
As the megakaryocyte undergoes polyploidisation it matures to contain all the machinery 
necessary for platelet release and platelet function. Secretory granules are formed in the 
cytosol including α granules and dense granules. α granules originate from the trans-Golgi 
network and contain either endogenously synthesised proteins such as PF4, β 
thromboglobulin, von Willebrand factor and platelet membrane proteins or endocytosed 
proteins such as albumin and fibrinogen although the latter may also be synthesised within 
the megakaryocyte (Podolak-Dawidziak et al. 1995). Dense granules contain haemostatically 
active substances that are released at platelet activation including serotonin, ADP, ATP, 
catecholamines and calcium. Electron microscopy studies have shown that multivescicular 
bodies are an intermediary stage of both α granule and dense granule maturation (Heijnen et 
al. 1998; Youssefian and Cramer 2000). As the megakaryocyte matures an extensive network 
of demarcation membrane composed of tubulin and microtubules develops in the cytoplasm 
(Yamada 1957), it is thought that these tubular membranes originate from invaginations of the 
megakaryocyte plasma membrane. This is a dynamic system and is thought to organise the 
cytoplasm into platelet territories and therefore may function as a membrane reserve in 
platelet formation. The mature megakaryocyte and its daughter platelets express the following 
cell surface markers, some of which are early markers and are also present on committed 
megakaryocyte progenitors (Section 1.1.5): GPIIb/IIIa (CD41/CD61), GPIb (CD42b), CXCR4 
and GPVI. 
 
1.1.8 Platelet formation 
 
The primary function and the defining feature of a mature megakaryocyte is the release of 
platelets. Several models of in vivo platelet production have been proposed. The widely 
accepted model of thrombopoiesis is the proplatelet model, where megakaryocytes in the 
bone marrow develop multiple long complex cytoplasmic extensions known as proplatelets 
that extend into the marrow sinusoids to release platelets into the circulation (Radley and 
Scurfield 1980). These platelet territories, within the megakaryocyte, have been suggested to 
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predetermine platelet size (Paulus, Bury, and Grosdent 1979). This model is supported by the 
documentation of a network of branching proplatelets in a culture system (Italiano et al. 1999) 
and imaging of this process in the bone marrow compartment in vivo, the release of 
proplatelets into the circulation and proplatelet fragmentation in the circulation itself (Junt et 
al. 2007). In vitro derived megakaryocytes have been used to study pro-platelet formation 
(Patel et al. 2005) and variations of this model have been used to produce functional cultured 
platelets for transfusion (Moreau et al. 2016). However, the extent to which current in vitro 
methods of platelet production reflect true physiology is unknown. 
 
Another model of platelet production suggests megakaryocyte fragmentation in the peripheral 
circulation (Behnke and Forer 1998). This is supported by the presence of megakaryocytes 
and megakaryocyte fragments in the peripheral circulation and the fact that it is possible to 
culture human megakaryocytes from cord blood and peripheral blood in vitro with the 
production of small numbers of functioning “platelets” means that the bone marrow niche may 
not be essential for platelet release.  
 
There is now mounting evidence for the lung as a major site for thrombopoiesis. Mature 
megakaryocytes have been shown in the pulmonary arterial circulation, with bare 
megakaryocyte nuclei found in the pulmonary capillary bed (Slater, Trowbridge, and Martin 
1983; Pedersen 1978). The pulmonary production model suggests that platelet production 
from circulating megakaryocytes occurs in the lungs where large circulating megakaryocytes, 
with significant kinetic energy from the right ventricle, impact on the pulmonary capillaries and 
fragment to platelets within the lung vasculature. It has also been noted that in disorders 
where megakaryocytes or megakaryocyte fragments could bypass the lung capillary network 
(e.g., right-to-left intracardiac shunts, lung disease with abnormal circulation) these large 
particles could reach the fingertips in axial vascular streams and impact there, releasing 
PDGF and other platelet-derived growth factors (Fox, Day, and Gatter 1991; Silveri et al. 
1996) which would leads to the clubbing observed in these conditions (Dickinson and Martin 
1987). A recent study has provided direct evidence of the pulmonary circulation as a major 
site for platelet production, proposing that beyond the mechanical model, the lung may 
contain unique signals to promote platelet release (Lefrançais et al. 2017). Platelets produced 
in the lung have been shown to be functional in an in vivo thrombosis model (Fuentes et al. 
2010). 
 
It is possible that all three models: thrombopoiesis in the bone marrow, peripheral circulation 
and lungs, play a physiological role. The relative contribution of each to platelet number is not 
clear, however it has been argued that pulmonary circulation could provide total platelet need 








Megakaryocyte differentiation from the HSC, as well as megakaryocyte maturation are 
primarily driven by TPO (Bartley et al. 1994; de Sauvage et al. 1994; Lok et al. 1994). TPO 
regulates both polyploidisation and cytoplasmic maturation by binding to its receptor on the 
megakaryocyte cell surface, MPL (CD110) (Bartley et al. 1994; de Sauvage et al. 1994). 
Binding and dimerisation of this receptor lead to the autophosphorylation of Janus kinase 2 
(JAK2) and downstream activation of further signalling pathways including mitogen-activated 
protein kinases (MAPK), phosphoinositol-3 kinase (PI3K) and signal transducers and 
activators of transcription (STATs) (Dorsch et al. 1997). Ultimately this drives each stage of 
megakaryocyte differentiation by modifying transcription. TPO is synthesised in the liver and 
binds to its receptor on circulating platelets. Regulation of circulating TPO levels have been 
described to be via platelet TPO/MPL mediated adsorption (Kaushansky 2005). However, a 
recent report shows that abnormal circulating platelets influence the Janus kinase 2 signalling 
and activation of transcription in the liver leading to increased TPO production (Grozovsky et 
al. 2015). Megakaryocytes from mice that express no TPO or MPL receptor are small and low 
in ploidy with significant reductions in circulating platelet levels (Alexander et al. 1996; Gurney 
et al. 1994). Moreover, human congenital MPL deficiency manifests in severe 
thrombocytopaenia (Ihara et al. 1999). Interestingly, TPO may be dispensable for platelet 
release or even inhibit platelet release as suggested by experiments in cultured 
megakaryocytes (Choi et al. 1995; Ng et al. 2014). Along with TPO, megakaryopoiesis is 
influenced by a network of cytokines including interleukin1B (IL1B), IL3 IL6, IL11 and stem 
cell factor (SCF), chemokines and extracellular matrix proteins (Zheng et al. 2008). 
 
Environmental signals are also crucial for megakaryocyte maturation and platelet formation. It 
has been shown that movement of the megakaryocyte into the vascular sinusoids and contact 
with the bone marrow endothelium induces maturation and platelet formation (Avecilla et al. 
2004; Hamada et al. 1998). This interaction is promoted by the chemokine CXCL12 (SDF1) 
and growth factor FGF4 (Avecilla et al. 2004) and enhanced by the pro-inflammatory cytokine 
IL1β (Josefsson et al. 2011; White et al. 2012). Furthermore, in vivo, the pro-inflammatory 
VEGFR1 pathway, through upregulation of the CXCL12 receptor on megakaryocyte surface 
(CXCR4), also increases platelet production (Pitchford, Lodie, and Rankin 2012), possibly 
accounting for the increased platelet count observed in inflammatory conditions. There is also 
evidence that the extracellular matrix influences platelet production, with type I collagen 
inhibiting proplatelet formation (Sabri et al. 2004) and fibrinogen (Bury et al. 2012) and VWF 
(Balduini et al. 2009) promoting proplatelet formation through their respective receptors: 




1.1.9.2 Transcription factors 
 
Haematopoietic differentiation is driven by transcription factors that direct lineage commitment 
by regulating gene expression (Iwasaki et al. 2006). MEP differentiation into the 
megakaryocyte lineage is known to be driven by the transcription factors FLI1, TAL1, GATA1, 
RUNX1 and MEIS1 (Watkins et al. 2009). The expression of this combination of transcription 
factors was identified as specific to megakaryocytes compared to other cells in the 
haematopoietic tree (L. Chen et al. 2014). Furthermore, lentiviral transduction with FLI1, 
GATA1, TAL1 have been used to forward program induced pluripotent stem cells (iPSCs) 
directly to megakaryocytes in culture (Moreau et al. 2016).  
 
Several transcription factors have been also implicated as drivers of megakaryocyte 
maturation (endomitosis, cytoplasmic maturation and platelet formation). GATA1 has been 
shown to be essential at all three points of maturation. By directly enhancing expression of 
Cyclin D1, GATA1 plays a crucial role in polyploidisation (Muntean et al. 2007). GATA1 
deficient megakaryocytes remain small and immature, with low ploidy levels (Shivdasani et al. 
1997). GATA1 directly enhances GP1BB expression, thereby is critical in platelet production 
and function, demonstrated by the Bernard-Soulier Syndrome phenotype of 
thrombocytopaenia and abnormal platelet function caused by a point mutation in the GATA1 
binding site in the GP1BB promoter region (Ludlow et al. 1996). RUNX1 plays an essential 
role in endomitosis and regulates constituents of the megakaryocyte cytoskeleton by the 
enhancing expression of MPL and MYL9 (myosin light chain 9) (Sun et al. 2007) and silencing 
MYH10 (non-muscle myosin IIb which specifically localises to the contractile ring in 
cytokinesis) (Lordier et al. 2012). FLI1 regulates the expression of MPL, GP1BA, GPIX and 
PF4 thereby influencing both polyploidisation and cytoplasmic maturation (L. Pang et al. 
2006). Knockout of transcription factor TAL1 leads to small immature low ploidy 
megakaryocytes with reduced platelet count but platelet function is preserved. This effect is in 
part due to its regulation of CDKN1A (cyclin-dependent kinase inhibitor 1A) (Chagraoui et al. 
2011) and likely other targets essential in cytoplasmic maturation which may include MEF2C 
(myocyte enhancer factor 2C) (Gekas et al. 2009). The transcription factor EVI1 promotes 
CDK2 (cyclin-dependent kinase 2) (Kilbey et al. 2005) and therefore implicated in 
endomitosis. The transcription factor NFE2 has been shown to be essential for platelet 
formation, and in turn is transactivated by GATA1 (Nakamura et al. 2014; Takayama et al. 
2010). NFE2 knockout mice completely lack circulating platelets (Zimmet, Toselli and Ravid 
1998). This may be due to the function of the NFE2 transcriptional targets: TUBB1 (β tubulin) 
(Lecine et al. 2000), RAB27β (Tiwari et al. 2003), CASP12 (Kerrigan et al. 2004) and 
HSD3B1 (Nagata et al. 2003). Clearly the control system of both megakaryopoiesis and later 
differentiation is highly complex and it is reasonable to suggest these transcription factors 
may act interdependently. In support of this, it has been shown that the five transcription 
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factors GATA1, GATA2, RUNX1, FLI1 and TAL1 work as a network and bind simultaneously, 
in cultured megakaryocytes, at a number of binding sites in the genome (Tijssen et al. 2011). 
 
1.1.10 Megakaryocyte maturation in vitro 
 
TPO is also a potent stimulator of megakaryocyte maturation in vitro. It increases the size, 
ploidy and number of megakaryocytes and is associated with the expression of maturity 
markers such as CD41, CD61 and CD42. The discovery of TPO significantly advanced the 
ability to study megakaryocytes in the culture system, enabling the in vitro production of 
mature megakaryocytes differentiated from cord and adult blood or fetal liver CD34+ cells.  
 
Despite this, it is not yet possible, in cultured human cells, to achieve ploidy levels that are as 
high as those observed in vivo. Cultured megakaryocytes from adult blood have a larger 
representation of the higher ploidy classes than cord blood or fetal liver derived 
megakaryocytes, but mean ploidy remains 2N-4N (Figure 1.4). This is very different to 
primary human bone marrow megakaryocytes where mean ploidy is 16N (Figure 1.2). 
Therefore, in order to study ploidy effectively, compounds that increase megakaryocyte 
ploidy, as well as their maturation are required. A number of compounds have previously 
been studied for this purpose. Phorbol 12-myristate 13-acetate (PMA) has been known for 
many years to promote megakaryocyte differentiation and polyploidisation in megakaryocyte 
like cell lines, including Dami cells (Greenberg et al. 1988) and K562 (X. Huang et al. 2004). 
Nicotinamide, as mentioned above, has also been shown to increase ploidy levels, this time in 
megakaryocytes cultured from human CD34+ cells (Giammona et al. 2006). However this is 
not accompanied by signs of megakaryocyte cytoplasmic maturation (Giammona et al. 2009). 
More recently, AURKA and AURKB inhibitors have been shown to increase ploidy and 
megakaryocyte differentiation. These include dimethylfasudil (diMF), an inhibitor of both 
AURKA and AURKB and MLN8237 (alisertib) that selectively inhibits AURKA. Alisertib is 
currently being used in clinical trials for a variety of tumours, including acute leukaemias and 
is thought to confer clinical benefit by inducing terminal cellular differentiation (Wen et al. 
2012). 
 
1.1.11 The megakaryocyte transcriptome 
 
The transcriptome of human primary megakaryocytes has not yet been defined due to the 
requirement of bone marrow sampling, the relative infrequency of megakaryocytes in the 
marrow and the difficulty to obtain a pure cell population.  
 
A small number of studies have profiled gene expression in megakaryocytes that have been 
cultured from CD34+ progenitor cells using whole genome expression arrays. Gene 
expression data that currently exists for human megakaryocytes cultured from progenitors 
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obtained from cord blood (Watkins et al. 2009), fetal liver (Bluteau et al. 2013) and adult blood 
(Shim et al. 2004; Raslova et al. 2007; Bluteau et al. 2013). These data provides a catalogue 
of genes that are specifically expressed at the transcript level in megakaryocytes. Apart from 
the differential expression of transcription factors, discussed above (Section 1.1.9), in adult 
blood derived megakaryocytes compared to haematopoietic progenitors, one third of the most 
highly upregulated genes are shown to participate in haemostasis (Shim et al. 2004). 
Comparison of megakaryocytes derived from fetal liver cells, cord blood and adult blood has 
shown that genes important in megakaryocyte maturation, platelet formation and function are 
switched on during ontogeny. This is reflected in the maturity and ploidy level of the 
megakaryocytes cultured from each source (Figure 1.4) as well as their ability to produce 
proplatelets in vitro (Bluteau et al. 2013). Comparing expressed genes between 2N-4N 
cultured megakaryocytes and 8N-16N cultured megakaryocytes gene transcripts were 
identified that were down regulated during polyploidisation, included those involved in DNA 
replication, cytokinesis and proliferation. Those genes that were upregulated during 
polyploidisation included transcripts for platelet glycoproteins, other important proteins with a 
role in platelet function e.g., VWF, P-selectin, thrombospondin and proteins involved in the 












Figure 1.2 Highly polyploid mature bone marrow megakaryocytes.  
A. Flow cytometry plot of enriched healthy human bone marrow megakaryocyte ploidy 
distribution measured by a DNA dye (figure adapted from Tomer, Harker and Burstein 1988); 
B. Morphology of healthy human bone marrow megakaryocytes in an enriched population 





Figure 1.3 Megakaryocyte endomitosis.  
A 2N megakaryocyte undergoes endomitosis to produce a 4N cell, with replication of its DNA 
without cell division. Continuation of this process to produce megakaryocytes up to 64N. (G1, 
Gap 1 of interphase; G2, Gap 2 of interphase; M, mitosis; S, synthesis of interphase). (Figure 
from Martin et al. 2012). 
 
 
Figure 1.4 Ploidy distribution of megakaryocytes differentiated from CD34+ cells.  
Flow cytometry plots of ploidy distribution measured by a DNA dye; (MKFL: megakaryocytes 
derived from fetal liver CD34+ cells, MKCB: megakaryocytes derived from cord blood CD34+ 
cells, MKAD: megakaryocytes derived from adult blood CD34+ cells. n: calculated mean 
ploidy). (Figure adapted from Bluteau et al. 2013). 
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1.2 Platelet Biology 
 
1.2.1 Platelet function 
 
Platelets released from the megakaryocyte are small anucleate cytoplasmic units typically 
measuring 2 to 5µm in diameter with a mean volume of 6 to 10fl. The average platelet 
lifespan is approximately ten days. Under steady-state conditions humans must produce at 
least 1 x1011 platelets each day to maintain a normal platelet count (150-400 x109/L) and this 
level of production increases under conditions of increased demand. The primary role of 
platelets is in haemostasis and as such platelets play a pathological role in acute 
atherothrombotic disease. Furthermore, it is increasingly recognised that platelets have less 
well understood roles in inflammation, atherosclerosis, tumor growth, metastasis and 
angiogenesis (Nurden 2011; Bertozzi, Hess and Kahn 2010; Watson, Herbert and Pollitt 
2010; Feng et al. 2011). They lack genomic DNA but contain megakaryocyte-derived mRNA 
and the translational machinery required for protein synthesis. Platelets contain numerous 
organelles, a circumferential microtubular system and a metabolically active membrane with a 
surface canalicular connection system giving a large surface area.  
 
In the bloodstream, platelets circulate close to the luminal surface of the endothelium due to 
their small size in relation to other blood cells. Platelets are kept in a quiescent state by 
prostaglandin l2 receptor (PGI2) acting through the inhibitory G-protein coupled receptor 
PTGI2R and nitric oxide (NO) that diffuses across the platelet membrane. PGI2 and NO are 
released by endothelial cells and act to inhibit intracellular calcium release (Gibbins 2004). 
Platelets respond rapidly to changes in endothelial integrity and exposure of sub-endothelial 
structures, by binding the damaged surface via glycoprotein receptors that richly populate 
their outer surface, spreading and further amplifying the platelet response by the release of 
activating factors. The end result is the formation of thrombus or platelet plug that preserves 
vascular integrity and therefore minimises blood loss (Gibbins 2004).  
 
The initial activation occurs when exposed sub-endothelial VWF and collagen interact with the 
receptor complexes GPIb/IX/V (López 1994) and GPVI-GPIa/IIa (Nieswandt and Watson 
2003) respectively on the surface of resting platelet. Tissue factor from damaged endothelium 
further activates factor X to generate thrombin, which is a potent activator of platelet protease 
activated receptors 1 and 4 (PAR) (Bouchard et al. 1997) This initial activation causes a shift 
in the platelet surface integrins from a low to high affinity binding state (Liddington and 
Ginsberg 2002), leading to high affinity binding of GPIa/IIa to collagen and GPIIb/IIIa to VWF 
which promotes further activation and aggregation. Activation results in a unique cytoskeleton 
rearrangement transforming the resting oblate spheroid platelet to a more stellate form with 
long pseudopodia with the exteriorisation or secretion of the contents of platelet storage 
granules. Alpha granules contain haemostatically active factors - fibrinogen, thrombospondin, 
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VWF, platelet-derived growth factor (PDGF), PF4, transforming growth factor beta (TGFβ), 
fibronectin and coagulation factors as well as new GPIIb/IIIa and GPIb/IX/V complexes which 
allow for crosslinking between platelets, platelet aggregation and thrombotic propagation 
(King and Reed 2002). Furthermore, P-selectin which is transferred to the platelet membrane 
by the alpha granules on activation facilitates the interaction between platelets and leucocytes 
(Michelson 2012). The release of ADP, calcium and serotonin from dense granules causes 
further platelet activation through the G-protein coupled receptors P2Y1 and P2Y12 
(Michelson 2012). Platelet activation also initiates the arachidonic acid pathway to produce 
thromboxane A2 which activates nearby platelets via the TXA2 receptor as well as markedly 
increasing local concentrations of thrombin and Factor X (Michelson 2012). Overall, this 
cascade of events leads to formation of a platelet plug supported by a matrix including fibrin 
and leucocytes. 
 
Platelet function can be measured by stimulating either whole blood or platelet rich plasma 
with agonists such as: ADP binding to P2Y1 and P2Y12 receptors, collagen binding to 
GPIa/IIa and GPVI and activating GPIIb/IIIa receptors; thrombin binding to PAR1 and PAR4 
(Garner et al. 2017). Assessment of the resulting activation can then be made using either 
flow cytometry or aggregation using light transmission aggregometry. 
 
1.2.2 Platelet physical characteristics 
 
Commonly measured platelet characteristics by haematology analysers are: platelet count 
(PLT) by both electrical impedance and optical fluorescence and mean platelet volume (MPV) 
derived from electrical impedance. These are highly heritable traits (Evans, Frazer, and 
Martin 1999; Bertin et al. 2007; Mahaney et al. 2005; Bray et al. 2007; Garner et al. 2000) and 
highly reproducible within an individual while varying widely within the population. Plateletcrit 
(PCT) – a measure of platelet total mass, the platelet distribution width (PDW) and platelet 
large cell ratio (P-LCR), are also derived from electrical impedance. Immature platelet fraction 
(IPF), is a measure of reticulated platelets that contain mRNA using flow cytometry by 
detection of a RNA dye.  
 
1.2.2.1 Mean platelet volume 
 
Platelet size, measured as MPV is, together with platelet count, the most frequently studied 
platelet physical variable. MPV is calculated by dividing plateletcrit (a measure of platelet 
mass) by number of platelets. Platelet volume can vary from 2fl to 60fl with a typical MPV of 
6-10fl. Unlike all other mammalian cells that undergo mitotic division, which have a Gaussian 
cell volume distribution, platelets fit instead a log Gaussian distribution curve (Paulus 1975) 
(Figure 1.5a). This means that the platelet volume distribution within an individual at any given 
time point demonstrates a greater heterogeneity or variation than in any other circulating cell 
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type. This has given rise to significant controversy as to how this unique volume distribution 
curve originates and what its physiological relevance is. As the platelet volume distribution 
changes, so do PDW and P-LCR. The PDW is the width of the size distribution curve in fl at 
the 20% level of the peak and the P-LCR is the number of cells falling above an arbitrary 
threshold of 12fl divided by the total platelet count. 
 
It was originally thought that the unique platelet volume distribution curve was explained by 
platelet ageing, because each platelet volume decreased during its lifespan in the circulation 
(Karpatkin and Charmatz 1969). However, methodological flaws in the data have since 
questioned this conclusion (Martin et al. 1982). Evidence from a variety of species, where the 
size and density of labeled platelets have been measured throughout platelet lifespan, 
indicates that platelet heterogeneity does not arise from ageing (Thompson et al. 1983; 
Schulman I 1971; Martin and Penington 1983; Savage et al. 1986; Boughton et al. 1990). The 
implication of these findings is that the platelet volume distribution curve arises from the 
unique non-mitotic manner of platelet formation from megakaryocytes and is defined at the 
time of thrombopoiesis. During steady state thrombopoiesis an inverse relationship exists 
between MPV and platelet count within an individual (Karpatkin 1978) to conserve a constant 
circulating functional platelet mass. This is known to be true at a population level where the 
same inverse relationship exists at both the population level with individuals with high platelet 
counts having a low MPV and vice versa (Bessman 1984) and between different species (von 
Behrens 1972). Therefore, it is reasonable to suggest that platelet volume is regulated at the 
point of production according to physiological haemostatic demand. When equilibrium 
between platelet production and destruction is disturbed, with drop in platelet count, the 
primary response is the rapid production of larger platelets to maintain overall circulating 
platelet mass. The pulmonary production model provides an explanation for the observed log 
Gaussian distribution of platelet size, because the fragmentation pattern is a series of binary 
divisions (Trowbridge and Harley 1984).  
 
Interestingly, a recent study has shown the generation of “platelet progeny” from platelets 
stored ex vivo either in culture media or within whole blood. The new “platelets” that are 
produced are in fact not smaller in size or volume and are shown to be functional (Schwertz et 
al. 2010). However the relevance of this phenomenon to the in vivo physiological setting is 
still unknown. 
 
The importance of MPV as a biological variable has been extensively studied. There is a 
convincing body of evidence suggesting a positive correlation between platelet size and 
platelet function measured as aggregation and granular content release. Preferential 
aggregation of large platelets is observed after addition of the agonist ADP to platelet 
suspensions (Karpatkin 1978; Haver and Gear 1981). Larger platelets are denser, contain 
more granules and mitochondria per unit volume (Martin et al. 1983), cause reduced bleeding 
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time (Kristensen, Bath, and Martin 1990; Martin et al. 1983), have a higher capacity for 
thromboxane A2 production (Martin et al. 1983) and TGFβ secretion (Thompson et al. 1982; 
Thompson et al. 1983) and express more GPIIb/IIIa receptors per unit area of plasma 
membrane (Giles, Smith, and Martin 1994) than smaller platelets. Platelet activation is 
significantly increased in larger compared to smaller platelets when these subpopulations are 
sorted by flow cytometry (Mangalpally et al. 2010). A negative correlation has also been 
observed between MPV and platelet activation in a large cohort of healthy individuals which 
has disputed the association between MPV and prothrombotic risk (Soranzo et al. 2009). 
However, more recently genome wide association studies have shown genetic loci associated 
with MPV that also have an effect on platelet function (Gieger et al. 2011). 
 
1.2.2.2 Immature platelet fraction 
  
“Immature platelets” and “reticulated platelets”, (terms that are commonly used 
interchangeably) are newly released platelets from the megakaryocyte and are identifiable on 
the basis of their RNA content (Ault et al. 1992). In animal studies, where platelet lifespan is 
shorter (4-5 days compare to 9-10 in humans), RNA usually degrades within 24 hours (Dale 
et al. 1995). As these platelets have just been released from megakaryocytes, IPF, as 
measured by a haematology analyser, is used as a surrogate marker for megakaryocyte 
activity and is increased in individuals with activated thrombopoiesis and increased platelet 
turnover (Ault and Knowles 1995). 
 
IPF is a quantification of reticulated platelets as a proportion of the total platelet population. 
The current method of measuring the IPF is based on the RNA content of a platelet detected 
by staining with an RNA dye as well as platelet size (Figure 1.5b) (Briggs et al. 2009). This 
method suggests that all newly formed platelets (reticulated platelets) are large. However, a 
major limitation of the method is that newly produced smaller platelets contain less RNA due 
to their size and may be below the limit of detection of the analyser. Therefore, the sensitivity 
of the test is low and it is likely that there are reticulated platelets not detected. The specificity 
is high, as all the platelets with high levels of mRNA are detected and these are by definition 
all reticulated platelets. These limitations however do not impact on the utility of the test, as it 
is used in the setting of activated thrombopoiesis where relative values are adequate, where a 
high IPF indicates increased megakaryocyte activity and platelet production. The term 
“immature” can therefore be somewhat confusing. Here the measured parameter will be 
referred to as IPF, as by convention and the newly formed platelets referred to as “reticulated 
platelets”. 
  
1.2.3 The platelet transcriptome 
Being anucleate, platelets are incapable of transcription of nuclear genes. Therefore all 
platelet proteins, except plasma proteins taken up by endocytosis, are derived from the 
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megakaryocyte. Platelets contain mRNA derived from the megakaryocyte and translational 
machinery for protein synthesis. Through a number of studies, that have analysed and 
defined the transcriptome of platelets (Gnatenko et al. 2003; Bugert et al. 2003; McRedmond 
et al. 2004; Hillmann et al. 2006; Rowley et al. 2011), it is now clear that platelets contain a 
rich repertoire of RNA although in quantity, a platelet will contain significantly less RNA than a 
leukocyte (Fink et al. 2003). As platelets are anucleate and unable to transcribe RNA, the 
platelet RNA profile provides an insight into the transcriptional state of megakaryocytes and 
the bone marrow signals involved in thrombopoiesis. While much of the platelet transcriptome 
data comes from microarrays, arguably the most useful data is from RNA-seq experiments 
(Rowley et al. 2011).  
 
It is generally assumed that mRNA expression in megakaryocytes and platelets reflect each 
other. However, differential packaging of mRNAs for matrix metalloproteases (MMPs) and 
tissue inhibitors of metalloproteases into platelets (TIMPs) has been shown (Cecchetti et al. 
2011) which supports the regulation of mRNA transfer at the point of platelet production. The 
study analyses transcript and protein expression of these 2 families of proteins in the 
megakaryocyte and the platelet. MMP-2 is expressed at mRNA and protein level in the 
megakaryocyte but only the protein is observed in platelets. Further, TIMP-2 mRNA and 
protein have been identified in megakaryocytes but only the mRNA is seen in platelets.  
 
Transcriptome analysis has been used in platelets to identify novel platelet proteins. Many of 
the most abundant platelet transcripts are products of known platelet genes PF4, PPBP, 
ITGA2B, GP1BB. However, there are a number of limitations to the study of the platelet 
transcriptome whereby it may not necessarily reflect the proteome of the platelet. The 
encoding transcript for proteins synthesised in the megakaryocyte and packaged into pro-
platelets may be absent from the platelet transcriptome. Due to the difference in amount of 
RNA in platelets compared to leucocytes the potential for contamination is substantial, despite 
the fact that this is usually well addressed experimentally. Finally the purified population of 






Figure 1.5 Platelet indices.  
A. Log Gaussian platelet volume distribution curve. Frequency distribution of platelet volumes 
in a representative human platelet population measured using electrical impedance. Shaded 
section: range of results, continuous line: predicted log Gaussian curve (PL, lower 
discrimination; PDW, platelet distribution width; P-LCR, platelets-large cell ratio; PU, upper 
discrimination); B. Representative IPF plot of a thrombocytopaenic patient with raised IPF, 
flow cytometry plot: y: forward scatter (size), x: RNA content. IPF is defined by an arbitrary cut 
off of RNA content. (Figure adapted from Briggs et al. 2009). 
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1.3 Megakaryocyte-platelet axis in states of increased haemostatic demand 
 
As discussed above, during steady state thrombopoiesis, a constant circulating platelet mass 
is maintained by an inverse relationship between platelet count and platelet volume at the 
point of thrombopoiesis. Therefore, in the setting of platelet consumption, such as acute blood 
loss or chronic immune thrombocytopaenia, the physiological response is the production of 
large platelets. As such, in these clinical scenarios, MPV and IPF values are increased. This 
phenomenon is demonstrated in animal models, where antiplatelet serum induced 
thrombocytopaenia results in an increase in MPV as well as platelet reactivity (Martin, 
Trowbridge, et al. 1983; Kuter, Beeler, and Rosenberg 1994), as well as in the clinical setting 
of immune thrombocytopaenia purpura where giant platelets are visualised on blood smear 
(Levin and Bessman 1983). Furthermore, in surgical patients on cardiopulmonary bypass, 
where platelets are acutely depleted in the extracorporeal circulation, a similar response is 
observed (Martin, Daniel, and Trowbridge 1987) (Figure 1.6). As shown in Figure 1.6, MPV 
remains unchanged immediately after the drop in platelet count, but then increases, arguably 
in response to the reduction in platelet number.  
 
There is also evidence to suggest that in settings where there is an acute or chronic decrease 
in circulating platelet mass, the megakaryocyte response is an increase in ploidy level and 
cytoplasmic volume in both animals (Stenberg et al. 1991; Corash and Levin 1990; Harris and 
Penington 1984) and humans (Mazur et al. 1988). For example, the distribution of 
megakaryocyte ploidy in the bone marrow is seen to shift to higher values in patients with 
immune thrombocytopaenia purpura (Tomer et al. 1989) which is also associated with larger 
platelets (Penington, Streatfield, and Roxburgh 1976; Bessman 1984). In acute 
thrombocytopaenia a number of studies have demonstrated that an acute fall in platelet count 
is associated with higher megakaryocyte ploidy (Martin et al. 1982; Harker and Finch 1969). 
However there appears to be a temporal delay of 24-48 hours between drop in platelet count 
and maximal megakaryocyte ploidy (Kuter, Beeler, and Rosenberg 1994; Kuter and 
Rosenberg 1995) indicating the need for DNA replication and megakaryocyte maturation.  
 
Taken together these evidence indicate that there is a physiological homeostatic control 
system that feeds back to the megakaryocyte and even possibly to the HSC to promote an 
increase in platelet production in states of increased haemostatic demand, when functional 
circulating platelet mass drops and results in the acute release of platelets of greater volume.  
 
This complex feedback system is in part mediated by TPO which binds to receptors on 
platelets, megakaryocytes and even HSCs and has been implicated in the maintenance of 
steady state peripheral platelet mass. The exact mechanism by which TPO regulates 
megakaryopoiesis, megakaryocyte maturation and subsequent thrombopoiesis, however, 
remains unclear. TPO levels have been shown to be inversely proportional to platelet mass 
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(Nichol et al. 1995; Shinjo et al. 1998; Engel et al. 1999; Kuter and Rosenberg 1995), with 
peripheral TPO concentrations rising to a maximum approximately 24 hours after acute 
platelet loss, followed by an increase in megakaryocyte ploidy levels (Kuter and Rosenberg 
1990; Kuter, Beeler, and Rosenberg 1994; Hirayama et al. 1998). A major component of TPO 
regulation is by the “sponge model” in which TPO production from the liver is constant 
(Stoffel, Wiestner, and Skoda 1996; Ulich et al. 1995) and the concentration of circulating 
TPO is determined by the level of TPO binding to MPL, its internalisation and degradation 
within circulating platelets. Thereby loss of platelet mass leads to increased circulating TPO 
levels and result in activated platelet production.  
 
However, regulation of platelet mass is likely to be more complex as this model does not hold 
true in all scenarios. Firstly, TPO levels are not increased in chronic thrombocytopaenias 
(Kosugi et al. 1996; Ichikawa et al. 1996). Secondly, in states of reactive thrombocytosis, TPO 
concentrations are higher than expected, with an increase in hepatic TPO mRNA levels 
secondary to increased concentrations of the acute phase cytokine IL-6 (Hsu et al. 1999; 
Griesshammer et al. 1999; Wolber et al. 2001; Kaser et al. 2001). Thirdly, in severe 
thrombocytopaenia bone marrow stromal cells dramatically increase TPO mRNA levels 
(Sungaran, Markovic, and Chong 1997). Furthermore, there is evidence to show that TPO is 
not indispensible for platelet production (Ng et al. 2014) with genetic ablation of TPO or MPL 
receptor leading to severe but not absolute thrombocytopaenia (Gainsford et al. 1998; Q. 
Chen et al. 1998). CXCL12 has been conceptualised to be responsible for TPO independent 
thrombopoiesis. It enhances megakaryocyte colony formation in vitro (Hodohara et al. 2000) 
and administration of CXCL12 in combination with FGF4 can nearly normalise the platelet 
count of MPL deficient mice (Avecilla et al. 2004). To add to this complexity, as described 
above, megakaryocytes within the stem cell niche influence HSC quiescense through PF4 
(Bruns et al. 2014) and TGFB (Zhao et al. 2014). 
 
In states of acute increased haemostatic demand such as haemorrhage or acute severe 
thrombocytopaenia where the rapid generation of large reactive platelets is required it has 
been suggested that this may occur via a slow or fast response (Martin et al. 2012). The 
evidence presented above demonstrates an increase in megakaryocyte size and ploidy in 
settings of acute thrombocytopaenia but this occurs 24-48 hours after the drop in platelet 
mass in response to rising TPO levels which could represent the slow response, part of the 
physiological feedback that maintains steady state thrombopoiesis. However, there have 
been studies to show immediate increases in platelet mass after induced acute 
thrombocytopaenia without appreciable increases in megakaryocyte ploidy (Corash et al. 
1987; Stenberg and Levin 1989) which suggests that in a pathological setting a fast response 
is activated for rapid thrombopoiesis. At the level of the megakaryocyte this could be from all 
levels of megakaryocyte ploidy or as a result of recruitment of a subset of megakaryocytes 
with a specialised transcriptional program or those of higher ploidy only. This feedback may 
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also occur at the level of the HSC. As described above it is now evident that megakaryocyte-
biased HSC compartment can give rise to megakaryocyte progenitors directly bypassing 
intermediate differentiation steps as well as through the bipotent MEP via the classical 
pathway which could represent the fast and slow responses respectively (Figure 1.7). 
Recruitment of this subset of megakaryocyte lineage primed HSCs, that express high levels 
of CD41 and VWF and bypass conventional lineage commitment steps, has been 
demonstrated to function as part of the fast response described as “emergency” or “stress” 






Figure 1.6 Changes in normalised platelet count (pink) and mean platelet volume (blue) 
following cardiopulmonary bypass surgery. The numbers above each value indicate the 






Figure 1.7 Steady state and accelerated thrombopoiesis. 
A haemostatic stimulus is hypothesised to lead to thrombopoiesis via a haemostatic sensor. This may 
be in the physiological steady state where or in states of increased haemostatic demand where 
accelerated thrombopoiesis is required to restore physiological platelet mass. It could also occur in 
pathological states of thrombosis where an inappropriate stimulus leads to accelerated 
thrombopoiesis, which could then go on to produce an inappropriate positive feedback loop. It is 
hypothesised that feedback could occur at the level of either the HSC or megakaryocyte. There is now 
evidence to suggest that there may be 2 separate pathways for megakaryocyte differentiation from the 
HSC, one through the classical differentiation pathway via intermediate progenitors (CMP, MEP) 
which could be suggested to be the “slow” or steady state pathway, and the other a direct 
differentiation from the HSC which bypasses intermediate progenitor states which could be suggested 
to be the “fast” or accelerated pathway. It is possible that the 2 differentiation pathways produce 2 
different megakaryocyte phenotypes, one which is primed for emergency thrombopoiesis. 




1.4 Megakaryocyte-Platelet axis in acute coronary syndrome 
 
1.4.1 Acute coronary syndromes 
 
Acute coronary syndromes (ACS) is an umbrella term referring to a spectrum of clinical 
diagnoses based on symptoms, electrocardiographic change and increased circulating 
cardiac markers (Hamm et al. 2009). It encompasses unstable angina, where there is partial 
coronary occlusion, and acute myocardial infarction (AMI), defined by total coronary occlusion 
and thereby myocardial necrosis. AMI is split into non-ST elevation myocardial infarction 
(NSTEMI), where coronary occlusion leads to partial thickness infarction and ST elevation 
myocardial infarction (STEMI), where coronary occlusion results in a full thickness infarction. 
ACS is both common and confers significant morbidity and mortality, despite improvement in 
prognosis with antiplatelet drugs and primary percutaneous coronary intervention (pPCI). 
According to the most recent figures approximately 30,000 people still die from AMI per year 
in the UK; this equates to over one third of AMI patients (Smolina et al. 2012).  
 
Pathological platelet thrombosis resulting in coronary artery occlusion defines ACS. ACS 
does not represent a single disease with a distinct cellular change or pathophysiological 
cause, rather several disease processes that lead to formation of intracoronary thrombus as 
the final common pathway. These include inflammatory cell activation, abnormal lipid 
metabolism and endothelial cell dysfunction as well as platelet hyperactivity. Platelets are 
known to be a major constituent of coronary thrombus and have been found histologically in 
patients who died from ACS. In approximately 70% of cases, observed at post mortem, 
coronary thrombi develop at the site of ruptured atherosclerotic plaques. In 20-25% cases 
thrombus occludes the vessel with no plaque rupture (Libby 2013; Falk et al. 2013). This is 
known as plaque erosion and although it is uncertain exactly what initiates thrombosis, it may 
well be a result of increased systemic thrombogenicity. The most convincing evidence for the 
participation of platelets in coronary arterial thrombosis comes from trials of antiplatelet drugs 
that have shown significant reductions in morbidity and mortality and that remain the 
cornerstone of ACS treatment (Steg et al. 2012).  
 
1.4.2 Platelet and megakaryocyte characteristics in ACS 
 
A number of clinical observational studies have shown that MPV is increased in ACS. 
Historical data from the pre pPCI era and the use of P2Y12 or GPIIb/IIIa antagonists shows 
that MPV is increased within 12 hours after AMI and remains raised for the following four 
months compared with controls (Martin, et al. 1983; Cameron et al. 1983; Kishk, Trowbridge, 
and Martin 1985). This relationship has also been observed in the era of routine dual 
antiplatelet and GPIIb/IIIa inhibitor use (Ranjith et al. 2009; Lippi et al. 2009; H. Chu et al. 
2011; S. G. Chu et al. 2010; Mathur et al. 2001; Sansanayudh et al. 2014). The functional 
	 31
relevance of this well documented finding remains unclear. Platelet function based on 
bleeding time (Milner and Martin 1985; Kristensen, Bath, and Martin 1990) and surface 
expression of GPIIb/IIIa receptors (Giles, Smith, and Martin 1994) have been correlated with 
large platelets in AMI, indicating that the increase in volume may be pathologically important. 
In support of this, a number of large studies have shown an association between MPV and 
prognosis; namely mortality and repeat infarction which is independent of other risk factors, 
both prior to and since the initiation of pPCI, dual antiplatelet and GPIIb/IIIa agents (Taglieri et 
al. 2011; Aksu et al. 2009; Azab et al. 2011; Goncalves et al. 2011). MPV has been 
associated with other morbidity endpoints including coronary restenosis (Smyth et al. 1993; A. 
Yang, Pizzulli, and Lüderitz 2006) and heart failure (Estévez-Loureiro et al. 2009; Pereg, 
Berlin, and Mosseri 2010; Yazici et al. 2011). Interestingly, in large prospective studies of 
healthy individuals MPV is found to be the strongest independent risk factor for development 
of first AMI (Klovaite et al. 2011) and also predict mortality due to coronary artery disease 
(Slavka et al. 2011). Increased MPV has also been seen in groups with low HDL (Varol et al. 
2014), diabetes (Guthikonda et al. 2008; Han et al. 2013) and obesity (Coban et al. 2005).  
 
There is also some evidence to suggest that megakaryocyte activity is altered in the setting of 
ACS although little direct evidence in the bone marrow. First, IPF is increased with MPV in 
patients with AMI compared with controls (Cesari et al. 2008; Guthikonda et al. 2008), also in 
patients with in-stent thrombosis on dual antiplatelet therapy (Würtz et al. 2010), suggesting 
that the number of reticulated platelets in this disease setting are increased reflecting 
increased megakaryocyte activity. Furthermore, the level of IPF is shown to be independently 
predictive of mortality in the same way as MPV (Cesari et al. 2013). Second, not only is the 
numerical value for MPV increased in AMI, the entire platelet volume distribution curve is 
shifted to the right, suggesting a change in thrombopoiesis (Trowbridge and Martin 1987; 
Khandekar et al. 2006). Third, increased circulating levels of TPO associated with increases 
in MPV have been demonstrated in AMI (Senaran et al. 2001). Finally, while megakaryocyte 
ploidy has not been measured in AMI, an early study shows increased megakaryocyte 
volume in AMI patients compared with controls, correlating with increased MPV (12,227fl, 
n=7; 7,875fl, n=6 respectively; p<0.001, t-test). In addition, megakaryocyte volume was 
increased in bone marrow from post mortem studies of patients dying with sudden cardiac 
death compared with death through road traffic accident (10,293fl, n=10; 7,368fl, n=11 
respectively; p<0.001, t-test) (Trowbridge et al. 1984). Increased volume of megakaryocytes 
in AMI also lends support to increased megakaryocyte activity in this setting.  
 
It is not known if the increase in MPV is an effect of the state of acute thrombosis or if it is 
causally related to the development of ACS. The possibility that increased platelet volume 
may be a downstream effect of the inflammatory changes that are seen in ACS, is supported 
by the fact that pro-inflammatory cytokines also promote megakaryocyte maturation and 
platelet release. Expression of toll-like receptor 2 (TLR2) has been shown in megakaryocyte 
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and platelets. These are receptors that recognise molecules released in the circulation from a 
ruptured atherosclerotic plaque. TLR2 stimulation in the megakaryocyte can influence 
maturation and potentially influence platelet production and function (Beaulieu et al. 2011). 
Moreover, binding of HDL to its receptor ABCG4, highly expressed on megakaryocytes, leads 
to reduced platelet release whereas its absence analogous to low HDL levels seen in 
atherosclerosis promote an increase in total platelets, reticulated platelets, enhanced 
activation, and increased platelet–leucocyte aggregates (Murphy et al. 2013). These data 
suggest that inflammation and processes specific to atherosclerotic plaque rupture might 
influence megakaryocyte phenotype and MPV. However, given that the lifespan of a platelet 
is 10 days, and that >90% of platelets measured shortly after AMI would have been 
circulating before the occlusive event, a causal relationship between ACS and platelet density 
or MPV has been suggested. This is supported by the prognostic data presented above 
(Section 1.4.2) that show that a raised MPV increases likelihood of death and re-infarction 
post event but also is an independent marker of the risk of a primary event in a healthy 
population.  
 
1.4.3 Alteration of megakaryocyte-platelet activity in ACS 
 
What triggers the upregulation of the megakaryocyte-platelet system to produce large 
platelets is unknown, however, it is hypothesised that there maybe both genetic and 
environmental factors. 
 
Genome wide association studies (GWAS) aim to find associations between particular genetic 
variants and a chosen phenotypic trait. These studies have dramatically increased the 
number of known disease-associated genetic variants (Hindorff et al. 2009). The largest 
GWAS for platelet count and MPV is a meta-analysis of 66,867 individuals that identified 43 
genetic variants associated with platelet count and 25 associated with MPV (Gieger et al. 
2011). One third of these variants were identified within or near to genes encoding proteins of 
known functional roles in megakaryopoiesis, thrombopoiesis, platelet survival or general 
haematopoiesis. A number of these genetic loci were also found to reach genome wide 
significance levels for association with platelet function (Johnson et al. 2010), supporting the 
link between MPV and platelet function.  
 
A number of GWAS have been carried out to identify genetic variants associated with the 
endpoint of coronary artery disease (CAD) which is combination of AMI and chronic stable 
angina/chronic coronary stenosis. In total 83 genetic loci have been identified as reaching 
genome wide significance (Howson et al. 2017; Deloukas et al. 2013; Kathiresan et al. 2009; 
IBC 50K CAD Consortium 2011; Samani et al. 2007; Schunkert et al. 2011; Erdmann et al. 
2009; Nikpay et al. 2015) including 10 from the recent GWAS meta-analysis of 185,000 CAD 
cases and controls using phased haplotypes from the 1000 Genomes Project (McVean et al. 
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2012; Auton et al. 2015) which has expanded coverage of lower frequency variants (Nikpay et 
al. 2015; Deloukas et al. 2013). These genetic loci have been linked to either a lipid trait, 
blood pressure or vascular integrity. Only 2 loci are found to overlap with those associated 
with the platelet phenotypes. This does not appear consistent with the idea of platelets being 
integral to the development of ACS. Furthermore, the possibility of a causal link between MPV 
and CAD has recently been challenged by large scale imputational GWAS study of 36 blood 
cell indices in 173,480 individuals (Astle et al. 2016). Here, through two sample Mendelian 
randomisation analysis the genetic traits that lead to reduction in MPV rather than increase 
are common to the development of CAD based on CAD GWAS data (Deloukas et al. 2013). 
This suggests that previously reported associations between MPV and cardiovascular 
disease may be non-causal, however, this analysis takes into account genetic signals only.  
 
It must be noted that the variants linked to CAD only account for 10.6% of CAD heritability 
(Deloukas et al. 2013) indicating that the GWAS data is far from complete. Moreover, the loci 
discovered in the platelet GWAS were estimated to account for 4.8% of the phenotypic 
variance observed in platelet count within the population and 9.9% seen in MPV (Gieger et al. 
2011). Taken together this supports a more prominent role for environmental determinants in 
platelet count and MPV as well as the development of CAD. Interestingly in the case of 
platelet indices, the majority of the GWAS signals are in noncoding regions, supporting the 
assertion that the principle mechanisms by which sequence variation alters phenotype are at 
the level of transcriptional regulation and/or splicing events (Gieger et al. 2011).  
 
While regulation of platelet indices is highly heritable (Evans, Frazer, and Martin 1999; Bertin 
et al. 2007; Mahaney et al. 2005; Bray et al. 2007; C. Garner et al. 2000), there are a number 
of non-genetic factors that may in part explain trait variance of platelet indices within the 
population, although the understanding of the non genetic regulation is limited. Both platelet 
count and MPV vary according to age, gender and ethnicity (Bain 1996; Segal and Moliterno 
2006; Saxena et al. 1987; Biino et al. 2011). In the largest study to date, MPV is shown to 
increase with age (Santimone et al. 2011) and in an elderly population MPV is found to 
increase with percentage body fat and fasting blood glucose (Muscari et al. 2008), which are 
also risk factors for acute coronary syndromes. It is certainly possible that the upregulation of 
the megakaryocyte-platelet system is the result of low grade increases in platelet 
consumption over a period of time caused by endothelial dysfunction such that is seen in 
chronic stable atherosclerotic disease or due to environmental coronary artery disease risk 
markers such as aging, smoking, hypertension or hypercholesterolaemia. 
 
1.4.4 Megakaryocyte-platelet transcriptome studies in ACS 
 
There are a few studies that have investigated platelet gene expression profiles in ACS.  
Transcriptional profiling of platelets is a novel opportunity to understand alterations in gene 
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expression preceding the acute coronary event without the confounding possibility that the 
event itself has provoked those. However, all of these studies are small and underpowered 
and therefore a robust association has not been confirmed. 
 
In one study 54 transcripts were found to be differentially expressed between 16 patients with 
STEMI and 44 controls using gene expression arrays (Healy et al. 2006). The genes strongly 
associated with STEMI were CD69 and myeloid-related protein MRP-14. In an independent 
validation study, MRP-8/14 was associated with first cardiovascular event rate, independent 
of standard risk factors. The same protein has also been found to be predictive of mortality 
after an acute event (Morrow et al. 2008). In another study, 45 differentially expressed 
transcripts were identified between 15 ACS patients and 14 controls. Here GP1BB was found 
to be strongly associated with ACS (Colombo et al. 2011). These studies suggest that in ACS 
patients, platelets are preconditioned at the transcriptional level from the megakaryocyte to a 
more prothrombotic phenotype.  
 
In another study 63 platelet transcripts were found to be associated with platelet function by 
assessing differential expression between healthy individuals grouped according to their 
platelet function (Goodall et al. 2010). These transcripts were then cross-referenced to 
genetic variants found to be associated with CAD in a larger case control study and 
expression of the genes COMMD7 and LRRFIP1 were found to be associated with CAD. 
Moreover, when these genes were silenced in zebrafish, thrombus formation was reduced 
suggesting that these particular transcripts are prothrombotic and potentially pathogenic. 
Racial difference in risk of atherothrombosis mediated by differences in the thrombin receptor 
PAR4 activity have also been linked to particular differentially expressed transcripts using 
transcriptome analysis (Edelstein et al. 2013). 
 
More recently, RNA-seq has been used to identify differentially expressed genes between 
patients with STEMI compared with NSTEMI. Although none of the transcripts were found to 
be significantly differentially expressed there were a number that were increased in STEMI 
compared with NSTEMI with enrichment in platelet related pathways and platelet aggregation 
pathways (Eicher et al. 2016). 
 
 
1.5 Application of next generation sequencing in transcriptome analysis 
 
Until recently the majority of studies that have analysed the transcriptome of megakaryocytes 
and platelet have been based on whole transcriptome expression arrays rather than 
transcriptional profiling using next generation sequencing. Expression arrays can only give 
information about known genes by hybridisation to probes designed to detect known 
transcripts. RNA-seq, however allows the assessment of the full repertoire of known and 
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novel transcript isoforms and splice junctions. Here RNA-seq libraries are prepared by the 
conversion of RNA to cDNA, sequencing adaptors are subsequently added to each cDNA 
fragment and a short sequence is obtained from each cDNA using high-throughput 
sequencing technology. The resulting sequence reads are aligned with the reference 
transcriptome, thereby allowing all parts of the transcriptome to be analysed including multiple 
transcripts for each gene. RNA-seq also allows for detection of alternative splicing which is a 
post-transcriptional process used in up to 94% of human genes that produces multiple distinct 
transcripts from a single gene (E. T. Wang et al. 2008; Pan et al. 2008) and may have an 
important role in disease causation (Singh and Cooper 2012). All considered, RNA-seq 
provides a more complete assessment of the transcriptome. In order to perform RNA-seq, a 
pure cell population is required and at the time of starting this thesis within our laboratory 
approximately 10,000 cells was the number required for robust transcript quantification.  
 
More recent advances in whole-transcriptome amplification and single cell isolation have 
allowed the high resolution sequencing of the minute amounts of RNA present in a single cell 
(less than 1 pg of mRNA (Kawasaki 2004)). This offers the opportunity to sequence rare cell 
populations and allows an insight into trancriptional heterogeneity within a phenotypically 
homogeneous cell population (S. Huang 2009). The transcriptome of an individual cell reflects 
its functionality and its responses to acute stimuli. Moreover, in conventional bulk sequencing 
of cell populations, genes thought to be co-expressed may in fact be mutually exclusive when 
single cell resolution is applied.  
 
 
1.6 Project aims 
 
The primary aim of this project was to gain insights into megakaryopoiesis and 
thrombopoiesis by utilising next generation sequencing to analyse the transcriptome of 
human HSCs, megakaryocytes and platelets in both the steady state and in states of 
accelerated thrombopoiesis that occurs due to haemostatic demand. 
 
Single cell RNA sequencing was used to investigate transcriptional heterogeneity within the 
primary human bone marrow HSC population. It was anticipated that differentially expressed 
genetic programmes would provide insight into lineage potential of HSC subpopulations and 
the early stages of megakaryocyte lineage potential and differentiation.  
 
Using low input and single cell RNA sequencing the transcriptome profile of the human bone 
marrow megakaryocyte was interrogated for the first time. In order to identify novel drivers of 
megakaryocyte maturation, human bone marrow megakaryocyte transcriptome was 
compared to that of their in vitro counterparts: megakaryocytes cultured from human CD34+ 
cells, a process known to generate immature megakaryocytes. Furthermore, transcriptional 
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signatures associated with increasing ploidy were then identified, again in primary bone 
marrow megakaryocytes.  
 
The pathological setting of acute coronary thrombosis was then used as a model for 
accelerated thrombopoiesis. Here megakaryocyte and platelet transcriptomes were compared 
between controls and patients with recent acute coronary thrombosis with the objective to 
identify transcripts related to thrombosis and accelerated thrombopoiesis. Finally the gene 
signatures relating to increasing ploidy and accelerated thrombopoiesis were correlated with 
differentially expressed genetic programmes within the HSC population in order to investigate 
if thrombopoiesis in different physiological states could be controlled at the level of the HSC. 
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CHAPTER 2 
Materials and Methods 
 
2.1 Sample collection 
 
2.1.1 Patient recruitment 
 
Sixty-six patients admitted either acutely or electively to Barts Health NHS Trust between 
June 2014 and February 2016 gave written informed consent to enter the ethically approved 
BAMI Platelet Sub-study (REC London City & East 13/LO/1760, PI Prof. Anthony Mathur, 
Queen Mary University of London, Appendix 1).  
 
The aim of the study was to obtain blood and bone marrow samples from 2 cohorts of 
patients: 1. Cases: individuals with recent acute myocardial infarction; 2. Controls: individuals 
with no evidence of coronary artery disease. Cohort 1: Cases were recruited through the 
multicentre phase III BAMI trial (The effect of intracoronary reinfusion of bone marrow derived 
mononuclear cells on all-cause mortality in acute myocardial infarction). Therefore, the main 
inclusion criteria for this arm were the inclusion criteria for BAMI, but only the individuals 
randomised to have bone marrow aspiration were recruited to the Sub-study. Briefly, the 
inclusion criteria were patients within 3-5 days of successfully reperfused STEMI, with a 
resultant left ventricular ejection fraction of <45%. STEMI was defined as ischaemic chest 
pain in the context of an ECG demonstrating >1-mm ST segment elevation in at least two 
contiguous limb leads or >2mm ST segment elevation in at least two contiguous chest leads 
or new left bundle branch block. Blood and the first 5ml bone marrow aspirate from the 
posterior iliac crest were collected from these individuals. Cohort 2: Controls were recruited 
as elective patients attending for non-coronary cardiac surgery. The main inclusion criteria 
were: no evidence of coronary disease requiring coronary artery bypass grafting on pre-
operative invasive or CT coronary angiography, normal pre-operative platelet count, Hb 
>8.5g/dl and no history or evidence on blood count of haematological malignancy. Blood and 
bone marrow scraping from sternotomy at the time of surgery were collected from these 
individuals. Out of 66 patients recruited in total 4 patients were recruited from the multicentre 
BAMI trial. These 4 individuals were excluded from analysis as slow recruitment to the BAMI 
trial meant that the numbers required for platelet and megakaryocyte transcriptional analysis 
were not achievable.   
 
As a result of this, the study design was modified, Cohort 1: Cases, these were recruited as 
patients admitted acutely with AMI defined as ischaemic chest pain and cardiac troponin rise, 
who then went on to have coronary artery bypass grafting. Therefore, these patients had an 
acute event on the background of progressive coronary artery disease.  Only patients with 
normal pre-operative platelet count, Hb >8.5g/dl and no history or evidence on blood count of 
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haematological malignancy were included. Blood and bone marrow scraping from sternotomy 
at the time of surgery were collected from these individuals. 
 
In total 66 patients provided informed consent for the BAMI Platelet Sub-study. 4 patients 
were recruited as BAMI trial patients and therefore excluded. 7 patients gave consent but 
samples were not taken due to logistical issues. There was not enough bone marrow material 
from 2 patients and these were therefore excluded. In 7 further patients, bone marrow 
material was used to optimise the protocol as described in Chapter 4. Blood and bone marrow 
material was collected from 46 individuals. Of these 19 were from Cohort 1: Cases and 27 
were from Cohort 2: Controls.  Baseline clinical characteristics were collected from each 
patient and all data was stored in an anonymised manner. 
 
2.1.2 Adult blood for haematological and platelet measurement 
 
Adult peripheral blood for haematological and platelet measurement was collected from all 
patients from whom bone marrow was also collected after informed consent and with ethical 
approval (as above). These were patients undergoing either urgent coronary artery bypass 
grafting following AMI or non-coronary cardiac surgery at Barts Health NHS Trust. Blood was 
collected after the patient had been anaesthetised into Vacutainer tubes: 4ml EDTA tube 
containing 1.8mg/ml K2EDTA (BD), 4ml serum tube (BD), 22ml into citrate tubes containing 
3.2% sodium citrate (BD). The samples were transported to the University of Cambridge at 
room temperature for further analysis. 
 
Adult peripheral blood from healthy volunteers was collected with ethical approval (REC East 
of England – Cambridge Central, 12/EE/0040, PI Prof. Willem Ouwehand, University of 
Cambridge) from Cambridge University Hospitals NHS Trust. This was used either for healthy 
platelet function as controls for the study patients or for isolation of mononuclear cells for 
optimisation of single cell RNA-seq library preparation. 
 
2.1.3 Adult bone marrow for megakaryocyte and HSC isolation 
 
2.1.3.1 Optimised method 
 
Adult bone marrow for megakaryocyte and HSC isolation was collected from patients 
undergoing either urgent coronary artery bypass grafting following AMI or non-coronary 
cardiac surgery at Barts Health NHS Trust after informed consent and with ethical approval 
REC (London – City & East) 13/LO/1760, PI Prof. Anthony Mathur, Queen Mary University of 
London). A sternal bone marrow scraping was taken after median sternotomy using a 
Volkmann’s spoon. The sample was collected into an EDTA Vacutainer tube containing 
1.8mg/ml EDTA. 4mL of Dulbecco’s phosphate buffered saline (PBS, Sigma) containing 10% 
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human serum albumin (HSA, Gemini Bio Products) was added and the whole volume was 
resuspended by pipetting 2-3 times. The sample was then put on metallic thermal beads 
(ThermoFisher Scientific) at a temperature between 0-4°C and transported to the University of 
Cambridge for further processing.  
 
2.1.3.2 Other trialled methods 
 
1. Bone marrow was taken as a 5mL aspirate from the posterior iliac crest from 4 patients 
who were originally recruited from the phase III multicentre BAMI trial. The 5mL aspirate was 
collected into an EDTA Vacutainer tube containing 1.8mg/ml EDTA. The sample was 
transported at room temperature to the University of Cambridge for further processing. These 
samples were removed from analysis as described in Section 2.1.1, as well as the poor yield 
of megakaryocytes from aspirates compared with bone marrow scrapings. 
 
2. Sternal bone marrow scraping was collected into an EDTA Vacutainer containing 1.8mg/ml 
EDTA and 4mL PBS with varying concentrations of HSA: 2%, 5% and 10%. 
 
3. Sternal bone marrow scrapings were collected into RNAlater (Ambion) and transported to 
the University of Cambridge for further processing. These samples could not be processed 
further due to cellular breakdown. 
 
2.1.3.3 Human bone marrow CD34+ cells for HSC isolation 
 
Cryopreserved human bone marrow CD34+ cells for HSC sorting and use in 
xenotransplantation experiments were purchased from Lonza, cat. 2M-101C (Lot no: 
0000500272, 0000312253, 0000312415). 
 
2.1.4 Adult blood for CD34+ cell isolation 
 
Adult peripheral blood cells from apheresis filter of healthy platelet donors belonging to the 
NHS Blood and Transplant, Cambridge were collected for CD34+ cell isolation. The blood 
donor consent procedure included the provision for such surplus materials to be used in an 
anonymised manner for research. After full platelet donation, the apheresis filter typically 
contained approximately the same number of blood mononuclear cells as 1 unit of blood (2-
5x109 mainly leucocytes).  
 
2.1.5 Animals used for megakaryocyte viability experiments 
 
Nbeal2+/- mice (heterozygous) (Wellcome Trust Sanger Institute) were used for harvesting of 
bone marrow for megakaryocyte viability experiments. As with human heterozygous carriers 
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of the NBEAL2 mutations, no phenotypic differences have been observed between wild-type 
mice and Nbeal2+/- mice. The mice were provided by Dr C Ghevaert’s Group, University of 
Cambridge (Nbeal2+/- mouse model was generated by the Wellcome Trust Sanger Institute). 
Animal experiments were performed in accordance to institutional guidelines approved by 
University of Cambridge Animal care committee. 
 
2.1.6 Animals used for xenotransplantation studies 
 
NOD/LtSz-scidIL2Rgnull mice (NSG) (Jackson Laboratory) were used for xenotransplant 
experiments. They were bred and housed at the Cancer Research Institute/Cambridge 
Institute for Medical Research animal care facility, Addenbrooke’s Hospital, University of 
Cambridge.  Animal experiments were performed in accordance to institutional guidelines 
approved by University of Cambridge Animal care committee. 
 
 
2.2 Whole blood measurements 
 
2.2.1 Platelet physical parameters 
 
Peripheral blood samples were collected into EDTA containing 1.8mg/ml K2EDTA. Platelet 
characteristics and haematological parameters were measured using an XE-5000 
haematology analyser (Sysmex) within 3 hours of blood collection. Along with the standard 
haematolgy parameters measured, the platelet parameters obtained from the analyser by 
measures of impedance included: platelet count (PLT, 109/L), plateletcrit (PCT, %) a measure 
of total platelet mass, mean platelet volume (MPV, fL) calculated as plateletcrit divided by 
platelet count, platelet distribution width (PDW, fL) the width of platelet size distribution, 
platelet large cell ratio (P-LCR, %) the ratio of platelets falling above the 12fL size cut-off. 
Finally, immature platelet fraction (IPF, %) was also measured. The analyser utilises 
automated flow cytometry and polymethine and oxazine fluorescent dyes that label nucleic 
acids thereby identifying RNA-containing  (reticulated) platelets. 
 
2.2.2 Platelet function 
 
Platelet activation and function work was performed in collaboration with Dr K Downes group, 
Department of Haematology, University of Cambridge. 
 
Platelet activation and function were measured by flow cytometry in whole blood collected in 
3.2% sodium citrate. Blood was processed at exactly 4 hours after collection. 5uL 10mM 
Aspirin (Sigma) and 5uL 1000U/mL hirudin (Sigma) were added to 500uL citrated whole 
blood. 5uL of this was added to 45uL of Hepes Buffered Saline (HBS) containing either 1. 
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3ug/ml crosslinked collagen related peptide (CRP-XL, gift from Richard Farndale, 
Biochemistry, University of Cambridge NHS Trust)/4U/mL apyrase (Sigma) or 2. 5uM 
adenosine diphosphate (ADP, Sigma) or 3. 8uM thrombin receptor activating peptide (TRAP-
6, Tocris)/4U/mL apyrase and either FITC–anti fibrinogen (Dako) or PE–anti-CD62P (P-
selectin, IBGRL Research Products, Bristol). Samples were incubated for 20 min at room 
temperature with and the reaction was stopped by 100-fold dilution in formyl saline (0.2% 
formaldehyde/0.9% NaCl, Sigma). Negative controls for the P-selectin antibodies were set 
using an appropriate isotype control and for the anti fibrinogen using samples incubated with 
the antibody in the presence of 10mM EDTA. [HBS: 150mM NaCl (Sigma), 5mM KCl (AnalaR 
BDH), 1mM MgSO4.7H20 (AnalaR BDH), 10mM Hepes (Sigma)]. 
 
Flow cytometric analysis was carried out on a FC500 flow cytometer (Beckman-Coulter Ltd). 
Platelets were identified by light scatter, and data was displayed as a histogram of 
fluorescence intensity against count and a threshold was set on the flow cytometer at 1% 
using platelets labelled with the respective PE and FITC negative control. Platelet activation 
was measured by resting surface expression of P-selectin. Platelet function results were 
recorded as the percentage of platelets positive for the relevant activation marker after 
incubation normalised for resting activation levels. All tests were performed in duplicate, and 
the average result were used for analysis. 
 
 
2.3 Cell isolation 
 
2.3.1 Isolation of platelets from peripheral blood 
 
To isolate platelets free from contaminating white blood cells a leucodepletion strategy was 
used, involving centrifugation steps to isolate platelet rich plasma (PRP) and anti-CD45 
magnetic beads were applied. 
 
22ml whole blood taken in 3.2% citrate vacutainer tubes. These were centrifuged at 150g for 
20 minutes with the brake off. The upper layer (PRP) was harvested and transferred to a 
fresh 15ml Falcon tube and centrifuged at 150g for 10minutes. The PRP layer was removed 
and transferred again to fresh 15ml Falcon tube and centrifuged for a third time at 150g for 
10minutes. The PRP layer was removed and mixed at room temperature for 20 minutes with 
50ul CD45 Dynabeads (Life technologies) per 2ml PRP. The Dynabeads had been washed in 
2ml PBS. White cells bound to the CD45 beads were then captured by placing the 15ml 
Falcon tube in a magnetic rack. The leucodepleted PRP was then harvested into a new 15ml 
Falcon tube and the platelets were pelleted by centrifugation at 1500g for 10 minutes. The 
supernatant was carefully discarded and the platelets were lysed with the addition of 1ml 
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Trizol reagent (Life Technologies) and stored at -80°C ahead of RNA extraction (Section 
2.3.5). 
 
2.3.2 Isolation of mononuclear cells from peripheral blood 
 
This was performed for 2 purposes: 1. For isolating CD34+ cells for megakaryocyte cultures 
(from apheresis filters of platelet donors), 2. For testing and optimising the single cell RNA-
seq library preparation method (Whole blood from volunteers).  
 
Blood was processed within 18 hours of collection. Adult blood from apheresis filters was 
diluted 1:20 with PBS, containing 1% Human Serum Albumin (HSA, Gemini Bioproducts) and 
100mM trisodium citrate (Sigma). Whole peripheral blood was diluted 1:1 with PBS containing 
1% HSA and 100mM trisodium citrate. This diluted blood was layered over Ficoll-Paque Plus 
(GE Healthcare), centrifuged at 800g for 15 minutes and the mononuclear cell layer 
recovered and washed.  
 
2.3.3 Isolation of megakaryocytes from human bone marrow 
 
2.3.3.1 Optimised method: Isolation of megakaryocytes by FACS  
 
Processing of clinical bone marrow took place 2-3 hours after harvest. The cellular content 
was flushed out of the bone marrow using PBS containing 1.2% HSA, 2mM EDTA (Sigma) 
and the red cells were lysed using ammonium chloride lysis.  
 
The cells were stained for surface megakaryocyte markers with mouse anti-human CD41a 
APC conjugated antibody (BD) and mouse anti-human CD42b PE conjugated antibody (BD) 
and for ploidy analysis with 1ug/ml Hoechst 33342 (Invitrogen). Hoechst DNA stain was used 
for ploidy quantification rather than other DNA stains such as 4',6-Diamidino-2-Phenylindole 
(DAPI) due to its ability to stain nuclear DNA without disrupting the cell or nuclear membrane 
and without the requirement for cell fixation which would prohibit the transcriptional analysis. 
After incubation at 37°C for 30 minutes the cells were kept at 4°C before sorting using a 
FACS Aria Fusion flow sorter (BD). Due to fragility cells were only centrifuged once at 120g 
for 8 minutes with the brake off. Megakaryocytes were FACS sorted approximately 5 hours 
after harvest. 
 
Single cells and megakaryocyte pools of 20-100 cells (hereafter multicellular pools) were 
sorted by FACS using a 100uM nozzle directly into individual wells of a 96-well plate each 
containing 2.5ul lysis buffer/well: 950uL RLT Plus buffer (Qiagen) and 50ul 20U/ul SUPERase 
In RNase inhibitor (Ambion) and stored at -80°C until library preparation. Due the time taken 
for single cell FACS and 100uM nozzle FAC sorting took place over approximately 3 hours. 
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Flow cytometry data for all samples was collected including frequency of megakaryocytes 
(defined as CD41+CD42+Hoechst+), frequency of 2n, 4n, 8n 16n, 32n cells. FACS sorting 
also allowed both single cell and multicellular pools to be collected according to ploidy level. 
 
2.3.3.2 Other trialled methods 
 
1. Density centrifugation of megakaryocyte population from bone marrow aspirates/scraping 
Whole bone marrow either aspirate or cellular content of scraping was diluted 1:1 with PBS 
containing 3% HSA, 75mM trisodium citrate, 5mM EDTA (Sigma) and mixed with Percoll 
(Sigma) to a final density of 1.020g/ml. This was then layered over Percoll at a density of 
1.050g/ml and over layered with PBS containing 0.15% HSA, 75mM trisodium citrate, 5mM 
EDTA. Following centrifugation at 400g for 20 minutes, the upper layer was removed and 
discarded. The middle Percoll layer and the cells at the lower interface were recovered and 
washed at 120g for 8 minutes.  
While this provided an enriched population of megakaryocytes, it was not pure. Following 
Percoll separation it was then possible to sort cells by FACS into lysis buffer and store at -
80°C until library preparation, however the time delay in sorting cells into lysis buffer and the 
cell loss due to processing was not thought to be ideal. 
 
2. Cell picking  
Individual megakaryocytes were picked under a x40 objective inverted light microscope using 
a glass pipette mounted on a micromanipulator and deposited into lysis buffer and stored at -
80°C until library preparation. This was trialled from whole bone marrow and from Percoll 
enriched megakaryocyte populations.  
The limitation of this method was low cell output. Despite competency and speed in cell 
picking it could take 2-4 hours to pick 96 single megakaryocytes. Furthermore, 
megakaryocytes were identified only on the basis of cell size relative to neighbouring cells 
and it was not possible to gain any ploidy information. 
 
3. Staining whole bone marrow for FACS sorting without red cell lysis 
A side-by-side analysis was made between whole bone marrow FACS with or without red cell 
lysis. The benefits of not performing red cell lysis including one less processing step thereby 
leaving the cells as undisturbed as possible and saving approximately 10minutes in 
processing time before taking bone marrow to be sorted. However, the overwhelming 
numbers of contaminating red cells at the sort prolonged the sort time by approximately 100% 
compared with the bone marrow that underwent red cell lysis. The overall numbers of 
megakaryocytes were the same in both, the ploidy distribution was the same and there were 
no differences in the quality of cDNA reverse transcribed at the single cell RNA-seq library 
preparation stage. Therefore, a red cell lysis step remained in the optimised method. 
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4. Isolation of megakaryocytes 1 day or more after bone marrow harvest 
Due to logistical issues this was trialled, however it was felt that due to low input rather than 
bulk RNA-seq, a time delay in sorting cells into lysis buffer might compromise sequencing 
quality. Therefore, bone marrow was processed as soon as logistically possible after harvest 
(within 2-3 hours, cells sorted into lysis buffer between 5-8 hours). 
 
5. Use of different cell lysis buffers 
A number of different lysis buffers were trialled to optimise quality of cDNA produced at the 
single cell RNA-seq library preparation stage. A total volume of 2.5uL/well was used. 
1. Smart-seq2 (Picelli2014): 950uL 0.2% Triton X-100 (Sigma) and 50ul 2U/ul Recombinant 
RNase inhibitor (Clontech). Good quality cDNA from peripheral blood mononuclear cells, 
K562 cell line and cultured megakaryocytes at the single cell RNA-seq library preparation 
stage. cDNA from bone marrow megakaryocytes was degraded. 
2. Smartseq2 lysis buffer modification: 950uL 0.2% Triton X-100 (Sigma) and 50ul 20U/ul 
SUPERase In RNase inhibitor (Ambion). Good quality cDNA from peripheral blood 
mononuclear cells, K562 cell line and cultured megakaryocytes at the single cell RNA-seq 
library preparation stage. cDNA from bone marrow megakaryocytes was degraded. 
3. Smartseq2 lysis buffer modification: 950uL 0.5% NP-40 (Sigma) and 50ul 20U/ul 
SUPERase In RNase inhibitor (Ambion). Poor quality cDNA produced for all cell types trialled 
at the single cell RNA-seq library preparation stage. 
4. G&T-seq (Macaulay et al. 2015): 950uL RLT Plus buffer (Qiagen) and 50ul 20U/ul 
SUPERase In RNase inhibitor (Ambion). Good quality cDNA produced from bone marrow 
megakaryocytes at the single cell RNA-seq library preparation stage. This was therefore used 
in the optimised method. 
 
2.3.3.3 Megakaryocyte imaging 
 
Bone marrow smears were produced for each bone marrow sample. To analyse the enriched 
bone marrow megakaryocyte population, Cytospins were produced on glass slides (Thermo 
Scientific) or the cell suspension was allowed to settle for 1 hour at 37°C on Polysine 
microscope adhesion slides (Thermo Scientific) within an area drawn using a water-repellent 
pen (Dako). To analyse cultured megakaryocyte morphology, Cytospins were generated on 
glass slides on the day of the culture harvest.  
 
To assess cell morphology, slides were stained with Rapid Romanowsky stain (TCS 
Biosciences) and observed by light microscopy.  
 
Immunofluorescent staining of the enriched bone marrow megakaryocyte population was 
performed using a VWF surface stain and a 4',6-Diamidino-2-Phenylindole (DAPI) DNA stain. 
The slide was fixed with 2% paraformaldehyde, washed with PBS containing 0.01% tween 
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and then stained with a 1/200 dilution of the primary antibody: unconjugated rabbit anti-
human VWF antibody (Abcam). The slide was washed and stained with a 1/500 dilution of the 
secondary antibody: FITC conjugated donkey anti-rabbit antibody (Abcam). After a further 
washing the slide was mounted with DAPI mounting media (VectaShield) and a coverslip. The 
slide was then analysed on an immunofluorescent microscope. 
 
2.3.3.4 Megakaryocyte viability experiments using mouse bone marrow 
 
Viability of ex-vivo megakaryocytes was examined in mouse bone marrow from Nbeal2+/- 
(heterozygous) male mice, 2-4 months old. 2 mice were sacrificed for harvesting of bone 
marrow. Bone marrow was flushed out of 2 femurs from each mouse into either: CATCH 
medium (Calcium and magnesium free Hanks balanced salt solution (Gibco), 2.9mM sodium 
citrate (Sigma), 1.4mM adenosine (Sigma), 2.7mM theophylline (Sigma), 3.5% bovine serum 
albumin (Sigma), 1ug/ml apyrase (Sigma), 1ug/ml PGE1 (Sigma)) or PBS with 10% HSA at 
either room temperature or on ice. Conditions of the experiment included room 
temperature/on ice and readouts at different time points up to 10 hours post bone marrow 
harvests. The following cell stains were used to assess viability: 
1. 0.4% Trypan Blue (Sigma): cell aliquot stained 1:1, observed under x10 objective light 
microscope, live cells counted, megakaryocytes were identified by size. Impermeable dye 
excluded by live cells. 
2. 7-AAD (Life Technologies): cells stained with 7AAD (cross over with PerCPCy5.5 488/695), 
and APC conjugated anti-CD41(BD)/Hoechst to identify megakaryocytes. Impermeable dye 
excluded by live cells. Flow cytometric analysis was carried out on a Gallios flow cytometer 
(Beckman-Coulter).  
3. PI (BD): cells stained with PI (cross over with PerCPCy5.5 488/695), and APC conjugated 
anti-CD41/Hoechst to identify megakaryocytes. Impermeable dye excluded by live cells. Flow 
cytometric analysis was carried out on a Gallios flow cytometer (Beckman-Coulter).  
4. Zombie Far Red (Life Technologies): cells stained with Zombie Far Red (cross over with 
APC 633/660), and PE conjugated anti-CD41(BD)/Hoechst to identify megakaryocytes. 
Impermeable dye excluded by live cells. Flow cytometric analysis was carried out on a Gallios 
flow cytometer.  
5. Calcein (Life Technologies) cells stained with Calcein (cross over with FITC 488/525), and 
APC conjugated anti-CD41/Hoechst to identify megakaryocytes. Actively taken up by living 
cells due to intracellular esterase activity, excluded by dead cells. Flow cytometric analysis 







2.3.4 Isolation of HSCs from human bone marrow 
 
2.3.4.1 HSCs from clinical human bone marrow samples 
 
Processing of clinical bone marrow occurred 2-3 hours after harvest. The cellular content was 
flushed out of the bone marrow using PBS containing 1.2% HSA, 2mM EDTA (Sigma) and 
the red cells were lysed using ammonium chloride lysis.  
 
In order to identify the HSC population as defined as: Lineage-, CD34+, CD38-, CD45RA-, 
CD90+, CD49f+ and measure surface expression of VWF, cells were stained with the 
following antibody cocktail: 
 
PECy5 conjugated anti-lineage specific antibodies: CD2 (BD), CD3 (BD), CD10 (BD), CD11b 
(BD), CD11c (BD), CD19 (BD), CD20 (BD), CD56 (BD), biotinylated CD42b (Pab5, NHS 
Blood and Transplant, International Blood Group Reference Laboratory [IBGRL]) and 
biotinylated GP6 (Pab5, NHS Blood and Transplant, International Blood Group Reference 
Laboratory [IBGRL]) both used in combination with PECy5 conjugated streptavidin 
(Biolegend). 
Alexa Fluor 700 conjugated anti-CD34 (BD) 
PerCP-Cy5.5 conjugated anti-CD38 (BD) 
Pacific Blue conjugated anti-CD45RA (Invitrogen) 
PECy7 conjugated anti-CD90 (BD) 
PE conjugated anti-CD49f (BD) 
FITC conjugated anti-VWF (Abcam) 
 
Stained cells were kept at 4°C and sorted using a FACS Aria instrument (BD). Single HSCs 
defined as Lineage-, CD34+, CD38-, CD45RA-, CD90+, CD49f+ cells were sorted by FACS 
directly into individual wells of a 96-well plate each containing 2.5ul lysis buffer/well: 950uL 
RLT Plus buffer (Qiagen) and 50ul 20U/ul SUPERase In RNase inhibitor (Ambion) and stored 
at -80°C until library preparation. Index sort data was collected for each single cell (Osborne 
2011).   
 
2.3.4.2 HSCs from purchased human bone marrow CD34+ cells (Lonza) 
 
Cryopreserved vials of human bone marrow CD34+ cells purchased from Lonza were used to 
isolate HSCs for xenotransplantation experiments. These were thawed in a waterbath set at 
37°C and thawing media consisting of PBS with 5% foetal calf serum (FCS, Gibco) at 37°C 
was added drop by drop to make up to a 1:10 cell dilution. Cell from 3 vials were combined at 
this stage and centrifuged at 500g for 5minutes at room temperature followed by 
resuspension in 150ul PBS/5%FCS. The cells were then stained as described in Section 
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2.3.4.1 with the addition of the viability stain Zombie Aqua (LifeTechnologies): 
excitation/emission: 405/516. 
 
Stained cells were kept at 4°C and sorted using a FACS Aria instrument (BD). Single HSCs 
defined as viable, Lineage-, CD34+, CD38-, CD45RA-, CD90+, CD49f+ cells were sorted by 
FACS directly into 2 Eppendorf tubes each containing 500ul PBS/5%FCS. VWF+ HSCs were 
FACS sorted into 1 Eppendorf tube and VWF- HSCs were sorted into the other ahead of 
transplantation into 10 sub lethally irradiated mice. 
 
2.3.5 Cultured cells 
 
2.3.5.1 K562 culture 
 
Cells from the lymphoblastic cell line K562 (ATCC) were maintained at 37°C in RPMI media 
1640 (Sigma) containing 10% foetal bovine serum (Sigma), 500µl Tylosin solution (Sigma) 
and 6ml MEM Amino acids with L-Glutamine (Sigma). For the purposes of testing and 
optimising the single cell RNA-seq library preparation method, they were washed 
resuspended in media and were manually picked into lysis buffer and stored at -80°C until 
library preparation. 
 
2.3.5.2 Megakaryocyte culture from adult blood CD34+ cells 
 
CD34+ cells were isolated from adult blood mononuclear cells using the human CD34 
isolation kit (Miltenyi) with an autoMACS separator (Miltenyi). To generate megakaryocytes, 
CD34+ cells were cultured for 10 days in CellGro (CellGenix) and supplemented with 
100ng/ml TPO (CellGenix) and 10ng/ml IL1β(R&D). For each experiment, cells were seeded 
in suspension plates at 1 x105 cells/ml. Media and cytokines were rejuvenated at days 3 and 
6. At day 10 cells were counted and harvested. Mature megakaryocytes were immunopurified 
using a mouse anti-human CD42b PE conjugated antibody (Pab5, NHS Blood and 
Transplant, International Blood Group Reference Laboratory [IBGRL]) and a PE-positive 
selection kit. Cells were lysed using TRIzol reagent (Life Technologies) and stored at -80°C 
ahead of RNA extraction, library preparation and RNA-seq. A small sample was also taken for 
morphological characterisation and flow cytometry. 
 
2.3.6 RNA extraction 
 
For bulk RNA-seq of using Poly-A selection for both cultured megakaryocytes and platelets as 
well as rRNA depletion for platelets, cells were lysed in TRIzol reagent and stored at -80°C 
prior to library preparation. RNA was then extracted from TRIzol reagent as per 
manufacturer’s instructions. Briefly, each sample was brought to room temperature and the 
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RNA was separated using 0.2ml chloroform (Sigma) per 1ml TRIzol and centrifugation in a 
phase-lock tube (Eppendorf). RNA was precipitated by adding 10ug RNase-free glycogen 
(Invitrogen) and 0.5ml 100% isopropanol (Sigma) and centrifugation. The RNA was washed 
twice with 1ml 70% ethanol (Sigma), allowed to air-dry and then resuspended in RNase-free 
water. The sample was then stored at -80°C until library preparation. 1µl was used for 
accurate RNA quantification using the Qubit 2.0 Fluorometer (Invitrogen) and Qubit RNA 
assay kit (Invitrogen). 1µl was used for checking the quality of the sample using the Agilent 
2100 Bioanalyzer (Agilent Technologies) and the Agilent RNA 6000 Pico Kit (Agilent 
Technologies) using the RNA integrity number (RIN). 
 
In the process of optimising the single cell RNA-seq library preparation method, the Single 
Cell RNA Purification Kit (Norgen Biotek) was trialled as per manufacturer’s instructions for 
single, 20, 50 and 100 peripheral blood mononuclear cells that had been FACS sorted. 
Briefly, each sample was sorted into wells containing 100ul lysis buffer provided with the kit. A 
further 100ul of 70% ethanol was added and this volume applied to 2 columns with a final 
elution step.  
 
 
2.4 Analysis of gene expression 
 
2.4.1 Poly(A) RNA-seq library preparation for bulk cultured megakaryocytes  
 
Non-strand specific poly(A) RNA libraries were prepared using the SMARTer Ultra Low Input 
RNA for Illumina Sequencing – HV kit (Clontech) following manufacturer’s instructions. This 
was used for cultured megakaryocytes. 
 
The input RNA quantity was 10ng. ERCC Spike-In RNA (Ambion) was added to provide 
artificial transcripts of known concentrations for RNA-seq analysis (Loven et al. 2012) at a 
concentration of 1:1000.  
 
First strand cDNA synthesis was performed by adding 5xfirst strand buffer, 100mM DTT, 
20mM dNTP mix, the Smarter transcript switching oligo, RNase inhibitor and Smartscribe 
reverse transcriptase according to the manufacturer’s instructions and incubating at 42°C for 
90min and the 70°C for 10min.  A 1:1 Ampure XP (Beckman Coulter) bead clean-up was 
performed.  The Advantage 2 PCR kit was used to perform global amplification of the cDNA 
by PCR by adding 10x Advantage 2 PCR buffer, Smart PCR primer, 10nM dNTP mix and the 
50x Advantage 2 polymerase mix according to manufacturer’s instructions. The PCR reaction 
consisted of heating to 95°C for 1 min, 14 PCR cycles (95°C/15 s, 65°C/30 s, 68°C/6 min) 
and incubation at 72°C for 10 min. A 1:1 Ampure XP (Beckman Coulter) bead clean-up was 
performed on the PCR product. The resultant product was quantified using the Qubit 2.0 
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Fluorometer and a Qubit High Sensitivity DNA assay kit (Invitrogen). This was followed by 
assessment of size distribution using an Agilent high-sensitivity DNA chip (Agilent 
technologies). 
 
RNA-seq libraries were prepared from 1ng of amplified cDNA using the Nextera XT DNA 
sample preparation kit (Illumina). This included a tagmentation step and 14 cycle PCR 
amplification of adapter-ligated fragments. Thereafter, a final 1:1 Ampure XP bead clean-up 
was performed. Final library concentrations were quantified by real-time quantitative-
polymerase chain reaction (RT qPCR) using a KAPA Library Quantification kit (KAPA 
Biosystems) according to manufacturer’s instructions. Each library was checked for fragment 
length using an Agilent High Sensitivity DNA chip prior to RNA-seq. 
 
2.4.2 Poly(A) RNA-seq library preparation for Smart-seq 2  
 
RNA libraries were prepared according to the published Smart-seq 2 protocol (Picelli et al. 
2014). This method was designed to produce full length non-strand specific poly(A) RNA 
libraries from single cells and low input purified RNA and is a modification of the SMARTer 
Ultra Low Input RNA for Illumina Sequencing kit described in Section 2.4.1.  
 
The input RNA quantity was 1ng and the volume made up to 2.5ul. ERCC Spike-In RNA was 
added to this in a dilution of in a dilution of 1:4,000,000. After hybridisation with 1ul oligo-dT 
primer: 5’-biotin-triethyleneglycol-AAGCAGTGGTATCAACGCAGAGTACT30VN-3’ where V is 
A/C/G and N is any base (IDT) and 1ul 10mM dNTP (Thermo Scientific) at 72°C for 3 min, the 
reverse transcription mix was added for first strand cDNA synthesis. The reverse transcription 
mix included: 0.5ul 200U/µl SuperScript II reverse transcriptase (Life technologies), 0.25ul 
20U/ul SUPERase In RNase inhibitor, 2ul 5x Superscript II First-Strand Buffer (Life 
technologies), 0.5ul 100mM DTT (Life technologies), 2ul 5M betaine (Sigma), 0.06ul 1M 
MgCl2 (Life technologies), 0.1ul 100mM Template-Switching Oligo: 5’-AAGCAGTGGTAT 
CAACGCAGAGTACrGrG+G-3’ where rG is a  ribo-guanosine and +G is a locked nucleic 
modified guanosine (Exiqon) and 5.70ul nuclease free water.  cDNA first strand synthesis was 
performed by incubating at 42°C for 90 min, followed by 10 cycles (50°C/2 min, 42°C /2 min) 
and 70°C for 15 min. 
 
Global amplification of the cDNA by PCR was then performed by adding PCR mastermix 
consisting of: 12.5ul 2x KAPA HiFi HotStart ReadyMix (KAPA Biosystems), 0.25ul 10mM 
Smart PCR primer: 5 ′ -AAGCAGTGGTATCAACGCAGAGT-3 ′  (Biomers) and 2.25ul 
nuclease-free water to the reverse transcription reaction mixture. The PCR reaction consisted 
of heating to 98°C for 3 min, 20 PCR cycles (98°C/20 s, 67°C/15 s, 72°C/6 min) and 
incubation at 72°C for 5 min. A 1:1 Ampure XP (Beckman Coulter) bead clean up was 
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performed on the PCR product. This was followed by assessment of size distribution using an 
Agilent high-sensitivity DNA chip (Agilent technologies). 
 
RNA seq libraries were prepared from between 0.5 and 10ng of amplified cDNA using the 
Nextera XT DNA sample preparation kit (Illumina). Including a tagmentation step and 12 cycle 
PCR amplification of adapter-ligated fragments. Thereafter, a final 1:1 Ampure XP bead clean 
up was performed on each sample. Final library concentrations were quantified by real-time 
quantitative-polymerase chain reaction (RT qPCR) using a KAPA Library Quantification kit 
(KAPA Biosystems) according to manufacturer’s instructions on the StepOnePlus system 
(Applied Biosystems). Each library was checked for fragment length using an Agilent High 
Sensitivity DNA chip prior to RNA-seq. 
 
2.4.3 Poly(A) RNA-seq library preparation for G&T-seq 
 
Single cells or mini-bulk samples (1-100 cells) were sorted into individual wells of a 96-well 
plate each containing 2.5ul lysis buffer/well: 950uL RLT Plus buffer (Qiagen) and 50ul 20U/ul 
SUPERase In RNase inhibitor (Ambion) and stored at -80°C until library preparation.  
 
ERCC spike-in RNA (Ambion) was added to the lysis buffer in a dilution of 1:4,000,000. cDNA 
synthesis and poly(A) enrichment was performed following the G&T-seq protocol (Macaulay 
et al. 2015), a variation of the Smart-seq2 protocol (Picelli et al. 2014). Using this protocol 
genomic DNA and mRNA were separated; the genomic DNA stored and the mRNA amplified. 
Briefly, streptavidin-coupled magnetic beads (Dynabeads, Life technologies) were conjugated 
to the biotinylated oligo-dT primer: 5’-biotin-triethyleneglycol-AAGCAGTGGTATCAACGC 
AGAGTACT30VN-3’ where V is A/C/G and N is any base (IDT) according to manufacturer’s 
instructions. Initial separation of DNA and RNA was performed using a Biomek FXP 
Laboratory Automation Workstation (Beckman Coulter). 10ul conjugated beads were added to 
the cell lysate and incubated for 20minutes at room temperature with continual mixing. This 
allowed the pull down of the polyadenylated mRNA. The mRNA bound to streptavidin beads 
was then magnetised to the side of the well and the genomic DNA containing supernatant 
was transferred to a different plate. The beads were further washed 4 times at room 
temperature with a wash buffer consisting of 50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM 
MgCl2, 10 mM DTT (Life technologies), 0.5% Tween-20, 0.1x 20U/ul SUPERase In RNase 
inhibitor.  
 
After this either the Superscript II or the Smartscribe reverse transcription (RT) mix (10ul) was 
added to the beads. Common to both mixes were: 0.25ul 20U/ul SUPERase In RNase 
inhibitor, 2ul 5M betaine (Sigma), 0.06ul 1M MgCl2 (Life technologies), 1ul 10mM dNTP mix 
(Thermo Scientific) and 1ul 100mM Template-Switching Oligo: 5’-AAGCAGTGGTAT 
CAACGCAGAGTACrGrG+G-3’ where rG is a  ribo-guanosine and +G is a locked nucleic 
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modified guanosine (Exiqon). The Superscript II RT mix also contained: 0.5ul 200U/ul 
Superscript II reverse transcriptase (Life technologies), 2ul 5x Superscript II First-Strand 
Buffer (Life technologies), 0.5ul 100mM DTT (Life technologies) and 3.59ul nuclease-free 
water (Life Technologies). The Smartscribe RT mix also contained: 1ul Smartscribe reverse 
transcriptase (Clontech), 2ul 5x Smartscribe First-Strand Buffer (Clontech), 1ul 20nM DTT 
(Clontech) and 2.59ul nuclease-free water. cDNA first strand synthesis was performed by 
incubating at 42°C for 60 min, followed by 50°C for 30 min and 60°C for 10 min with mixing on 
a Thermomixer (Eppendorf). 
 
Global amplification of the cDNA by PCR was then performed by adding PCR mastermix 
consisting of: 12.5ul 2x KAPA HiFi HotStart ReadyMix (KAPA Biosystems), 0.25ul 10mM 
Smart PCR primer: 5 ′ -AAGCAGTGGTATCAACGCAGAGT-3 ′  (Biomers) and 2.25ul 
nuclease-free water to the reverse transcription reaction mixture. The PCR reaction consisted 
of heating to 98°C for 3 min, 22 PCR cycles (98°C/20 s, 67°C/15 s, 72°C/6 min) and 
incubation at 72°C for 5 min. A 1:1 Ampure XP (Beckman Coulter) bead clean-up was 
performed on the PCR product. This was followed by assessment of size distribution using an 
Agilent high-sensitivity DNA chip (Agilent technologies) and expression of selected transcripts 
was also examined at this stage using Taqman real-time PCR (Section 2.4.6). 
 
RNA seq libraries were prepared from between 0.5 and 10ng of amplified cDNA using the 
Nextera XT DNA sample preparation kit (Illumina). Including a tagmentation step and 12 cycle 
PCR amplification of adapter-ligated fragments. Thereafter, samples from each 96 well plate 
were pooled using 3ul of PCR product from each sample and a 1:1 Ampure XP bead clean-up 
was performed. Final library concentrations were quantified by real-time quantitative-
polymerase chain reaction (RT qPCR) using a KAPA Library Quantification kit (KAPA 
Biosystems) according to manufacturer’s instructions on the StepOnePlus system (Applied 
Biosystems). Each library was checked for fragment length using an Agilent High Sensitivity 
DNA chip prior to RNA-seq. 
 
2.4.4 Ribosomal RNA depleted RNA-seq library preparation for platelets 
 
Strand specific ribosomal RNA depleted libraries were prepared using the KAPA Stranded 
RNA-seq kit with Riboerase (Kapa Biosystems) following manufacturer’s instructions.  
 
The input RNA quantity was 50ng in a volume of 10ul. After hybridisation with 10ul 
hybridisation oligonucleotides designed to bind to rRNA at 95°C for 2 min the reaction mix 
was treated with 5ul RNaseH mix to remove rRNA, a 2.2x Ampure XP bead clean up and 22ul 
DNase mix to remove hybridisation oligonucleotides followed by a second 2.2x Ampure XP 
bead clean up. The RNA was then eluted from the beads and fragmented by incubation at 
high temperature before first strand synthesis with 9ul first strand synthesis buffer and 1ul 
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KAPA script provided in the kit. cDNA first strand synthesis was performed by incubating at 
25°C for 10 min, followed by 42°C for 15 min and 70°C for 15 min. 30ul second strand 
synthesis buffer was then added for a further incubation at 16°C for 60 min converting the 
cDNA:RNA hybrid to double stranded cDNA followed by a 1.8x Ampure XP bead clean up. 
30ul A-tailing master mix including the A-tailing enzyme was then added to the beads with 
cDNA and incubated at 30°C for 30 min and 60°C for 30 min in order to add dAMP to the 3’ 
ends of the cDNA library fragments. 30ul adapter ligation master mix including DNA ligase 
enzyme and adapters (TrueSeq LT) was then added where double stranded adapters with a 
3’ dTMP overhang are ligated to the A-tailed library. This was followed by two 1:1 Ampure XP 
bead clean ups.  
 
Global amplification of the cDNA by PCR was then performed by adding PCR mastermix 
consisting of: 25ul 2x KAPA HiFi HotStart ReadyMix, 5ul 10x KAPA Library Amplification 
Primer mix. The PCR reaction consisted of heating to 98°C for 45 s, 14 PCR cycles (98°C/15 
s, 60°C/30 s, 72°C/30 s) and incubation at 72°C for 5 min. A 1:1 Ampure XP (Beckman 
Coulter) bead clean-up was performed on the PCR product. This was followed by assessment 
of size distribution using an Agilent high-sensitivity DNA chip (Agilent technologies). 
 
Final library concentrations were quantified by real-time quantitative-polymerase chain 
reaction (RT qPCR) using a KAPA Library Quantification kit (KAPA Biosystems) according to 
manufacturer’s instructions. Each library was checked for fragment length using an Agilent 




The libraries were sequenced at the Cancer Research Institute sequencing facility on the 
Addenbrooke’s campus. 150 base pair (bp) paired-end sequencing was performed on the 
Illumina HiSeq 4000 instrument using TruSeq reagents (Illumina), according to 
manufacturer’s instructions. 
 
2.4.6 Taqman Real-time qPCR 
 
The expression of selected transcripts was quantified from 1 to 5ng of amplified cDNA PCR 
product prior to Nextera XT library preparation in methods 2.4.2 and 2.4.4 by performing 
Taqman Real-time qPCR. TaqMan Fast Advanced Master Mix (Applied Biosystems) and the 
listed transcript Taqman probes (Applied Biosystems) were used to perform real-time PCR 
reactions over 40 cycles according to manufacturer’s instructions on the StepOnePlus 
system. At least 2 technical replicates for each sample were performed. 
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Selected transcript probes included: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
Hs02758991_g1), Beta-2-microglobulin (B2M, Hs00187842_m1), von Willebrand factor 
(VWF, Hs01109446_m1), Mitochondrial genome encoded 16S RNA (MT-RNR2, 






As described in Section 2.3.4.2 cryopreserved vials of human bone marrow CD34+ cells 
purchased from Lonza were used to isolate HSCs for xenotransplantation experiments using 
FACS. Single HSCs defined as viable, Lineage-, CD34+, CD38-, CD45RA-, CD90+, CD49f+ 
cells were sorted as either VWF+ or VWF- prior to transplantation. 1653 VWF+ HSCs were 
sorted by FACS, 138,386 VWF- HSCs were sorted by FACS. Cells were centrifuged at 600xg 
for 5min. 
 
All mouse work was performed in collaboration with Dr E Laurenti’s group, University of 
Cambridge. 12-week-old mice were sub lethally irradiated (2.40 Gy) 24 hr before transplant. 
Prior to transplantation, mice were temporarily sedated with isoflurane. A 27g needle was 
used to drill the right femur and cells were transplanted in a 25mL volume using a 28.5g 
insulin needle. 8 mice were transplanted with 400 cells (4 mice: VWF+ HSCs; 4 mice: VWF-
HSCs), 2 mice were transplanted with 68,000 VWF-HSCs, 1 mouse was not transplanted and 
kept as a control. 
 
At 16 weeks after transplantation all mice were sacrificed and the right and left femur and 
tibiae and peripheral blood were analysed for human cell engraftment. Cells were stained in 
PBS/2% FBS and analysed by flow cytometry (LSRII, Becton Dickinson). The marrow and 
blood was analysed with GlyA PE (Beckman Coulter, clone 11E4B-7-6 [KC16]): marker of 
erythroid cells; CD45 PeCy5 (Beckman Coulter, clone J33), CD45 BV510 (BD): marker of 
leucocytes; CD3 APCCy7 (BD): marker of T cells; CD19 FITC (BD), CD19 AF700 (BD): 
marker of B cells; CD14 PeCy7 (Beckman Coulter, clone RMO52), CD33 APC (BD, clone 
P67.6): markers of myeloid cells. A small aliquot was also stained with CD41 APC (BD), 
CD42 PE (BD) and Hoechst to identify megakaryocytes in the bone marrow. 
 
 
2.6 Clinical statistics 
 
Clinical data were analysed using Students T-test for comparison of means between two 
groups and ANOVA was used for multiple means testing. Correlations were performed using 
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the Spearman rank method. All calculations were performed using Graphpad Prism software 
(version 5.0). Statistical significance was taken to be p<0.05. 
 
 
2.7 RNA-seq analysis 
 
Up to the point of functional analysis, single cell and low input RNA-seq data was analysed by 
Dr Frederik Bagger, European Bioinformatics Institute, Hinxton and platelet RNA-seq data 
was analysed by Dr Romina Petersen and Dr Luigi Grassi, Department of Haematology, 
University of Cambridge. 
 
Paired-end reads were trimmed of both PCR and sequencing adapters <32bp using 
TrimGalore!(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ 2014). The 
trimmed reads were then mapped to the human reference genome (GRCh37) using STAR 
(Dobin et al. 2013) creating an expression matrix. Quality metrics were assessed for each 
sample at this stage. These included: total reads: total sum of all features including spike-in 
transcripts, alignment rate: rate of reads mapped to the reference genome using STAR, 
ERCC ratio: the proportion of reads mapped to spike-in transcripts (an enrichment of reads 
mapping to ERCCs indicative of loss of endogenous RNA), number of called genes: number 
of expressed features in each cell with non-zero counts, ratio of exonic reads to total reads, 
ratio of reads mapping to the mitochondrial genome to total reads. These metrics were 
illustrated using: http://servers.binf.ku.dk:8890/sinaplot/. 
 
2.7.1 Single cell RNA-seq analysis: HSCs 
 
Cell filtering to distinguish high-quality single cells from low-quality cells was performed using 
a machine learning model able to simultaneously detect subtle patterns across a number of 
quality metrics based on a previously described method (Ilicic et al. 2016). Here the list of 
technical and biological variables were modified and used to train a support vector machine to 
recognise cells that shared features with cells expressing the house-keeping gene, GAPDH. 
These cells were then taken forward for downstream analysis.  
 
Transcript expression was normalised across single cells using Scater package (McCarthy et 
al. 2017) in order to correct for technical and biological variance between cells using 
previously described methods (Lun, McCarthy, and Marioni 2016). This was based on the 
assumption that most genes are not differentially expressed between cells, therefore systemic 
differences are removed by scaling. Since ERCC spike-ins were added in the same quantity 
to all cells, and therefore exhibit only technical and no biological variability, variance in spike-
in expression was used to model the trend in technical variability. Genes that exhibited 
variance that did not fit this trend were identified as genes that drive biological heterogeneity.  
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Unsupervised clustering of the cells according to similarity of gene expression was performed 
firstly by constructing pairwise comparisons between the first 3 principal components of 
variation in transcript expression (PCA: principal component analysis) and secondly using 
consensus clustering of RNA-seq data known as SC3 (Kiselev et al. 2017) which is a 
heirrachical clustering based on correlation in the PCA space. The robustness of the clusters 
was determined by the Silhuoette index (Rousseeuw 1987). Using SC3, cluster marker genes 
were identified by a value to each gene denoting how well it is a predictor for each cluster. A 
p-value was then assigned to each gene using the Wilcoxen signed-rank test. Genes with 
P<0.001 were defined as marker genes. 
 
Cells were then clustered using the Monocle 2 single-cell analysis toolset (Trapnell et al. 
2014; Qiu et al. 2017). Here the cells were ordered in terms of differential gene expression 
incorporating correlation distances, whereby each cell was placed along a differentiation 
trajectory, with branch points indicating where cells exhibit alternative cell differentiation 
programs. Cluster marker genes were those that were consistently differentially expressed 
compared to all other genes. These were identified using the Wilcoxon Rank test. 
 
In order to assess expression of known haematopoietic gene signatures within the single cells 
clusters, gene signatures for each cell type in the DMAP dataset (Novershtern et al. 2011) 
were created using the LIMMA package (Ritchie et al. 2015). Here a one vs all comparison 
was made for all cell types. P values were adjusted for multiple hypothesis testing with a false 
discovery rate <0.05. Genes that were considered to be part of the gene signature were 
defined as those with log2 fold change of >1. The expression of genes from each DMAP gene 
signature was then assessed in each individual single cell and this information was 
superimposed on the Monocle 2 plots. Furthermore, expression of cluster marker genes 
within haematopoietic progenitor populations in the Blueprint dataset (L. Chen et al. 2014) 
was assessed using the Blueprint progenitors tools portal: https://blueprint.haem.cam.ac.uk. 
 
2.7.2 Single cell RNA-seq analysis: Megakaryocytes 
 
The lower quality metrics of the single cell megakaryocytes samples meant that the single cell 
data for this cell type was used for validation of and comparison with low input multicell 
megakaryocyte pools only. Therefore the machine learning model that was used to predict 
high quality cells for downstream analysis was a random forest classifier (Breiman 2001). The 
training dataset that was used were the multicell megakaryocyte pools and 5 rounds of 
training were used to identify cells taken forward for differential expression analysis. 




2.7.3 Differential expression analysis: megakaryocytes and platelets 
 
DE-Seq2 (Love, Huber, and Anders 2014) was used to find genes that were differentially 
expressed between different datasets in single megakaryoyctes, megakaryocyte multicellular 
pools, cultured bulk megakaryocytes and platelets. Here the Wald test is used for hypothesis 
testing. Differentially expressed genes were defined as p<0.05. For more than one 
comparison correlations were performed using the Spearman rank method. 
 
2.7.4 Functional gene list analysis 
 
Gene ontology (GO) analysis was performed and its visual representation generated using 
the online tool, Fidea (D’Andrea et al. 2013): http://circe.med.uniroma1.it/fidea. Here 
enrichment analysis is performed by statistically assessing whether a pathway or process is 
enriched in the specific gene list. This is achieved by the hypergeometric test with the 
resulting p-values corrected using the Benjamini and Yekutieli FDR method (Yekutieli and 
Benjamini 2001). This method was used for highly expressed gene lists, cluster marker genes 




CHAPTER 3  
Single cell RNA-seq reveals transcriptional variation and megakaryocyte 




The first evidence of heterogeneity in the HSC compartment came from mouse spleen colony 
forming unit (CFU) assays, that showed high degrees of variability in numbers and types of 
daughter cell colonies produced (Siminovitch, McCulloch, and Till 1963; Till, McCulloch, and 
Siminovitch 1964). This challenged the traditional concept of a single homogenous 
population. However, direct evidence of HSC heterogeneity came from methods that allow 
assessment of mature cell outputs from limiting numbers and even single HSCs (Kiel et al. 
2005; Osawa et al. 1996). These include the ability of purified single HSCs to repopulate a 
secondary myelo-ablated host and cellular barcoding whereby lentiviral transfer is used to 
uniquely label individual HSCs allowing their progenies to be tracked within the transplanted 
host (Lu et al. 2011; Gerrits et al. 2010). With improvement in cell purification techniques and 
functional clonal assays, as well as transplantation experiments, human HSCs are now 
thought to reside within the Lin-CD34+CD38-CD45RA-CD90+CD49f+ surface markers defined 
compartment (Notta et al. 2011). Functionally distinct HSC subsets within these gates have 
been distinguished, as defined by their mature cell output, as myeloid-biased, lymphoid-
biased or balanced (Muller-Sieburg et al. 2004, 2012; Dykstra et al. 2007; Pang et al. 2011; 
Cavazzana-Calvo et al. 2011). However, the retrospective nature of these assays has meant 
that cells are not available for further analysis. There remains no reliable method for 
prospectively distinguishing these subpopulations. Therefore, it is evident that despite having 
the same cell surface markers subsets exist within the HSC population with distinct 
transcriptional programs. 
 
Almost all the accrued knowledge of the HSC transcriptome is derived from studies at 
population level that do not take into account the heterogeneity within the population, the 
extent of which remains largely unknown. Therefore, a study of HSCs at single cell resolution 
is essential to define the heterogeneity that underpins many biological processes including 
distinct cell fate decision.  
 
A human cell is predicted to contain less that 1pg of mRNA with the majority of transcripts 
being expressed at less than 100 transcript copies per cell (Kawasaki 2004). Therefore, it can 
be envisaged that genes co-expressed at population level are in fact mutually exclusive at the 
single-cell level. This implies that subsets within a cell population could be functionally 
distinct, for example in the HSC population, it would mean separate subgroups of cells with 
different mature cell lineage output. Recent technological advances have allowed single cell 
transcriptome profiling using methods ranging from the probe dependent fluorescent in situ 
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hybridization to single-cell reverse transcription and transcriptome wide amplification methods 
including qPCR, microarray, and more recently, NGS analyses of the transcriptomes of single 
cells; previously reviewed (Kalisky, Blainey, and Quake 2011; Tang, Lao, and Surani 2011; 
Saliba et al. 2014; Etzrodt, Endele, and Schroeder 2014). Human HSCs have been studied at 
the single cell level using qPCR targeting specific transcripts (Guo et al. 2013; Adolfsson et 
al. 2005; Forsberg et al. 2006; Månsson et al. 2007; Akashi et al. 2003; Hu et al. 1997; 
Miyamoto et al. 2002). At the time of beginning this project single cell RNA-seq had not been 
used in human HSCs to investigate HSC heterogeneity.    
 
As described, a new model of human haematopoiesis using functional clonal assays and 
improved cell purification suggests that megakaryocyte lineage commitment can bypass 
intermediate differentiation steps (CMP and MEP), becoming completely independent of 
these steps in adult bone marrow (Notta et al. 2016). Furthermore, a megakaryocyte-biased 
HSC subset has been identified in the mouse (Sanjuan-Pla et al. 2013; Gekas and Graf 
2013). VWF gene expression has been described as a marker of a megakaryocyte-biased 
HSC subset, which defines a population leading to long term hematopoietic reconstitution 
with platelet bias when serially transplanted in limiting numbers or single cell (Sanjuan-Pla et 
al. 2013). VWF is a large multimeric plasma glycoprotein that is synthesised by 
megakaryocytes and are packaged into the platelet alpha granule to be released on 
activation. There is some evidence that VWF is also found independently of the alpha granule 
release on the surface of platelets activated by ADP (Parker, Shafer, and Gralnick 1987; 
Parker, Rick, and Gralnick 1985). It is also synthesised in endothelial cells, packaged into 
specialised vesicles called Weibel-Palade bodies and released into the extracellular space. 
Its transcripts are expressed in HSC, megakaryocytes and platelets (Novershtern et al. 2011; 
Rowley et al. 2011; L. Chen et al. 2014). It has a major role in platelet aggregation by forming 
a molecular bridge between the subendothelial collagen matrix and the platelet surface 
receptor: GP1b-IX-V. 
 
The work described in this chapter, includes the use of single cell RNA-seq combined with 
fluorescence-activated cell index sorting to analyse transcriptional variation within the human 
bone marrow HSC population and identify subpopulations biased to different cell fates with a 
particular focus on defining a megakaryocyte-biased HSC subset. Since VWF transcript 
expression has been proposed as a marker of a megakaryocyte or platelet-biased HSC 
population, differential expression analysis was also performed between VWF+ and VWF- 
HSCs. Finally, although VWF is not known to be a cell surface protein, it has been 
hypothesised that it could play a physiological regulatory role in HSCs and therefore its 
surface expression at the single cell level was also measured and correlated to transcript 
expression. HSCs sorted according to presence or absence of surface VWF were 





3.2.1 HSC phenotype 
 
Single HSCs were flow sorted from sternal bone marrow from 5 individuals for the purpose of 
single cell RNA-seq (Section 2). Table 3.1 shows the baseline characteristics for these 
individuals, they were either undergoing mitral (n=3) or aortic valve surgery (n=2), 2 had mild 
to moderately impaired LV systolic function and there was no evidence of coronary artery 
disease (on pre-operative coronary angiography). Mean age was 65, with haemoglobin 
concentration, white cell count and platelet count all within normal limits. 
 
Figure 3.1 illustrates the experimental design. Bone marrow samples were prepared for 
FACS sorting as described in Section 2.2.4.1. The HSC population was identified as Lineage 
negative, CD34+, CD38-, CD45RA-, CD90+, CD49f+. The following antibodies were used as 
lineage cocktail: CD2, CD3, CD10, CD11b, CD11c, CD19, CD20, CD56, in order to gate out 
any mature cells as well platelets with CD42b and GP6. An antibody to VWF was also added 
to measure the surface expression of VWF. Figure 3.2 shows the gating strategy used after 
doublets had been excluded from analysis.  
 
In total, 884 HSCs were FACS sorted and index data collected (Osborne 2011). For each 
single cell to enable post-sort review of where each cell was located within the gates as well 
as the exact flow cytometric phenotype including information on forward/side scatter and the 
7 additional surface markers. Specifically, the surface expression of VWF was analysed using 
index data for each individual HSC. Approximately 50% HSCs were found to be VWF+ by 
surface marker expression. Figure 3.1 shows the cell numbers sorted from each individual 
with mean fluorescent intensities across the sorted populations for forward and side scatter 
as well as all surface markers used. There were no significant differences in index data, or 
VWF expression within the HSC population between individuals.   
 
Table 3.1 Baseline characteristics 
 Healthy controls (n=5) 
 
Gender M 3 





Coronary disease 0 
Antiplatelets 0 
Left ventricular dysfunction 2 
Aortic valve surgery 2 
Mitral valve surgery 3 
Hb (mean ± SD) 12.18 ± 1.8 
WC (mean ± SD) 8.0 ± 0.89 




Figure 3.1 Experimental design 
Sternal bone marrow was harvested from 5 patients undergoing non-coronary cardiac 
surgery. It was stained with antibodies for surface markers that define the human HSC 
population and sorted as single cells using index FACS into cell lysis buffer. Single cell RNA 
sequencing libraries were then prepared using a modified Smart-seq2 method and libraries 








Figure 3.1 HSC flow and raw index data. 
Fluorescence activated cell sorting of primary HSCs from clinical samples of whole human 
bone marrow. Cells were sorted into lysis buffer within 6 to 8 hours after bone marrow 
harvest. Whole bone marrow was stained with PECy5 conjugated anti-lineage antibodies: 
CD2/CD3/CD10/CD11b/CD11c/CD19/CD20/CD56, biotinylated CD42b/GP6 plus PECy5 
conjugated streptavidin, AlexaFluor 700 conjugated anti-CD34, PerCP- Cy5.5 conjugated 
anti-CD38, Pacific Blue conjugated anti-CD45RA, PECy7 conjugated anti-CD90, PE 
conjugated anti-CD49f, FITC conjugated anti-VWF. The data shown is from Pt ID FX7. NS: 
non significant.  
  
Pt ID 60Z G1U FX7 GBA GPJ p value 
HSCs sorted 192 192 288 96 116 NS 
MFI       
  FS 59276.4 72028.2 51447.3 42393.9 50659.6 NS 
  SS 22733.5 34762.7 26194.1 24324.1 24098.6 NS 
  Lineage 6150.77 11750.3 6583.63 2300.40 5881.84 NS 
  CD34 13552.8 17624.1 24386.1 13493.7 39248.5 NS 
  CD38 -2235.28 388.24 -498.83 736.85 2720.25 NS 
  CD45RA -2355.41 -268.26 -640.36 -476.45 -559.81 NS 
  CD90 6524.80 7286.85 10805.6 8909.76 5842.78 NS 
  CD49f 43608.5 17600.3 13224.9 16380.7 6845.60 NS 
  VWF 21090.8 12405.2 12718.3 11619.9 18585.8 NS 
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3.2.2 Single cell RNA-seq library preparation: quality measures 
 
3.2.2.1 Choice of reverse transcriptase 
 
The Smart-seq2 protocol was used to generate a high yield of full length cDNA for single cell 
transcriptome analysis. The recommended Superscript II reverse transcriptase was used for 
first strand synthesis in the initial 116 single HSCs processed (ID GPJ). However, the 
resulting BioAnalyser traces showed suboptimal cDNA quality with a wide distribution of 
fragments size. Upon testing alternative reverse transcriptases, Smartscribe demonstrated 
improved efficiency in producing full length cDNA from both purified RNA and other cell types 
as well as HSCs and was therefore used instead of Superscript II for the remaining 768 single 
HSCs (Figure 3.3).   
 
3.2.2.2 Expression of GAPDH as a house-keeping gene 
 
In order to detect high quality single cell cDNA for the first 4 HSC plates amplified, Taqman 
real-time PCR assays for the presence of the house-keeping gene GAPDH were used. Figure 
3.4 shows the number of cells expressing GAPDH in the first 4 plates. The mean no. of 
GAPDH expressing cells per 96 well plate was 19 ± 3.2 (mean ± SD). It is noted that despite 
suboptimal BioAnalyser traces for the cells reverse transcribed using Superscript II (GPJ P1) 
rather than Smartscribe (G1U P1, G1U P2, FX7 P1) the numbers of cells expressing GAPDH 
were comparable. 
 
As high expression of mitochondrial transcripts led to their overrepresentation the RNA-seq 
data for megakaryocytes (Chapter 4), the expression of the most highly expressed 
mitochondrial gene: MT-RNR2 was measured by Taqman real-time PCR alongside GAPDH 
expression in the same 4 HSC plates and compared to the same measurement in a plate of 
megakaryocytes. Figure 3.5 shows that the ∆CT between GAPDH and MT-RNR2 expression 
in GAPDH positive megakaryocytes was significantly higher than the more favourable ∆CT in 
HSCs. That is, MT-RNR2 was detected a mean of 4 PCR cycles before GAPDH in 
megakaryocytes compared with HSCs where both GAPDH and MT-RNR2 transcripts were 
detected at approximately the same PCR cycle number.  
 
3.2.2.3 Cell selection for RNA sequencing 
 
In order to investigate whether GAPDH expression was an adequate marker for cDNA quality 
and therefore a criterion to select cells for RNA-seq, expression of B2M was analysed 
alongside GAPDH in a single 96 well plate of HSCs. Figure 3.6 shows that although many 
cells co-expressed both housekeeping transcripts, there were cells that expressed either one 
or the other. The data shown is from patient and plate ID FX7 P1. Here GAPDH alone 
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identified 16 cells, whereas if high quality cDNA were to be defined by expression of either 
GAPDH or B2M this would identify 27 cells in total. 
 
Next, a set of 48 cells GAPDH selected cells from plates G1U P1 and G1U P2 and a single 
unselected 96 well plate (FX7 P1) were sequenced. Preliminary quality checks were made to 
compare the 2 datasets. This included alignment rate, exon/exon+intron ratio and ERCC 
ratio. Figure 3.7 shows that the majority of GAPDH selected cells had higher quality by these 
criteria compared with unselected cells. Using preliminary and arbitrary cut-offs based on the 
performance of the GAPDH selected cells, 26 cells from the unselected plate (FX7 P1) were 
defined by sequencing as high quality. Figure 3.8 shows that, by using this definition of 
quality, 6 more cells were deemed good quality than would have been selected on the basis 
of a combination of GAPDH and B2M expression alone. To maximise the number of good 
quality cells sequenced it was therefore decided to unselectively sequence all 884 cells and 
filter the data post RNA-seq rather than prospectively selecting cells according to single gene 
expression using Taqman real-time qPCR.  
 
3.2.2.4 Correlation between surface and transcript expression of VWF by qPCR 
 
To investigate if expression of VWF on the surface of HSCs could be related to the presence 
of VWF transcript, Taqman real-time qPCR was used to quantify expression of the VWF 
transcript in cDNA from all single HSCs. This was correlated with MFI from FACS index data 
for VWF. In total VWF transcript was identified in 43 out of 884 single cells. Figure 3.9 shows 
that although there is a weakly significant r value there is no clear correlation between surface 
marker expression and transcript expression of VWF.  
 
3.2.2.5 Batch effects 
 
Batch effects, have been widely reported as a major challenge in high-throughput 
technologies (Leek et al. 2010) and especially in single cell RNA-seq as it is more difficult to 
randomise batches across sequencing lanes or flow cells (Stegle, Teichmann, and Marioni 
2015). Systematic error has been shown to explain a substantial percentage of observed cell-
to-cell expression variability in a number of previous studies (Hicks, Teng, and Irizarry 2015). 
Table 3.2 shows each HSC 96 well plate and which sequencing lane ID whereas Table 3.3 
outlines the batches in which samples were collected, cDNA was reverse 







Figure 3.3 Smartscribe improves generation of full length cDNA. 
BioAnalyser electropherograms of cDNA libraries; x axis shows fragment size (bp), y axis 
shows quantity. A. cDNA reverse transcribed from purified RNA using Superscript II (red) 
compared with Smartscribe (blue). BioAnalyser trace prior to PCR clean-up, showing large 
peak of primer-dimers. (Performed by Ricardo Miragaia, WTSI/EBI, Hinxton). B. cDNA 
reversed transcribed from regulatory T cells using Superscript II (red) compared with 
Smartscribe (blue). (Performed by Ricardo Miragaia, WTSI/EBI, Hinxton, UK). C. cDNA 
reverse transcribed from six randomly selected single HSCs from Patient ID GPJ using 
Superscript II. D. cDNA reverse transcribed from six randomly selected single HSCs from 







Figure 3.4 Number of GAPDH expressing cells over the first 4 HSC plates amplified. 
Taqman real-time PCR was used to investigate the expression of GAPDH in cDNA from 96 




Figure 3.5 Expression of GAPDH compared to MT-RNR2 in HSCs and megakaryocytes. 
Taqman real-time PCR was used to investigate the expression of GAPDH and MT-RNR2 in 
HSCs and megakaryocytes. Data is presented as ∆CT between CT value for GAPDH and CT 
value for MT-RNR2. Each bar represents the range of values for ∆CT in each plate of cells 
with the line at the mean. A more negative value indicates a higher GAPDH expression than 
MT-RNR2, whereas a more positive value indicates higher MT-RNR expression. (*p<0.05, 
**p<0.001, ***p<0.0001 

















































Figure 3.6 Expression of GAPDH and B2M in a single 96 well plate of HSCs. Taqman real-time 
PCR was used to investigate the expression of GAPDH and B2M in cDNA from single HSCs. Data 
shown is from FX7 P1. Data is presented as CT i.e., the cycle number at which the transcript was 




Figure 3.7 Preliminary RNA sequencing quality. Data for 48 GAPDH selected HSCs from G1U P1 
and G1U P2 and unselected HSCs from FX7P1 is presented. GAPDH selected HSCs had a 








Figure 3.8 Overlap of good quality as 
defined by sequencing quality and 
expression of housekeeping genes 
using Taqman real-time PCR. 
Sequencing quality was defined as high 
alignment rate and exon/intron ratio as 
well as low ERCC ratio. Arbitrary cut offs 
were used based on the performance of 
GAPDH selected cells. Data shown is 
















































































































































































































































Figure 3.9 Correlation between VWF surface and transcript expression by qPCR. 
VWF surface expression is in MFI measured by FACS index sorting for each individual cell. 
Transcript expression was measured by Taqman real-time PCR. Data is presented as CT 
value, the lower the cycle number or CT at which the transcript was detected, the higher the 




Plate ID Lane sequenced 
60Z P1 SLX-11217 
60Z P2 SLX-11218 
FX7 P1 SLX-10542 
FX7 P2 SLX-11219 
FX7 P3 SLX-11220 
G1U P1 GAPDH+ SLX-10548 
G1U P1 GAPDH- SLX-11215 
G1U P2 GAPDH+ SLX-10548 
G1U P2 GAPDH- SLX-11216 
GBA P1 SLX-10543 
GPJ P1 SLX-11221 
GPJ P2 SLX-11216 
 
Table 3.2 Patient and plate ID on each sequencing lane 
 
Sample collection Amplification Nextera Library prep / RNA-seq 
1 1 1 
  60Z P1   GPJ P2   SLX-10548 
  60Z P2 2 2 
2   GPJ P1   SLX-10542 
  FX7 P1 3   SLX-10543 
  FX7 P2   G1U P1 3 
  FX7 P3 4   SLX-11215 
3   G1U P1   SLX-11216 
  G1U P1   60Z P1   SLX-11217 
  G1U P2 5   SLX-11218 
4   FX7 P1   SLX-11219 
  GBA P1   GBA P1   SLX-11220 
5 6   SLX-11221 
  GPJ P1   FX7 P2   
  GPJ P2   FX7 P3   
    60Z P2   
 

















3.2.3 Single cell RNA sequencing data: Quality measures 
 
3.2.3.1 Quality control data 
 
Figure 3.10 shows metrics per sequencing lane for total read count, alignment to the 
reference transcriptome (GRCh37), proportion of reads mapped to external spike-in ERCCs 
compared to endogenous transcripts, number of genes called, proportion of reads mapping to 
annotated exonic regions and the proportion of reads mapping to the mitochondrial genome.  
 
All lanes (with the exception of SLX-10548, SLX-11217, SLX-11218) demonstrate similar 
quality metrics.  The majority of cells have a total read count <5x106, alignment rate <50%, 
ERCC ratio >50%, number of called genes <1000, exonic ratio <50%. Lanes SLX-11217 and 
SLX-11218 demonstrate particularly poor quality with relatively lower alignment rates, genes 
called, and exonic reads and higher proportion of reads mapped to ERCC spike-in transcripts. 
These 2 lanes were FACS sorted on the same day and therefore the similarity in overall 
quality metrics may be representative of batch effect. 
 
As previously discussed in 3.2.2.3, lane SLX-10548, consisting of cells selected on the basis 
of GAPDH expression, had relatively better performance with significantly higher total read 
count, alignment rate, number of called genes, and reads mapping to exonic regions and 
significantly lower ERCC ratio and reads mapping to the mitochondrial genome. However, a 
smaller proportion of GAPDH negative cells from the same individuals (Lanes SLX-11215 and 
SLX11216) also shared similar favourable metrics demonstrating a lower specificity than 
sensitivity of GAPDH as a quality marker.  
 
3.2.3.2 Cell filtering 
 
Several approaches have been proposed to filter out low quality single cell data at the point of 
data analysis, but they require arbitrarily set filtering thresholds which perhaps only capture 
part of the entire landscape and are ideally suited to bulk sequencing (Hartley and Mullikin 
2015; Okonechnikov, Conesa, and García-Alcalde 2015). To ensure that only high quality 
cells were taken forward for downstream analysis, a recently developed classification 
approach for identifying low-quality cells was used (Ilicic et al. 2016). This takes into account 
both technical and biological measures of cell quality. The principle component analysis 
(PCA) performed and the specific variables driving the PCA are shown in Figure 3.11a. 
However, the model failed to identify cells with high alignment rates and low ERCC ratios as 
high quality, instead filtering these out (Figure 3.11b). It has to be noted that this machine 
learning model used mouse data which may explain its limitations in analysing primary human 
bone marrow HSCs.  
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The list of technical and biological variables used was then modified (Figure 3.12a) and used 
to train a support vector machine (SVM) model to identify cells that resembled GAPDH +ve 
cells (lane SLX-10548). The variables included mapping statistics, gene expression and its 
variance as well as gene expression signatures based on gene ontology. GAPDH expression 
was excluded as a feature. The cells identified as of good quality share features with GAPDH 
+ve cells, including low ERCC ratio, and mitochondrial mapping as well as higher number of 
reads mapping to exonic regions and number of genes called (Figure 3.12b). In this way 119 
out of 884 cells were taken forward to downstream analysis. 
 
3.2.3.3 Gene filtering 
 
Normalisation of overall transcript expression within a population of single cells is a critical 
step in single cell RNA-seq analysis to correct for cell to cell differences and ensure that 
downstream relative expression analysis between cells is valid. Gene filtering allows 
identification of a subset of genes that drive heterogeneity across the population of cells. In 
order to identify these highly variable genes, variance in expression of each gene was plotted 
against its expression level within the single cell population using a method described by Lun 
and Marioni (Lun, McCarthy, and Marioni 2016). This included the expression level of the 
ERCC spike-in transcripts, that should exhibit no biological variability and therefore 
represents the technical component of the expression variance observed. 2000 genes that 
demonstrated a higher variance than that of the ERCC curve fit were used for gene 
















Figure 3.10 Quality control metrics/sequencing lane. A. Total reads; B. Rate of alignment 
to transcriptome; C. Ratio of reads mapping to ERCCs; D. No. genes called; E. Ratio of 





Figure 3.11 Filtering cells: Method 1. 
Method 1 uses the SVM model described by Ilicic et al 2016. A. PCA performed on the 
technical and biological quality variables on which the model is based. The most explanatory 
variables for high and low quality are plotted; B. High and low-quality cells shown by 

















































































































































































































































































































































































































































































































































































































































































Figure 3.12 Filtering cells: Method 2. 
Method 2 is a modification of the SVM model described by Ilicic et al 2016, using GAPDH 
positive cells as “good quality”. A. Modified technical and biological features on which the 
model is based; B. High and low-quality cells shown by ERCC ratio, exonic ratio, number of 















Figure 3.13 Filtering genes: Lun & Marioni Method. 
Variance of normalized log-expression values for each gene in the HSC dataset, plotted 
against the mean log-expression. Variance estimates for ERCC spike-in transcripts and curve 





3.2.4 Gene expression analysis 
 
The 200 most highly expressed genes in the HSC dataset (n=119) with their raw total read 
counts are shown in Table 3.4. The most highly expressed genes are mitochondrial (MT-
RNR2, MT-RNR1) and ribosomal subunits. There are also a number of lineage specific genes 
that feature as highly expressed, particularly apparent are those of the 
megakaryocyte/platelet lineage: PPBP (ranked 19), PF4 (ranked 29), PLEK (ranked 56), 
SDPR (ranked 107), ITGA2B (ranked 119), VWF (ranked 134), CD36 (ranked 138), CD63 
(ranked 199).  
 
GO classification is a systematic way in which large gene lists from RNA-seq are analysed to 
group genes according to their biological process, molecular function and/or site of cellular 
expression. This method highlights functionally related clusters of genes in a hierarchical 
manner and allows the identification of biologically relevant groups. In order to group the 
highly expressed HSC genes into biological processes, the data was analysed using the 
online tool Fidea (http://circe.med.uniroma1.it/fidea/) (D’Andrea et al. 2013). While the full GO 
analysis can be found in Appendix 3, Table S3.1, Figure 3.14a shows a visual representation 
of the GO biological processes over-represented in the top 200 genes. The most significant 
are related to translation and protein localisation within the cell, in fact 64 out of the 200 
genes encoded for ribosomal subunits. Figure 3.14b shows the enriched GO biological 
processes with the ribosomal transcripts removed in order to reveal the next most significant 
functional classes: platelet degranulation/activation, exocytosis/cell secretion, wound healing, 




No ENSEMBL_GENE_ID HGNC_symbol Gene_name Total_reads 
1 ENSG00000210082 MT-RNR2 Mitochondrially Encoded 16S RNA (MT-RNR2) 10021645 
2 ENSG00000198804 COX1 cytochrome c oxidase subunit I(COX1) 1939185 
3 ENSG00000198886 ND4 NADH dehydrogenase, subunit 4 (complex I)(ND4) 1509724 
4 ENSG00000205542 TMSB4X thymosin beta 4, X-linked(TMSB4X) 1452232 
5 ENSG00000231500 RPS18 ribosomal protein S18(RPS18) 1235180 
6 ENSG00000198938 COX3 cytochrome c oxidase III(COX3) 1188536 
7 ENSG00000166710 B2M beta-2-microglobulin(B2M) 1125812 
8 ENSG00000198727 CYTB cytochrome b(CYTB) 1035874 
9 ENSG00000211459 MT-RNR1 Mitochondrially Encoded 12S RNA (MT-RNR1) 967361 
10 ENSG00000198712 COX2 cytochrome c oxidase subunit II(COX2) 938267 
11 ENSG00000198899 ATP6 ATP synthase F0 subunit 6(ATP6) 861381 
12 ENSG00000156508 EEF1A1 eukaryotic translation elongation factor 1 alpha 1(EEF1A1) 721606 
13 ENSG00000137154 RPS6 ribosomal protein S6(RPS6) 631701 
14 ENSG00000198763 ND2 MTND2(ND2) 625597 
15 ENSG00000112306 RPS12 ribosomal protein S12(RPS12) 623679 
16 ENSG00000198888 ND1 NADH dehydrogenase, subunit 1 (complex I)(ND1) 613192 
17 ENSG00000164587 RPS14 ribosomal protein S14(RPS14) 595091 
18 ENSG00000089157 RPLP0 ribosomal protein lateral stalk subunit P0(RPLP0) 575666 
19 ENSG00000163736 PPBP pro-platelet basic protein(PPBP) 575218 
20 ENSG00000198786 ND5 NADH dehydrogenase, subunit 5 (complex I)(ND5) 573750 
21 ENSG00000122406 RPL5 ribosomal protein L5(RPL5) 568956 
22 ENSG00000122026 RPL21 ribosomal protein L21(RPL21) 554861 
23 ENSG00000142541 RPL13A ribosomal protein L13a(RPL13A) 543703 
24 ENSG00000137818 RPLP1 ribosomal protein lateral stalk subunit P1(RPLP1) 538550 
25 ENSG00000174748 RPL15 ribosomal protein L15(RPL15) 517654 
26 ENSG00000100316 RPL3 ribosomal protein L3(RPL3) 498646 
27 ENSG00000177954 RPS27 ribosomal protein S27(RPS27) 488591 
28 ENSG00000075624 ACTB actin beta(ACTB) 485622 
29 ENSG00000163737 PF4 platelet factor 4(PF4) 484140 
30 ENSG00000142937 RPS8 ribosomal protein S8(RPS8) 483196 
31 ENSG00000187514 MIR1244-1 microRNA 1244-1(MIR1244-1) 460569 
32 ENSG00000080824 HSP90AA1 heat shock protein 90 alpha family class A member 1(HSP90AA1) 439388 
33 ENSG00000140988 RPS2 ribosomal protein S2(RPS2) 426732 
34 ENSG00000071082 RPL31 ribosomal protein L31(RPL31) 425537 
35 ENSG00000197756 RPL37A ribosomal protein L37a(RPL37A) 413026 
36 ENSG00000163220 S100A9 S100 calcium binding protein A9(S100A9) 400980 
37 ENSG00000108298 RPL19 ribosomal protein L19(RPL19) 397777 
38 ENSG00000170323 FABP4 fatty acid binding protein 4(FABP4) 397273 
39 ENSG00000147604 RPL7 ribosomal protein L7(RPL7) 394005 
40 ENSG00000204592 HLA-E major histocompatibility complex, class I, E(HLA-E) 386203 
41 ENSG00000143947 RPS27A ribosomal protein S27a(RPS27A) 376764 
42 ENSG00000105372 RPS19 ribosomal protein S19(RPS19) 355547 
43 ENSG00000251562 MALAT1 metastasis associated lung adenocarcinoma transcript 1(MALAT1) 354207 
44 ENSG00000110700 RPS13 ribosomal protein S13(RPS13) 346524 
45 ENSG00000149273 RPS3 ribosomal protein S3(RPS3) 346231 
46 ENSG00000109475 RPL34 ribosomal protein L34(RPL34) 334276 
47 ENSG00000167526 RPL13 ribosomal protein L13(RPL13) 316593 
48 ENSG00000198034 RPS4X ribosomal protein S4, X-linked(RPS4X) 314848 
49 ENSG00000008988 RPS20 ribosomal protein S20(RPS20) 312428 
50 ENSG00000133112 TPT1 tumor protein, translationally-controlled 1(TPT1) 310585 
51 ENSG00000144713 RPL31 ribosomal protein L31(RPL31) 306935 
52 ENSG00000142534 RPS11 ribosomal protein S11(RPS11) 303491 
53 ENSG00000115268 RPS15 ribosomal protein S15(RPS15) 293437 
54 ENSG00000143546 S100A8 S100 calcium binding protein A8(S100A8) 285860 
55 ENSG00000277048  ENSG00000277048 285203 
56 ENSG00000115956 PLEK pleckstrin(PLEK) 278887 
57 ENSG00000142676 RPL11 ribosomal protein L11(RPL11) 273439 
58 ENSG00000145592 RPL37 ribosomal protein L37(RPL37) 270502 
59 ENSG00000158710 TAGLN2 transgelin 2(TAGLN2) 263545 
60 ENSG00000204628 RACK1 receptor for activated C kinase 1(RACK1) 263178 
61 ENSG00000184009 ACTG1 Actin Gamma 1(ACTG1) 260016 
62 ENSG00000234745 HLA-B major histocompatibility complex, class I, B(HLA-B) 259346 
63 ENSG00000212907 ND4L NADH dehydrogenase, subunit 4L (complex I)(ND4L) 255164 
64 ENSG00000143933 CALM2 calmodulin 2(CALM2) 253703 
65 ENSG00000117632 MIR3917 microRNA 3917(MIR3917) 251082 
66 ENSG00000105640 RPL18A ribosomal protein L18a(RPL18A) 248305 
67 ENSG00000182004 SNRPE small nuclear ribonucleoprotein polypeptide E(SNRPE) 247799 
68 ENSG00000135486 HNRNPA1 heterogeneous nuclear ribonucleoprotein A1(HNRNPA1) 235022 
69 ENSG00000092841 MYL6 myosin light chain 6(MYL6) 232341 
70 ENSG00000189403 HMGB1 high mobility group box 1(HMGB1) 232190 
71 ENSG00000181163 NPM1 nucleophosmin(NPM1) 231304 
72 ENSG00000148303 RPL7A ribosomal protein L7a(RPL7A) 228175 
73 ENSG00000083845 RPS5 ribosomal protein S5(RPS5) 225977 
74 ENSG00000198755 RPL10A ribosomal protein L10a(RPL10A) 225131 
75 ENSG00000163041 H3F3A H3 histone family member 3A(H3F3A) 221907 
76 ENSG00000087086 FTL ferritin light chain(FTL) 219103 
Table 3.4 The most highly expressed transcripts in the HSC dataset (n=119) 
	 76
77 ENSG00000196262 PPIA peptidylprolyl isomerase A(PPIA) 217041 
78 ENSG00000162244 RPL29 ribosomal protein L29(RPL29) 214130 
79 ENSG00000138326 RPS24 ribosomal protein S24(RPS24) 213403 
80 ENSG00000164032 H2AFZ H2A histone family member Z(H2AFZ) 212982 
81 ENSG00000145425 RPS3A ribosomal protein S3A(RPS3A) 208431 
82 ENSG00000137076 MIR6852 microRNA 6852(MIR6852) 205803 
83 ENSG00000245532 NEAT1 nuclear paraspeckle assembly transcript 1 (NEAT1) 205233 
84 ENSG00000161016 MIR6850 microRNA 6850(MIR6850) 204611 
85 ENSG00000182899 RPL35A ribosomal protein L35a(RPL35A) 204500 
86 ENSG00000127314 RAP1B RAP1B, member of RAS oncogene family(RAP1B) 201747 
87 ENSG00000130255 RPL37 ribosomal protein L37(RPL37) 200917 
88 ENSG00000063177 RPL18 ribosomal protein L18(RPL18) 199397 
89 ENSG00000147403 RPL10 ribosomal protein L10(RPL10) 198665 
90 ENSG00000111640 GAPDH glyceraldehyde-3-phosphate dehydrogenase(GAPDH) 195029 
91 ENSG00000136942 RPL35 ribosomal protein L35(RPL35) 194164 
92 ENSG00000105193 RPS16 ribosomal protein S16(RPS16) 193968 
93 ENSG00000163682 RPL9 ribosomal protein L9(RPL9) 191854 
94 ENSG00000070756 MIR7705 microRNA 7705(MIR7705) 186143 
95 ENSG00000168028 RPSA ribosomal protein SA(RPSA) 185500 
96 ENSG00000177600 RPLP2 ribosomal protein lateral stalk subunit P2(RPLP2) 184892 
97 ENSG00000118181 RPS25 ribosomal protein S25(RPS25) 184461 
98 ENSG00000111669 TPI1 triosephosphate isomerase 1(TPI1) 184247 
99 ENSG00000229117 RPL41 ribosomal protein L41(RPL41) 183968 
100 ENSG00000135535 CD164 CD164 molecule(CD164) 182743 
101 ENSG00000197958 RPL12 ribosomal protein L12(RPL12) 180717 
102 ENSG00000171863 RPS7 ribosomal protein S7(RPS7) 179684 
103 ENSG00000127920 GNG11 G protein subunit gamma 11(GNG11) 179018 
104 ENSG00000233276 GPX1 glutathione peroxidase 1(GPX1) 176487 
105 ENSG00000096384 HSP90AB1 heat shock protein 90 alpha family class B member 1(HSP90AB1) 169829 
106 ENSG00000132475 MIR4738 microRNA 4738(MIR4738) 168437 
107 ENSG00000168497 SDPR serum deprivation response(SDPR) 168342 
108 ENSG00000131469 RPL27 ribosomal protein L27(RPL27) 163219 
109 ENSG00000114942 EEF1B2 eukaryotic translation elongation factor 1 beta 2(EEF1B2) 159002 
110 ENSG00000163687 DNASE1L3 deoxyribonuclease 1 like 3(DNASE1L3) 158764 
111 ENSG00000166441 RPL27A ribosomal protein L27a(RPL27A) 157719 
112 ENSG00000187109 NAP1L1 nucleosome assembly protein 1 like 1(NAP1L1) 157465 
113 ENSG00000198840 ND3 NADH dehydrogenase, subunit 3 (complex I)(ND3) 156704 
114 ENSG00000122566 HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1(HNRNPA2B1) 156375 
115 ENSG00000125691 RPL23 ribosomal protein L23(RPL23) 154183 
116 ENSG00000169567 HINT1 histidine triad nucleotide binding protein 1(HINT1) 152518 
117 ENSG00000233927 RPS28 ribosomal protein S28(RPS28) 152123 
118 ENSG00000084207 GSTP1 glutathione S-transferase pi 1(GSTP1) 151430 
119 ENSG00000005961 ITGA2B integrin subunit alpha 2b(ITGA2B) 150685 
120 ENSG00000169756 LIMS1 LIM zinc finger domain containing 1(LIMS1) 150341 
121 ENSG00000204525 HLA-C major histocompatibility complex, class I, C(HLA-C) 150220 
122 ENSG00000174444 RPL4 ribosomal protein L4(RPL4) 149572 
123 ENSG00000196531 NACA nascent polypeptide-associated complex alpha subunit(NACA) 148095 
124 ENSG00000124172 ATP5E ATP synthase, mitochondrial F1 complex, epsilon subunit(ATP5E) 147228 
125 ENSG00000170889 RPS9 ribosomal protein S9(RPS9) 145452 
126 ENSG00000109971 HSPA8 heat shock protein family A (Hsp70) member 8(HSPA8) 143774 
127 ENSG00000111348 ARHGDIB Rho GDP Dissociation Inhibitor Beta (ARHGDIB) 143114 
128 ENSG00000166913 YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 141312 
129 ENSG00000089009 RPL6 ribosomal protein L6(RPL6) 139467 
130 ENSG00000104904 OAZ1 ornithine decarboxylase antizyme 1(OAZ1) 139057 
131 ENSG00000075415 SLC25A3 solute carrier family 25 member 3(SLC25A3) 136085 
132 ENSG00000188846 RPL14 ribosomal protein L14(RPL14) 135401 
133 ENSG00000167658 EEF2 eukaryotic translation elongation factor 2(EEF2) 133525 
134 ENSG00000110799 VWF von Willebrand factor(VWF) 132184 
135 ENSG00000019582 CD74 CD74 molecule(CD74) 132044 
136 ENSG00000189043 HMGB1 high mobility group box 1(HMGB1) 131818 
137 ENSG00000198695 ND6 NADH dehydrogenase, subunit 6 (complex I)(ND6) 131303 
138 ENSG00000135218 CD36 CD36 molecule(CD36) 130215 
139 ENSG00000164104 HMGB2 high mobility group box 2(HMGB2) 128054 
140 ENSG00000163466 ARPC2 actin related protein 2/3 complex subunit 2(ARPC2) 127487 
141 ENSG00000206503 HLA-A major histocompatibility complex, class I, A(HLA-A) 127440 
142 ENSG00000111716 LDHB lactate dehydrogenase B(LDHB) 125782 
143 ENSG00000171858 RPS21 ribosomal protein S21(RPS21) 124758 
144 ENSG00000173812 EIF1 eukaryotic translation initiation factor 1(EIF1) 122384 
145 ENSG00000074800 ENO1 enolase 1(ENO1) 117956 
146 ENSG00000140319 SRP14 signal recognition particle 14(SRP14) 117504 
147 ENSG00000125356 NDUFA1 NDUFA4, mitochondrial complex associated(NDUFA4) 117367 
148 ENSG00000198830 HMGN2 high mobility group nucleosomal binding domain 2(HMGN2) 117319 
149 ENSG00000198918 RPL39 ribosomal protein L39(RPL39) 116076 
150 ENSG00000115310 RTN4 reticulon 4(RTN4) 115917 
151 ENSG00000125743 SNRPD2 small nuclear ribonucleoprotein D2 polypeptide(SNRPD2) 115695 
152 ENSG00000197746 PSAP prosaposin(PSAP) 114857 
153 ENSG00000118680 MYL12B myosin light chain 12B(MYL12B) 111497 
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154 ENSG00000113648 H2AFY H2A histone family member Y(H2AFY) 110153 
155 ENSG00000131143 COX4I1 cytochrome c oxidase subunit 4I1(COX4I1) 108912 
156 ENSG00000108654 MIR3064 microRNA 3064(MIR3064) 107373 
157 ENSG00000213741 LOC100288910 uncharacterized LOC100288910(LOC100288910) 107018 
158 ENSG00000087460 GNAS GNAS complex locus(GNAS) 106704 
159 ENSG00000172809 RPL38 ribosomal protein L38(RPL38) 105433 
160 ENSG00000123975 CKS2 CDC28 protein kinase regulatory subunit 2(CKS2) 105232 
161 ENSG00000127184 MIR3607 microRNA 3607(MIR3607) 104800 
162 ENSG00000169714 CNBP CCHC-type zinc finger nucleic acid binding protein(CNBP) 104638 
163 ENSG00000070081 LOC105376575 uncharacterized LOC105376575(LOC105376575) 103918 
164 ENSG00000196924 FLNA filamin A(FLNA) 103811 
165 ENSG00000114391 RPL24 ribosomal protein L24(RPL24) 102943 
166 ENSG00000213719 CLIC1 chloride intracellular channel 1(CLIC1) 102908 
167 ENSG00000132341 RAN RAN, member RAS oncogene family(RAN) 102761 
168 ENSG00000021355 SERPINB1 serpin family B member 1(SERPINB1) 102195 
169 ENSG00000143549 TPM3 tropomyosin 3(TPM3) 101822 
170 ENSG00000109332 UBE2D3 ubiquitin conjugating enzyme E2 D3(UBE2D3) 101208 
171 ENSG00000164919 COX6C cytochrome c oxidase subunit 6C(COX6C) 101060 
172 ENSG00000145741 BTF3 basic transcription factor 3(BTF3) 98668 
173 ENSG00000101182 PSMA7 proteasome subunit alpha 7(PSMA7) 98618 
174 ENSG00000142168 SOD1 serine and arginine rich splicing factor 11(SRSF11) 97214 
175 ENSG00000136156 ITM2B superoxide dismutase 1, soluble(SOD1) 97021 
176 ENSG00000116754 SRSF11 integral membrane protein 2B(ITM2B) 95966 
177 ENSG00000131747 TOP2A topoisomerase (DNA) II alpha(TOP2A) 95964 
178 ENSG00000152795 HNRNPDL heterogeneous nuclear ribonucleoprotein D like(HNRNPDL) 94057 
179 ENSG00000122545 SEPT7 septin 7(SEPT7) 93553 
180 ENSG00000154518 ATP5G3 ATP synthase,mitochondrial Fo complex subunit C3 (ATP5G3) 93362 
181 ENSG00000112081 SRSF3 serine and arginine rich splicing factor 3(SRSF3) 93253 
182 ENSG00000139644 TMBIM6 transmembrane BAX inhibitor motif containing 6(TMBIM6) 93032 
183 ENSG00000265972 TXNIP thioredoxin interacting protein(TXNIP) 91404 
184 ENSG00000255302 EID1 EP300 interacting inhibitor of differentiation 1(EID1) 91241 
185 ENSG00000135390 ATP5G2 ATP synthase, mitochondrial Fo complex subunit C2(ATP5G2) 91141 
186 ENSG00000175063 UBE2C ubiquitin conjugating enzyme E2 C(UBE2C) 89829 
187 ENSG00000049323 LTBP1 latent transforming growth factor beta binding protein 1(LTBP1) 88971 
188 ENSG00000120885 MIR6843 microRNA 6843(MIR6843) 88778 
189 ENSG00000131171 SH3BGRL SH3 domain binding glutamate rich protein like(SH3BGRL) 88746 
190 ENSG00000034510 TMSB10 thymosin beta 10(TMSB10) 88240 
191 ENSG00000068796 KIF2A kinesin family member 2A(KIF2A) 87845 
192 ENSG00000142669 SH3BGRL3 SH3 domain binding glutamate rich protein like 3(SH3BGRL3) 87166 
193 ENSG00000149925 ALDOA aldolase, fructose-bisphosphate A(ALDOA) 86756 
194 ENSG00000185201 IFITM2 interferon induced transmembrane protein 2(IFITM2) 86729 
195 ENSG00000100650 SRSF5 serine and arginine rich splicing factor 5(SRSF5) 85729 
196 ENSG00000140264 SERF2 small EDRK-rich factor 2(SERF2) 85443 
197 ENSG00000110955 ATP5B ATP synthase, mitochondrial F1 complex, beta 85203 
198 ENSG00000167978 SRRM2 serine/arginine repetitive matrix 2(SRRM2) 84996 
199 ENSG00000135404 CD63 CD63 molecule(CD63) 84190 
200 ENSG00000198668 CALM1 calmodulin 1(CALM1) 84131 
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Figure 3.14 Over-represented gene ontologies in the highly expressed HSC gene set 
The full GO analysis may be found in Appendix 1. The word cloud is a visual representation of the over-represented GO biological processes with their size 




3.2.4.1 Gene expression profiling reveals 5 clusters within the HSC population 
 
To identify subpopulations within the HSC population to explain heterogeneity, unsupervised 
clustering was performed based on Pearson’s correlation of the cells within the PCA space 
(i.e., a quantification of correlation between the cells based on the principal components of 
variation in gene expression). This revealed 5 clusters (Figure 3.15a). The silhouette plot 
demonstrates how well each cell fits into its cluster (Figure 3.15b). Cluster 1 (n=46), cluster 2 
(n=39) and cluster 5 (n=10) are the most homogeneous whereas cluster 4 (n=10) appears to 
have 2 subpopulations and cluster 3 (n=14) is the most heterogeneous. The PCA plots shown 
in Figure 3.15c demonstrate the separation of clusters 1-5 according to the first 4 components 
that contribute most to the variance with cells with similar expression profiles located closer 
together. Figure 3.15d demonstrates that PC1 and PC2 are not explained by patient or plate 
ID and shows a good spread of cells from all patients/plates across the clusters.  
 
In order to further characterise the relationship between distinct single cell clusters the 
Monocle 2 single-cell analysis toolset (Qiu et al. 2017) was used to apply an order to cells in 
terms of differential gene expression. Here, the sequence of changes in gene expression is 
analysed from one cluster to another in an unsupervised manner, thereby allowing each 
single cell to be placed at the appropriate position along that trajectory depending on differing 
gene expression. This model builds trajectories via which differentiation may occur between 
cell populations where trajectory branches are considered as the point at which cell fate 
decisions are made. The resulting unbiased trajectory has ordered cells as shown in Figure 
3.16 where clusters 2 and 5 are furthest apart with clusters 1 and 4 branching from the same 
trajectory. Cells in cluster 3 appear to remain near the root of the trajectory. 
 
 
3.2.4.2 Identification of marker genes 
 
Each cluster was first assessed in terms of the most highly expressed transcripts. The most 
striking observation was that there was a higher expression of megakaryocyte/platelet 
associated genes in cluster 4 compared to other clusters (16%; 8 out of 50 most highly 
expressed, Appendix 3, Table S3.2). Indeed, when examined in terms of GO categories 
(Appendix 3, Figure S3.1) the GO term platelet degranulation was the most significantly 
enriched category in cluster 4. However, this analysis was superseded by the identification of 
genes specific to each cluster, or “cluster marker genes”. 
 
Marker genes for each cluster were identified as those that were consistently differentially 
expressed in one cluster compared to the others (Wilcoxon Rank test p<0.001 (Kiselev et al. 
2017)). Figure 3.17 shows the top 20 marker genes for each cluster visualised by heatmap 
indicating distinct expression profiles and functional states. Thus, cells from the cluster of 
interest can be identified by their marker genes that are systematically up-regulated. No 
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marker gene set was identified for cluster 3, as there were no genes that met the set 
threshold for significance, which is consistent with the Pearson correlation plot (Figure 3.15).  
 
The function of the 20 marker genes for each cluster as well as the platelet expression of the 
protein encoded by each gene	 was assessed using the online GeneCards tool 
(www.genecards.org). This is shown in Table 3.4. The full list of marker genes for each 
cluster is presented in Appendix 3, Table S3.3; cluster 1: n=313, cluster 2: n=108, cluster 4: 
n=19, cluster 5: n=62. Cluster 1 marker genes include several known megakaryocyte and 
platelet associated genes: ANGPT1, IL1b, HEMGN, GUCY1A3, NPM1, TSPAN32, NRIP1. 
Other megakaryocyte lineage associated genes present in the cluster 1 marker gene list (not 
top 20) include SELP, SERPINB1, GfI1B, NFE2. Of the 19 cluster 4 marker genes, 13 show 
high protein expression in platelets and megakaryocytes including TUBB1, CCL5, CDKN1A, 
CDKN2D, TUBA4A, TMEM40, F13A1, GNAZ, ZNF185, SNN, HIST1H2AC, PTCRA, GRAP2. 
Cluster 2 marker genes have functions primarily related to angiogenesis, with none showing 
significant protein expression in platelets. Cluster 5 marker genes are related to the immune 
response although 2 of the marker genes give rise to protein expression in platelets: 
SERPINA1, S100P. 
 
The data was then compared to the most recently published haematopoietic cell RNA-seq 
gene set, the Blueprint progenitor database, where RNA was sequenced from eight human 
primary haematopoietic progenitor populations including erythroblasts and megakaryocytes  
both cultured from primary CD34+ cells (L. Chen et al. 2014). Expression of the putative 
marker genes for each cluster within the Blueprint populations is demonstrated in heatmap 
form in Figure 3.18. Marker genes for HSC cluster 1 are seen to be highly expressed in 
megakaryocytes as well as the megakaryocyte precursors according to the classical model 
for hierarchical haematopoietic differentiation: MEP, GMP, CMP, MPP and HSC, but not in 
the erythroblast population which also arises from the MEP or the CLP. Cluster 4 marker 
genes are also expressed at high levels in megakaryocytes within the Blueprint dataset with 
significantly lower expression in the other progenitor populations.  
 
To assess the expression of known haematopoietic cell type gene signatures within the 
clustered single cell HSCs and how this was ordered in terms of differentiation trajectories, 
Monocle 2 was used to overlay different cell type gene signatures from the recently published 
DMAP database, where expression arrays were performed on 38 haematopoietic cell 
populations (Novershtern et al. 2011), onto the previously constructed unbiased trajectory in 
Figure 3.16. The megakaryocyte signature is largely restricted to clusters 1 and 4 which 
branch from the same trajectory (Figure 3.19a). In keeping with the data shown in Figure 3.18 
the MEP signature is restricted to cluster 1 only while these genes are downregulated in the 
other megakaryocyte like cluster 4 which has a similar expression of the MEP signature to 
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clusters 2, 3 and 5 (Figure 3.19b). The monocyte signature is expressed most highly in cluster 
5 and B cell signature most highly in cluster 2 (Figure 3.19c&d). 
  
3.2.4.3 Gene ontology of cluster marker genes  
 
To investigate the biological themes that are differentially represented according to HSC 
cluster a GO analysis was performed. A comparison based on the biological processes of the 
cluster marker genes highlights the differences in lineage potential of these HSC subsets. The 
full datasets may be found in Appendix 1 with over-represented GO categories identified 
using a low stringency statistical cut-off (<0.1), therefore the categories with lower 
significance levels should be regarded as qualitative only. The data shown in the 
representative word clouds in Figures 3.20 and 3.21 are significant (p<0.05). 
 
Cluster 1 transcriptome appears to have an ontological bias towards translation, ribosomal 
function and protein localisation with 25% (77 out of 313) of cluster 1 marker genes encoding 
ribosomal proteins (Figure 3.20, Appendix 3, Table S3.4). Apart from ribosomal functionality 
other enriched GO biological processes in cluster 1 are related to cellular metabolism, 
coagulation and haemostasis. The cluster 2 marker genes appear to have an ontological bias 
towards angiogenesis, endothelial cell function and wound healing (Figure 3.20, Appendix 3, 
Table S3.5). The over-represented GO categories for cluster 4 are related to negative 
regulation of cell death/apoptosis, cell cycle, protein folding and exocytosis (Figure 3.20, 
Appendix 3, Table S3.6). The cluster 5 gene signature showed over-representation of 
categories related to immunity and leukocyte function (Figure 3.20, Appendix 3, Table S3.7). 
Specific categories relating to a spectrum of immune cells are present: neutrophil 
chemotaxis/aggregation, phagocytosis, fungal response, antigen processing and 
presentation, mast cell degranulation.  
 
3.2.4.4 Expression of VWF 
 
Taqman RT-qPCR was previously used to correlate VWF transcript expression with surface 
expression of VWF by flow cytometry demonstrating a weak correlation only (Figure 3.8). 
However, this was based on all HSCs prior to sequencing. In order to assess true correlation 
at the single cell level, VWF transcript expression was correlated with index FACS data in 
only high-quality cells post cell filtering (n=119). Figure 3.21 shows VWF surface expression 
plotted against and its transcription within the HSC as well as cluster information. According 
to compensation controls on flow cytometry, positive VWF surface expression was defined as 
MFI>4000. Interestingly, within clusters 1 and 2 which both show high expression of VWF 
(ranked: 238 cluster 1; 22 cluster 2) there is some correlation between surface and transcript 
expression. However, this is not the case across all cells. It should be noted that despite 
correlation within clusters 1 and 2 very few of the cells would be defined as showing positive 
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surface expression by flow cytometry (MFI>4000).  
 
As described above gene expression of VWF has been identified as a marker for a 
platelet/megakaryocyte biased HSC population in the mouse (Sanjuan-Pla et al. 2013). While 
VWF ranked highly within the most abundantly expressed genes within the HSC population 
(rank: 134) as well as in clusters 1 and 2, it did not emerge as a cluster marker gene. To 
assess if the transcription of VWF could define a functional subpopulation a differential 
expression analysis was performed between HSCs with transcript expression of VWF and 
those without. This analysis demonstrated no significant differences in gene expression 
















Figure 3.15 Unsupervised clustering of HSCs based on highly variable gene expression. 
A. Pearson’s correlation map of HSCs in unsupervised clusters by distance within the PCA space, 
dendrograms are formed by hierarchical clustering on the Euclidean distances between cells; B. 
Silhouette plot showing how similar each cell is to cells in its cluster, compared to other clusters, 
Silhouette widths -1 to 1; C. PCA plot constructed from normalized log-expression values of 
correlated highly variable genes, where each point represents a cell in the HSC dataset. First, 
second third and fourth components are shown, along with the percentage of variance explained; D. 




Figure 3.16 Ordering single cell differentiation between cell clusters using Monocle 2.  
Individual cells are connected by a minimum spanning tree with branch points (thin lines), 


















clusters 1 2 3 4 5
	 85
 
Figure 3.17  Heatmap to show top marker gene expression according to clusters. 
Heatmap of mean-centred normalized and corrected log-expression values for the top 20 
marker genes for each cluster. Dendrograms are formed by hierarchical clustering on the 
Euclidean distances between genes (row). Column colours represent the cluster to which 










1 ENSG00000154188 ANGPT1 angiopoietin 1(ANGPT1) 6.09E-18 x 
Protein 
coding 
Mediates cAMP-dependent signalling triggered by receptor binding to GPCRs. Regulates 
diverse cellular processes such as cell proliferation, the cell cycle, differentiation and 
regulation of microtubule dynamics, chromatin condensation and decondensation, nuclear 
envelope disassembly and reassembly, regulation of intracellular transport mechanisms 
and ion flux.  
1 ENSG00000226777 FAM30A 
Family With Sequence Similarity 
30 Member A (FAM30A) 1.37E-15 
RNA 
gene 
Affiliated with the non-coding RNA class. 
1 ENSG00000180530 NRIP1 
nuclear receptor interacting 
protein 1(NRIP1) 3.10E-15 xs 
Protein 
coding 	
Modulates transcriptional activation by steroid receptors such as NR3C1, NR3C2 and 
ESR1. Also modulates transcriptional repression by nuclear hormone receptors. Positive 
regulator of the circadian clock gene expression. 
1 ENSG00000146386 ABRACL ABRA C-terminal like(ABRACL) 6.73E-15 x 
Protein 
coding 	   
1 ENSG00000164116 GUCY1A3 
guanylate cyclase 1 soluble 
subunit alpha(GUCY1A3) 1.11E-14 x 
Protein 
coding 	
Guanylyl Cyclases (GC) are a group of enzymes that, in the presence of a metal ion co-
factor such as Mg2+ or Mn2+, convert guanosine-5'-triphosphate (GTP) into 3',5'-
guanosine monophosphate (cGMP) and pyrophosphate.  
1 ENSG00000144057 ST6GAL2 
ST6 beta-galactoside alpha-2,6-
sialyltransferase 2(ST6GAL2) 2.43E-14 
Protein 
coding 	
Transfers sialic acid from the donor of substrate CMP-sialic acid to galactose containing 
acceptor substrates. Has alpha-2,6-sialyltransferase activity toward oligosaccharides that 
have the Gal-beta-1,4-GlcNAc sequence at the non-reducing end of their carbohydrate 
groups, but it has weak or no activities toward glycoproteins and glycolipids. 
1 ENSG00000136929 HEMGN hemogen(HEMGN) 6.60E-14 x 
Protein 
coding 	
Regulates the proliferation and differentiation of hematopoietic cells. Overexpression block 
the TPA-induced megakaryocytic differentiation in the K562 cell model. May also prevent 
cell apoptosis through the activation of the nuclear factor-kappa B  
1 ENSG00000125538 IL1B interleukin 1 beta(IL1B) 6.99E-14 x 
Protein 
coding 	
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, 
induces prostaglandin synthesis, neutrophil influx and activation, T/B-cell  activation and 
cytokine production and antibody production, and fibroblast proliferation and collagen 
production.  
1 ENSG00000142875 PRKACB 
protein kinase cAMP-activated 
catalytic subunit beta(PRKACB) 1.43E-13 x 
Protein 
coding 	
Mediates cAMP-dependent signaling triggered by receptor binding to GPCRs. PKA 
activation regulates diverse cellular processes such as cell proliferation, the cell cycle, 
differentiation and regulation of microtubule dynamics, chromatin condensation and 
decondensation, nuclear envelope disassembly and reassembly, as well as regulation of 
intracellular transport mechanisms and ion flux.  
1 ENSG00000111716 LDHB lactate dehydrogenase B(LDHB) 1.60E-13 x 
Protein 
coding 	
This gene encodes the B subunit of lactate dehydrogenase enzyme, which catalyses the 
interconversion of pyruvate and lactate with concomitant interconversion of NADH and 
NAD+ in a post-glycolysis process. 
1 ENSG00000160190 SLC37A1 
solute carrier family 37 member 
1(SLC37A1) 2.99E-13 x 
Protein 
coding 	
Inorganic phosphate and glucose-6-phosphate antiporter. May transport cytoplasmic 
glucose-6-phosphate into the lumen of the endoplasmic reticulum and translocate 
inorganic phosphate into the opposite direction. Independent of a luminal glucose-6-
phosphatase.  
1 ENSG00000185344 ATP6V0A2 
ATPase H+ transporting V0 
subunit a2(ATP6V0A2) 3.04E-13 
Protein 
coding 	
Part of the proton channel of V-ATPases. Essential component of the endosomal pH-
sensing machinery. May play a role in maintaining the Golgi functions, such as 
glycosylation maturation, by controlling the Golgi’s pH. 
1 ENSG00000181163 NPM1 nucleophosmin(NPM1) 3.96E-13 
Protein 
coding 	
Involved in diverse cellular processes such as ribosome biogenesis, centrosome 
duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of 
tumour suppressors p53/TP53 and ARF. Binds ribosome presumably to drive ribosome 
nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-
stranded nucleic acids.  
1 ENSG00000136938 ANP32B 
acidic nuclear phosphoprotein 
32 family member B(ANP32B) 6.40E-13 
Protein 
coding 	
Multifunctional protein working as a cell cycle progression factor as well as a cell survival 
factor. Required for the progression from the G1 to the S phase. Anti-apoptotic protein 
which functions as a caspase-3 inhibitor. Exhibits histone chaperone properties, stimulating 
core histones to assemble into a nucleosome. 
1 ENSG00000064201 TSPAN32 tetraspanin 32(TSPAN32) 8.22E-13 x Protein Member of the tetraspanin superfamily, one of several tumour-suppressing sub 
	
87
coding 	 transferable fragments located in the imprinted gene domain of chromosome 11p15.5 
1 ENSG00000122026 RPL21 ribosomal protein L21(RPL21) 1.07E-12 
Protein 
coding 	
Encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs 
to the L21E family of ribosomal proteins. It is located in the cytoplasm.  





Involved in the base excision repair (BER) pathway, by catalysing the poly(ADP-
ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture 
and in DNA metabolism.  





coding 	   
1 ENSG00000112306 RPS12 ribosomal protein S12(RPS12) 1.18E-12 x 
Protein 
coding 	
Encodes a ribosomal protein that is a component of the 40S subunit. The protein belongs 
to the S12E family of ribosomal proteins. It is located in the cytoplasm. 
1 ENSG00000173674 EIF1AX 
eukaryotic translation initiation 
factor 1A, X-linked(EIF1AX) 1.92E-12 
Protein 
coding 	
Required for maximal rate of protein biosynthesis. Enhances ribosome dissociation into 
subunits and stabilizes the binding of the initiator Met-tRNA(I) to 40 S ribosomal subunits. 
2 ENSG00000165810 BTNL9 butyrophilin like 9(BTNL9) 9.22E-19 
Protein 
coding 	 Related pathway: Innate Immune System 
2 ENSG00000277494 GPIHBP1 
glycosylphosphatidylinositol 
anchored high density 




Plays a key role in the lipolytic processing of chylomicrons. Required for the transport of 
lipoprotein lipase LPL into the capillary lumen 
 
2 ENSG00000175745 NR2F1 
nuclear receptor subfamily 2 




The protein encoded by this gene is a nuclear hormone receptor and transcriptional 
regulator. The encoded protein acts as a homodimer and binds to 5'-AGGTCA-3' repeats.  
2 ENSG00000130300 PLVAP 
plasmalemma vesicle 
associated protein(PLVAP) 2.49E-17 
Protein 
coding 	
Involved in the formation of stomatal and fenestral diaphragms of caveolae. May function in 
microvascular permeability. 
2 ENSG00000163687 DNASE1L3 




This gene encodes a member of the deoxyribonuclease I family. The encoded protein 
hydrolyses DNA, is not inhibited by actin, and mediates the breakdown of DNA during 
apoptosis.  
2 ENSG00000141753 IGFBP4 
insulin like growth factor binding 
protein 4(IGFBP4) 1.12E-16 
Protein 
coding 	
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit 
or stimulate the growth promoting effects of the IGFs on cell culture. They alter the 
interaction of IGFs with their cell surface receptors 
2 ENSG00000204301 NOTCH4 notch 4(NOTCH4) 1.42E-16 
Protein 
coding 	
Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to 
regulate cell-fate determination. Upon ligand activation through the released notch 
intracellular domain (NICD) it forms a transcriptional activator complex with 
RBPJ/RBPSUH and activates genes of the enhancer of split locus. Affects the 
implementation of differentiation, proliferation and apoptotic programs.  
2 ENSG00000179776 CDH5 cadherin 5(CDH5) 6.38E-16 
Protein 
coding 	
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with 
themselves in a homophilic manner in connecting cells; cadherins may thus contribute to 
the sorting of heterogeneous cell types. This cadherin may play a important role in 
endothelial cell biology through control of the cohesion and organization of the intercellular 
junctions. It associates with alpha-catenin forming a link to the cytoskeleton.  
2 ENSG00000152583 SPARCL1 SPARC like 1(SPARCL1) 1.03E-15 
Protein 
coding 	 GO annotations related to this gene include calcium ion binding.  
2 ENSG00000170323 FABP4 




Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. 
Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus 
2 ENSG00000118257 NRP2 neuropilin 2(NRP2) 2.12E-15 
Protein 
coding 	
High affinity receptor for semaphorins 3C, 3F, VEGF-165 and VEGF-145 isoforms of 
VEGF, and the PLGF-2 isoform of PGF 
2 ENSG00000162444 RBP7 retinol binding protein 7(RBP7) 2.16E-15 
Protein 
coding 	 Intracellular transport of retinol. 
2 ENSG00000112936 C7 complement C7(C7) 2.38E-15 Protein 
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and 
adaptive immune response by forming pores in the plasma membrane of target cells. C7 
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coding 	 serves as a membrane anchor. 
2 ENSG00000176435 CLEC14A 
C-type lectin domain family 14 
member A(CLEC14A) 2.70E-15 
Protein 
coding 	
Member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members 
of this family share a common protein fold and have diverse functions, such as cell 
adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune 
response. This family member plays a role in cell-cell adhesion and angiogenesis. 
2 ENSG00000116016 EPAS1 




Transcription factor involved in the induction of oxygen regulated genes. Binds to core 
DNA sequence 5-[AG]CGTG-3 within the hypoxia response element (HRE) of target gene 
promoters. Regulates the vascular endothelial growth factor (VEGF) expression 
2 ENSG00000142798 HSPG2 




Integral component of basement membranes. Component of the glomerular basement 
membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and 
which provides a barrier which is both size- and charge-selective. It serves as an 
attachment substrate for cells. Plays essential roles in vascularization. Critical for normal 
heart development and for regulating the vascular response to injury. Also required for 
avascular cartilage development. 
2 ENSG00000106991 ENG endoglin(ENG) 8.59E-15 
Protein 
coding 	
Major glycoprotein of vascular endothelium. Involved in the regulation of angiogenesis. 
May play a critical role in the binding of endothelial cells to integrins and/or other RGD 
receptors. Acts as TGF-beta co-receptor and is involved in the TGF-beta/BMP signalling 
cascade.  
2 ENSG00000037280 FLT4 




This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and 
D. The protein is thought to be involved in lymphangiogenesis  
2 ENSG00000069122 ADGRF5 
adhesion G protein-coupled 
receptor F5(ADGRF5) 1.16E-14 
Protein 
coding 	
Receptor that plays a critical role in lung surfactant homeostasis. May play a role in 
controlling adipocyte function. 
 
2 ENSG00000174804 FZD4 frizzled class receptor 4(FZD4) 1.16E-14 
Protein 
coding 	
Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin 
(CTNNB1) canonical signalling pathway, which leads to the activation of dishevelled 
proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of 
Wnt target genes.  
4 ENSG00000100351 GRAP2 
GRB2-related adaptor protein 
2(GRAP2) 7.66E-12 x 
Protein 
coding 	 Interacts with SLP-76 to regulate NF-AT activation. Binds to tyrosine-phosphorylated shc. 
4 ENSG00000162366 PDZK1IP1 
PDZK1 interacting protein 
1(PDZK1IP1) 6.50E-11 xs 
Protein 
coding 	   
4 ENSG00000088726 TMEM40 
transmembrane protein 
40(TMEM40) 2.58E-10 xs 
Protein 
coding 	   
4 ENSG00000171611 PTCRA 
pre T-cell antigen receptor 
alpha(PTCRA) 2.69E-09 xs 
Protein 
coding 	
The pre-T-cell receptor complex (composed of PTCRA, TCRB and the CD3 complex) 
regulates early T-cell development. 
4 ENSG00000124762 CDKN1A 
cyclin dependent kinase inhibitor 
1A(CDKN1A) 3.25E-09 xs 
Protein 
coding 	
May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to 
DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing 
phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle 
progression. 
4 ENSG00000101162 TUBB1 tubulin beta 1 class VI(TUBB1) 1.82E-08 xs 
Protein 
coding 	
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an 
exchangeable site on the beta chain and one at a non-exchangeable site on the alpha 
chain (By similarity). 
4 ENSG00000111644 ACRBP acrosin binding protein(ACRBP) 6.63E-08 
Protein 
coding 	
May be involved in packaging and condensation of the acrosin zymogen in the acrosomal 
matrix via its association with proacrosin. 
4 ENSG00000271503 CCL5 
C-C motif chemokine ligand 
5(CCL5) 1.01E-07 x 
Protein 
coding 	
Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the 
release of histamine from basophils and activates eosinophils. May activate several 
chemokine receptors  
4 ENSG00000108960 MMD 
monocyte to macrophage 
differentiation associated(MMD) 3.39E-07 
Protein 
coding 	
This protein is expressed by in vitro differentiated macrophages but not freshly isolated 
monocytes. Although sequence analysis identifies seven potential transmembrane 
domains, this protein has little homology to G-protein receptors and it has not been 
positively identified as a receptor.  
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4 ENSG00000229754 CXCR2P1 
C-X-C Motif Chemokine 
Receptor 2 Pseudogene 1 
(CXCR2P1) 1.79E-06 
Pseudo 
gene   
4 ENSG00000180573 HIST1H2AC 
histone cluster 1 H2A family 
member c(HIST1H2AC) 9.93E-06 
Protein 
coding 	
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, 
limiting DNA accessibility to the cellular machineries which require DNA as a template. 
Histones thereby play a central role in transcription regulation, DNA repair, DNA replication 
and chromosomal stability.  
4 ENSG00000124491 F13A1 
coagulation factor XIII A 
chain(F13A1) 1.46E-05 x 
Protein 
coding 	
Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyses 
the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus 
stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the 
alpha chains of fibrin. highly expressed in platelet 




coding 	   
4 ENSG00000147394 ZNF185 





coding 	 May be involved in the regulation of cellular proliferation and/or differentiation. 





Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an 
exchangeable site on the beta chain and one at a non-exchangeable site on the alpha 
chain. 




coding 	 Plays a role in endosomal maturation 
4 ENSG00000128266 GNAZ 






Guanine nucleotide-binding proteins (G proteins) are involved as modulators or 
transducers in various transmembrane signalling systems. 
4 ENSG00000129355 CDKN2D 






This protein has been shown to form a stable complex with CDK4 or CDK6, and prevent 
the activation of the CDK kinases, thus function as a cell growth regulator that controls cell 
cycle G1 progression. The abundance of the transcript of this gene was found to oscillate 
in a cell-cycle dependent manner with the lowest expression at mid G1 and a maximal 
expression during S phase.  
4 ENSG00000157514 TSC22D3 






Protects T-cells from IL2 deprivation-induced apoptosis through the inhibition of FOXO3A 
transcriptional activity that leads to the down-regulation of the pro-apoptotic factor 
BCL2L11. In macrophages, plays a role in the anti-inflammatory and immunosuppressive 
effects of glucocorticoids and IL10. In T-cells, inhibits anti-CD3-induced NFKB1 nuclear 
translocation. 
5 ENSG00000186529 CYP4F3 
cytochrome P450 family 4 
subfamily F member 3(CYP4F3) 3.91E-19 
Protein 
coding 	
This gene, CYP4F3, encodes a member of the cytochrome P450 superfamily of enzymes. 
The cytochrome P450 proteins are monooxygenases which catalyze many reactions 
involved in drug metabolism and synthesis of cholesterol, steroids and other lipids.  
5 ENSG00000182885 ADGRG3 
adhesion G protein-coupled 
receptor G3(ADGRG3) 1.46E-18 
Protein 
coding 	
Orphan receptor that regulates migration of lymphatic endothelial cells in vitro via the small 
GTPases RhoA and CDC42 (PubMed:24178298). Regulates B-cell developmen 
5 ENSG00000085265 FCN1 ficolin 1(FCN1) 2.29E-17 
Protein 
coding 	
Extracellular lectin functioning as a pattern-recognition receptor in innate immunity. Binds 
the sugar moieties of pathogen-associated molecular patterns (PAMPs) displayed on 
microbes and activates the lectin pathway of the complement system. 
5 ENSG00000121552 CSTA cystatin A(CSTA) 2.69E-17 
Protein 
coding 	
This is an intracellular thiol proteinase inhibitor. Has an important role in desmosome-
mediated cell-cell adhesion in the lower levels of the epidermis. 
5 ENSG00000128383 APOBEC3A 
apolipoprotein B mRNA editing 




DNA deaminase (cytidine deaminase) with restriction activity against viruses, foreign DNA 
and mobility of retrotransposons. Exhibits antiviral activity against adeno-associated virus 
(AAV) and human T-cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility of 
LTR and non-LTR retrotransposons.  
5 ENSG00000163563 MNDA 
myeloid cell nuclear 
differentiation antigen(MNDA) 2.99E-16 
Protein 
coding 	
May act as a transcriptional activator/repressor in the myeloid lineage. Plays a role in the 
granulocyte/monocyte cell-specific response to interferon. Stimulates the DNA binding of 
the transcriptional repressor protein YY1. 
5 ENSG00000116701 NCF2 




NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the 
latent NADPH oxidase  
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5 ENSG00000165168 CYBB 




Critical component of the membrane-bound oxidase of phagocytes that generates 
superoxide. It is the terminal component of a respiratory chain that transfers single 
electrons from cytoplasmic NADPH across the plasma membrane to molecular oxygen on 
the exterior.  
5 ENSG00000171051 FPR1 formyl peptide receptor 1(FPR1) 1.32E-13 
Protein 
coding 	
This gene encodes a G protein-coupled receptor of mammalian phagocytic cells that is a 
member of the G-protein coupled receptor 1 family. The protein mediates the response of 
phagocytic cells to invasion of the host by microorganisms and is important in host defense 
and inflammation. 





Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in 
inflammatory processes. 
5 ENSG00000101336 HCK 
HCK proto-oncogene, Src family 
tyrosine kinase(HCK) 2.84E-13 
Protein 
coding 	
The protein encoded by this gene is a member of the Src family of tyrosine kinases. This 
protein is primarily hemopoietic, particularly in cells of the myeloid and B-lymphoid 
lineages. It may help couple the Fc receptor to the activation of the respiratory burst. In 
addition, it may play a role in neutrophil migration and in the degranulation of neutrophils.  
5 ENSG00000197249 SERPINA1 
serpin family A member 
1(SERPINA1) 3.27E-13 x 
Protein 
coding 	
The protein encoded by this gene is secreted and is a serine protease inhibitor whose 
targets include elastase, plasmin, thrombin, trypsin, chymotrypsin, and plasminogen 
activator.  
5 ENSG00000158517 NCF1 




NCF2, NCF1, and a membrane bound cytochrome b558 are required for activation of the 
latent NADPH oxidase  
5 ENSG00000160883 HK3 hexokinase 3(HK3) 9.70E-13 
Protein 
coding 	
Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most 
glucose metabolism pathways. This gene encodes hexokinase 3.  
5 ENSG00000101265 RASSF2 
Ras association domain family 
member 2(RASSF2) 2.16E-12 
Protein 
coding 	
Potential tumor suppressor. Acts as a KRAS-specific effector protein. May promote 
apoptosis and cell cycle arrest.  
5 ENSG00000177663 IL17RA 




Interleukin 17A (IL17A) is a proinflammatory cytokine secreted by activated T-lymphocytes. 
It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into 
neutrophils. The transmembrane protein encoded by this gene (interleukin 17A receptor; 
IL17RA) is a ubiquitous type I membrane glycoprotein that binds with low affinity to 
interleukin 17A. Interleukin 17A and its receptor play a pathogenic role in many 
inflammatory and autoimmune diseases such as rheumatoid arthritis. 
5 ENSG00000132965 ALOX5AP 
arachidonate 5-lipoxygenase 
activating protein(ALOX5AP) 7.40E-12 
Protein 
coding 	
Required for leukotriene biosynthesis by ALOX5 (5-lipoxygenase). Anchors ALOX5 to the 
membrane. Binds arachidonic acid, and could play an essential role in the transfer of 
arachidonic acid to ALOX5. Binds to MK-886, a compound that blocks the biosynthesis of 
leukotrienes. 
5 ENSG00000165178 NCF1C 
neutrophil cytosolic factor 1C 
pseudogene(NCF1C) 1.00E-11 
Pseudo 
gene May be required for activation of the latent NADPH oxidase  
5 ENSG00000000938 FGR 
FGR proto-oncogene, Src family 
tyrosine kinase(FGR) 3.82E-11 
Protein 
coding 	
Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors 
devoid of kinase activity and contributes to the regulation of immune responses, including 
neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in 
response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes 
mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis.  
5 ENSG00000163993 S100P 
S100 calcium binding protein 
P(S100P) 6.50E-11 x 
Protein 
coding 	
May function as calcium sensor and contribute to cellular calcium signaling. In a calcium-
dependent manner, functions by interacting with other proteins, such as EZR and PPP5C, 
and indirectly plays a role in physiological processes like the formation of microvilli in 
epithelial cells.  
 
Table 3.4 HSC cluster top 20 marker genes 
Top 20 marker genes for HSC clusters 1,2,4,5, showing significance level (Pvalue), Protein expression in platelets, gene biotype and functional summary from the 
online tool: Genecards. (Platelet protein: x indicates expressed, xs indicates cell specific expression)  
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Figure 3.18 Heatmap to show expression of cluster marker genes in Blueprint dataset 
Heatmap of mean-centred normalized and corrected log-expression values from the Blueprint 
progenitors’ dataset for the top 20 marker genes for each HSC cluster (rows). Column colours 









Figure 3.19 Single cell differentiation trajectories using Monocle 2 showing expression 
of cell type gene signatures from DMAP dataset. 
Individual cells are connected by a minimum spanning tree with branch points (thin lines), 
representing the differentiation trajectory and clusters are differentiated by colour. Expression 
of gene signature is indicated by the size of each single cell. a. Megakaryocyte signature; b. 
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Figure 3.20  Over-represented gene ontologies within each HSC cluster marker genes 
The full GO analysis may be found in Appendix 1. The word cloud is a visual representation of the over-represented GO biological processes 
with their size an indicator of significance for clusters 1,2,4 and 5. 
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Figure 3.21 Correlation between VWF surface and transcript expression by RNA-seq. 
VWF surface expression measured by FACS index sorting (MFI, Yaxis) for each HSC plotted 





3.2.5 Flow cytometric index sorting analysis 
 
In order to prospectively sort the different HSC clusters, a unique pattern of surface marker 
expression would need to be identified for cells belonging to each cluster. To investigate if 
there was a correlation between cell surface markers that had been used to FACS sort the 
HSCs, the indexed flow cytometry data was retrospectively analysed within each gate that 
was sorted, including VWF expression that was also recorded but not used as criteria on 
which to sort (Figure 3.22). This shows that the cells taken forward for gene expression 
analysis on the basis of high quality sequencing data were representative of all cells sorted 
(low quality cells marked in grey, Figure 3.22). Furthermore, cells from each subset also tend 
to cluster on the basis of surface marker expression.  
 
Figure 3.23 shows normalised surface marker expression for each individual cluster. Cluster 
1 and 4 which are both megakaryocyte-like HSC subsets are similar in expression of CD38, 
CD45RA, and CD90. However, cluster 4 has higher expression of CD49f and VWF than 
cluster 1 and lower expression of CD34. On the basis of the data presented it is not possible 





Figure 3.22 Flow cytometry plots for HSCs sorted for RNA-seq. 
Retrospective analysis of flow FACS analysis for each individual HSC sorted showing: A. 
CD34 vs CD38; B. CD90 vs CD45RA; C. CD90 vs CD49f; D. VWF vs CD49f. Individual 
surface marker expression was normalised. Cluster 1: red, cluster 2: yellow, cluster 3: green, 





Figure 3.23 Flow cytometry index data by HSC cluster. 
Difference in normalised surface marker expression (y axis) between HSC clusters 1, 2, 3, 4, 









3.2.6 Functional validation of HSC reconstitution capacity 
 
To verify the functional capacity of the sorted HSC population in terms of multilineage 
reconstitution, human bone marrow HSCs were transplanted into sub-lethally irradiated NSG 
mice by methods detailed in Section 2.5. Cells from cryopreserved human bone marrow 
CD34+ cells were FACS sorted using the gating strategy shown in Figure 3.1. They were also 
sorted according to VWF surface expression positive or negative. 400 VWF+ HSCs per 
mouse were transplanted by right femoral injection into 4 mice; 400 VWF- HSCs per mouse 
were transplanted into 4 mice, 68,000 VWF- HSCs per mouse were transplanted into 2 mice, 
1 mouse was kept as a negative control. After 16 weeks, the mice were sacrificed and their 
peripheral blood and bone marrow were harvested and stained with antibodies to detect 
engraftment of human lymphoid, myeloid and megakaryocytic cells by flow cytometry.  
 
Table 3.5 shows the level of engraftment in each animal, with the right femur and rest of bone 
marrow analysed separately. There was no engraftment seen in the peripheral blood and no 
megakaryocytes were identified in the bone marrow for any of the mice by flow cytometry. 
The 2 mice with 68,000 VWF- HSCs transplanted both engrafted showing both lymphoid and 
myeloid engraftment. From the 8 mice with only 400 cells transplanted, 3 mice engrafted, 2 
mice that were transplanted with VWF+ HSCs and 1 mouse transplanted with VWF- HSCs. 
All 3 of the mice demonstrated both myeloid and lymphoid reconstitution. 
 
 
Animal Transplanted HSCs 
RIGHT FEMUR REST OF BONE MARROW 
Engraftment 
CD45+ CD33+ CD19+ CD45+ CD33+ CD19+ 
1 VWF+ 400 cells 3 2 1 0 0 0 0 
2 VWF+ 400 cells 0 0 0 1 0 1 0 
3 VWF+ 400 cells 114 6 98 1 0 0 1 
4 VWF+ 400 cells 3 0 3 12 0 8 1 
5 VWF- 400 cells 0 0 0 0 0 0 0 
6 VWF- 400 cells 11 0 9 0 0 0 1 
7 VWF- 400 cells 1 0 0 0 0 0 0 
8 VWF- 400 cells 0 0 0 0 0 0 0 
9 VWF- 68K cells 60 5 45 3 0 2 1 
10 VWF- 68K cells 89 3 76 1186 28 1050 1 
11 Control 0 0 0 4 0 3 0 
Table 3.5 Blood cell reconstitution 16 weeks post xenotransplantation with VWF+/- 
human HSCs in sub lethally irradiated NSG mice. 





The aim of this work was to uncover transcriptional variation and identify subpopulations 
within the human bone marrow HSC compartment in order to gain insights into the 
heterogeneity displayed by the HSC as well as insights into early megakaryopoiesis. The first 
studies using single cell RNA-seq to demonstrate HSCs as a transcriptionally heterogeneous 
population have recently been published in mouse (Wilson et al. 2015; Grover et al. 2016) 
and zebrafish (Macaulay et al. 2016). During the course of this project, human bone marrow 
HSCs were simultaneously sequenced at the single cell level by another group (Velten et al. 
2017). However, the work presented here represents the first single cell RNA-seq analysis in 
human bone marrow HSCs to define transcriptionally distinct cell populations within the HSC 
compartment itself.  
 
In this study, ex-vivo primary human bone marrow cells collected as sternal samples from five 
individuals undergoing aortic/mitral valve replacement. Fresh cells were stained with a panel 
of 16 surface markers and HSCs (defined as Lin-CD34+CD38-CD45RA-CD90+CD49f+) were 
index sorted for transcriptome analysis. To ensure that the cells that were sorted and studied 
were in fact HSCs with both multilineage engraftment potential, cells sorted within these gates 
were transplanted into sub lethally irradiated NSG mice and indeed demonstrated both 
myeloid and lymphoid engraftment at 16 weeks.  
 
Whole transcriptome amplification was performed on the index sorted HSCs using a modified 
Smart-seq2 protocol and a total of 884 cells were sequenced. Previous transcriptome studies 
on human HSCs have been performed on CD34+ fraction of peripheral and cord blood or on 
preserved/frozen bone marrow samples (Notta et al. 2016). Here fresh human bone marrow 
was used in an attempt to provide the most physiological transcriptional representation of 
HSCs that reside in the bone marrow stem cell niche. The challenges of working with ex-vivo 
primary human cells necessitated rigorous quality filtering of the RNA-seq data using a 
machine learning cell filtering method (Section 2.6). Finally, 119 cells were used for gene 
expression analysis.  
 
Unsupervised clustering revealed 5 transcriptionally distinct cell population “clusters” within 
the HSC compartment which separated out according to Pearson’s correlation. When the 
cells were clustered using a different method by which each single cell was placed according 
to differing gene expression creating differentiation trajectories, the cells clustered into the 
similar groupings adding confidence to the robustness of the original clusters. Cluster 3, as 
the most heterogeneous group lay at the root/branch point of the trajectories with the more 
homogenous clusters 1, 2 and 5 furthest apart on separate trajectories. Cluster 4 was seen to 
branch from the same trajectory as cluster 1 indicating a closer relationship.  
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A number of genes of megakaryocyte lineage featured in the top 200 most highly expressed 
genes in the HSC population as a whole including PPBP, PF4, SDPR, ITGA2B and VWF. 
Transcription of genes that are known to be expressed at both transcript and protein level in 
published megakaryocyte and platelet datasets demonstrates that the genetic programs 
required to produce the megakaryocyte lineage and platelets are switched on early in the 
HSC in agreement with studies in the mouse (Wilson et al. 2015; Grover et al. 2016; Sanjuan-
Pla et al. 2013; Gekas and Graf 2013).  
 
Identification of marker genes for each cluster revealed a number of megakaryocyte lineage 
genes as markers for cluster 1 and cluster 4. Comparison of cluster marker genes with 
recently published progenitor RNA-seq datasets from the Blueprint (L. Chen et al. 2014) and 
DMAP (Novershtern et al. 2011)  databases added a further degree of confidence in these 
observations (Figure 3.18, 3.19). Again, this showed that cluster 1 and 4 marker genes were 
also expressed in megakaryocytes derived in vitro from blood CD34+ cells. While cluster 4 
marker genes were specific to megakaryocytes, cluster 1 markers genes were expressed in 
megakaryocyte lineage population from the HSC population, through CMP, GMP, MPP to 
MEP populations (Figure 3.18). This observation was confirmed when placing the DMAP 
gene signatures onto the Monocle 2 differentiation trajectories (Figure 3.19). This showed that 
while the megakaryocyte signature was over-represented in cluster 1 and 4, the MEP 
signature was over-represented in only cluster 1 cells. The monocyte signature was over-
represented in cluster 5 whilst cluster 2 expressed genes from the B cell signature. Cluster 3 
had no significantly expressed marker genes which is in keeping with its position on the 
Monocle 2 differentiation trajectories.  
 
A GO analysis of the cluster 1 marker genes indicated that the most significantly enriched GO 
categories for biological process were related to ribosomal function and protein localisation. 
While genes encoding for ribosomal or translational proteins made up only two of the top 20 
marker genes, 77 out of the total 313 significant cluster 1 marker genes were ribosomal. This 
was a much greater proportion than any other cluster and it would indicate that the processes 
involved in translation, protein packaging are functionally important in this HSC cluster and its 
lineage committed progeny. After translation, the most significantly enriched GO biological 
processes were related to cellular metabolism, coagulation, haemostasis, translation and 
RNA splicing. 313 marker genes were identified for cluster 1 which was the largest HSC 
cluster comprising 46 single cells. However, only 19 marker genes were identified for cluster 
4 which was made up of only 10 cells. The GO categories significantly enriched in cluster 4 
pertained to the negative regulation of programmed cell death, cell cycle, protein folding and 
exocytosis. While it did not meet significance the GO category platelet degranulation also 
ranked highly. As suggested by the correlation with DMAP data, cluster 5 was significantly 
enriched for GO categories related to the immune response particularly with innate immunity 
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and GO analysis for cluster 2 suggested that the genes upregulated in this cluster were 
related to blood vessel development and endothelial cell function. 
 
When the marker genes for each cluster are compared with published transcriptome datasets 
for megakaryocytes (cultured in vitro from CD34+cells) and other haematopoietic cells (L. 
Chen et al. 2014; Novershtern et al. 2011; Watkins et al. 2009) and platelets (Rowley et al. 
2011; Goodall et al. 2010), cluster 1 and 4 marker genes show high levels of expression in 
megakaryocytes and platelets. In cluster 1, 7 out of 20 marker genes are highly expressed in 
both megakaryocytes and platelets with a further 11 out of 20 highly expressed in 
megakaryocytes with low to moderate expression in platelets. All 19 of cluster 4 marker 
genes show at least moderate expression in megakaryocytes and high expression in 
platelets. The evidence presented suggests that while both HSC cluster 1 and cluster 4 may 
be biased to the megakaryocyte lineage, HSCs in cluster 4 are already primed for platelet 
production and haemostatic functionality. In contrast marker genes from clusters 2 and 5 
have much lower expression levels within the megakaryocyte lineage. Out of 20 marker 
genes in cluster 5 only 7 are seen to be expressed in megakaryocytes but with little or no 
expression in platelets and only 1 out of 20 of cluster 2 marker genes show transcript 
expression in megakaryocytes.  
 
Of the cluster 1 marker genes, three encode proteins that are directly involved in platelet 
function. ANGPT1, located to chromosome 8, encodes the glycoprotein growth factor 
angiopoietin 1. It is stored in platelet alpha granules and released on platelet activation with 
thrombin (Y. Q. Huang, Li, and Karpatkin 2000; J. J. Li et al. 2001), as such it is present at the 
protein level in platelets with high quantity (Genecards.org). It is essential for blood vessel 
development where it functions by binding to a tyrosine kinase receptor, however it also has 
high transcript expression in the HSC (Forsberg et al. 2010; Cabezas-Wallscheid et al. 2014) 
as well as in stromal cells within the stem cell niche (Méndez-Ferrer et al. 2010; Ding et al. 
2012) and therefore may also have an important role in haematopoiesis. IL1B, located on 
chromosome 2, encodes for the pro-inflammatory cytokine interleukin1B and is also a cluster 
1 marker gene that has been shown to be important in platelet function (Beaulieu et al. 2014). 
While it is known to be released from activated macrophages as part of the inflammatory 
response platelet activation has also been shown to induce the synthesis and release of IL-1β 
via shedding of membrane-bound vesicles or release of exosomes (Denis et al. 2005; 
Weyrich et al. 2009). It is also well known to promote megakaryopoiesis and platelet release 
both in vivo and in vitro (Kimura et al. 1990; Jiang et al. 1994) and recently been shown to 
play a regulatory role in HSC (Espín-Palazón et al. 2014). It is highly expressed at the 
transcript level in HSCs, megakaryocytes (Novershtern et al. 2011; L. Chen et al. 2014) and 
platelet (Rowley et al. 2011). Another cluster 1 marker gene, TSPAN32, located on 
chromosome 11, that encodes a transmembrane protein of the tetraspanin family has also 
been shown to have an essential role in platelet function. TSPAN32 is a positive regulator of 
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the GPIIb/IIIa signalling and thrombus formation with TSPAN32 knockout mice demonstrating 
bleeding phenotypes (Goschnick et al. 2006; Orlowski et al. 2009). TSPAN32 has been 
shown to be expressed in megakaryocytes (Novershtern et al. 2011; L. Chen et al. 2014) as 
well as platelets (Rowley et al. 2011). A fourth cluster 1 marker gene has also been 
implicated in the regulation of platelet activation although as a negative regulator. GUCY1A3, 
a gene located on chromosome 4, encodes for the soluble alpha-3 subunit of guanylate 
cyclase which is an important signalling pathway in VEGF-induced angiogenesis, however 
the same pathway has been shown to inhibit platelet activation (Moro et al. 1996). The 
transcript has been seen to have an increased expression in HSCs and is upregulated in 
megakaryocytes compared to other mature cells lineages (Watkins et al. 2009). It is 
expressed at high transcript (Rowley et al. 2011) and protein levels in platelets 
(Genecards.org). 
 
A number of significant marker genes for cluster 1 have also been shown to play a role in 
megakaryopoiesis, in addition to IL1B described above. HEMGN, a gene located on 
chromosome 9, encodes a nuclear protein that has been shown to be expressed in immature 
erythroid and megakaryocyte precursors and down regulated with further differentiation (L. V. 
Yang et al. 2001; Krüger et al. 2002). From DMAP and Blueprint data it is expressed 
throughout the megakaryocyte precursors (Novershtern et al. 2011; L. Chen et al. 2014) as 
well as in platelets at both transcript (Rowley et al. 2011) and protein level (Genecards.org). 
Interestingly in recent GWAS data HEMGN has been associated with platelet traits PLT, PCT, 
PDW. NPM1, located on chromosome 3, which encodes the protein nucleophosmin 1 and 
can either be nuclear or cytoplasmic is expressed highly in HSCs and megakaryocytes 
(Novershtern et al. 2011; L. Chen et al. 2014) but at lower levels in the platelet (Rowley et al. 
2011). It is known to be integral to a number of cellular processes including cell cycle, 
translation and histone assembly. Mutation in the NPM1 gene (which is commonly seen in 
acute myeloid leukaemia), leads to expansion of the megakaryocyte compartment with 
impaired megakaryocyte function and resultant reduced platelet counts (Sportoletti et al. 
2013). Another of the cluster 1 marker genes PRKACB, located on chromosome 1, encodes 
the catalytic B subunit of cAMP dependent protein kinase which mediates cAMP signalling. It 
is integral to a number of cellular processes including cell proliferation and differentiation and 
it has recently been shown that TAL1 activity in megakaryocytes is likely to be mediated 
through this pathway (Kuvardina et al. 2017). TAL1 is an important transcription factor in 
determining megakaryocyte cell fate (Tijssen et al. 2011). Accordingly, PRKACB is shown to 
be upregulated in megakaryocytes compared to other mature cells. Although lower transcript 
levels are expressed in the platelet (Rowley et al. 2011), high levels of the protein are seen 
(Genecards.org), indeed PRKACB has been positively correlated with platelet function 
(Goodall et al. 2010). 
 
	 103
NRIP1 (chromosome 21) and PARP1 (chromosome 1) encode two nuclear proteins that were 
significantly upregulated in cluster 1 and while they are also expressed in the megakaryocyte 
lineage, they have regulatory effects on the HSC itself. NRIP1 encodes for a nuclear protein 
described as a transcriptional co-regulator that modulates transcription by activation of steroid 
receptors. Although it is ubiquitously expressed, it is thought to be an important factor 
required for the maintenance and function of normal quiescent HSCs as it has shown high 
HSC transcript expression (T. S. Huang et al. 2008) and with downregulation with further 
differentiation (Forsberg et al. 2010). NRIP1 protein is also expressed in platelets although 
with unclear function.  PARP1 encodes a nuclear binding protein that mediates post-
translational protein modification. It also has an important role in DNA repair which is 
demonstrated by its upregulation in cancer cells and the emerging therapeutic role for PARP1 
inhibition (Rouleau et al. 2010). In a similar way it is thought to protect HSC DNA from self-
renewal defects (X. Li et al. 2012; Du et al. 2016). Its particular significance here is that it may 
also have a role in megakaryopoiesis. ETS-1 is a transcription factor known to switch on 
megakaryocyte differentiation and as PARP1 DNA repair can be mediated through ETS-1 
(Legrand et al. 2013) it could be important in fulfilling cell fate decisions. In accordance with 
this PARP1 has been shown to be expressed in HSCs, other progenitors and at higher levels 
in megakaryocytes (Novershtern et al. 2011; L. Chen et al. 2014). 
 
Several other genes involved in cellular metabolism were upregulated in cluster 1 compared 
to the other HSC subsets include LDHB (chromosome 12), SLC37A1 (chromosome 21) and 
ATP6V0A2 (chromosome 12) and have previously been reported to be expressed in the 
megakaryocyte lineage (Novershtern et al. 2011; L. Chen et al. 2014; Rowley et al. 2011). 
While LDHB is expressed in all cells it is highly enriched in HSCs suggesting that anaerobic 
metabolism plays an important role in HSCs (Cabezas-Wallscheid et al. 2014). SLC37A1 
encodes an endoplasmic reticulum transporter protein and is specifically upregulated in 
megakaryocytes (Watkins et al. 2009) with protein expression in platelets (Genecards.org). 
ATP6V0A2 encodes an enzyme transporter ubiquitous to all endomembrane organelles. 
LAPTM4B, located on chromosome 8 also encodes an endomembrane protein, it has 
unknown function but is expressed highly in HSCs and megakaryocytes. Another 
transmembrane protein specific to the golgi membrane is encoded by another significant 
cluster 1 marker gene, ST6GAL2 located on chromosome 2. Interestingly this gene has not 
previously been reported to be expressed in haematopoietic cells. 
 
Other nuclear genes significantly upregulated in cluster 1 compared with the other HSC 
subsets include: ABRACL (or C6orf115), a gene located on chromosome 6, which encodes a 
costar family protein shown to be one of the top 50 platelet proteins (Gevaert et al. 2003) 
although its function is unknown. ANP32B (chromosome 9) which encodes a protein highly 
expressed in HSCs, megakaryocytes and platelets that is anti-apoptotic and involved in 
transcriptional regulation. EIF1AX, located on the X chromosome, is expressed highly in 
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HSCs and megakaryocytes and involved in protein translation, as are RPS12 (chromosome 
6) and RPL21 (chromosome 13) both encoding ribosomal subunits highly expressed through 
from HSC to megakaryocyte and in platelets. The final cluster 1 marker gene, FAM30A 
(chromosome 14) is a non-coding RNA gene. 
 
In summary, while three of cluster 1 marker genes encode proteins that play a direct role in 
platelet activation, a number of genes are involved in megakaryopoiesis from the HSC. 
Although all but 2 (ST6GAL2, FAM30A) of the cluster genes have previously reported high 
levels of transcript expression in megakaryocytes, only ANGPT1, GUCY1A3 and SLC37A1 
are seen to be upregulated in megakaryocytes compared with other differentiated 
haematopoietic cells, and none are solely expressed in megakaryocytes compared with the 
other progenitors. This is in keeping with the known expression of cluster 1 marker genes in 
all intermediate progenitors from HSC to megakaryocyte in the Blueprint data (Figure 3.18) 
and the overlap between expression of cluster 1 marker genes with both megakaryocyte and 
MEP from the DMAP dataset (Figure 3.19). 
 
Conversely as discussed below, 7 out of 19 of cluster 4 marker genes are directly involved in 
platelet activation and platelet function and 12 of the genes are upregulated or expressed 
specifically in the megakaryocyte lineage. Furthermore all 19 genes have previously reported 
high transcript levels in platelets (Rowley et al. 2011).  
 
Two of the cluster 4 markers genes that are known to play an important role in platelet 
function are tubulin B1 (TUBB1, located on chromosome 20) and tubulin A4 (TUBA4A, 
located on chromosome 2) which are highly specific to the megakaryocyte/platelet lineage. 
They are expressed at low levels in HSCs (Novershtern et al. 2011; L. Chen et al. 2014) but 
highly expressed in megakaryocytes as well as having high platelet transcript and protein 
expression (Rowley et al. 2011; Genecards.org). These genes encode proteins integral to 
organisation of the cytoskeleton and both are thereby directly involved in proplatelet formation 
and platelet conformational change. Transcripts of important proteins released by the platelet 
during activation were also upregulated in the cluster 4 markers genes. F13A1, a gene 
located on chromosome 6, encodes for platelet coagulation factor XIII alpha chain. It is known 
to reside in the platelet alpha granule and is released at the time of platelet degranulation. 
While previous datasets have demonstrated low expression in HSCs, F13A1 is specifically 
expressed at high levels in megakaryocytes (Novershtern et al. 2011; L. Chen et al. 2014) 
and platelets at both the transcript and protein levels (Rowley et al. 2011; Genecards.org). 
The gene for the chemokine CCL5 was also a cluster 4 marker gene and is one of the 
chemokine genes found on chromosome 17. CCL5 encodes a chemokine known to be highly 
expressed in the platelet and is released upon platelet activation.	 Recently it has been 
suggested to have regulatory feedback activity on the megakaryocyte through its receptor 
CCR5 (Machlus et al. 2016). CCL5 is known to be specifically expressed in megakaryocytes 
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with low levels of expression in the HSC (Novershtern et al. 2011; L. Chen et al. 2014). 
Cluster 4 marker genes also included three genes involved in signal transduction during 
platelet activation. The most significantly upregulated gene in cluster 4 was GRAP2 
(chromosome 22), that encodes an adaptor involved in protein tyrosine kinase signalling on 
activation of the GPVI collagen receptor, that results in a cascade of integrin activation, 
platelet shape change and platelet degranulation. In previous data sets GRAP2 is expressed 
at relatively low levels in HSCs (Novershtern et al. 2011; L. Chen et al. 2014). The levels of 
transcription are much higher levels in megakaryocytes, with expression increasing with 
megakaryocyte differentiation (Kim et al. 2002; Shim et al. 2004). Both transcript and protein 
expression are high in platelets (Rowley et al. 2011; Genecards). Another transcript involved 
in signalling within the cell, found to be a significant marker gene of cluster 4, is ZNF185 
(located on the X chromosome). It encodes a LIM and zinc finger domain protein that 
mediates protein-protein interactions and thereby regulates a number of cellular processes, 
including cytoskeletal change. Current data suggests that while the transcript is only 
expressed at low levels in the HSC, there are high transcript levels in the megakaryocyte 
(Novershtern et al. 2011; L. Chen et al. 2014) and platelet (Rowley et al. 2011) and is thereby 
specific to the megakaryocyte lineage. GNAZ (chromosome 22), is also upregulated in cluster 
4 but with expression at lower levels. It encodes the signal transduction G protein subunit 
alpha Z which has been shown to be present in human megakaryocytes and platelets, and is 
phosphorylated during platelet activation (Gagnon et al. 1991). It is present at transcript level 
in HSCs, other progenitors as well as megakaryocytes and platelets (Novershtern et al. 2011; 
L. Chen et al. 2014; Rowley et al. 2011).  
 
Three out of 19 cluster 4 marker genes encode for transmembrane proteins that are specific 
to the megakaryocyte/platelet lineage. PDZK1IP1 (also known as MAP17) was the second 
most highly significant cluster 4 marker gene. It is located on chromosome 1 in close 
proximity to TAL1 (regulator of megakaryocyte/erythroid differentiation) and encodes a small 
plasma membrane associated protein with a PDZ-binding domain and two transmembrane 
domains. It has been shown to be specifically expressed at high levels in platelets both at the 
transcript and protein level (Rowley et al. 2011), although levels of transcript expression in 
HSCs and megakaryocytes are far lower (Novershtern et al. 2011; L. Chen et al. 2014). It has 
however been shown to be expressed at higher levels in the murine HSC (Cabezas-
Wallscheid et al. 2014; Forsberg et al. 2010; Wilson et al. 2015) with a major contribution of 
PDZK1IP1 expressing cells to all lineages after transplantation especially platelets (Sawai et 
al. 2016). In humans, however, its physiological role is unclear. TMEM40 was also found to 
be a highly significant marker gene for cluster 4. It is found on chromosome 3 and encodes a 
transmembrane protein that has been localised to the exosome within the cell. TMEM40 
demonstrates moderate levels of transcript expression in the HSC (Novershtern et al. 2011; 
L. Chen et al. 2014), it has been shown to be upregulated in megakaryocytes compared with 
erythroblasts (Macaulay et al. 2007) and shows high levels of expression in the platelet 
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(Rowley et al. 2011) as well as high levels of platelet protein expression (Genecards.org). 
PTCRA, another significant marker gene for cluster 4, is pre-T cell receptor alpha on 
chromosome 6. It encodes a plasma membrane protein which along with TCR and CD3 form 
the immature T cell receptor complex. What its function is on the surface of the HSC, 
megakaryocyte or platelet is unknown. It is seen to be expressed at low levels in HSCs and 
megakaryocytes (Novershtern et al. 2011; L. Chen et al. 2014). However, it is upregulated at 
the transcript as well as protein level in platelets as well as the lymphoid lineage 
(Genecards.org).  
 
Two of the cluster 4 marker genes encoded the negative regulators of proliferation: cyclin 
dependent kinase inhibitors CDKN1A and CDKN2D (chromosome 6, 19 respectively). They 
have both been shown to be expressed in HSCs and megakaryocytes at the transcript level 
(Novershtern et al. 2011; L. Chen et al. 2014) as well as platelets as transcript and protein 
(Rowley et al. 2011; Genecards.org). A further two of the cluster 4 marker genes encode 
proteins related to transcriptional regulation. HIST1H2AC (chromosome 6) was found to a be 
highly significant cluster 4 marker gene. It encodes a chromosome organisational protein, a 
core component of the nucleosome and through its own post-translational modification it 
regulates transcription. While this gene is expressed across all progenitors it has a higher 
expression in megakaryocytes (Novershtern et al. 2011; L. Chen et al. 2014) and platelets 
(Rowley et al. 2011), also being part of the platelet proteome (Genecards.org). Another 
cluster 4 marker gene, TSC22D3 (X chromosome) encodes for a DNA binding protein with 
transcription factor activity and is a known to be a down regulator of pro-apoptotic factors. It is 
upregulated in megakaryocytes compared with HSCs (Novershtern et al. 2011; L. Chen et al. 
2014) and remains highly expressed in platelets (Rowley et al. 2011; Genecards.org).  
 
Of the remaining cluster 4 marker genes, three encode organelle membrane proteins, 
ACRBP, SNN, MMD (chromosomes 12, 16 and 17 respectively) and although all are 
expressed highly in megakaryocytes although not-specifically (Novershtern et al. 2011; L. 
Chen et al. 2014) and platelets (Rowley et al. 2011) their function in this setting is unclear. 
Other cluster 4 marker genes include the pseudogene CXCR2P1 (chromosome 2) and 
C21orf7 (chromosome 21) both of uncertain significance. 
 
As previously discussed, to date megakaryocyte transcriptome data which is available is from 
cultured megakaryocytes that have been derived in vitro from peripheral blood CD34+ cells, 
under the influence of TPO and IL1B. Therefore, they are not representative of in vivo 
megakaryocytes. In an attempt to analyse the transcriptome of higher ploidy cells one study 
has assessed differential transcript expression between in vitro derived 2-4N megakaryocytes 
and 8-16N megakaryocytes which are found in much smaller quantities (Raslova et al. 2007). 
Interestingly, of the cluster 1 marker genes only ANGPT1 was seen to be upregulated with 
increasing ploidy, 17 of the cluster 1 marker genes were not differentially expressed and 
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expression of NPM1 was downregulated. Of the cluster 4 marker genes, 10 genes were 
upregulated with increasing ploidy: TUBB1, TUBA4A, F13A1, CCL5, GRAP2, PTCRA, 
CDKN2D, HIST1H2AC, ACRBP, SNN with the remaining not being differentially expressed.  
 
Taken together it is hypothesised that while HSC subsets 1 and 4 are megakaryocyte biased, 
HSCs in cluster 1 are primed to produce HSCs through the classical differentiation pathway 
and, whereas cluster 4 HSCs already express many of the necessary transcripts to produce 
megakaryocytes directly bypassing intermediate progenitors, and even have many of the 
genes required for platelet function. In keeping with this the genes upregulated in cluster 1 
compared to other HSC subsets have previously been shown to be expressed in 
megakaryocyte progenitors as well as megakaryocytes but often not in platelets, a number of 
them are related to HSC function and megakaryopoiesis, while fewer encode proteins 
involved in platelet function. Moreover, cluster 4 upregulated genes are more specifically 
expressed in megakaryocytes, with low expression in megakaryocyte progenitors and high 
expression at both transcript and protein level in platelets. Many of the upregulated cluster 4 
genes encode proteins directly involved in platelet activation and function. Therefore cluster 4 
could be analogous to the lineage-restricted HSC subset primed to produce emergency or 
“stress” megakaryocytes as previously described (Haas et al. 2015). 
 
In an attempt to investigate whether it was possible to prospectively identify clusters 1 and 4 
the index FACS sorting data was analysed. While cluster 1 and 4 differed in terms of their 
surface expression of CD34 and CD49F. While cluster 1 had high CD34, and lower CD49F 
expression, cluster 4 had expressed lower CD34 and higher CD49F on the surface. It would 
also be possible to differentiate some cluster 1 cells from clusters 2, 3 and 5 on the basis of 
CD45RA expression. However, prospectively differentiation cluster 4 from clusters 3 and 5 on 
this basis would be difficult. Further work is required to assess whether differentiating clusters 
1 and 4 from the whole HSC population is indeed possible with the existing surface markers 
or if work is required on adding new markers. From the work on cluster 1 and 4 marker genes 
It may also be possible to target cluster 1 and 4 marker genes that are known to be encode 
proteins expressed on the cell surface such as TSPAN32 for cluster 1 and PTCRA and 
PDZK1IP1 for cluster 4. If these could be prospectively differentiated, further in vitro 
differentiation, transplantation or RNA sequencing or larger cell numbers could be attempted 
to gain further understanding of the role of these 2 HSC subpopulations. 
 
The main limitations of the methods used are the limitations of any single cell RNA-seq 
analysis. There remains no standardised analysis for normalising for technical dropouts or 
“zeros”, although in this study the Lun method (Lun, McCarthy, and Marioni 2016) was 
chosen for normalisation. Furthermore, as with any PCR amplification process there is a 
heavy bias towards amplification of more abundant transcripts which may result in 
overrepresentation of these transcripts in the resulting data. This is of course may be more 
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apparent in single cell analysis as it leads to a disparity between overrepresented abundant 
transcripts and technical dropouts which may be false negatives. Nevertheless, the clustering 
methods used here are robust and previously validated in published work (Kiselev et al. 2017; 
Trapnell et al. 2014; Qiu et al. 2017). Another limitation was number of cells with only 119 
deemed to be of high quality and taken forward for gene expression analysis from a total of 
884 cells. The proportion of high quality cells amongst the number of cells sorted may be 
related to the time taken from cell harvest to sorting into lysis buffer which was at least 3 
hours. Further work would include increasing the number of cells to further validate the 
transcriptional differences found in this study. 
 
The gene signatures presented in this chapter relating to the two megakaryocytes biased 
clusters have been compared to previously published cultured megakaryocyte gene 
expression. In the following chapters the transcriptome of ex-vivo human bone marrow 
megakaryocytes is analysed at different levels of polyploidisation and in the setting of 
coronary thrombosis which is hypothesised to produce stress megakaryopoiesis. HSC cluster 
1 and 4 signatures are then correlated with the bone marrow megakaryocyte transcriptome to 








The molecular mechanisms controlling megakaryopoiesis, including megakaryocyte 
maturation, remain largely unknown due to a number of technical challenges that have 
precluded the study of cellular and molecular events. These include obtaining human bone 
marrow samples from patients who do not clinically require bone marrow aspiration, the rarity 
of the cell population, estimated to make up less than 0.05% of the nucleated bone marrow 
cell compartment and the size, and fragility of the megakaryocyte. This has so far prevented 
transcriptome analysis of primary human bone marrow megakaryocytes. However, with the 
ability to interrogate single cell transcriptomes it has now become possible. Our current 
megakaryocyte knowledge is largely based on gene expression array data of 
megakaryocytes cultured from haematopoietic progenitors obtained from foetal liver, cord 
blood and adult blood (Bluteau et al. 2013; Watkins et al. 2009; Shim et al. 2004; Raslova et 
al. 2007; L. Chen et al. 2014), as well as knowledge of the platelet transcriptome (Gnatenko 
et al. 2003; Bugert et al. 2003; McRedmond et al. 2004; Hillmann et al. 2006; Rowley et al. 
2011). When comparing megakaryocytes cultured from adult blood with their precursor 
CD34+ cells one third of the upregulated genes have been shown to be directly involved in 
haemostasis or platelet function (Shim et al. 2004). Many of the transcripts that were 
upregulated are known to play key roles in thrombus formation such as glycoprotein V and 
IIIa, von Willebrand factor, integrins B3 and a6, P-selectin, coagulation factor XIII (Shim et al. 
2004).  
 
Gene expression profiles of cultured megakaryocytes of differing ploidies have also been 
analysed, with comparison made between 2-4N and 8-16N megakaryocytes to gain further 
understanding of megakaryocyte maturation (Raslova et al. 2007). This has shown further 
upregulation of haemostasis and platelet related genes. Concomitantly, with increasing 
ploidy, there was a downregulation of genes participating in cell cycle functions. The ploidy 
profile of megakaryocytes cultured from human CD34+ cells is known to be dramatically 
different to that found physiologically within the bone marrow, with mean ploidy levels of 2N 
and 16N respectively. It is therefore likely that there are putative drivers of in-vivo 
megakaryocyte differentiation and maturation that have yet to be identified. Consequently, the 
small numbers of 8N and 16N megakaryocytes cultured in vitro from CD34+ cells may 
functionally differ from those found in bone marrow.  
 
Substantial work has gone into generating platelets in vitro on a large scale, for transfusion 
purposes (Moreau et al. 2016). Despite the ability to produce large numbers of 
megakaryocytes from iPSCs, the platelet output is relatively small and remains inadequate to 
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meet the needs of platelet transfusion. This may be a direct result of the differences between 
megakaryocytes produced in culture and megakaryocytes in the bone marrow niche in terms 
of ploidy level, cytoplasmic maturation or extracellular signals. There is currently no evidence 
that explains a direct function for mean megakaryocyte ploidy levels of 16N, whether ploidy 
level is a marker of maturity, or if it is associated with the capability to produce platelets. 
Studies of the transcriptome of bone marrow megakaryocytes may provide important insights, 
including the identification of novel drivers of megakaryocyte maturation that could enable 
more physiological levels of in vitro platelet production.  
 
In this chapter single cell and low input RNA sequencing techniques are applied and 
optimised to investigate the transcriptome of primary human bone marrow megakaryocytes. 
Bone marrow megakaryocyte transcriptomes are compared to cultured megakaryocytes and 





4.2.1 Protocol optimisation for analysis of megakaryocyte transcriptome 
 
Out of a total of 53 patients recruited to this study, bone marrow material for 7 patients was 
used solely for protocol optimisation. This was due to initial technical difficulties in isolating 
megakaryocytes and optimal preparation of single cell or low-input pooled RNA-seq libraries. 
Of the remaining 46 patients, megakaryocytes were FACS sorted from bone marrow material 
from 34 patients for transcriptome analysis. Study design and samples used are shown in 
Appendix 1 and 2 respectively.  
 
4.2.1.1 Optimisation of megakaryocyte isolation 
 
A number of methods to obtain pure megakaryocyte populations from whole bone marrow 
scrapings for the purposes of RNA-seq were trialled. Figure 4.1a shows a bone marrow 
smear with megakaryocytes located in particles within whole bone marrow. In an attempt to 
optimise isolation of megakaryocytes a Percoll gradient was trialled (Section 2.3.3.2). Percoll 
enrichment has been reported to increase megakaryocyte frequency in a cell suspension 
from 0.05% to 1.5% (30 fold increase) and has only been carried out in a small number of 
studies, with different methodologies (Tomer, Harker, Burstein 1988; Brown et al. 1997; 
Ishibashi et al. 1986). The method used here is described in Chapter 2. Figure 4.1b shows a 
cytospin slide from this enriched population; direct observation demonstrated a much higher 
density of megakaryocytes than in whole bone marrow but a large number of contaminating 
cells remained. Megakaryocyte identity was verified with by immunofluorescence staining 
using a DAPI (4',6-diamidino-2-phenylindole) dye to stain DNA and VWF surface staining to 
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identify megakaryocytes (Figure 4.1c). 
 
Two methods for collecting purified megakaryocytes were then tested, as outlined in Section 
2.3.3. These were: 1. Cell picking, where individual megakaryocytes were picked under a 40x 
objective inverted light microscope, using a glass pipette which was trialled on both whole 
bone marrow and from Percoll enriched populations (Section 2.3.3.2). However, this was 
limited by time to cell lysis, even when only small cell numbers were picked and reliance only 
on relative cell size in distinguishing megakaryocytes from other cell types. 2. FACS cell 
sorting, which became possible with use of a large bore FACS nozzle (100uM).  Ultimately, in 
order to decrease time from bone marrow collection to cell lysis and therefore reduce the 
chance of cell/RNA degradation, whole bone marrow was FACS sorted without Percoll 
density separation. Therefore, megakaryocytes were isolated according to ploidy level from 
whole bone marrow scrapings using FACS with an initial treatment with ammonium chloride 
red cell lysis solution and then staining for the markers of megakaryocyte maturity CD41 and 
CD42 as well as Hoechst 33342 DNA stain to allow for quantification of DNA content without 
the requirement for cell permeabilisation (as described in Section 2.3.3). Figure 4.1d shows 
the sorting strategy used. 
 
As described above, the aim of this project had been to perform single cell megakaryocyte 
RNA-seq. Therefore, much of the FACS sorted megakaryocyte material was collected as 
single cell according to ploidy (27/34 patients), 6/34 patients had megakaryocyte pools FACS 
sorted according to ploidy and 16/34 patients had megakaryocyte pools FACS sorted 









Figure 4.1 Bone marrow megakaryocyte phenotype 
A. Human bone marrow smear stained with Rapid Romanowsky, 10x objective (Control); B. 
Cytocentrifugation of enriched megakaryocyte population stained with Roberts stain, 40x objective 
(Control); C. Immunofluorescent staining of enriched megakaryocyte population with DAPI DNA stain 
(blue) and VWF surface stain (green) (Control); D. Fluorescence activated cell sorting strategy for 
primary megakaryocytes from clinical samples of whole human bone marrow. Cells were sorted into 
lysis buffer within 6-8 hours of bone marrow harvest. Whole bone marrow was stained with APC 
conjugated anti-CD41a, PE conjugated anti-CD42a and Hoechst staining. Ploidy data was collected 
from all samples (Control); E. Flow cytometry data of mouse megakaryocytes at 10 hours after 
collection, kept at room temperature, stained with APC conjugated anti-CD41a, Hoechst staining and 
FITC conjugated Calcein. 98% megakaryocytes are seen to take up this live cell stain. 
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4.2.1.2 Megakaryocytes take up live/dead stains 
 
In order to ensure that collected cells were viable a number of live/dead stains were tested. 
However, it was apparent that even in the absence of any processing all megakaryocytes 
were positive for basic live/dead stains. This included trypan blue stain which was added to 
clinical bone marrow material as early after sampling as 10 minutes and it was confirmed to 
hold true for ex-vivo mouse megakaryocytes. This was seen to be the case for all stains 
based on dye uptake by dead cells due to loss of plasma membrane integrity, such as 7AAD 
and propidium iodide. No changes in the experimental procedure resulted in an amelioration 
of this phenomenon. It was postulated that these findings could be explained by the extensive 
demarcation membrane system that is a system of invaginated plasma membrane that fills 
the megakaryocyte cytoplasm and therefore it may in fact be an artifactual result. To test this 
theory, mouse bone marrow cells were stained with fluorescent calcein dye under varying 
conditions and time points followed by flow cytometric analysis. Calcein relies on intracellular 
esterase activity and active uptake in living cells whereby live cells take up the dye and dead 
cells exclude it (King 2000; Fritzsche and Mandenius 2010). Calcein was shown to be taken 
up by 98% megakaryocytes even up to 10 hours after sampling demonstrating that the 
“uptake” of loss of plasma membrane integrity stains were indeed artifactual (Figure 4.1e).   
 
4.2.1.3 Use of G&T-seq protocol for RNA-seq library preparation 
 
The ability to generate full length cDNA using the Smart-seq2 protocol (Picelli et al. 2014) 
was trialled on a range of cell types at single cell level to ensure it was robust before 
beginning to use it on clinical bone marrow samples recruited for the study. Here cells were 
flow sorted into the Smart-seq2 lysis buffer, a mild hypotonic lysis buffer containing a 
ribonuclease inhibitor that blocks RNA degradation and stabilizes the RNA. Figure 4.2a-c 
shows BioAnalyser traces of cDNA generated from single cells of the K562 cell line, 
megakaryocytes cultured from adult blood CD34+ cells and primary peripheral blood 
mononuclear cells. In contrast, much shorter fragments of cDNA were generated from 
megakaryocytes and other nucleated cells from clinical bone marrow  (Figure 4.2d, e, f).   
 
The generation of fragmented cDNA has been suggested to indicate RNA degradation prior 
to collection of cells within lysis buffer related to cell condition (Picelli et al. 2014). Therefore, 
a number of different variables were trialled in an attempt to optimise the condition of the cells 
at the point of flow sorting into lysis buffer. These conditions included: 1. Bone marrow 
scraping or aspirate as starting material; 2. Transportation at room temperature or on ice; 3. 
Different strengths of human serum albumin in transportation buffer (2%, 5%, 10%); 4. 
Collection into RNAlater solution (Florell et al. 2001); 5. Processing of bone marrow harvest 
immediately or following day; 6. Manual cell picking either on same day of harvest, up to 5 
days post-harvest or flow sorting; 7. Collection of cells from whole bone marrow, after red cell 
lysis or after Percoll separation. Cells collected under these conditions generated fragmented 
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cDNA with consistent BioAnalyser traces and therefore did not reveal the underlying cause 
for the discrepancy between primary bone marrow cells compared to primary blood cells. 
While this experience formed the basis of the fully optimised bone marrow collection, 
transportation and processing protocol that was taken forward (Chapter 2), it also suggested 
that RNA degradation may not play a major role in generating poor quality cDNA.  
 
To investigate this possibility further, total RNA was extracted from >1x106 nucleated bone 
marrow cells using TRIzol reagent 5 days after bone marrow harvest. 1ng of purified RNA 
was then reverse transcribed and amplified using the Smart-seq2 protocol revealing high 
quality full length cDNA on BioAnalyser traces (Figure 4.3a). This suggested that 
modifications in RNA lysis buffer might improve the quality of cDNA generated. In order to 
assess the effects of different methods of preserving RNA the Norgen single cell RNA 
purification kit was trialled on peripheral blood mononuclear cells with single cells, 20 cells, 50 
cells and 100 cells. This kit did not yield any appreciable cDNA, likely due to loss of material 
within magnetic columns and large buffer volumes used. Therefore, it was not tested in 
clinical bone marrow samples. Figure 4.3b-d shows BioAnalyser traces for cDNA from bone 
marrow megakaryocytes collected in Triton x-100 based lysis buffer, NP-40 based lysis buffer 
and Qiagen RLT Plus buffer. RLT Plus buffer is the lysis buffer used in G&T-seq (Macaulay et 
al. 2015), described in Section 2.4.4, allowing analysis of both RNA as well as genomic DNA. 
It contains the chaotropic agent guanidinium thiocyanate which lyses the cell and is able to 
denature RNase and DNase. Use of this lysis buffer consistently lead to full length cDNA 
amplification in 20x megakaryocytes (Figure 4.3d) and improved amplification in single cells, 
although in single cells with more variable results (Figure 4.4). This suggested a more 
complete or efficient lysis of bone marrow cells using Qiagen RLT Plus buffer compared to 
the SMART-seq2 Triton-based hypotonic lysis buffer.  
 
The G&T-seq protocol was therefore employed for RNA-seq library preparation for all bone 
marrow cells, both single cell and multicellular pools (1-100cells). The aim was to perform 
mainly single cell RNA-seq, therefore much of the sample collection was of single cells 
according to ploidy. Single megakaryocytes were FACS sorted for transcriptome analysis in 
27 out of 34 patients. Multicellular pools were sorted from 16/34 patients and pools formed 
according to ploidy were sorted from 6 patients.  
 
Initial RNA-seq libraries were prepared for 1160 single megakaryocytes with a ploidy level 
ranging from 2N to 32N in 5 patients and 55 multicellular pools between 20-100 
megakaryocytes from 7 control individuals. 125bp paired-end sequencing was performed at 
an average sequencing depth of 64 either single cells or multicellular pools per Hi-seq lane. In 
terms of batch effects Table 4.1 shows each sample plate ID and corresponding sequencing 
lane ID whereas Table 4.2 outlines the batches in which samples were collected, cDNA 
reverse transcribed/amplified and Nextera libraries prepared and sequenced. 
	 115
 
Figure 4.2 cDNA generated using Smart-seq2 
BioAnalyser electropherograms of cDNA using Smart-seq2. cDNA generated from: A. single 
cell: K562 cell line; B. 20x megakaryocytes cultured from adult blood CD34+ cells; C. 20x 
primary human peripheral blood mononuclear cells; D. 20x bone marrow megakaryocytes; E. 
single cell: bone marrow megakaryocyte; F. 20x nucleated bone marrow mononuclear cells. 
 
 
Figure 4.3 cDNA generated using Smart-seq2: cell lysis 
BioAnalyser electropherograms of cDNA generated from: A. 1ng purified RNA extracted with 
TRIzol from >1 million nucleated bone marrow mononuclear cells; B. 20x bone marrow 
megakaryocytes lysed in Triton-based lysis buffer; C. 20x bone marrow megakaryocytes 
lysed in NP-40 based lysis buffer; D. 20x bone marrow megakaryocytes lysed in Qiagen 
















Figure 4.4 Quality of cDNA amplified from single cell bone marrow megakaryocytes 
BioAnalyser electropherograms of cDNA generated from 11 single cell bone marrow 




Plate ID Sequencing Lane ID 
03G  SLX-8757 
60Z 16N SLX-9491 
60Z 32N SLX-9492 
60Z 8N SLX-9493 
60Z 4N/2N SLX-9494 
7TA 16N SLX-9495 
7TA 32N SLX-9496 
CYH 16N SLX-9490 
CYH 32N SLX-9497 
CYH 8N SLX-9488 
CYH 4N SLX-9489 
CYH 2N SLX-10160 
CUP 8N SLX-10154 
CUP 16N SLX-10155 
CUP 32N SLX-10156 
CUP 4N/2N SLX-10157 
CST 2N SLX-10158 







Table 4.1 Patient and plate ID on each sequencing lane 
 
 
Sample collection Amplification Nextera Library prep / RNA-seq 
1 1 1 
  03G    03G   SLX-8757 
2 2 2 
  318   60Z 16N   SLX-9491 
3   60Z 32N   SLX-9492 
  3XI   60Z 8N   SLX-9493 
4   60Z 4N/2N   SLX-9494 
  60Z 16N 3   SLX-9495 
  60Z 32N   7TA 16N   SLX-9496 
  60Z 8N   7TA 32N 3 
  60Z 4N/2N 4   SLX-9490 
5   CYH 16N   SLX-9497 
  7TA 16N   CYH 32N   SLX-9488 
  7TA 32N   CYH 8N   SLX-9489 
  7TA 8N   CYH 4N   SLX-10160 
6   CYH 2N 4 
  ATZ 5   SLX-10154 
7   CUP 8N   SLX-10155 
  CUP 8N   CUP 16N   SLX-10156 
  CUP 16N   CUP 32N   SLX-10157 
  CUP 32N   CUP 4N/2N   SLX-10158 
  CUP 4N/2N   CST 2N 5 
8 6   SLX-10208 (multicellular pools) 
  CST 2N   318 6 
9 7   SLX-10482 (multicellular pools) 
  CYH 16N   H4K  
  CYH 32N   ATZ  
  CYH 8N 8  
  CYH 4N   3XI  
  CYH 2N   DSP  
10 9  
  DSP   M8T  
11     
  H4K   
12   
  M8T   
 
Table 4.2 Megakaryocyte collection, amplification, library preparation/RNA-seq batches 
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4.2.1.4 RNA sequencing data: Quality measures 
 
Figure 4.5 shows metrics per sequencing lane for total read count, alignment to the reference 
transcriptome (GRCh37), proportion of reads mapped to external spike-in ERCCs compared 
to endogenous transcripts, no of genes called, proportion of reads mapping to annotated 
exonic regions and the proportion of reads mapping to mitochondria transcripts.  
 
It is clearly evident that the quality data for the 2 lanes formed of megakaryocyte pools rather 
than single cells (SLX-10208, SLX-10482) was better with higher total read count, alignment 
rate, and lower ERCC ratio than the single cell lanes. In approximately 10% of all single cell 
and multicellular samples >50% reads were mapped to mitochondrial transcripts. While this 
may be a reflection of the biology of these cells, it effectively reduced the sequencing depth 
for each sample. Mitochondrial transcripts were found to form the top 10 genes expressed in 
all sequencing lanes (including: MT-RNR2, MT-CO1, MT-RNR1, MT-ND4, MT-CO2, MT-
CO3). There was a higher proportion of reads mapping to the mitochondria in the multicellular 
samples compared with the single cells (samples with >50% reads mapping to mitochondrial 
transcripts: 36% and 8% respectively) (Figure 4.5) which might partially explain the better 
alignment rates. 
 
While the vast majority of single cell sequencing demonstrated low quality metrics, the 
multicellular samples performed better. Despite this, saturation of sequencing capacity by 
reads mapping to mitochondrial transcripts was problematic in both single cell and 
multicellular samples. While posing an unexpected and substantial technical challenge this is 
in keeping with previously reported human platelet RNA-seq datasets (Rowley et al. 2011; 
Eicher et al. 2016) and the knowledge that both megakaryocytes and platelets are densely 
populated with mitochondria. In an attempt to overcome this challenge, BioAnalyser traces 
and Taqman real time qPCR were used in an attempt to identify samples to take forward for 
downstream sequencing analysis as sequencing all samples with such low yield of useful 
transcriptome data would not be financially viable. Therefore, the aim was to identify features 
at the cDNA stage of library preparation that would allow discrimination of samples (single-
cell or multicellular pools) for RNA-seq.  
 
As described above cDNA from multicellular pools were consistently of good quality i.e., full 
length cDNA, and therefore for multicellular pools BioAnalyser would be unable to predict 
which samples would perform favourably in gene expression analysis. The quality of cDNA 
according to BioAnalyser traces in single cells was more variable. Taqman real-time qPCR 
assays were used to assess levels of the following transcripts in low and high quality single 
cell cDNA (according to BioAnalyser trace): MT-RNR2 (most highly expressed transcript in 
sequencing data, PPBP (most highly expressed genes in megakaryocyte/platelet). As 
demonstrated in Figure 4.6 while higher quality single cell cDNA expresses higher levels of 
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MT-RNR2 than lower quality single cell cDNA, PPBP levels are undetectable irrespective of 
cDNA quality by BioAnalyser. This indicates that quality of cDNA reverse transcribed from 
RNA from either multicellular pools or single megakaryocytes does not help to differentiate 
between samples with higher numbers of called genes/complexity of gene expression. 
Moreover, it reflects a more efficient reverse transcription of the most abundant signal – which 
in this case is mitochondrial reads. 
 
Taqman real-time qPCR assays for transcripts known to be highly expressed in the 
megakaryocyte/platelet lineage (PPBP, PF4, SDPR) were then correlated with their RNA-seq 
expression levels in both single cell and multicellular samples to ascertain whether qPCR 
data might be a useful predictor of samples that would be more useful to take forward for 
downstream RNA-seq analysis. cDNA from single cells in sequencing lane SLX-9489 was 
selected as either highly expressed in RNA-seq results or not expressed. The corresponding 
level on using qPCR Taqman assays was then correlated (Table 4.3). No correlation was 
demonstrated between qPCR and RNA-seq transcript expression. Therefore, it was 
concluded that it is not possible to prospectively identify cDNA from single cells for further 
transcriptome analysis.  
 
In the multicellular pools however, a clear correlation was found between RNA-seq 
expression of the highly expressed megakaryocyte/platelet transcript PPBP and detection by 
Taqman qPCR probes as demonstrated in Figure 4.7a (r2=0.507). While PPBP and PF4 were 
consistently detected in multicellular pools, the level varied with only detection at high levels 
correlating with detection of reads at RNA-seq (Figure 4.7b and c). Figure 4.7b shows the 
typical amplification profile for MT-RNR2, PPBP and PF4 seen for cells with low 
megakaryocyte/platelet specific transcript counts on RNA-seq. Figure 4.7c conversely shows 
the same typical amplification profile for cells with higher megakaryocyte/platelet specific 
transcript counts on RNA-seq. Interestingly the latter group have similar MT-RNR2 and PPBP 
CT detection levels on qPCR, compared with the former in which MT-RNR2 is detected 
significantly earlier on qPCR.  
 
On the basis that there is no reliable method to prospectively identify single cells prior to 
sequencing that could provide informative RNA-seq data either by qPCR or BioAnalyser 









4.2.1.5 Sequencing approach for megakaryocytes 
 
Given the technical challenges described above, particularly with single cells, in order to 
optimise the acquisition of informative RNA-seq data from bone marrow megakaryocytes in a 
financially viable manner, the following approach was taken.  
 
As there was no way to prospectively identify high quality single megakaryocytes prior to 
sequencing, no further single megakaryocytes were sequenced and the single cell RNA-seq 
data shown above (5 patients) were subject to stringent quality filtering at the time of analysis 
to ascertain the value and reliability of further downstream analysis.  
 
All megakaryocyte pools collected by ploidy, were	 sequenced irrespective of prospective 
qPCR data due to the small numbers (samples from 6/34 patients only, 1-2 wells collected 
per ploidy group, per patient).  
 
16/34 patients had megakaryocyte pools sorted irrespective of ploidy level, with between 8-96 
wells collected per patient depending on the quantity of the starting bone marrow material. 
From these multicellular pools, samples were be prospectively identified and selected for 
RNA-seq on the basis of cDNA gene expression using Taqman probes as described below. 
 
PPBP was selected as the most useful marker gene to identify high quality multicellular pools. 
This was on the basis that it is the most highly expressed platelet specific transcript based on 
reported RNA-seq data (Rowley et al. 2011), therefore it is the most likely of all highly 
expressed megakaryocyte/platelet transcripts to be detected at qPCR. Furthermore, PPBP 
CT was seen to be highly correlated with expression at RNA-seq (Figure 4.7a). To investigate 
if expression levels of PPBP could act as a quality marker its level of expression was 
correlated with no of called genes in those samples. No. of called genes was found to 
correlate positively with PPBP expression at RNA-seq level, r2=0.261 (Figure 4.8a) and no. 
called genes was significantly higher in samples with a PPBP read count above 300 reads, 
p=0.0003 (t-test) (Figure 4.8b). Furthermore, expression of the housekeeping gene B2M at 
RNA-seq was only found in the samples with a PPBP read count of >300 reads.  
 
However, the main challenge identified with RNA-seq analysis in megakaryocytes was the 
saturation of sequencing capacity with mitochondrial transcripts, seen clearly in the quality 
metrics of RNA-seq data (Figure 4.5F) and in the typical qPCR amplification plots with large 
∆CTs observed between MT-RNR2 and PPBP/PF4 (Figure 4.7b). To investigate if ∆CT 
PPBP – MT-RNR2 based on qPCR using MT-RNR2 and PPBP Taqman probes might be the 
ideal marker of quality, ∆CT PPBP – MT-RNR2 was correlated with PPBP gene expression in 
the multicellular RNA-seq data and no. of called genes. Figure 4.9a shows a strong inverse 
correlation between ∆CT PPBP – MT-RNR2 and PPBP read count (r2=0.610, more significant 
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than PPBP CT alone, Figure 4.7a). Figure 4.10a also shows an inverse correlation between 
∆CT PPBP – MT-RNR2 and no. of called genes (r2=0.298).   
 
Various arbitrary ∆CT PPBP – MT-RNR2 cut-offs for inclusion were trialled. A ∆CT level 
between expression of PPBP and MT-RNR2 by Taqman qPCR assay of 7 or less was used 
to prospectively identify multicellular megakaryocyte samples for RNA-seq. Figure 4.9b 
demonstrates significantly higher PPBP read counts in samples with ∆CT PPBP – MT-RNR2 
<7 compared with >7 (p=0.0109), whereas there is no significant difference in PPBP read 
counts between samples with ∆CT PPBP – MT-RNR2 <8 compared with >8 (Figure 4.9c). 
Similar observations were made with no. of called genes: Figure 4.10b shows significantly 
greater no. of called genes in samples with ∆CT PPBP – MT-RNR2 <7 compared with >7 
(p=0.0005) (t-test). Setting the cut-off as a ∆CT PPBP – MT-RNR2 of 8 reduced this 



















Figure 4.5 Quality control metrics/sequencing lane. A. Total reads; B. Rate of alignment 
to transcriptome; C. Ratio of reads mapping to ERCCs; D. No. genes called; E. Ratio of 





Figure 4.6 Full length cDNA from single cell megakaryocytes correlates with MT-RNR2 
expression. 
Representative high quality(A) and low quality(B) single megakaryocyte BioAnalyser 
electropherograms. C. Taqman qPCR amplification plot for cell A and cell B showing the 
amplification of 2 transcripts: MT-RNR2 and PPBP, X axis shows the cycle number or CT at 
which amplification begins. 
 
 
Single cell RNAseq ID 













SLX.9489.N707_N502 Undetermined 30077 35.41544724 15651 Undetermined 1887 
SLX.9489.N706_N502 Undetermined 21139 Undetermined 9101 Undetermined 976 
SLX.9489.N704_N501 Undetermined 493 Undetermined 898 Undetermined 1691 
SLX.9489.N703_N506 Undetermined 25858 Undetermined 8042 Undetermined 866 
SLX.9489.N706_N501 Undetermined 393 Undetermined 876 Undetermined 2180 
SLX.9489.N705_N501 Undetermined 247 Undetermined 1393 Undetermined 336 
SLX.9489.N706_N503 Undetermined 0 Undetermined 0 Undetermined 0 
SLX.9489.N705_N508 Undetermined 0 Undetermined 2 Undetermined 5 
SLX.9489.N703_N508 Undetermined 1 36.77412033 0 Undetermined 0 
SLX.9489.N711_N506 Undetermined 0 Undetermined 0 Undetermined 0 
SLX.9489.N712_N503 37.05277252 0 36.98429108 0 Undetermined 0 
SLX.9489.N703_N504 Undetermined 0 Undetermined 0 Undetermined 0 
       
 
 
Table 4.3 Transcript detection in single megakaryocytes. Correlation of detection of 
PPBP, PF4 and SDPR by qPCR and RNA-seq in single cells from SLX-9489. Samples were 
selected on the basis of expression of PPBP, PF4 and SPDR by RNA-seq (n=6 high 
expression - shaded orange, n=6 low expression). Taqman real-time qPCR was then 
performed on cDNA for these samples for the expression of PPBP, PF4 and SDPR.  
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Figure 4.7 Transcript detection in multicellular megakaryocytes. A. Inverse correlation 
between CT expression of PPBP by Taqman real-time qPCR and PPBP read count on RNA-
seq, r2=0.507. Representative amplification plots showing cycle no at which MT-RNR2, PPBP 
and PF4 are detected using Taqman real-time qPCR for multicellular samples with low PPBP 
























Figure 4.8 No. of called genes according to PPBP Read Count in multicellular pool 
megakaryocyte RNA-seq. A. Correlation between PBPP read count by RNA-seq and no. of 
called genes in that sample, r2=0.261. Read counts >3000 were removed; B. No. of called genes 
according to PPBP read count above or below 300 as an abitrary cut off shows that samples with 
>300 PPBP read counts have significantly higher numbers of called genes (t-test, p=0.0003). 
	 126
 
Figure 4.9 Relationship between ∆CT PPBP – MT-RNR2 and PPBP read count. A. 
Inverse correlation between ∆CT PPBP – MT-RNR2 by Taqman real-time qPCR and PPBP 
read count on RNA-seq, r2=0.610, in multicellular megakaryocyte samples. B. Significantly 
higher PPBP read count in samples with ∆CT PPBP – MT-RNR2 <7 compared to >7, 
p=0.0109. C. No significant difference in PPBP read count in samples with ∆CT PPBP – MT-






















































Figure 4.10 Relationship between ∆CT PPBP – MT-RNR2 and No. of called genes. A. 
Inverse correlation between ∆CT PPBP – MT-RNR2 by Taqman real-time qPCR and No. of 
called genes on RNA-seq, r2=0.298, in multicellular megakaryocyte pools. B. Significantly 
higher no. of called genes in samples with ∆CT PPBP – MT-RNR2 <7 compared to >7, 
p=0.0005. C. Significantly higher no. of called genes in samples with ∆CT PPBP – MT-RNR2 
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4.2.2 Defining the primary human megakaryocyte transcriptome 
 
4.2.2.1 Sample preparation and RNA-seq library preparation 
 
To define the primary human megakaryocyte transcriptome in the context of current evidence, 
the objective was to make comparisons with the known megakaryocyte transcriptome from 
megakaryocytes cultured from human CD34+ cells. 
 
Bone marrow megakaryocytes were flow sorted from sternal bone marrow collected from 6 
individuals without coronary artery disease as multicellular pools (20-100 multicellular pools) 
for the purpose of defining for the first time the primary human megakaryocyte transcriptome. 
The modified Smart-seq2 protocol (G&T-seq) was used, as described above, to generate 
RNA-seq libraries for transcriptome analysis from a total of 85 megakaryocyte multicellular 
pools that were FACS sorted irrespective of megakaryocyte ploidy. Table 4.4 shows the 
baseline characteristics for these individuals. All individuals were undergoing non-coronary 
cardiac surgery and had no evidence of coronary artery disease (by pre-operative coronary 
angiography).  
 
To enable a comparison with cultured megakaryocytes, megakaryocytes were derived from 
human adult blood CD34+ cells as described in Section 2. The phenotypic appearance of the 
cultured megakaryocytes (Figure 4.11) was in contrast to the bone marrow megakaryocytes 
(Figure 4.1) due to size and nuclear appearance. 4 biological replicates were used and RNA-
seq libraries were generated using the SMARTer Ultra Low Input RNA for Illumina 
Sequencing kit which utilises the same poly A pulldown as the Smart-seq2 protocol. Of note 
ERCC spike-ins were added in a concentration of 1:1000, compared with a concentration of 
1:4x106 in the Smartseq2 protocol for bone marrow megakaryocytes. 
 
85 megakaryocyte multicellular pools sorted irrespective of ploidy were prospectively 
identified on the basis of ∆CT PPBP – MT-RNR2 as defined by Taqman qPCR gene 
expression as described above (data presented in Section 5.2.2.2). 125bp paired-end 
sequencing was performed at an average sequencing depth of approximately 50 million 
reads/sample. 3 multicellular pools with the lowest ∆CT PPBP – MT-RNR2 were also 
selected from each individual to take forward for deeper 125bp paired-end sequencing at a 
depth of 500 million reads/sample (data presented in Section 5.2.2.2). All 4 biological 
replicates of the megakaryocytes derived from CD34+ cells were sequenced over a single 
125bp paired end High-seq lane (~500 million reads/sample).  
 
In terms of batch effects Table 4.5 shows each sample plate ID and corresponding 
sequencing lane ID whereas Table 4.6 outlines the batches in which samples were collected, 
cDNA reverse transcribed/amplified and Nextera libraries prepared and sequenced. 
	 129
 
4.2.2.2 RNA sequencing data: Quality measures 
 
Figure 4.12 shows metrics per sequencing lane for total read count, alignment to the 
reference transcriptome (GRCh37), proportion of reads mapped to external spike-in ERCCs 
compared to endogenous transcripts, no of genes called, proportion of reads mapping to 
annotated exonic regions and the proportion of reads mapping to the mitochondria. The most 
marked differences are in comparison of the low input sequencing with bulk cultured 
megakaryocytes where there are a higher number of genes called and a significantly greater 
representation of ERCC spike-ins. There are also markedly lower numbers of reads mapping 




Table 4.4 Baseline patient characteristics 
 Non-coronary disease controls (n=6) 
 
Gender M 2 





Coronary disease 0 
Antiplatelets 2 
Left ventricular dysfunction 3 
Aortic valve surgery 3 
Mitral valve surgery 3 
Hb (mean ± SD) 13.6 ± 1.2 
WC (mean ± SD) 6.9 ± 1.9 


















Sample collection Amplification Nextera Library prep / RNA-seq 
1 1 1 
  Cultured 
megakaryocytes 
  Cultured 
megakaryocytes 
  SLX-7719 
2 2 2 
  3XI   H4K   SLX-10208 
3   ATZ 3 
  ATZ 3   SLX-10482 
4   3XI 4 
  DSP    DSP   SLX-10546 
5 4 5 
  H4K   M8T   SLX-11601 
6 5   SLX-11602 
  M8T   Q6H   SLX-11603 
7    SLX-11604 
Q6H    SLX-11605 
   
 






Plate ID Sequencing Lane ID 
Megakaryocytes:  
  3XI  SLX-10208, SLX-10546, SLX-11601 
  DSP SLX-10208, SLX-10546, SLX-11602 
  ATZ SLX-10208, SLX-10546, SLX-11603 
  H4K SLX-10208, SLX-10546, SLX-11604 
  M8T SLX-10482, SLX-11605 







A                         B 
 
 
Figure 4.11 Cultured megakaryocyte phenotype 
A. Harvested cell suspension was stained with APC conjugated anti-CD41a, PE conjugated anti-CD42a and Hoechst. Flow cytometry data of cultured 
megakaryocytes showing 81% to be CD41+CD42+, Hoechst staining demonstrates 61% of these are 2N, 30% are 4N, 5% are 8N and less than 1% are 16N. 





















Figure 4.12 Quality control metrics/sequencing lane. A. Total reads; B. Rate of alignment 
to transcriptome; C. Ratio of reads mapping to ERCCs; D. No. genes called; E. Ratio of 
exonic reads to exonic+intronic; F. Ratio of reads mapping to mitochondrial genes.  
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4.2.2.3 Gene expression analysis 
 
The 100 most highly expressed genes in cultured megakaryocytes and bone marrow 
megakaryocytes are shown in Table 4.7. In total, there were 30 genes that overlapped 
between the most highly expressed genes between the two lists (Figure 4.13). The most 
highly expressed transcripts in cultured megakaryocytes appear to be ERCC spike-ins (18 out 
of 100) likely to be a result of the high concentrations at which were added in RNA-seq library 
preparation (also seen in QC data; Figure 4.12c). As expected there is a similarity between 
the 2 lists, with a number of megakaryocyte/platelet lineage genes expressed highly. Both 
cultured and bone marrow megakaryocytes expressed high levels of PPBP, PF4, PLEK, 
TUBA4A, ACTB, RAP1B and TMSB4X which have important functions in platelet activation. 
Furthermore, bone marrow megakaryocytes also expressed high levels of the platelet 
glycoproteins ITGA2B (CD41) and CD36. Cultured megakaryocytes also had high expression 
of the platelet activation markers CD9 and CD63. There were a number of other genes with 
shared high expression between the 2 datasets including those encoding proteins involved in 
cellular respiration and metabolism such as cytochrome c oxidase subunits, NADH 
dehydrogenase subunits and genes encoding ribosomal subunits. MT-RNR1 and MT-RNR2 
were the most highly expressed genes overall in bone marrow megakaryocytes.  
 
A GO analysis of the two lists and their overlapped 30 genes shows the main biological 
themes significantly over-represented (Figure 4.14, 4.15) and full GO lists are found in 
Appendix 4, Tables S4.1, S4.2, S4.3. The main biological processes enriched in bone marrow 
megakaryocytes were involved in cellular metabolism and respiration, coagulation, 
haemostasis and wound healing, then platelet degranulation and cytoskeleton, followed by 
translation and protein targeting. These were also important biological themes in cultured 
megakaryocytes, and shared in the overlapping GO analysis (Figure 4.15). However, defence 
response was unique to the bone marrow megakaryocytes with the presence of the following 
transcripts:  S100A9, CAMP, LYZ, DEFA3, LTF, S100A8, DEFA4, S100A12. 
 
A differential expression analysis was then performed between the normalised read count 
data from both cultured and bone marrow megakaryocytes in order to discover quantitative 
changes in gene expression levels between the two data sets. Of the 521 differentially 
expressed features, 51 were shown to be significantly upregulated in bone marrow 
megakaryocytes relative to cultured megakaryocytes (P<0.05, Wald test). The full list is 
shown in Table 4.8 with levels of significance. Interestingly 9 out of 51 transcripts identified as 
upregulated in bone marrow megakaryocytes encoded for regions of immunoglobulins, 8 
encode for constant domains of the immunoglobulin heavy chains alpha, gamma, kappa and 
lambda; 1 encoded the variable domain of the immunoglobulin kappa light chain. Apart from 
these, other upregulated genes included those involved in the immune response: S100A9, 
AZU1, CAMP, LYZ, DEFA3, LTF, S100A8, DEFA4, S100A12, as well as a number of highly 
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significant differentially expressed genes that map to the mitochondrial transcriptome. To 
reflect this the most highly expressed GO biological processes were defence response to 
fungus, bacteria, neutrophil aggregation and inflammatory response (Figure 4.15, Appendix 4, 
Table S4.5). The top 50 genes downregulated in bone marrow megakaryocytes (or 
upregulated in cultured megakaryocytes) are shown with significance levels in Table 4.9 and 
the full list of 470 genes are shown in Appendix 4, Table S4.4. The significance levels for the 
downregulated gene are markedly lower (p>1x10-4, compared with p>1x10-39) (Wald test). By 
contrast the most highly enriched GO biological processes were translation, protein 




Cultured megakaryocytes Bone marrow megakaryocytes 
HGNC_ID Gene_name HGNC_ID Gene_name 
1 ERCC-00096 ERCC-00096 MT-RNR2 
mitochondrially Encoded 16S RNA (MT-
RNR2) 
2 ERCC-00002 ERCC-00002 COX1 cytochrome c oxidase subunit I(COX1) 
3 ERCC-00074 ERCC-00074 MT-RNR1 
mitochondrially Encoded 12S RNA (MT-
RNR1) 
4 COX1 cytochrome c oxidase subunit I(COX1) ND4 
NADH dehydrogenase, subunit 4 (complex 
I)(ND4) 
5 ERCC-00130 ERCC-00130 COX2 cytochrome c oxidase subunit II(COX2) 
6 ACTB actin beta(ACTB) ATP6 ATP synthase F0 subunit 6(ATP6) 
7 MALAT1 
metastasis associated lung adenocarcinoma 
transcript 1 (MALAT1) 
ND1 
NADH dehydrogenase, subunit 1 (complex 
I)(ND1) 
8 COX2 cytochrome c oxidase subunit II(COX2) CYTB cytochrome b(CYTB) 
9 MT-RNR2 
mitochondrially Encoded 16S RNA (MT-
RNR2) 
ND2 MTND2(ND2) 
10 CYB cytochrome b(CYTB) COX3 cytochrome c oxidase III(COX3) 
11 PPBP pro-platelet basic protein(PPBP) ND5 
NADH dehydrogenase, subunit 5 (complex 
I)(ND5) 
12 ND4 
NADH dehydrogenase, subunit 4 (complex 
I)(ND4) 
ND4L 
NADH dehydrogenase, subunit 4L (complex 
I)(ND4L) 
13 TMSB4X thymosin beta 4, X-linked(TMSB4X) MTATP6P1 MTATP6P1 
14 FTL ferritin light chain(FTL) ND3 
NADH dehydrogenase, subunit 3 (complex 
I)(ND3) 
15 PLEK pleckstrin(PLEK) HBB haemoglobin subunit beta(HBB) 
16 COX3 cytochrome c oxidase III(COX3) ND6 
NADH dehydrogenase, subunit 6 (complex 
I)(ND6) 
17 ERCC-00004 ERCC-00004 ERCC-00074 ERCC-00074 
18 ERCC-00113 ERCC-00113 IGHG2 IGHG2 
19 ERCC-00046 ERCC-00046 ACTB actin beta(ACTB) 
20 B2M beta-2-microglobulin(B2M) S100A8 S100 calcium binding protein A8(S100A8) 
21 ATP6 ATP synthase F0 subunit 6(ATP6) S100A9 S100 calcium binding protein A9(S100A9) 
22 ERCC-00136 ERCC-00136 TMSB4X thymosin beta 4, X-linked(TMSB4X) 
23 ERCC-00009 ERCC-00009 JCHAIN 
joining chain of multimeric IgA and 
IgM(JCHAIN) 
24 ERCC-00108 ERCC-00108 MALAT1 
metastasis associated lung adenocarcinoma 
transcript 1 (MALAT1) 
25 ND5 
NADH dehydrogenase, subunit 5 (complex 
I)(ND5) 
PPBP pro-platelet basic protein(PPBP) 
26 RPL3 ribosomal protein L3(RPL3) B2M beta-2-microglobulin(B2M) 
27 TPI1 triosephosphate isomerase 1(TPI1) PF4 platelet factor 4(PF4) 
28 MIR4738 microRNA 4738(MIR4738) MTCO1P12 MTCO1P12 
29 EEF1A1 
eukaryotic translation elongation factor 1 alpha 
1(EEF1A1) 
FTL ferritin light chain(FTL) 




ATP8 ATP synthase F0 subunit 8(ATP8) 
32 MT-RNR1 




Rho GDP dissociation inhibitor 
beta(ARHGDIB) 
ACTG1 actin gamma 1(ACTG1) 
34 HBD Haemoglobin subunit delta(HBD) MTCO1P12 MTCO1P12 
35 MIR1244-1 microRNA 1244-1(MIR1244-1) IGLC2 IGLC2 
36 SH3BGRL3 
SH3 domain binding glutamate rich protein like 
3(SH3BGRL3) 
SRGN serglycin(SRGN) 
37 PF4 platelet factor 4(PF4) IGHV3-53 IGHV3-53 
38 LDHB lactate dehydrogenase B(LDHB) ERCC-00096 ERCC-00096 
39 ND2 MTND2(ND2) MTND1P23 MTND1P23 
40 ERCC-00171 ERCC-00171 IGHA1 IGHA1 
41 RPLP0 
ribosomal protein lateral stalk subunit 
P0(RPLP0) 
LYZ lysozyme(LYZ) 
42 ALDOA aldolase, fructose-bisphosphate A(ALDOA) NEAT1 
nuclear paraspeckle assembly transcript 1 
(non-protein coding)(NEAT1) 
43 LIMS1 LIM zinc finger domain containing 1(LIMS1) CTTN cortactin(CTTN) 
44 ERCC-00003 ERCC-00003 MTND2P28 MTND2P28 
45 ERCC-00043 ERCC-00043 LTF lactotransferrin(LTF) 
46 H2AFZ H2A histone family member Z(H2AFZ) HNRNPH1 
heterogeneous nuclear ribonucleoprotein 
H1 (H)(HNRNPH1) 
47 RPS6 ribosomal protein S6(RPS6) ERCC-00130 ERCC-00130 
48 RACK1 receptor for activated C kinase 1(RACK1) HLA-E 
major histocompatibility complex, class I, 
E(HLA-E) 
49 HSPA8 




ATP synthase, mitochondrial F1 complex, 
betapolypeptide(ATP5B) 
CAMP cathelicidin antimicrobial peptide(CAMP) 
51 TAGLN2 transgelin 2(TAGLN2) LIMS1 LIM zinc finger domain containing 1(LIMS1) 
52 MIR6843 microRNA 6843(MIR6843) DAAM1 
dishevelled associated activator of 
morphogenesis 1(DAAM1) 
53 RPL15 ribosomal protein L15(RPL15) ITGA2B integrin subunit alpha 2b(ITGA2B) 
54 CD63 CD63 molecule(CD63) MYL6 myosin light chain 6(MYL6) 
55 PKM pyruvate kinase, muscle(PKM) ERCC-00046 ERCC-00046 
56 ENO1 enolase 1(ENO1) HBA2 haemoglobin subunit alpha 2(HBA2) 
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57 CLIC1 chloride intracellular channel 1(CLIC1) PLEK pleckstrin(PLEK) 
58 RSU1 Ras suppressor protein 1(RSU1) EEF1A1 
eukaryotic translation elongation factor 1 
alpha 1(EEF1A1) 
59 RPL5 ribosomal protein L5(RPL5) MYL12A myosin light chain 12A(MYL12A) 
60 LDHA lactate dehydrogenase A(LDHA) CAPZA1 
capping actin protein of muscle Z-line alpha 
subunit 1(CAPZA1) 
61 RPS3 ribosomal protein S3(RPS3) HBD haemoglobin subunit delta(HBD) 
62 NPM1 nucleophosmin(NPM1) SSR4 signal sequence receptor subunit 4(SSR4) 
63 UBC ubiquitin C(UBC) MT-TF MT-TF 
64 EIF1 eukaryotic translation initiation factor 1(EIF1) GNG11 G protein subunit gamma 11(GNG11) 
65 RPL7 ribosomal protein L7(RPL7) OAZ1 ornithine decarboxylase antizyme 1(OAZ1) 
66 TALDO1 transaldolase 1(TALDO1) CLC Charcot-Leyden crystal galectin(CLC) 
67 GATA1 GATA binding protein 1(GATA1) IGLV2-14 IGLV2-14 
68 ND1 
NADH dehydrogenase, subunit 1 (complex 
I)(ND1) 
PPP1CB 






70 MIR3064 microRNA 3064(MIR3064) RPLP1 
ribosomal protein lateral stalk subunit 
P1(RPLP1) 
71 HMGB1 high mobility group box 1(HMGB1) RAP1B 
RAP1B, member of RAS oncogene 
family(RAP1B) 
72 RPL10 ribosomal protein L10(RPL10) S100A12 S100 calcium binding protein A12(S100A12) 
73 LAPTM5 lysosomal protein transmembrane 5(LAPTM5) TAGLN2 transgelin 2(TAGLN2) 
74 RAP1B 
RAP1B, member of RAS oncogene 
family(RAP1B) 
RPS27A ribosomal protein S27a(RPS27A) 
75 RPL19 ribosomal protein L19(RPL19) RPL9 ribosomal protein L9(RPL9) 
76 ACAT2 acetyl-CoA acetyltransferase 2(ACAT2) SAT1 
spermidine/spermine N1-acetyltransferase 
1(SAT1) 
77 KPNA2 karyopherin subunit alpha 2(KPNA2) SAR1A 
secretion associated Ras related GTPase 
1A(SAR1A) 
78 CAP1 adenylate cyclase associated protein 1(CAP1) MIR4738 microRNA 6852(MIR6852) 
79 TUBA4A tubulin alpha 4a(TUBA4A) RPL21 ribosomal protein L21(RPL21) 
80 STOM stomatin(STOM) RPS20 ribosomal protein S20(RPS20) 
81 MIR3917 microRNA 3917(MIR3917) RPS25 ribosomal protein S25(RPS25) 
82 GPX1 glutathione peroxidase 1(GPX1) CD36 CD36 molecule(CD36) 
83 ERCC-00145 ERCC-00145 IGKC IGKC 
84 HSP90AB1 
heat shock protein 90 alpha family class B 
member 1(HSP90AB1) YWHAZ 
tyrosine 3-monooxygenase activation 
protein zeta(YWHAZ) 
85 HSP90AA1 
heat shock protein 90 alpha family class A 
member 1(HSP90AA1) HLA-B 
major histocompatibility complex, class I, 
B(HLA-B) 
86 ATP5A1 
ATP synthase, mitochondrial F1 complex, 
alpha subunit 1(ATP5A1) C6orf25 
chromosome 6 open reading frame 
25(C6orf25) 
87 ERCC-00111 ERCC-00111 H3F3A H3 histone family member 3A(H3F3A) 
88 ERCC-00042 ERCC-00042 TUBA4A tubulin alpha 4a(TUBA4A) 
89 CD9 CD9 molecule(CD9) FERMT3 fermitin family member 3(FERMT3) 
90 TMBIM6 
transmembrane BAX inhibitor motif containing 
6(TMBIM6) DEFA4 
defensin alpha 4(DEFA4) 
91 SRSF3 
serine and arginine rich splicing factor 
3(SRSF3) HSP90AA1 
heat shock protein 90 alpha family class A 
member 1(HSP90AA1) 
92 RPS18 ribosomal protein S18(RPS18) SRF3 
serine and arginine rich splicing factor 
3(SRSF3) 
93 ERCC-00116 ERCC-00116 TPM4 tropomyosin 4(TPM4) 
94 HNRNPA1 
heterogeneous nuclear ribonucleoprotein 
A1(HNRNPA1) CDC42 
cell division cycle 42(CDC42) 
95 HNRNPA2B1 
heterogeneous nuclear ribonucleoprotein 
A2/B1(HNRNPA2B1) ERCC-00004 
ERCC-00004 
96 RPS14 ribosomal protein S14(RPS14) PTP4A2 
protein tyrosine phosphatase type IVA, 
member 2(PTP4A2) 
97 CALM2 calmodulin 2(CALM2) SRSF6 
serine and arginine rich splicing factor 
6(SRSF6) 
98 TPM3 tropomyosin 3(TPM3) RPS13 ribosomal protein S13(RPS13) 
99 ERCC-00092 ERCC-00092 MIR1244-1 microRNA 1244-1(MIR1244-1) 
100 HMGN2 
high mobility group nucleosomal binding 
domain 2(HMGN2) RPL15 
ribosomal protein L15(RPL15) 





Figure 4.13 Venn diagram to show commonly highly expressed genes between cultured 
megakaryocytes (cMK) and bone marrow megakaryocytes (bmMK)	
 
Commonly expressed genes: 
ACTB MIR4738 MIR1244-1 ATP6 TUBA4A COX2 LIMS1 ND2 STOM TMSB4X ND1 MT-RNR2 PPBP PLEK ACTG1 COX3 RAP1B 
COX1 B2M HBD MALAT1 ND5 ND4 TAGLN2 EEF1A1 MT-RNR1 HSP90AA1 FTL PF4 RPL15 
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Bone marrow megakaryocytes             Cultured megakaryocytes (derived from CD34+ cells) 
Figure 4.14  Over-represented gene ontologies in most highly expressed megakaryocyte genes 
The full GO analysis may be found in Appendix 4, Table 4.1, Table 4.2. The word cloud is a visual representation of the over-represented GO biological processes  







Figure 4.15 Over-represented gene ontologies common highly expressed genes 



















Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 
elimination of bound antigens  
ENSG00000211892 IGHG4 
Immunoglobulin Heavy 
Constant Gamma 4 (G4m 
Marker) -23.1315936 9.80E-15 
Protein 
coding 
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 
elimination of bound antigens  
ENSG00000143546 S100A8 






S100A8 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory 
processes and immune response. 
ENSG00000210082 MTRNR2 






Plays a role as a neuroprotective factor. Protects against death induced by multiple different familial Alzheimer 
disease genes and beta amyloid proteins in Alzheimer disease. Suppresses apoptosis by binding to BAX and 
preventing the translocation of BAX from the cytosol to mitochondria. Binds to IGFBP3 and specifically blocks 
IGFBP3-induced cell death Induces chemotaxis of mononuclear phagocytes via FPR2. Reduces the 
aggregation and fibrillary formation by suppressing the effect of APP on mononuclear phagocytes and acts by 
competitively inhibiting the access of FPRL1 to APP. 
ENSG00000210049 MT-TF 
Mitochondrially Encoded 










S100A9 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory 
processes and immune response. 
ENSG00000198840 ND3 
NADH dehydrogenase, subunit 





Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is 
believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to 
be ubiquinone (By similarity). 
ENSG00000210194 MT-TE 
Mitochondrially Encoded 

















Defensin 2 and defensin 3 have antibiotic, fungicide and antiviral activities. Has antimicrobial activity against 
Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their 
plasma membrane. Defensins are a family of antimicrobial and cytotoxic peptides thought to be involved in 
host defense. They are abundant in the granules of neutrophils and also found in the epithelia of mucosal 
surfaces such as those of the intestine, respiratory tract, urinary tract, and vagina. Members of the defensin 
family are highly similar in protein sequence and distinguished by a conserved cysteine motif. The protein 
encoded by this gene, defensin, alpha 3, is found in the microbicidal granules of neutrophils and likely plays a 















Regulates insulin sensitivity and metabolic homeostasis. Inhibits the folate cycle, thereby reducing de novo 
purine biosynthesis which leads to the accumulation of the de novo purine synthesis intermediate 5-
aminoimidazole-4-carboxamide (AICAR) and the activation of the metabolic regulator 5-AMP-activated protein 
kinase (AMPK).  
ENSG00000163221 S100A12 
S100 calcium binding protein 
A12(S100A12) -10.0211077 8.48E-07 
Protein 
coding 
S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of 

















Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 











Oxidoreductase Core Subunit 
4 Pseudogene 12 -4.71975486 1.87E-05 
Pseudog
ene 





Has antimicrobial activity against Gram-negative bacteria, and to a lesser extent also against Gram-positive 
bacteria and fungi. Defensins are a family of antimicrobial and cytotoxic peptides thought to be involved in 
host defense. They are abundant in the granules of neutrophils and also found in the epithelia of mucosal 
surfaces such as those of the intestine, respiratory tract, urinary tract, and vagina. Members of the defensin 
family are highly similar in protein sequence and distinguished by a conserved cysteine motif. Several alpha 




Oxidoreductase Core Subunit 







Constant Gamma 2 (G2m 
Marker) -11.5887655 1.62E-4 
Protein 
coding 
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 








Pattern receptor that binds to murein peptidoglycans (PGN) of Gram-positive bacteria. Has bactericidal activity 
towards Gram-positive bacteria. May kill Gram-positive bacteria by interfering with peptidoglycan biosynthesis. 
Binds also to Gram-negative bacteria, and has bacteriostatic activity towards Gram-negative bacteria. Plays a 



















coding Binds to bacterial lipopolysaccharides (LPS), has antibacterial activity. 
ENSG00000237973 MTCO1P12 
Mitochondrially Encoded 







NADH dehydrogenase, subunit 
1 (complex I)(ND1) -2.37505821 9.46E-4 
Protein 
coding 
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is 
believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to 
be ubiquinone (By similarity). 





Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity 
against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous 
acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance 












Constant 2 -8.04273591 2.27E-3 
Protein 
coding 
Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 
elimination of bound antigens  
ENSG00000105374 NKG7 










5.665161981  3.88E-3 
RNA 
gene 




coding Hormone that seems to suppress insulin ability to stimulate glucose uptake into adipose cells.  





This gene encodes a sialoglycoprotein that is expressed on mature granulocytes and B cells and modulates 
growth and differentiation signals to these cells. The precursor protein is cleaved to a short 32 amino acid 
mature peptide which is anchored via a glycosyl phosphatidylinositol (GPI) link to the cell surface. This gene 
was missing from previous genome assemblies, but is properly located on chromosome 6.Modulates B-cell 
activation responses. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 
carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Promotes 
AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells. 
ENSG00000169385 RNASE2 






This is a non-secretory ribonuclease. It is a pyrimidine specific nuclease with a slight preference for U. 









Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 








Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil 
enzyme release and chemotaxis. 
ENSG00000051523 CYBA 
cytochrome b-245 alpha 
chain(CYBA) -5.44612098 9.10E-3 
Protein 
coding 
Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. Associates with 
NOX3 to form a functional NADPH oxidase constitutively generating superoxide. 
ENSG00000163993 S100P 






The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-
binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and 
involved in the regulation of a number of cellular processes such as cell cycle progression and 
differentiation. May function as calcium sensor and contribute to cellular calcium signaling.  
ENSG00000211895 IGHA1 
Immunoglobulin Heavy 





Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 
elimination of bound antigens  





This gene is a member of the transferrin family of genes and its protein product is found in the secondary 
granules of neutrophils. The protein is a major iron-binding protein in milk and body secretions with an 
antimicrobial activity, making it an important component of the non-specific immune system. The protein 
demonstrates a broad spectrum of properties, including regulation of iron homeostasis, host defense against a 
broad range of microbial infections, anti-inflammatory activity, regulation of cellular growth and differentiation 
and protection against cancer development and metastasis. 





Extracellular lectin functioning as a pattern-recognition receptor in innate immunity. Binds the sugar moieties 
of pathogen-associated molecular patterns (PAMPs) displayed on microbes and activates the lectin pathway 










May act as a transcriptional activator/repressor in the myeloid lineage. Plays a role in the 
granulocyte/monocyte cell-specific response to interferon. Stimulates the DNA binding of the transcriptional 








V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition. 
Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B 
lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as 
receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B 
lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector 
phase of humoral immunity, which results in the elimination of bound antigens  





Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel 
domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to 
function in modulating the activity of the immune system during the acute-phase reaction. 





Azurophil granules, specialized lysosomes of the neutrophil, contain at least 10 proteins implicated in the 
killing of microorganisms. This gene encodes a preproprotein that is proteolytically processed to generate a 
mature azurophil granule antibiotic protein, with monocyte chemotactic and antimicrobial activity. It is also an 
important multifunctional inflammatory mediator. This encoded protein is a member of the serine protease 
gene family but it is not a serine proteinase, because the active site serine and histidine residues are 
replaced. The genes encoding this protein, neutrophil elastase 2, and proteinase 3 are in a cluster located at 
chromosome 19pter.  
ENSG00000228253 ATP8 






Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in 
the presence of a proton gradient across the membrane which is generated by electron transport complexes 
of the respiratory chain. F-type ATPases consist of two structural domains, F(1) – containing the 
extramembraneous catalytic core and F(0) – containing the membrane proton channel, linked together by a 
central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled 
via a rotary mechanism of the central stalk subunits to proton translocation. Part of the complex F(0) domain. 
Minor subunit located with subunit a in the membrane (By similarity). 
ENSG00000132465 JCHAIN 






Serves to link two monomer units of either IgM or IgA. In the case of IgM, the J chain-joined dimer is a 
nucleating unit for the IgM pentamer, and in the case of IgA it induces larger polymers. It also help to bind 
these immunoglobulins to secretory component. 




coding Plays a role as a neuroprotective and antiapoptotic factor. 
ENSG00000096006 CRISP3 
cysteine rich secretory protein 
3(CRISP3) 
-
5.911851146  4.78E-2 
Protein 
coding 
This gene encodes a member of the cysteine-rich secretory protein (CRISP) family within the CRISP, antigen 
5 and pathogenesis-related 1 proteins superfamily. The encoded protein has an N-terminal CRISP, antigen 5 
and pathogenesis-related 1 proteins domain, a hinge region, and a C-terminal ion channel regulator domain. 
This protein contains cysteine residues, located in both the N- and C-terminal domains, that form eight  bonds, 








The protein encoded by this intronless gene is a bZIP transcription factor which can bind as a homodimer to 
certain DNA regulatory regions. It can also form heterodimers with the related protein CEBP-alpha. The 
encoded protein is important in the regulation of genes involved in immune and inflammatory responses, and 
may be involved in the regulation of genes associated with activation and/or differentiation of macrophages.  
ENSG00000211897 IGHG3 
Immunoglobulin Heavy 






Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are 
membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral 
immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific 
antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting 
plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the 
elimination of bound antigens  














B(LDHB) 6.981085767 1.20E-4 
Protein 
coding 
This gene encodes the B subunit of lactate dehydrogenase enzyme, which catalyzes the interconversion of 
pyruvate and lactate with concomitant interconversion of NADH and NAD+ in a post-glycolysis process. 
ENSG00000152234 ATP5A1 
ATP synthase, H+ 
transporting, mitochondrial F1 
complex, alpha subunit 1, 
cardiac muscle(ATP5A1) 6.156129178 1.20E-4 
Protein 
coding 
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in 
the presence of a proton gradient across the membrane which is generated by electron transport complexes 
of the respiratory chain.  
ENSG00000079459 FDFT1 
farnesyl-diphosphate 
farnesyltransferase 1(FDFT1) 8.852331677 1.29E-4 
Protein 
coding This gene encodes a membrane-associated enzyme located at a branch point in the mevalonate pathway.  
ENSG00000148484 RSU1 
Ras suppressor protein 
1(RSU1) 7.039094583 2.77E-4 
Protein 
coding 
This gene encodes a protein that is involved in the Ras signal transduction pathway, growth inhibition, and 
nerve-growth factor induced differentiation processes, as determined in mouse and human cell line studies.  
ENSG00000132967 HMGB1P5 
High Mobility Group Box 1 




SH3 domain binding glutamate 
rich protein like 3(SH3BGRL3) 6.281939497 4.10E-4 
Protein 
coding Could act as a modulator of glutaredoxin biological activity. 
ENSG00000173812 EIF1 
eukaryotic translation initiation 
factor 1(EIF1) 5.69146454 4.72E-4 
Protein 
coding 
Necessary for scanning and involved in initiation site selection. Promotes the assembly of 48S ribosomal 
complexes at the authentic initiation codon of a conventional capped mRNA. 
ENSG00000099797 TECR microRNA 639(MIR639) 7.177161877 6.26E-4 
Protein 
coding 
Catalyzes the last of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic 
reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain 
fatty acids/VLCFAs per cycle.  
ENSG00000111669 TPI1 
triosephosphate isomerase 
1(TPI1) 7.282297504 1.09E-3 
Protein 
coding 
This gene encodes an enzyme, consisting of two identical proteins, which catalyzes the isomerization of 
glyceraldehydes 3-phosphate (G3P) and dihydroxy-acetone phosphate (DHAP) in glycolysis and 
gluconeogenesis.  
ENSG00000132475 H3F3B microRNA 4738(MIR4738) 5.747596478 1.13E-3 
Protein 
coding 
Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. 
Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin 
independently of DNA synthesis.  
ENSG00000175567 UCP2 uncoupling protein 2(UCP2) 8.060929314 1.13E-3 
Protein 
coding 
UCP are mitochondrial transporter proteins that create proton leaks across the inner mitochondrial membrane, 
thus uncoupling oxidative phosphorylation from ATP synthesis. As a result, energy is dissipated in the form of 
heat. 
ENSG00000142227 EMP3 
epithelial membrane protein 
3(EMP3) 6.431466011 1.37E-3 
Protein 
coding 
The protein encoded by this gene belongs to the PMP-22/EMP/MP20 family of proteins. The protein contains 
four transmembrane domains and two N-linked glycosylation sites. It is thought to be involved in cell 
proliferation, cell-cell interactions and function as a tumor suppressor.  
ENSG00000115956 PLEK pleckstrin(PLEK) 6.606771366 1.40E-3 
Protein 
coding Major protein kinase C substrate of platelets. 
ENSG00000100316 RPL3 ribosomal protein L3(RPL3) 5.981957468 1.49E-3 
Protein 
coding The L3 protein is a component of the large subunit of cytoplasmic ribosomes. 
ENSG00000150991 UBC ubiquitin C(UBC) 6.024907408 1.49E-3 
Protein 
coding 
This gene represents a ubiquitin gene, ubiquitin C. The encoded protein is a polyubiquitin precursor. 
Conjugation of ubiquitin monomers or polymers can lead to various effects within a cell, depending on the 
residues to which ubiquitin is conjugated. Ubiquitination has been associated with protein degradation, DNA 
repair, cell cycle regulation, kinase modification, endocytosis, and regulation of other cell signaling pathways. 
ENSG00000251562 MALAT1 
metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding)(MALAT1) 5.074887685 1.59E-3 
RNA 
gene 
This gene produces a precursor transcript from which a long non-coding RNA is derived by Rnase P cleavage 
of a tRNA-like small ncRNA (known as mascRNA) from its 3’ end. The resultant mature transcript lacks a 
canonical poly(A) tail but is instead stabilized by a 3’ triple helical structure. This transcript is retained in the 
nucleus where it is thought to form molecular scaffolds for ribonucleoprotein complexes. It may act as a 
transcriptional regulator for numerous genes, including some genes involved in cancer metastasis and cell 
migration, and it is involved in cell cycle regulation. 
ENSG00000111348 ARHGDIB 
Rho GDP dissociation inhibitor 
beta(ARHGDIB) 5.924163811 1.82E-3 
Protein 
coding 
Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from 
them, and the subsequent binding of GTP to them (PubMed:8356058, PubMed:7512369). Regulates 
reorganization of the actin cytoskeleton mediated by Rho family members (PubMed:8262133). 
ENSG00000087086 FTL ferritin light chain(FTL) 4.407116736 2.27E-3 
Protein 
coding 
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in 
the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. 
Mediates iron uptake in capsule cells of the developing kidney (By similarity). 
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ENSG00000167996 FTH1 ferritin heavy chain 1(FTH1) 4.996277272 2.65E-3 
Protein 
coding 
Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase 
activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a 
role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity). 
ENSG00000149925 ALDOA 
aldolase, fructose-
bisphosphate A(ALDOA) 5.832348323 2.85E-3 
Protein 
coding 
Plays a key role in glycolysis and gluconeogenesis. In addition, may also function as scaffolding protein (By 
similarity). 
ENSG00000075624 ACTB actin beta(ACTB) 5.214051666 3.03E-3 
Protein 
coding 
This gene encodes one of six different actin proteins. Actins are highly conserved proteins that are involved in 
cell motility, structure, and integrity. This actin is a major constituent of the contractile apparatus and one of 
the two nonmuscle cytoskeletal actins. 
ENSG00000091164 TXNL1 thioredoxin like 1(TXNL1) 7.167904918 3.07E-3 
Protein 
coding Active thioredoxin with a redox potential of about -250 mV. 
ENSG00000149485 FADS1 microRNA 1908(MIR1908) 7.348958389 3.07E-3 
Protein 
coding 
The protein encoded by this gene is a member of the fatty acid desaturase (FADS) gene family. Desaturase 
enzymes regulate unsaturation of fatty acids through the introduction of double bonds between defined 
carbons of the fatty acyl chain. FADS family members are considered fusion products composed of an N-
terminal cytochrome b5-like domain and a C-terminal multiple membrane-spanning desaturase portion, both 
of which are characterized by conserved histidine motifs. 
ENSG00000140374 ETFA 
electron transfer flavoprotein 
alpha subunit(ETFA) 5.742945282 3.17E-3 
Protein 
coding 
The electron transfer flavoprotein serves as a specific electron acceptor for several dehydrogenases, including 
five acyl-CoA dehydrogenases, glutaryl-CoA and sarcosine dehydrogenase. It transfers the electrons to the 
main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase). 
ENSG00000165629 ATP5C1 
ATP synthase, H+ 
transporting, mitochondrial F1 
complex, gamma polypeptide 
1(ATP5C1) 6.528620171 3.23E-3 
Protein 
coding 
This gene encodes a subunit of mitochondrial ATP synthase. Mitochondrial ATP synthase catalyzes ATP 
synthesis, utilizing an electrochemical gradient of protons across the inner membrane during oxidative 
phosphorylation. ATP synthase is composed of two linked multi-subunit complexes: the soluble catalytic core, 
F1, and the membrane-spanning component, Fo, comprising the proton channel. The catalytic portion of 
mitochondrial ATP synthase consists of 5 different subunits (alpha, beta, gamma, delta, and epsilon) 
assembled with a stoichiometry of 3 alpha, 3 beta, and a single representative of the other 3.  
ENSG00000130816 DNMT1 
DNA methyltransferase 
1(DNMT1) 5.22759368 3.36E-3 
Protein 
coding 
Protein arginine methyltransferases are enyzmes that catalyze the transfer of methyl groups from S-
adenosylmethionine (SAM) to the arginine residues on histones and other proteins.  
ENSG00000059377 TBXAS1 
thromboxane A synthase 
1(TBXAS1) 7.462968009 3.88E-3 
Protein 
coding 
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 
proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of 
cholesterol, steroids and other lipids. However, this protein is considered a member of the cytochrome P450 
superfamily on the basis of sequence similarity rather than functional similarity. This endoplasmic reticulum 
membrane protein catalyzes the conversion of prostglandin H2 to thromboxane A2, a potent vasoconstrictor 
and inducer of platelet aggregation.  
ENSG00000127314 RAP1B 
RAP1B, member of RAS 
oncogene family(RAP1B) 4.349835715 4.01E-3 
Protein 
coding 
GTP-binding protein that possesses intrinsic GTPase activity. Contributes to the polarizing activity of KRIT1 
and CDH5 in the establishment and maintenance of correct endothelial cell polarity and vascular lumen. 
Required for the localization of phosphorylated PRKCZ, PARD3 and TIAM1 to the cell junction. Plays a role in 
the establishment of basal endothelial barrier function. 
ENSG00000054118 THRAP3 
thyroid hormone receptor 
associated protein 3(THRAP3) 5.823109092 4.35E-3 
Protein 
coding 
Involved in pre-mRNA splicing. Remains associated with spliced mRNA after splicing which probably involves 
interactions with the exon junction complex (EJC). Can trigger mRNA decay which seems to be independent 
of nonsense-mediated decay involving premature stop codons (PTC) recognition. May be involved in nuclear 
mRNA decay. Involved in regulation of signal-induced alternative splicing.  
ENSG00000143226 FCGR2A 
Fc fragment of IgG receptor 
Iia(FCGR2A) 5.306413589 4.51E-3 
Protein 
coding 
Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular 
responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens. 
ENSG00000198242 RPL23A 
ribosomal protein 
L23a(RPL23A) 4.76496201 4.93E-3 
Protein 
coding This protein binds to a specific region on the 26S rRNA. 
ENSG00000110934 BIN2 bridging integrator 2(BIN2) 5.503489991 5.06E-3 
Protein 
coding 
Promotes cell motility and migration, probably via its interaction with the cell membrane and with podosome 
proteins that mediate interaction with the cytoskeleton. Modulates membrane curvature and mediates 
membrane tubulation. Plays a role in podosome formation. Inhibits phagocytosis. 
ENSG00000100353 EIF3D 
eukaryotic translation initiation 
factor 3 subunit D(EIF3D) 6.955622621 5.68E-3 
Protein 
coding 
Eukaryotic translation initiation factor-3 (eIF3), the largest of the eIFs, is a multiprotein complex composed of 
at least ten nonidentical subunits. The complex binds to the 40S ribosome and helps maintain the 40S and 
60S ribosomal subunits in a dissociated state. It is also thought to play a role in the formation of the 40S 






synthase(FDPS) 8.531009093 5.68E-3 
Protein 
coding 
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a 
precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and 
ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the 
sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl 
pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl 
pyrophosphate. 
ENSG00000161203 AP2M1 
adaptor related protein 
complex 2 mu 1 
subunit(AP2M1) 6.66057589 5.68E-3 
Protein 
coding 
This gene encodes a subunit of the heterotetrameric coat assembly protein complex 2 (AP2), which belongs 
to the adaptor complexes medium subunits family. The encoded protein is required for the activity of a 
vacuolar ATPase, which is responsible for proton pumping occurring in the acidification of endosomes and 
lysosomes.  
ENSG00000235655 H3F3AP4 
H3 Histone, Family 3A, 




ATP synthase, H+ 
transporting, mitochondrial F1 
complex, beta 
polypeptide(ATP5B) 6.880049327 6.01E-3 
Protein 
coding 
This gene encodes a subunit of mitochondrial ATP synthase. Mitochondrial ATP synthase catalyzes ATP 
synthesis, utilizing an electrochemical gradient of protons across the inner membrane during oxidative 
phosphorylation. ATP synthase is composed of two linked multi-subunit complexes: the soluble catalytic core, 
F1, and the membrane-spanning component, Fo, comprising the proton channel. The catalytic portion of 
mitochondrial ATP synthase consists of 5 different subunits (alpha, beta, gamma, delta, and epsilon) 
assembled with a stoichiometry of 3 alpha, 3 beta, and a single representative of the other 3. The proton 
channel consists of three main subunits (a, b, c).  
ENSG00000198898 CAPZA2 
capping actin protein of muscle 
Z-line alpha subunit 
2(CAPZA2) 5.249095992 7.03E-3 
Protein 
coding 
The protein encoded by this gene is a member of the F-actin capping protein alpha subunit family. It is the 
alpha subunit of the barbed-end actin binding protein Cap Z. By capping the barbed end of actin filaments, 
Cap Z regulates the growth of the actin filaments at the barbed end.  
ENSG00000108671 PSMD11 
proteasome 26S subunit, non-
ATPase 11(PSMD11) 5.570801143 7.33E-3 
Protein 
coding 
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of 
ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing 
misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose 
functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, 
including cell cycle progression, apoptosis, or DNA damage repair.  
ENSG00000149357 LAMTOR1 
late endosomal/lysosomal 
adaptor, MAPK and MTOR 
activator 1(LAMTOR1) 5.949555526 7.70E-3 
Protein 
coding 
As part of the Ragulator complex it is involved in amino acid sensing and activation of mTORC1, a signaling 
complex promoting cell growth in response to growth factors, energy levels, and amino acids. Activated by 
amino acids through a mechanism involving the lysosomal V-ATPase, the Ragulator functions as a guanine 
nucleotide exchange factor activating the small GTPases Rag. Activated Ragulator and Rag GTPases 
function as a scaffold recruiting mTORC1 to lysosomes where it is in turn activated. LAMTOR1 is directly 
responsible for anchoring the Ragulator complex to membranes. Also required for late endosomes/lysosomes 
biogenesis it may regulate both the recycling of receptors through endosomes and the MAPK signaling 




A1(HNRNPA1) 5.436961839 7.90E-3 
Protein 
coding 
Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A) mRNA from the nucleus to 
the cytoplasm and may modulate splice site selection. 
ENSG00000116288 PARK7 
Parkinsonism associated 
deglycase(PARK7) 5.571874119 7.94E-3 
Protein 
coding 
The product of this gene belongs to the peptidase C56 family of proteins. It acts as a positive regulator of 
androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor 
for oxidative stress, and it apparently protects neurons against oxidative stress and cell death.  
ENSG00000254999 BRK1 
BRICK1, SCAR/WAVE actin 
nucleating complex 
subunit(BRK1) 6.163344524 8.01E-3 
Protein 
coding 
Involved in regulation of actin and microtubule organization. Part of a WAVE complex that activates the Arp2/3 
complex. As component of the WAVE1 complex, required for BDNF-NTRK2 endocytic trafficking and signaling 
from early endosomes (By similarity). 
ENSG00000168003 SLC3A2 
solute carrier family 3 member 
2(SLC3A2) 6.94514985 8.25E-3 
Protein 
coding 
This gene is a member of the solute carrier family and encodes a cell surface, transmembrane protein. The 
protein exists as the heavy chain of a heterodimer, covalently bound through di-sulfide bonds to one of 
several possible light chains. The encoded transporter plays a role in regulation of intracellular calcium levels 




A'(SNRPA1) 5.686022399 8.44E-3 
Protein 




receptor for activated C kinase 
1(RACK1) 5.573898576 8.44E-3 
Protein 
coding 
Involved in the recruitment, assembly and/or regulation of a variety of signaling molecules. Interacts with a 
wide variety of proteins and plays a role in many cellular processes. Component of the 40S ribosomal subunit 
involved in translational repression 
ENSG00000233276 GPX1 
glutathione peroxidase 
1(GPX1) 5.092046956 8.44E-3 
Protein 
coding Protects the haemoglobin in erythrocytes from oxidative breakdown. 
ENSG00000085662 AKR1B1 
aldo-keto reductase family 1 
member B(AKR1B1) 7.799142359 8.48E-3 
Protein 
coding 
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their 
corresponding alcohols with a broad range of catalytic efficiencies. 
ENSG00000174748 RPL15 ribosomal protein L15(RPL15) 4.599841155 8.68E-3 
Protein 
coding This gene encodes a member of the L15E family of ribosomal proteins and a component of the 60S subunit.  
ENSG00000111640 GAPDH 
glyceraldehyde-3-phosphate 
dehydrogenase(GAPDH) 5.738486429 8.935E-3 
Protein 
coding 
Has both glyceraldehyde-3-phosphate dehydrogenase and nitrosylase activities, thereby playing a role in 
glycolysis and nuclear functions, respectively. Participates in nuclear events including transcription, RNA 
transport, DNA replication and apoptosis. Nuclear functions are probably due to the nitrosylase activity that 
mediates cysteine S-nitrosylation of nuclear target proteins such as SIRT1, HDAC2 and PRKDC. Modulates 
the organization and assembly of the cytoskeleton.  




Upregulated in bone marrow megakaryocytes    Upregulated in cultured megakaryocytes (derived from CD34+cells) 
 
 
Figure 4.16  Over-represented gene ontologies in upregulated genes in bone marrow megakaryocytes and in cultured megakaryocytes 
The full GO analysis may be found in Appendix 4, Table 4.5, Table 4.6. The word cloud is a visual representation of the over-represented GO biological processes  
with their size an indicator of significance for upregulated genes in bone marrow megakaryocytes and cultured megakaryocytes derived from CD34+ cell
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4.2.3 Ploidy associated megakaryocyte transcriptional signatures 
 
4.2.3.1 Sample preparation and RNA-seq library preparation 
 
In order to investigate changes in gene expression associated with endomitotic replication 
and subsequent increase in megakaryocyte ploidy level, bone marrow megakaryocytes were 
FACS sorted for RNA-seq according to ploidy level. The majority of cells collected were as 
single cell. As discussed above the low quality of single cell megakaryocyte sequencing 
compared to multicellular pools as a result of oversaturation by mitochondrial transcripts 
meant that after an initial round of sequencing, no further single cells were amplified or 
sequenced. Megakaryocytes from 10 individuals undergoing non-coronary cardiac surgery 
were collected as single cells and megakaryocyte pools according to ploidy level from 2N to 
32N. Table 4.10 shows the baseline characteristics for these individuals.  
 
32 megakaryocyte pools (20-50 cells) FACS sorted according to ploidy were collected from 5 
individuals from the control group: 2N: n=3, 4N: n=6, 8N: n=7, 16N: n=8, 32N: n=8. 125bp 
paired-end sequencing was performed at a depth of approximately 500 million reads/sample. 
In total 1106 single megakaryocytes had also been sorted from a further 5 individuals from 
the control group, 2N: n=220, 4N: n=158, 8N: n=200, 16N: n=272, 32N: n=256. Here again 
125bp paired-end sequencing was performed but at an approximate depth of 50 million 
reads/sample.  
 
In terms of batch effects Table 4.11 shows each sample plate ID and corresponding 
sequencing lane ID whereas Table 4.12 outlines the batches in which samples were 
collected, cDNA reverse transcribed/amplified and Nextera libraries prepared and sequenced. 
 
 
Table 4.10 Baseline patient characteristics 
 Healthy controls (n=10) 
 
Gender M 6 





Coronary disease 0 
Antiplatelets 2 
Left ventricular dysfunction 3 
Aortic valve surgery 7 
Mitral valve surgery 4 
Hb (mean ± SD) 13.12 ± 2.54 
WC (mean ± SD) 7.12 ± 1.90 







Plate ID Sequencing Lane ID 
60Z 16N SLX-9491 
60Z 32N SLX-9492 
60Z 8N SLX-9493 
60Z 4N/2N SLX-9494 
7TA 16N SLX-9495 
7TA 32N SLX-9496 
CYH 16N SLX-9490 
CYH 32N SLX-9497 
CYH 8N SLX-9488 
CYH 4N SLX-9489 
CYH 2N SLX-10160 
CUP 8N SLX-10154 
CUP 16N SLX-10155 
CUP 32N SLX-10156 
CUP 4N/2N SLX-10157 
CST 2N SLX-10158 
M8T SLX-10482 




Table 4.11 Patient and plate ID on each sequencing lane 
 
Sample collection Amplification Nextera Library prep / RNA-seq 
1 1 1 
  0DX   60Z 16N   SLX-9491 
2   60Z 32N   SLX-9492 
  1FP   60Z 8N   SLX-9493 
3   60Z 4N/2N   SLX-9494 
  3XI 2   SLX-9495 
4   7TA 16N   SLX-9496 
  60Z 16N   7TA 32N 2 
  60Z 32N 3   SLX-9490 
  60Z 8N   CYH 16N   SLX-9497 
  60Z 4N/2N   CYH 32N   SLX-9488 
5   CYH 8N   SLX-9489 
  7TA 16N   CYH 4N   SLX-10160 
  7TA 32N   CYH 2N 3 
  7TA 8N 4   SLX-10154 
6   CUP 8N   SLX-10155 
  CUP 8N   CUP 16N   SLX-10156 
  CUP 16N   CUP 32N   SLX-10157 
  CUP 32N   CUP 4N/2N   SLX-10158 
  CUP 4N/2N   CST 2N 4 
7 5   SLX-10208 
  CST 2N   H4K 5 
8 6   SLX-10482 
  CYH 16N   M8T 6 
  CYH 32N 7   SLX-11606 
  CYH 8N   0DX     SLX-11607 
  CYH 4N 8   SLX-11608 
  CYH 2N   3XI   SLX-11609 
9   1FP  
  H4K   
10   
  M8T   
 





4.2.3.2 RNA sequencing data: Quality measures 
 
1. Quality control 
 
Figure 4.17 shows metrics per sequencing lane for total read count, alignment to the 
reference transcriptome (GRCh37), proportion of reads mapped to external spike-in ERCCs 
compared to endogenous transcripts, no of genes called, proportion of reads mapping to 
annotated exonic regions and the proportion of reads mapping to mitochondrial transcripts.  
 
The single cells have lower total read counts more variable alignment rates to the reference 
transcriptome, higher ERCC to mapped transcript ratio and lower number of genes called in 
comparison with the multicellular megakaryocyte pools and therefore have overall lower 
quality. The exon/(exon+intron) ratio is variable throughout and there is a high proportion of 
reads taken up by mitochondrial reads in all sequencing lanes. 
 
2. Cell filtering 
 
In order to filter out higher quality single cells for downstream gene expression analysis the 
machine learning approach (random forest) described in Section 2.6.2 was used. Good 
quality cells were those that had low ERCC ratios and mitochondrial mapping, higher number 
of reads mapping to exonic regions and genes called. Figure 4.18 shows the cells deemed to 
be of low quality were taken out of further analysis. From a total of 1106 cells sequenced, 282 


















Figure 4.17 Quality control metrics/sequencing lane. A. Total reads; B. Rate of alignment 
to transcriptome; C. Ratio of reads mapping to ERCCs; D. No. genes called; E. Ratio of 




Figure 4.18 Filtering single cells. 
High and low-quality cells shown by ERCC ratio, exonic ratio, number of called genes and mitochondrial mapping after cell filtering using a random forest 
classifier (Breiman2001). Green denotes high quality, red denotes low quality. 
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4.2.3.3 Gene expression analysis: Megakaryocyte pools 
 
Gene expression analysis was performed on megakaryocyte pools before single cells due to 
their higher sequencing quality (4.2.3.2). The 100 most highly expressed genes in each ploidy 
group: 2N, 4N, 8N, 16N, 32N are shown in Table 4.13. In all groups, there was a high 
expression of transcripts mapping to mitochondrial transcripts and a number of genes 
involved in cellular metabolism as seen in the megakaryocyte pools sorted irrespective of 
ploidy level in section 4.2.2 above.  Genes that are known to be involved in platelet function 
are highlighted orange in Table 4.13. Platelet transcripts highly expressed in 2N cells these 
included PPBP (growth factor released by platelets), PLEK (a major protein kinase C 
substrate in platelets), TMSB4X and ACTB (important in cytoskeletal change), RAP1B 
(located in the plasma membrane and regulator of outside-in signalling in platelets), SRGN 
(Granule proteoglycan released on platelet activation), CD47 (thrombospondin adhesion 
receptor on platelets). In addition to these platelet genes, the following were also highly 
expressed in 4N and 8N cells:  ITGA2B (CD41), PF4 (chemokine released from platelet alpha 
granules), CD36 (platelet glycoprotein that binds collagen and thrombospondin on platelet 
activation), F13A1 (Coagulation factor XIII), ACTG1 (important in cytoskeletal change). Other 
genes expressed in 4N and 8N cells included those involved in immune defense and 
translation. By contrast, in 16N and 32N cells, far fewer platelet transcripts are present in the 
most highly expressed genes, only TMSB4X, SGRN, ACTB. There are highly levels of 
expression of genes involved in cellular metabolism, translation and protein transport and 
localisation (Table 4.13). All ploidy groups show high expression of the housekeeping gene 
B2M and a number of immunoglobulin regions. 
 
Shared expression of highly expressed genes in each ploidy group shown in Venn diagram 
format (Figure 4.20a) demonstrated that there were number of shared features between 2N, 
4N and 8N cells, and separate shared features between 16N and 32N with fewer genes 
shared between the other pairs. Overall all ploidy groups shared 28 highly expressed genes 
involved in cellular metabolism and respiration. A similar pattern was seen when assessing 
shared GO categories (Figure 4.20b) with an overlap of 20 GO categories between all ploidy 
groups pertaining to cellular metabolism, mitochondrial transcripts. The shared GO categories 
are listed in Table 4.14. While 4N and 8N shared 15 additional GO categories related to 
platelet activation, cell secretion and defense response only 6 additional categories were 
shared between 2N, 4N and 8N. 16N and 32N shared 40 additional GO categories all related 
to processes involved in translation and protein localisation. There were very few shared GO 
categories between other pairs. The transition in biological processes based on the 100 most 
highly expressed genes in each ploidy group can be seen in the individual GO word clouds in 
Figures 4.21, 4.22 and the full GO analysis may be found in Appendix 4, Tables S4.7, S4.8, 




No 2N 4N 8N 16N 32N 
1 MT-RNR2 MT-RNR2 MT-RNR2 MT-RNR2 MT-RNR2 
2 HBB COX1 COX1 COX1 COX1 
3 COX2 HBB MT-RNR1 HBB MT-RNR1 
4 ND4 ND4 ND4 MT-RNR1 ND4 
5 COX3 MT-RNR1 COX2 ND4 ERCC-00074 
6 COX1 COX2 CYTB COX2 COX2 
7 CYTB CYTB COX3 COX3 CYTB 
8 MT-RNR1 COX3 ATP6 CYTB COX3 
9 ATP6 ND2 ND2 ATP6 ND1 
10 ERCC-00074 ATP6 ND1 ND1 ATP6 
11 IGHG2 ND1 ERCC-00074 ND5 ND2 
12 ND1 ND5 ND5 ND2 HBB 
13 MALAT1 MALAT1 HBB ERCC-00074 ND5 
14 IGHG1 ERCC-00074 ERCC-00046 ERCC-00046 ERCC-00046 
15 ND2 HBA2 ND4L S100A9 S100A8 
16 ND5 IGHG1 ND3 S100A8 S100A9 
17 ERCC-00046 ND4L IGHG1 HBD CLC 
18 H2AFZ PPBP ERCC-00096 ND4L PRG3 
19 B2M NEAT1 ERCC-00130 HBA2 ERCC-00004 
20 HBA ND3 MALAT1 ERCC-00004 ND4L 
21 HSP90AA1 PF4 MTATP6P1 ND3 ERCC-00002 
22 TMSB4X TMSB4X ERCC-00002 ERCC-00002 ERCC-00130 
23 ITM2B ERCC-00046 ND6 ERCC-00130 B2M 
24 HMGB1 IGHA1 ERCC-00004 MTATP6P1 ND3 
25 SNRPE MTATP6P2 S100A8 ERCC-00096 IGHG1 
26 DEFA3 HBD ERCC-00042 ND6 HBD 
27 IGHA1 DEFA3 S100A9 PNRC2 RNASE2 
28 SRSF3 B2M IGLC2 TNPO1 HBA2 
29 MIR1244-1 S100A8 PPBP S100A12 ERCC-00096 
30 S100A9 ND6 ASNSD1 MTCO1P12 ND6 
31 CALM2 ACTB HBA2 ARFIP1 IGKV3-20 
32 LOC105376575 S100A9 IGHM TMSB4X MTATP6P1 
33 HNRNPH1 ERCC-00002 B2M FTL TMSB4X 
34 PPP1CB HSP90AA1 PF4 CAMP LOC105376575 
35 S100A8 ERCC-00004 UHMK1 B2M RPLP1 
36 JCHAIN ERCC-00096 SDCBP LYZ HSP90AA1 
37 ERCC-00004 ERCC-00130 ERCC-00003 AHSP LTF 
38 LIPA GNG11 ERCC-00113 MNDA MALAT1 
39 NAP1L1 LOC105376575 MTND2P28 CALM2 MTCO1P12 
40 MIR3917 SRGN TMSB4X CA1 EPX 
41 HBD MTCO1P13 ERCC-00136 ERCC-00136 RPL21 
42 MIR4738 DEFA4 ACTB ACTG1 FTL 
43 ND4L SAT1 HBD SAR1A HNRNPH1 
44 WTAP LIMS1 MTCO1P12 USP12 EEF1A1 
45 RPL21 RAP1B ATP8 ERCC-00043 SRGN 
46 RPS13 SUB1 DEFA3 ERCC-00113 RNASE3 
47 FTL C6orf25 PPARGC1A HNRNPH1 S100A12 
48 ND3 IGKC FTL ATP8 RPS25 
49 PTGES3 PLEK NEAT1 UBE2D1 ZNF442 
50 RAP1B ACTG1 ERCC-00043 ARPC5 RPS20 
51 CDC42 CTTN TMEM200C ACTB MNDA 
52 CAPZA1 HBA1 IGKC LTF RPS27A 
53 MARCKS ITGA2B IGLV3-21 HSPA8 ERCC-00171 
54 SAR1A ATP8 MYL12B PPP1CB DEFA3 
55 ACTB YWHAZ ERCC-00108 MALAT1 RPL5 
56 SNRPG EEF1A1 STGN FNTA SUB1 
57 HNRNPA2B1 TPT1 F13A1 MTND2P28 ACTB 
58 SAT1 HBM ITGA2B LCN2 ERCC-00113 
59 TPT1 ABCC3 ERCC-00171 METTL9 RPS13 
60 DNAJB9 DAAM1 LIMS1 TLK2 CD63 
61 SUB1 FTL GNG11 BTG1 ERLEC1 
62 PTP4A2 SLC25A37 INIP H2AFZ IGHG2 
63 UBE2D3 RPL21 ERCC-00092 RPL21 HMGB1 
64 VCAM1 MIR3064 JCHAIN RANBP2 H2AFZ 
65 HMGN2 HNRNPH1 CDC42EP3 EEF1A1 TPT1 
66 NDUFA4 MTND2P29 RNASE2 RPL15 RPLP2 
67 RPL9 TLK1 C22orf39 SNX3 LCN2 
68 TM9SF2 NAP1L1 RPSP1 TMEM9B RPS2 
69 IGKV2D-28 MIR6852 SDPR HNRNPA2B1 HSPA8 
70 PPA2 CD47 RNASE3 RPS18 RPL19 
71 SMC4 ACRBP MTND1P23 ERCC-00171 ERCC-00043 
72 THUMPD1 TPM4 C6orf25 ERCC-00003 RPL9 
73 PPBP TTK GRN UBE2W RPS12 
74 MNDA HLA-E CLC RPL7 RPS16 
75 AK6 SNRPE PLEK RPL9 CALM2 
76 CNBP DNM3 EEF1A1 H3F3A ERCC-00003 
77 SRGN ITM2B ERCC-00095 HSP90AA1 RPLP0 
78 RPL5 HNRNPA2B1 MNDA DCLRE1C ATP8 
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79 CD47 MAX LYZ RPL13A SSR4 
80 CD74 AHSP ZBTB34 RPL19 RPS27 
81 BNIP3L F13A1 DAD1 MITD1 RPS6 
82 EAF2 GPX1 HLA-E SLC25A37 RPS18 
83 MTCO1P12 IFNAR1 RPLP0 HMGB1 EEF1B2 
84 LYZ SDPR RPL9 MIR1244-1 SH3BGRL 
85 UGP2 SSR3 S100A12 TRMT10C WTAP 
86 ND6 RPLP1 EIF4G2 HBM IGHA1 
87 SRP14 NORAD ACTG1 MSRB1 MIR3607 
88 PLEK RPLP0 IGHV3-33 WTAP RPL27 
89 APOE SSR4 CALM2 LINC00920 PRTG 
90 ARL8B CD36 SSR4 CPNE3 COX7B 
91 RNF13 CDC42 RAD54L NDC1 FCF13 
92 POMP PPP1R12A RPS20 RGS2 RPL7 
93 MORF4L1 ERCC-00113 RPUSD3 GYPA CA1 
94 HSPA8 SRSF3 RPL21 MIR3917 ERCC-00136 
95 MYL12B MIR3652 MCL1 HMGN2 CAPZA1 
96 MIR3064 SARAF CD36 YPEL5 RPL13A 
97 SET SNX3 IGKV1D-39 SRGN TKT 
98 CKS2 NCOA4 MIR4738 ERCC-00108 SSR3 
99 SNX3 EAF2 LOC101927345 RPS2 ABI1 
100 EEF1A1 STOM PSMA3 SFT2D1 RPL11 
Table 4.13 The 100 most highly expressed genes in each megakaryocyte ploidy group.  
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Figure 4.20 Venn diagrams to show commonality between ploidy groups. 




 GO_BP_ID GO_BP_NAME 
2N, 4N, 8N, 16N, 32N GO:0055114 oxidation-reduction process 
GO:0006796 phosphate-containing compound metabolic process 
GO:0010035 response to inorganic substance 
GO:0042775 mitochondrial ATP synthesis coupled electron transport 
GO:0050832 defense response to fungus 
GO:0015980 energy derivation by oxidation of organic compounds 
GO:0006091 generation of precursor metabolites and energy 
GO:0032119 sequestering of zinc ion 
GO:0022904 respiratory electron transport chain 
GO:0006979 response to oxidative stress 
GO:0006793 phosphorus metabolic process 
GO:0070488 neutrophil aggregation 
GO:0016310 phosphorylation 
GO:0006123 mitochondrial electron transport, cytochrome c to oxygen 
GO:0042773 ATP synthesis coupled electron transport 
GO:0006950 response to stress 
GO:0006119 oxidative phosphorylation 
GO:0022900 electron transport chain 
GO:0006120 mitochondrial electron transport, NADH to ubiquinone 
GO:0045333 cellular respiration 
2N, 4N, 8N GO:0042060 wound healing 
GO:0007596 blood coagulation 
GO:0007599 hemostasis 
GO:0050817 coagulation 
GO:0050878 regulation of body fluid levels 
GO:0009611 response to wounding 
4N, 8N GO:0042330 taxis 
GO:0051707 response to other organism 
GO:0065008 regulation of biological quality 
GO:0042542 response to hydroperoxide 
GO:0006935 chemotaxis 
GO:0009607 response to biotic stimulus 
GO:0009617 response to bacterium 
GO:0034109 homotypic cell-cell adhesion 
GO:0042221 response to chemical stimulus 
GO:0046903 secretion 
GO:0001775 cell activation 
GO:0002576 platelet degranulation 
GO:0030168 platelet activation 
GO:0032940 secretion by cell 
GO:0006887 exocytosis 
16N, 32N GO:0022411 cellular component disassembly 
GO:0006605 protein targeting 
GO:0019058 viral infectious cycle 
GO:0006402 mRNA catabolic process 
GO:0009057 macromolecule catabolic process 
GO:0006415 translational termination 
GO:0033214 iron assimilation by chelation and transport 
GO:0006414 translational elongation 
GO:0006413 translational initiation 
GO:0022415 viral reproductive process 
GO:0016071 mRNA metabolic process 
GO:0015031 protein transport 
GO:0000184 
nuclear-transcribed mRNA catabolic process, nonsense-mediated 
decay 
GO:0006412 translation 
GO:0000956 nuclear-transcribed mRNA catabolic process 
GO:0015701 bicarbonate transport 
GO:0033036 macromolecule localization 
GO:0019080 viral genome expression 
GO:0045184 establishment of protein localization 
GO:0071822 protein complex subunit organization 
GO:0009056 catabolic process 
GO:0034621 cellular macromolecular complex subunit organization 
GO:0046907 intracellular transport 
GO:0006886 intracellular protein transport 
GO:0019083 viral transcription 
GO:0008104 protein localization 
GO:0033365 protein localization to organelle 
GO:0043624 cellular protein complex disassembly 
GO:0070727 cellular macromolecule localization 
GO:0032984 macromolecular complex disassembly 
GO:0033212 iron assimilation 
GO:0044265 cellular macromolecule catabolic process 
GO:0016032 viral reproduction 
GO:0034613 cellular protein localization 
GO:0071845 cellular component disassembly at cellular level 
GO:0043241 protein complex disassembly 
GO:0034623 cellular macromolecular complex disassembly 
GO:0051704 multi-organism process 
GO:0044248 cellular catabolic process 
GO:0006401 RNA catabolic process 




Figure 4.21 Over-represented gene ontologies in highly expressed genes in 2N, 4N and 8N ploidy groups. The full GO analysis may be found in Appendix 2. 







Figure 4.22 Over-represented gene ontologies in highly expressed genes in 16N and 32N ploidy groups. The full GO analysis may be found in Appendix 2. 






4.2.3.4 Differential expression analysis: Megakaryocyte pools 
 
The initial differential expression analysis of megakaryocyte ploidy was focused on comparing 
the extreme ends of ploidy to ascertain if there is differential gene expression as 
polyploidisation occurs. Further pairwise expression analysis is currently in progress.  
 
There was an experimental concern regarding the purity of the 2N cells. They were collected 
on the basis of the same FACS gating as shown in Figure 4.1 using surface markers of CD41 
and CD42 antibodies. Therefore, by definition these are megakaryocytes. However, given 
that the entirety of the nucleated bone marrow cell population from which megakaryocytes 
were sorted were also 2N and large megakaryocytes may be fragile and break down into 
smaller platelet-like particles particularly during the sorting process, there was a concrete and 
nor experimentally controllable risk that the 2N population may be contaminated with non-
megakaryocytes conjugated to platelet-like particles. The highly expressed gene analysis 
presented above (Section 4.2.3.3) shows the 2N cells to express a number of genes that are 
also expressed in other ploidy groups, however apart from the genes that are shared between 
all groups, mainly related to cell metabolism, there is little other overlap with other groups. 
Furthermore, there were only 3 2N ploidy megakaryocyte pools collected from 3 individuals 
compared with 6-8 megakaryocyte pools of other ploidy groups collected from 5 individuals. 
As there was some theoretical uncertainty, differential expression analysis was performed 
between 2N and 32N cells as well as 4N and 32N cells. While both of these analyses were 
performed and are presented here, the focus has been on the quantitative differences in gene 
expression between 4N and 32N. 
 
A differential expression analysis was then performed between 32N ploidy group and the 4N 
ploidy group. Of the 944 differentially expressed features, 373 were shown to be significantly 
upregulated in 32N megakaryocytes compared with 4N (P<0.05, Wald test), full list is shown 
in Appendix 4, Table S4.12 with levels of significance. The top 50 upregulated genes are 
shown in Table 4.15 along with their localisations within the cell. Of the top 50, 17 transcripts 
encode proteins that localise to the cell membrane of these are the three G-protein coupled 
receptors: prostaglandin E2 receptor, pyrimidinergic receptor P2Y and the opioid receptor mu 
1. Others include two low density lipoprotein receptors (LRP6, LRP1B), a receptor from the 
tumour necrosis factor receptor superfamily (TNFRSF1B) and a number of ion channels: 
UNC80, KCNK5, CACNA2D1 and TRPM2. The 373 upregulated genes were annotated for 
GO based on biological process (Appendix 4, Table S4.14; Figure 4.23). 20 GO categories 
were significantly enriched within the upregulated gene list and all of these were related to the 
same 17 genes consisting of a number of ribosomal transcripts. The over-represented GO 
categories all related to translational initiation, elongation and termination, protein localisation, 
cellular protein complex disassembly and inflammatory response.  
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571 transcripts were found to be significantly downregulated with increasing ploidy. The full 
list is shown in Appendix 4, Table S4.13 and the top 50 downregulated transcripts are 
presented in Table 4.16 below, with their localisation within the cell. One of the most 
significantly downregulated genes was tubulin folding cofactor E (TBCE) which is involved 
with cytoskeletal change and protein folding. There were 10 genes in the downregulated list 
that encode proteins involved in signalling including: CYP7B1, PIK3IP1, ING2, RAB38, 
LEFTY1, XAF1. 2 of the genes were related to cell-cell adhesion, encoding secreted proteins: 
SRPX2 and EPDR1 and 2 encode proteins involved in chromatin remodelling and gene 
expression as well as DNA repair: KAT5, SWI5. Performing GO analysis on the full 571 
genes revealed the most over-represented biological themes included platelet degranulation, 
coagulation, haemostasis, wound healing, vesicle mediated transport and exocytosis 
(Appendix 4, Table S4.15; Figure 4.23). A number of genes related to platelet function were 
significantly downregulated with increased ploidy including: PF4, ITGA2B, ITGB3, PDGFB, 
PDGFA, PLEK, F13A1 and RAP1B.  To give further confidence to these results, this dataset 
was compared with the differential expression analysis between 32N and 2N megakaryocytes 
by way of a Venn diagram, it showed 352 genes were shared between downregulated gene 
lists in the two analyses, and 48 genes were shared between upregulated gene lists 
(Appendix 4, Figure S4.1; Table S4.19, for reference the differential expression analysis is 
presented in Appendix 4, Table S4.20, S4.21, S4.22, S4.23). 
 
4.2.3.5 Identification of transcripts encoding megakaryocyte transmembrane proteins 
 
Using the Ensembl database (Zerbino et al. 2017) the genes upregulated with ploidy were 
annotated in terms of their localisation within the cell. Of all upregulated genes 78 contained 
transmembrane domains and localised to the cell membrane. These were further broken 
down into structural and functional categories, shown in Table 4.17. Table 4.18 shows all 
localisations for the upregulated genes, 77 were annotated as encoding cytoplasmic proteins, 
57 as nuclear proteins, 27 as internal membrane proteins, 18 as mitochondrial proteins, 18 
and secreted proteins and for 104 transcripts there was no localisation information available. 
 
As seen in Table 4.18, plasma proteins upregulated in 32N cells have a wide range of 
functionality with 6 belonging to the immunoglobulin superfamily and 6 being G-protein 
coupled receptors. 2 of the immunoglobulin superfamily are immunoglobulin variable chains. 
Of the G-protein coupled receptors, PTGER2 is known to be expressed on the platelet 
membrane. This is also true of the tetraspanin CD63, the TNF alpha receptor TNFRSF1B and 
the lysophosphatidic acid receptor PPAP2A. A number of genes encode ion transporter 
channels were also upregulated. 
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ENSG00000144406 UNC80 unc-80 homolog (C. elegans) [26582] 50.30615971 5.17E-69 
Cell 
membrane 
ENSG00000176485 PLA2G16 phospholipase A2, group XVI [17825] 51.86601985 1.28E-50 Cytoplasm 




phosphodiesterase 1C, calmodulin-dependent 70kDa 
[8776] 45.76676733 1.10E-44 Cytoplasm 
ENSG00000125384 PTGER2 
prostaglandin E receptor 2 (subtype EP2), 53kDa 




Rho guanine nucleotide exchange factor (GEF) 10-like 
[25540] 52.0539922 1.02E-40 Cytoplasm 
ENSG00000115295 CLIP4 
CAP-GLY domain containing linker protein family, 
member 4 [26108] 45.25946636 4.16E-40 Cytoplasm 
ENSG00000176040 TMPRSS7 transmembrane protease, serine 7 [30846] 51.97533467 2.92E-39 
Cell 
membrane 
ENSG00000178445 GLDC glycine dehydrogenase (decarboxylating) [4313] 47.04831453 3.03E-38 Mitochondria 
ENSG00000066813 ACSM2B 
acyl-CoA synthetase medium-chain family member 2B 
[30931] 49.96867869 3.02E-37 Mitochondria 
ENSG00000198963 RORB RAR-related orphan receptor B [10259] 43.43630612 3.67E-37 Nucleus 
ENSG00000213753 CENPBD1P1 
CENPB DNA-binding domains containing 1 
pseudogene 1 [28421] 47.06938471 8.86E-36 NA 
ENSG00000171163 ZNF692 zinc finger protein 692 [26049] 45.3983006 5.40E-35 Nucleus 
ENSG00000100473 COCH cochlin [2180] 47.63080837 2.38E-34 Secreted 
ENSG00000161944 ASGR2 asialoglycoprotein receptor 2 [743] 53.68317198 6.93E-34 
Cell 
membrane 
ENSG00000272754 ENSG00000272754 RNA gene 42.94039269 6.23E-31 NA 
ENSG00000169040 PMCHL2 
pro-melanin-concentrating hormone-like 2, 
pseudogene [9111] 47.85078026 1.14E-29 NA 
ENSG00000165238 WNK2 WNK lysine deficient protein kinase 2 [14542] 48.56998379 7.34E-29 Cytoplasm 
ENSG00000184967 NOC4L nucleolar complex associated 4 homolog [28461] 46.26348016 9.21E-29 Nucleus 
ENSG00000164626 KCNK5 
potassium channel, two pore domain subfamily K, 
member 5 [6280] 47.44254629 4.63E-27 
Cell 
membrane 
ENSG00000264825 LOC105372017 RNA gene 47.31231763 1.68E-22 NA 
ENSG00000173572 NLRP13 NLR family, pyrin domain containing 13 [22937] 49.89010587 1.81E-22 Cytoplasm 
ENSG00000153956 CACNA2D1 
calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 [1399] 28.19752661 2.54E-22 
Cell 
membrane 
ENSG00000204348 DXO decapping exoribonuclease [2992] 45.82662906 2.58E-22 Nucleus 
ENSG00000196979 LOC401554 RNA gene 50.41775517 4.54E-22 NA 
ENSG00000174473 GALNTL6 
polypeptide N-acetylgalactosaminyltransferase-like 6 
[33844] 36.85291755 7.88E-22 Golgi 
ENSG00000116761 CTH cystathionine gamma-lyase [2501] 35.42696832 1.64E-21 Cytoplasm 
ENSG00000260742 ENSG00000260742 RNA gene 44.5450049 2.85E-21 NA 
ENSG00000280120 ENSG00000280120 41.2001224 3.21E-21 NA 
ENSG00000104413 ESRP1 epithelial splicing regulatory protein 1 [25966] 38.80339998 4.02E-21 Nucleus 
ENSG00000171631 P2RY6 
pyrimidinergic receptor P2Y, G-protein coupled, 6 




methylmalonic aciduria (cobalamin deficiency) cblA 
type [18871] 43.65871028 1.65E-20 Mitochondria 
ENSG00000140538 NTRK3 neurotrophic tyrosine kinase, receptor, type 3 [8033] 26.68937579 1.26E-19 
Cell 
membrane 
ENSG00000258628 RHPN2P1 Pseudogene 23.88306708 2.20E-19 NA 
ENSG00000279078 SND1-IT1 SND1 intronic transcript 1 [24158] 43.2920309 2.89E-19 NA 
ENSG00000254226 ENSG00000254226 uncharacterized LOC101927115 [101927115] 43.70424897 2.55E-18 NA 
ENSG00000101276 SLC52A3 
solute carrier family 52 (riboflavin transporter), member 
3 [16187] 48.62643273 2.58E-18 
Cell 
membrane 
ENSG00000173175 ADCY5 adenylate cyclase 5 [236] 41.65120701 5.75E-18 
Cell 
membrane 
ENSG00000251022 THAP9-AS1 THAP9 antisense RNA 1 [44172] 31.51449173 9.40E-18 NA 
ENSG00000028137 TNFRSF1B 
tumor necrosis factor receptor superfamily, member 1B 
[11917] 24.71550514 1.16E-17 
Cell 
membrane 
ENSG00000112038 OPRM1 opioid receptor, mu 1 [8156] 35.81585473 1.74E-17 
Cell 
membrane 
ENSG00000070018 LRP6 low density lipoprotein receptor-related protein 6 [6698] 23.81938493 1.94E-17 
Cell 
membrane 
ENSG00000184414 ENSG00000184414 38.33320975 2.35E-17 NA 
ENSG00000042304 C2orf83 chromosome 2 open reading frame 83 [25344] 41.65507917 2.50E-17 Nucleus 
ENSG00000168702 LRP1B 
low density lipoprotein receptor-related protein 1B 
[6693] 20.71952594 4.68E-17 
Cell 
membrane 
ENSG00000119888 EPCAM epithelial cell adhesion molecule [11529] 36.24207499 1.10E-16 
Cell 
membrane 
ENSG00000159761 C16orf86 chromosome 16 open reading frame 86 [33755] 44.06890648 1.72E-16 Nucleus 
ENSG00000242516 LINC00960 long intergenic non-protein coding RNA 960 [48710] 33.15482787 1.80E-16 NA 
ENSG00000130208 APOC1 apolipoprotein C-I [607] 22.03458584 5.28E-16 Secreted 
ENSG00000242641 LINC00971 long intergenic non-protein coding RNA 971 [48737] 24.6489451 7.12E-16 NA 
Table 4.15 Top 50 upregulated genes in 32N compared with 4N megakaryocytes 
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ENSG00000134548 SPX spexin hormone [28139] -54.21517882 5.35E-76 Secreted 
ENSG00000116957 TBCE tubulin folding cofactor E [11582] -52.98486843 4.44E-76 Cytoplasm  
ENSG00000267575 ENSG00000267575 -50.31497884 6.75E-57 NA 
ENSG00000246889 ENSG00000246889 -48.79508752 1.36E-48 NA 
ENSG00000163637 PRICKLE2 prickle homolog 2 [20340] -49.54589448 4.23E-40 Nucleus 
ENSG00000119965 C10orf88 chromosome 10 open reading frame 88 [25822] -48.5087549 1.79E-37 Nucleus 
ENSG00000243709 LEFTY1 left-right determination factor 1 [6552] -50.27240975 1.91E-37 Secreted 
ENSG00000132530 XAF1 XIAP associated factor 1 [30932] -52.25072835 1.94E-37 Cytoplasm 
ENSG00000086289 EPDR1 ependymin related 1 [17572] -50.40423414 3.67E-37 Secreted 
ENSG00000100100 PIK3IP1 
phosphoinositide-3-kinase interacting protein 1 
[24942] -48.8193452 1.01E-36 
Cell 
membrane 
ENSG00000224805 LINC00853 long intergenic non-protein coding RNA 853 [43716] -53.57223474 6.20E-36 NA 
ENSG00000172927 MYEOV myeloma overexpressed [7563] -46.43016992 7.67E-35 Nucleus 
ENSG00000102359 SRPX2 sushi-repeat containing protein, X-linked 2 [30668] -46.79981641 2.83E-34 Secreted 
ENSG00000069509 FUNDC1 FUN14 domain containing 1 [28746] -48.6174538 3.45E-33 Mitochondria 
ENSG00000259869 ENSG00000259869 -51.81349731 1.16E-32 NA 
ENSG00000132109 TRIM21 tripartite motif containing 21 [11312] -45.34389945 2.22E-32 Cytoplasm 
ENSG00000168994 PXDC1 PX domain containing 1 [21361] -49.53984716 7.91E-32 Mitochondria 
ENSG00000259225 ENSG00000259225 -41.55628328 4.48E-31 NA 
ENSG00000120526 NUDCD1 NudC domain containing 1 [24306] -39.31853818 2.74E-30 Cytoplasm 
ENSG00000249274 PDLIM1P4 PDZ and LIM domain 1 pseudogene 4 [48947] -51.7483801 5.38E-30 NA 
ENSG00000172977 KAT5 K(lysine) acetyltransferase 5 [5275] -51.20319815 1.05E-29 Nucleus 
ENSG00000279476 ENSG00000279476 -41.17247665 1.22E-28 NA 
ENSG00000154146 NRGN 
neurogranin (protein kinase C substrate, RC3) 
[8000] -24.92441388 1.70E-28 Mitochondria 
ENSG00000170627 GTSF1 gametocyte specific factor 1 [26565] -40.88939062 4.34E-28 Nucleus 
ENSG00000172817 CYP7B1 
cytochrome P450, family 7, subfamily B, polypeptide 
1 [2652] -51.90226179 6.66E-28 
Internal 
membrane 
ENSG00000175294 CATSPER1 cation channel, sperm associated 1 [17116] -46.62517637 1.12E-27 Cytoplasm 
ENSG00000156239 N6AMT1 
N-6 adenine-specific DNA methyltransferase 1 
(putative) [16021] -51.88504515 3.22E-27 Cytoplasm 
ENSG00000237181 ENSG00000237181 -52.08954422 4.52E-27 NA 
ENSG00000168556 ING2 inhibitor of growth family, member 2 [6063] -50.32067709 1.38E-26 Nucleus 
ENSG00000182795 C1orf116 chromosome 1 open reading frame 116 [28667] -49.61671706 2.38E-26 Cytoplasm 
ENSG00000224490 TTC21B-AS1 TTC21B antisense RNA 1 [41115] -43.81020591 2.88E-25 NA 
ENSG00000118939 UCHL3 
ubiquitin carboxyl-terminal esterase L3 (ubiquitin 
thiolesterase) [12515] -40.20461126 1.04E-24 Cytoplasm 
ENSG00000275964 ENSG00000275964 -51.64776396 1.89E-24 NA 
ENSG00000236320 SLFN14 schlafen family member 14 [32689] -53.47697412 3.13E-24 Nucleus 
ENSG00000173626 TRAPPC3L trafficking protein particle complex 3-like [21090] -42.56900468 1.74E-23 
Internal 
membrane 
ENSG00000088356 PDRG1 p53 and DNA-damage regulated 1 [16119] -43.89524747 9.31E-23 Cytoplasm 
ENSG00000269220 LINC00528 long intergenic non-protein coding RNA 528 [26875] -42.27916854 2.76E-22 NA 
ENSG00000123892 RAB38 RAB38, member RAS oncogene family [9776] -48.60336386 1.78E-21 
Cell 
membrane 
ENSG00000232667 ENSG00000232667 -52.37893194 2.42E-21 NA 




family with sequence similarity 127, member C 
[33156] -46.77627963 1.71E-20 Mitochondria 
ENSG00000175854 SWI5 
SWI5 homologous recombination repair protein 
[31412] -24.22649855 4.64E-20 Nucleus 
ENSG00000105388 CEACAM5 
carcinoembryonic antigen-related cell adhesion 
molecule 5 [1817] -46.73755876 9.86E-20 
Cell 
membrane 
ENSG00000078177 N4BP2 NEDD4 binding protein 2 [29851] -25.67727207 1.12E-19 Cytoplasm 
ENSG00000156127 BATF 
basic leucine zipper transcription factor, ATF-like 
[958] -30.58506166 1.36E-19 Nucleus 
ENSG00000224616 RTCA-AS1 RTCA antisense RNA 1 [50573] -48.21465088 3.57E-19 NA 
ENSG00000270061 ENSG00000270061 -49.82983008 3.33E-18 NA 
ENSG00000165983 PTER phosphotriesterase related [9590] -24.19139896 4.62E-17 Cytoplasm 
ENSG00000126464 PRR12 proline rich 12 [29217] -36.7527534 4.71E-17 Nucleus 
ENSG00000206605 RNU6-946P RNA, U6 small nuclear 946, pseudogene [47909] -41.63265249 1.03E-16 NA 









Figure 4.23 Over-represented gene ontologies in upregulated and downregulated genes in 32N compared with 4N megakaryocytes.  
The full GO analysis may be found in Appendix 2. The word cloud is a visual representation of the over-represented GO biological processes with their size 
an indicator of significance.
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ENSG00000137809 ITGA11 integrin, alpha 11 [6136] 5.49E-07 
Immunoglobulin superfamily 
ENSG00000211962 IGHV1-46 immunoglobulin heavy variable 1-46 [5554] 9.73E-10 
ENSG00000211659 IGLV3-25 immunoglobulin lambda variable 3-25 [5908] 2.80E-04 
ENSG00000164520 RAET1E retinoic acid early transcript 1E [16793] 4.03E-04 
ENSG00000124731 TREM1 triggering receptor expressed on myeloid cells 1 [17760] 2.31E-03 
ENSG00000081237 PTPRC protein tyrosine phosphatase, receptor type, C [9666] 1.43E-02 
ENSG00000186818 LILRB4 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 
[6608] 3.49E-02 
G-protein coupled receptors 
ENSG00000125384 PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa [9594] 1.29E-43 
ENSG00000171631 P2RY6 pyrimidinergic receptor P2Y, G-protein coupled, 6 [8543] 5.08E-21 
ENSG00000112038 OPRM1 opioid receptor, mu 1 [8156] 1.74E-17 
ENSG00000107518 ATRNL1 attractin-like 1 [29063] 9.05E-07 
ENSG00000157542 KCNJ6 potassium channel, inwardly rectifying subfamily J, member 6 [6267] 8.47E-04 
ENSG00000171049 FPR2 formyl peptide receptor 2 [3827] 9.22E-03 
Leucine Rich Repeat proteins 
ENSG00000185158 LRRC37B leucine rich repeat containing 37B [29070] 9.14E-03 
Tetraspanins 
ENSG00000135404 CD63 CD63 molecule [1692] 2.83E-02 
Cytokine/chemokine/complement receptors 
ENSG00000028137 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B [11917] 1.16E-17 
ENSG00000203710 CR1 complement component (3b/4b) receptor 1 (Knops blood group) [2334] 5.34E-15 
ENSG00000134470 IL15RA interleukin 15 receptor, alpha [5978] 6.19E-11 
ENSG00000131724 IL13RA1 interleukin 13 receptor, alpha 1 [5974] 2.24E-08 
ENSG00000054967 RELT RELT tumor necrosis factor receptor [13764] 2.79E-03 
Low density lipoprotein receptors 
ENSG00000168702 LRP1B low density lipoprotein receptor-related protein 1B [6693] 4.68E-17 
ENSG00000070018 LRP6 low density lipoprotein receptor-related protein 6 [6698] 1.94E-17 
Lectins 
ENSG00000161944 ASGR2 asialoglycoprotein receptor 2 [743] 6.93E-34 
ENSG00000184293 CLECL1 C-type lectin-like 1 [24462] 7.43E-03 
Transporter proteins 
ENSG00000144406 UNC80 unc-80 homolog (C. elegans) [26582] 5.17E-69 
ENSG00000164626 KCNK5 potassium channel, two pore domain subfamily K, member 5 [6280] 4.63E-27 
ENSG00000153956 CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 [1399] 2.54E-22 
ENSG00000101276 SLC52A3 solute carrier family 52 (riboflavin transporter), member 3 [16187] 2.58E-18 
ENSG00000142185 TRPM2 transient receptor potential cation channel, subfamily M, member 2 [12339] 1.58E-15 
ENSG00000181333 HEPHL1 hephaestin-like 1 [30477] 2.73E-11 
ENSG00000148408 CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit [1389] 3.54E-11 
ENSG00000091138 SLC26A3 solute carrier family 26 (anion exchanger), member 3 [3018] 8.78E-10 
ENSG00000167614 TTYH1 tweety family member 1 [13476] 3.93E-08 
ENSG00000164124 TMEM144 transmembrane protein 144 [25633] 1.37E-07 
ENSG00000137571 SLCO5A1 solute carrier organic anion transporter family, member 5A1 [19046] 3.13E-04 
ENSG00000033867 SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 [11033] 3.61E-03 
ENSG00000153253 SCN3A sodium channel, voltage gated, type III alpha subunit [10590] 1.30E-02 
ENSG00000154864 PIEZO2 piezo-type mechanosensitive ion channel component 2 [26270] 1.41E-02 
ENSG00000144452 ABCA12 ATP-binding cassette, sub-family A (ABC1), member 12 [14637] 1.55E-02 
ENSG00000182389 CACNB4 calcium channel, voltage-dependent, beta 4 subunit [1404] 1.82E-02 
ENSG00000141485 SLC13A5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 [23089] 3.03E-02 
ENSG00000180773 SLC36A4 solute carrier family 36 (proton/amino acid symporter), member 4 [19660] 3.35E-02 
Enzymatic activity 
ENSG00000140538 NTRK3 neurotrophic tyrosine kinase, receptor, type 3 [8033] 1.26E-19 
ENSG00000067113 PPAP2A phosphatidic acid phosphatase type 2A [9228] 1.80E-10 
ENSG00000167261 DPEP2 dipeptidase 2 [23028] 1.93E-09 
ENSG00000168594 ADAM29 ADAM metallopeptidase domain 29 [207] 2.31E-08 
ENSG00000257335 MGAM maltase-glucoamylase [7043] 4.30E-03 
ENSG00000178568 ERBB4 erb-b2 receptor tyrosine kinase 4 [3432] 6.98E-03 
ENSG00000151651 ADAM8 ADAM metallopeptidase domain 8 [215] 4.09E-02 
Other 
ENSG00000176040 TMPRSS7 transmembrane protease, serine 7 [30846] 2.92E-39 
ENSG00000119888 EPCAM epithelial cell adhesion molecule [11529] 1.10E-16 
ENSG00000162542 TMCO4 transmembrane and coiled-coil domains 4 [27393] 6.07E-12 
ENSG00000141574 SECTM1 secreted and transmembrane 1 [10707] 5.12E-11 
ENSG00000156738 MS4A1 membrane-spanning 4-domains, subfamily A, member 1 [7315] 5.42E-06 
ENSG00000181143 MUC16 mucin 16, cell surface associated [15582] 1.18E-03 
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ENSG00000235568 NFAM1 NFAT activating protein with ITAM motif 1 [29872] 1.83E-03 
ENSG00000178075 GRAMD1C GRAM domain containing 1C [25252] 2.92E-03 
ENSG00000038945 MSR1 macrophage scavenger receptor 1 [7376] 5.32E-03 
ENSG00000092421 SEMA6A 
sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A 
[10738] 9.17E-03 
ENSG00000146839 ZAN zonadhesin (gene/pseudogene) [12857] 1.59E-02 
ENSG00000147872 PLIN2 perilipin 2 [248] 2.23E-02 
ENSG00000002933 TMEM176A transmembrane protein 176A [24930] 2.60E-02 
ENSG00000155719 OTOA otoancorin [16378] 4.67E-02 
Signalling 
ENSG00000138792 ENPEP glutamyl aminopeptidase (aminopeptidase A) [3355] 1.02E-47 
ENSG00000173175 ADCY5 adenylate cyclase 5 [236] 5.75E-18 
ENSG00000031081 ARHGAP31 Rho GTPase activating protein 31 [29216] 5.34E-15 
ENSG00000101384 JAG1 jagged 1 [6188] 2.44E-08 
ENSG00000185527 PDE6G phosphodiesterase 6G, cGMP-specific, rod, gamma [8789] 4.24E-06 
ENSG00000133818 RRAS2 related RAS viral (r-ras) oncogene homolog 2 [17271] 1.18E-04 
ENSG00000126709 IFI6 interferon, alpha-inducible protein 6 [4054] 4.21E-04 
ENSG00000134594 RAB33A RAB33A, member RAS oncogene family [9773] 6.58E-04 
ENSG00000198010 DLGAP2 discs, large (Drosophila) homolog-associated protein 2 [2906] 5.23E-03 
ENSG00000266028 SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 [19751] 8.76E-03 
ENSG00000196975 ANXA4 annexin A4 [542] 2.44E-02 
ENSG00000131381 RBSN rabenosyn, RAB effector [20759] 2.53E-02 
ENSG00000130475 FCHO1 FCH domain only 1 [29002] 4.16E-02 
Scaffold proteins 
ENSG00000180900 SCRIB scribbled planar cell polarity protein [30377] 4.23E-07 
ENSG00000215045 GRID2IP glutamate receptor, ionotropic, delta 2 (Grid2) interacting protein [18464] 4.16E-05 
Table 4.17 Upregulated transmembrane proteins in high ploidy megakaryocytes. 
Transcripts have been arranged into platelet associated protein families and functional groups and 





Localisation Significantly upregulated genes in 32N megakaryocyte pools compared with 4N 
Cell membrane UNC80, ENPEP, PTGER2, TMPRSS7, ASGR2, KCNK5, CACNA2D1, P2RY6, NTRK3, SLC52A3, ADCY5, TNFRSF1B, 
OPRM1, LRP6, LRP1B, EPCAM, TRPM2, ARHGAP31, CR1, TMCO4, HEPHL1, CACNA1B, SECTM1, IL15RA, 
PPAP2A, SLC26A3, IGHV1-46, DPEP2, MYO1B, IL13RA1, ADAM29, JAG1, TTYH1, TMEM144, SCRIB, ITGA11, 
ATRNL1, PDE6G, MS4A1, GRID2IP, RRAS2, IGLV3-25, SLCO5A1, RAET1E, IFI6, RAB33A, KCNJ6, MUC16, NFAM1, 
TREM1, RELT, GRAMD1C, SLC4A7, MGAM, DLGAP2, MSR1, ERBB4, CLECL1, SRGAP2, LRRC37B, SEMA6A, 
FPR2, SCN3A, PIEZO2, PTPRC, ABCA12 
ZAN, CACNB4, PLIN2, ANXA4, RBSN, TMEM176A, CD63, SLC13A5, SLC36A4, LILRB4, ADAM8, FCHO1, OTOA 
Cytoplasm PLA2G16, PDE1C, ARHGEF10L, CLIP4, WNK2, NLRP13, CTH, USP13, KRT23, MYH4, GDPGP1, PRG3, TTLL4, 
GYS1, GSDMA, NAF1, MYO7A, UNC13C, SPATA21, CAMSAP1, PLEKHS1, ARHGEF26, PRKAA2, OAS3, GAS2, 
ASZ1, RGS7, KIF20A, APAF1, KLHL22, GALK1, MYO10, SAC3D1, SCLT1, FRY, DNAH8, CHORDC1, SPHK2, RPL38, 
CNKSR2, TANC2, CDC45, SACS, SEPT14, CCNG2, HS3ST1, PTPN13, DIAPH3, FAM49B, RPLP2, EPB41L4A, 
GPALPP1, RPS21, PIWIL3, RPLP1, SLFN13, HOOK2, RPL27, PSMB7, UBA6, SWAP70, FRMPD1, PSMA6, DOCK3, 
PLBD1, TTC6, HINT3, FEZ1, RPS12, PSMB9, CHODL, SLC24A4, RPL27A, RPS17, MTHFD1, RPS26 
Internal 
membrane 
GALNTL6, SNX24, CCZ1B, CFTR, YIF1A, CCDC51, POMT2, LDAH, ACAP1, STEAP2, TMEM38B, NCS1, PIPOX, 
ST6GALNAC1, PIGK, RETSAT, FAM21C, UBIAD1, SMPD4, SNX14, EMC10, RYR1, GCNT1, VPS18, TRAPPC8, 
AGPAT9, SNX13 
Mitochondria GLDC, ACSM2B, MMAA, GRAMD4, OMA1, SFXN4, TFB1M, MCCC1, GOT2, COX7B, IDH3B, ATP5G2, ABAT, 
NDUFB11, COX7C, MARC1, SURF1, NDUFC2, CENPBD1P1 
Nucleus RORB, ZNF692, NOC4L, DXO, ESRP1, C2orf83, C16orf86, NUF2, NLE1, ZNF234, KIAA0556, ZNF763, ASF1B, FIGN, 
SH2D6, ZNF347, ZCCHC4, NUP35, NOVA1, POLR3H, ZNF343, PELO, CCDC155, TATDN1, ZNF780A, PWP2, IQCA1, 
CHTF18, KIAA0101, AIM1, CDCA5, RHNO1, ZNF174, WDHD1, ZNF543, WDR12, WDFY3, PRIM2, COMMD6, ZMYM5, 
LRRIQ1, FBXO48, DNASE1L3, NCAPD2, PPARG, ZWILCH, ATAD2, MAP2K6, ZNF154, LYRM1, BRAT1 
Secreted 
 
COCH, APOC1, TIMP2, TLL2, CDNF, AGR3, GDF11, OVCH1, ADAMTS1, CES4A, CPAMD8, HSD11B1L, LAMA3, 
S100A8, OSCAR, VCAN, CFD, S100A9 






4.2.3.6 Gene expression analysis: Megakaryocyte single cell 
 
Based on single cell quality filtering 282 single cell megakaryocytes were taken forward for 
gene expression analysis (Section 4.2.3.2). A PCA was performed to identify correlation 
between the cells based on the principal components of variation in gene expression. Figure 
4.24 shows separation of cell according to the first two principal components and indicate that 
the ploidy groups do not cluster together. 
 
A differential expression analysis was then performed to identify genes that were consistently 
upregulated with increasing levels of ploidy from 2N cells up to 32N cells. Further analysis of 
their data is in progress with particular attention to pairwise comparisons between individual 
ploidy classes.  
 
In total 328 genes were found to be differentially expressed. Of these 28 genes were found to 
be consistently upregulated with increasing ploidy, shown in Table 4.19 with their localisation.  
The main group of genes significantly upregulated across increasing ploidy in the single cell 
analysis was ribosomal transcripts and others involved in all parts of translation and protein 
targeting as seen before adding strength to this observation. Interestingly there were also a 
number of upregulated genes encoding proteins involved in platelet function including: ACTB, 
RAP1B, TMSB4X and TUBA4A that was not seen in the megakaryocyte pool ploidy analysis 
where these genes were found to be downregulated in 32N cells. Out of the 28 upregulated 
genes, 8 encoded for proteins localised to the nucleus, 14 encoded for cytoplasmic proteins, 
2 genes encoded plasma membrane proteins, 1 localised to internal membrane and 1 to the 
mitochondria. The cell membrane encoding genes included HLA-E and RAP1B. 
 
320 genes were significantly downregulated with increasing ploidy. The top 50 genes are 
shown in Table 4.20 with their localisations and the full list can be found in Appendix 4, Table 
S4.16. Of the downregulated genes, those associated with platelet function include: PLEK, 
PECAM1 (platelet endothelial cell adhesion molecule 1), TPM1, ANGPT1, PDGFA, PDGFB, 
PTGIR2 (prostacyclin receptor).  
 
GO analysis performed to ascertain which biological processes were enriched with increasing 
ploidy based on the single cell expression data. In keeping with the multicellular ploidy pools, 
the enriched GO terms for the genes upregulated with increasing ploidy were related to 
translation, protein targeting and cellular mRNA disassembly. By contrast genes 
downregulated with increasing ploidy had an ontological bias towards coagulation, 
haemostasis, platelet degranulation, exocytosis and wound healing as was seen in the 
megakaryocyte multicellular pool ploidy analyses. The GO analysis is presented in word 





Figure 4.24 Unsupervised clustering of single cell megakaryocytes: highly variable gene 
expression. 
PCA plot constructed from normalized log-expression values of correlated highly variable genes, 
where each point represents a cell in the HSC dataset. First and second principal components are 
shown, along with the percentage of variance explained and ploidy level identified for each cell. 
 
 





ENSG00000137154 RPS6 ribosomal protein S6 [10429] 3.183026171 0 Nucleus 
ENSG00000174444 RPL4 ribosomal protein L4 [10353] 3.137861447 0 Nucleus 
ENSG00000142676 RPL11 ribosomal protein L11 [10301] 2.622808412 0 Nucleus 
ENSG00000100316 RPL3 ribosomal protein L3 [10332] 2.620738572 0 Nucleus 
ENSG00000110700 RPS13 ribosomal protein S13 [10386] 2.598318566 0 Nucleus 
ENSG00000177954 RPS27 ribosomal protein S27 [10416] 2.539357652 0 Nucleus 
ENSG00000109475 RPL34 ribosomal protein L34 [10340] 2.461253922 0 Cytoplasm 
ENSG00000122566 HNRNPA2B1 
heterogeneous nuclear ribonucleoprotein A2/B1 
[5033] 2.33894906 0 Nucleus 
ENSG00000156508 EEF1A1 
eukaryotic translation elongation factor 1 alpha 1 
[3189] 2.264242007 0 Cytoplasm 
ENSG00000144713 RPL32 ribosomal protein L32 [10336] 2.216490508 0 Cytoplasm 
ENSG00000109971 HSPA8 heat shock 70kDa protein 8 [5241] 2.212457967 0 Cytoplasm 
ENSG00000108298 RPL19 ribosomal protein L19 [10312] 2.142127333 0 Cytoplasm 
ENSG00000251562 MALAT1 
Metastasis-associated lung adenocarcinoma transcript 
1   2.062369743 0 NA 
ENSG00000136167 LCP1 lymphocyte cytosolic protein 1 (L-plastin) [6528] 2.030492545 0 Cytoplasm 
ENSG00000180879 SSR4 signal sequence receptor, delta [11326] 1.784311093 0 
Internal 
membrane 
ENSG00000204592 HLA-E major histocompatibility complex, class I, E [4962] 1.65275616 0 Cell membrane 
ENSG00000075624 ACTB actin, beta [132] 1.629435694 0 Cytoplasm 
ENSG00000196262 PPIA peptidylprolyl isomerase A (cyclophilin A) [9253] 1.528351964 0 Cytoplasm 
ENSG00000142669 SH3BGRL3 
SH3 domain binding glutamate-rich protein like 3 
[15568] 1.471993812 0 Cytoplasm 
ENSG00000127314 RAP1B RAP1B, member of RAS oncogene family [9857] 1.356731701 0 Cell membrane 
ENSG00000205542 TMSB4X thymosin beta 4, X-linked [11881] 0.654205228 1.83E-165 Cytoplasm 
ENSG00000127824 TUBA4A tubulin, alpha 4a [12407] 1.015278925 1.82E-93 Cytoplasm 
ENSG00000196924 FLNA filamin A, alpha [3754] 0.781610326 5.21E-81 Cytoplasm 
ENSG00000233276 GPX1 glutathione peroxidase 1 [4553] 0.588387748 2.39E-53 Cytoplasm 
ENSG00000101608 MYL12A 
myosin, light chain 12A, regulatory, non-sarcomeric 
[16701] 0.403757228 1.26E-16 Cytoplasm 
ENSG00000249119 MTND6P4 MT-ND6 pseudogene 4 [39467] 0.088909274 5.51E-03 Mitochondria 
ENSG00000112576 CCND3 cyclin D3 [1585] 0.132308239 8.35E-03 Nucleus 
ERCC-00044 ERCC-00045 0.041129269 4.00E-02 NA 
Table 4.19 Upregulated genes with increasing ploidy in single cell megakaryocytes 




























ENSG00000172889 EGFL7 EGF-like-domain, multiple 7 [20594] -1.405588023 2.13E-109 Secreted 
ENSG00000149781 FERMT3 fermitin family member 3 [23151] -0.55228455 2.04E-36 Cytoplasm 
ENSG00000175538 KCNE3 
potassium channel, voltage gated subfamily E 




germinal center-associated, signaling and motility-
like [29583] -0.565362592 1.22E-14 Nucleus 
ENSG00000081041 CXCL2 chemokine (C-X-C motif) ligand 2 [4603] -0.478482101 6.73E-12 Secreted 
ENSG00000267279 ENSG00000267280 -0.529413699 2.25E-11 NA 
ENSG00000115956 PLEK pleckstrin [9070] -0.259756908 3.11E-10 
Cell 
membrane 




core-binding factor, runt domain, alpha subunit 2; 
translocated to, 3 [1537] -0.388466758 9.44E-10 Nucleus 
ENSG00000261371 PECAM1 
platelet/endothelial cell adhesion molecule 1 
[8823] -0.259713049 3.92E-09 
Cell 
membrane 
ENSG00000144893 MED12L mediator complex subunit 12-like [16050] -0.298571295 6.85E-08 Nucleus 
ENSG00000160190 SLC37A1 
solute carrier family 37 (glucose-6-phosphate 
transporter), member 1 [11024] -0.303833455 1.33E-07 
Cell 
membrane 
ENSG00000223551 TMSB4XP4 thymosin beta 4, X-linked pseudogene 4 [11886] -0.157090467 1.51E-07 NA 
ENSG00000106077 ABHD11 abhydrolase domain containing 11 [16407] -0.322363877 6.17E-07 Mitochondria 
ENSG00000187653 TMSB4XP8 thymosin beta 4, X-linked pseudogene 8 [11885] -0.139808966 1.04E-06 NA 
ENSG00000154146 NRGN 
neurogranin (protein kinase C substrate, RC3) 
[8000] -0.255505957 3.81E-06 Mitochondria 
ENSG00000160013 PTGIR prostaglandin I2 (prostacyclin) receptor (IP) [9602] -0.268074194 8.68E-06 
Cell 
membrane 
ENSG00000047648 ARHGAP6 Rho GTPase activating protein 6 [676] -0.305996489 1.50E-05 Cytoplasm 
ENSG00000137449 CPEB2 
cytoplasmic polyadenylation element binding 
protein 2 [21745] -0.269642079 1.75E-05 Cytoplasm 
ENSG00000167460 TPM4 tropomyosin 4 [12013] -0.214371351 2.40E-05 Cytoplasm 
ENSG00000154188 ANGPT1 angiopoietin 1 [484] -0.297951969 3.44E-05 Secreted 
ENSG00000010671 BTK 
Bruton agammaglobulinemia tyrosine kinase 
[1133] -0.234362074 3.67E-05 Cytoplasm 
ENSG00000081087 OSTM1 
osteopetrosis associated transmembrane protein 
1 [21652] -0.2660356 4.63E-05 
Internal 
membrane 
ENSG00000181104 F2R coagulation factor II (thrombin) receptor [3537] -0.306239198 4.87E-05 
Cell 
membrane 
ENSG00000035403 VCL vinculin [12665] -0.169847357 6.50E-05 Cytoplasm 
ENSG00000197563 PIGN 
phosphatidylinositol glycan anchor biosynthesis, 




polycystic kidney and hepatic disease 1 




phosphatidylinositol-5-phosphate 4-kinase, type II, 




ATPase, Ca++ transporting, type 2C, member 1 
[13211] -0.215356598 9.88E-05 
Internal 
membrane 
ENSG00000177697 CD151 CD151 molecule (Raph blood group) [1630] -0.264987752 1.65E-04 
Cell 
membrane 
ENSG00000277048 ENSG00000277048 -0.101174062 1.79E-04 NA 
ENSG00000185052 SLC24A3 
solute carrier family 24 
(sodium/potassium/calcium exchanger), member 
3 [10977] -0.271097886 1.90E-04 
Cell 
membrane 
ENSG00000071127 WDR1 WD repeat domain 1 [12754] -0.161861544 2.10E-04 Cytoplasm 
ENSG00000068383 INPP5A 
inositol polyphosphate-5-phosphatase, 40kDa 
[6076] -0.260094512 3.22E-04 
Cell 
membrane 
ENSG00000172757 CFL1 cofilin 1 (non-muscle) [1874] -0.124005504 3.47E-04 Nucleus 
ENSG00000151702 FLI1 
Fli-1 proto-oncogene, ETS transcription factor 
[3749] -0.175687065 3.56E-04 Nucleus 
ENSG00000175701 LINC00116 
long intergenic non-protein coding RNA 116 
[27339] -0.2472789 3.86E-04 
Cell 
membrane 
ENSG00000108839 ALOX12 arachidonate 12-lipoxygenase [429] -0.265892496 3.91E-04 Cytoplasm 
ENSG00000158769 F11R F11 receptor [14685] -0.222992927 3.91E-04 
Cell 
membrane 




actin related protein 2/3 complex, subunit 4, 
20kDa [707] -0.156279405 5.94E-04 Cytoplasm 




CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 2 [1801] -0.195695857 7.33E-04 Mitochondria 
ENSG00000131236 CAP1 
CAP, adenylate cyclase-associated protein 1 




UPF3 regulator of nonsense transcripts homolog 
A (yeast) [20332] -0.173921756 7.79E-04 Nucleus 
ENSG00000125534 PPDPF 
pancreatic progenitor cell differentiation and 
proliferation factor [16142] -0.186288949 8.88E-04 Nucleus 




small nuclear ribonucleoprotein polypeptide N 
[11164] -0.212731259 1.02E-03 Nucleus 
ENSG00000173230 GOLGB1 golgin B1 [4429] -0.176591809 1.02E-03 
Internal 
membrane 
ENSG00000213719 CLIC1 chloride intracellular channel 1 [2062] -0.142037678 1.14E-03 Nucleus 
Table 4.20 Top 50 downregulated genes with increasing ploidy in single cell megakaryocytes 
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Upregulated           Downregulated 
 
 
Figure 4.25 Over-represented gene ontologies in upregulated and downregulated genes with increasing ploidy in single cell megakaryocytes.  
The full GO analysis may be found in Appendix 2. The word cloud is a visual representation of the over-represented GO biological processes with their size an 
indicator of significance. 
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4.2.3.7 Expression of megakaryocyte ploidy signatures in HSC clusters 
 
To assess the expression of the megakaryocyte ploidy gene signature within the clustered 
single cell HSCs from Chapter 3, the expression of the genes upregulated in increasing and 
those upregulated in decreasing ploidy was overlaid onto the Monocle 2 plot in Figure 3.16. 
This not only shows the HSC clusters but also the differentiation trajectories that the single 
cells follow. In keeping with previously published datasets of in vitro derived megakaryocytes 
the expression of megakaryocyte ploidy signatures was mainly restricted to cluster 1. There 
was little or no expression of ploidy associated gene signatures in cluster 4 which was 
thought to be another megakaryocyte-biased subset from Chapter 3, Figure 4.26. Here the 





A           B 
 
 
Figure 4.26 Single cell HSC differentiation trajectories using Monocle 2 showing expression of megakaryocyte ploidy signatures: multicellular pools. 
Individual HSCs are connected by a minimum spanning tree with branch points (thin lines), representing the differentiation trajectory and clusters are differentiated 




The aim of this chapter was to obtain transcriptome data primary human bone marrow 
megakaryocytes for the first time, to compare them to their in vitro counterparts cultured from 
human CD34+ cells and to examine differences in gene expression with increasing ploidy 
class. Current knowledge on the megakaryocyte transcriptome is based on in vitro derived 
cells (L. Chen et al. 2014) which are phenotypically different from megakaryocytes found in 
vivo. They reach a mean ploidy of 2-4N and in conditions of prolonged culture are able to 
produce small numbers of platelets known as proplatelets with limited functionality (Moreau et 
al. 2016; Machlus and Italiano 2013). In contrast in vivo, megakaryocytes reach mean ploidy 
levels of 16N and with each cell releasing thousands of platelets into the circulation. An 
understanding of the transcriptional profile of megakaryocytes in vivo and if gene expression 
is regulated with changes in ploidy may provide insight the processes of megakaryocyte 
maturation and platelet production.    
 
Until this study no transcriptome data existed for ex-vivo megakaryocytes. This pertains to a 
number of technical difficulties in isolating pure megakaryocyte populations which are 
required for meaningful transcriptomics. Here megakaryocytes were isolated from fresh 
sternal bone marrow scrapings from patients undergoing non-coronary cardiac surgery 
(aortic/mitral valve replacement). After substantial optimisation of protocols full length RNA-
seq of megakaryocytes was achieved as single cells and multicellular pools of up to 100 cells. 
Whole bone marrow was stained using megakaryocyte markers CD41 and CD42 as well as 
the DNA dye Hoechst. Viable megakaryocytes were then sorted as single cells or multicellular 
pools; either by specific ploidy groups based on Hoechst staining or as whole populations in 
pools up to 100 cells with ploidy levels the same as in vivo proportions. The cells were sorted 
into a DNA and RNA lysis buffer and RNA-seq libraries were prepared using a recently 
published modified Smartseq2 protocol (G&T-seq (Macaulay et al. 2015)) from which both 
genome and transcriptome may be simultaneously amplified if required (megakaryocyte DNA 
was stored only). While the amplified cDNA produced was of good quality according to length 
it was shown to contain overwhelming levels of mitochondrial transcript according to both 
qPCR and RNA-seq, which saturated much of the sequencing capacity. Based on 
significantly low proportion of single cells containing house-keeping/megakaryocyte lineage 
genes on qPCR and RNA-seq as well as poor RNA-seq quality measures compared with 
multicellular pools, attention was then focused on multicellular pools only. Multicellular 
megakaryocyte pools that were collected irrespective of ploidy were then selected for RNA-
seq based on low relative levels of mitochondrial transcript on qPCR and multicellular ploidy 
pools were all sequenced due to smaller numbers. The vast majority of multicellular pool 
sequencing data showed good quality statistics. The single cell RNA-seq data was of poorer 
quality but was then subjected to stringent cell selection on the basis of a number of quality 
measures using a machine learning model as described in Section 2.6.2. 
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In order to compare the transcriptome from bone marrow megakaryocytes with that of 
cultured megakaryocytes which forms the current knowledge base, megakaryocytes were 
derived in vitro from adult blood CD34+ cells. The main differences in library preparation was 
the input material. For cultured megakaryocytes, 1ng of RNA from >1x106cells was used, 
whereas for bone marrow megakaryocytes, all the RNA from 50-100 cells was used as input 
material into the Smart reaction. Therefore, when comparing data from cultured 
megakaryocytes which is bulk RNA-seq and bone marrow megakaryocytes certain caveats 
must be kept in mind. In single cell and low input RNA-seq there is a relative paucity of 
starting material giving rise to an abundance of both biological and technical zeros or gene 
‘drop-out’ and increased variability. However, in this analysis the transcriptome data from a 
number of technical and biological replicates were combined in order to perform differential 
gene expression analysis between the two datasets. The phenotypic difference in terms of 
ploidy level of the cells should also be noted here; the megakaryocytes derived in vitro had a 
mean ploidy of 2N to 4N although appeared polyploid on microscopy whereas the bone 
marrow megakaryocytes in multicellular pools had a mean ploidy of 16N and were larger by 
size (Figures 4.1, 4.11). 
 
A number of the most abundantly expressed transcripts in bone marrow megakaryocytes 
encoded for platelet proteins involved in activation and showed shared expression in cultured 
megakaryocytes. Of the most highly expressed genes in bone marrow megakaryocytes were 
the glycoproteins: ITGA2B (CD41) and CD36 and RAP1B involved in integrin signalling. Also, 
highly expressed were PPBP and PF4 which are potent chemokines released from platelets 
on activation and are also activators of neutrophils in the platelet response. A number of 
genes involved in the process of cytoskeletal rearrangement that occurs in proplatelet 
formation and platelet activation/spreading showed high gene expression in bone marrow 
megakaryocytes including TUBA4A, ACTB, MYL12a and MYL6 encoding tubulin, actin and 
myosin light chain proteins. Furthermore, the structural regulators PLEK (a major protein 
kinase C substrate in platelets), the actin-capping protein CAPZA1 and actin polymerisation 
regulator TMSB4X were also highly expressed.  
 
Many of the highly expressed transcripts encoded genes important in cellular respiration. 
Transcripts mapping to the mitochondria were the most highly expressed genes in both 
cultured and bone marrow megakaryocytes. The overwhelming presence of mitochondrial 
transcripts in the RNA-seq libraries was a challenge but likely to be a biological phenomenon 
as the level of mitochondrial transcripts was orders of magnitude greater in megakaryocytes 
compared with HSCs (Figure 3.5) and these transcripts have previously been shown to be 
highly expressed in the platelet transcriptome (Eicher et al. 2016). This is likely to be 
functional as compared with other circulating leukocytes, platelets have demonstrated 
increased metabolic activity (Kramer et al. 2014). This may be related to their relatively small 
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size and high surface area associated with the extensive open canalicular system of the cell 
as well as ATP-dependent calcium and other ion channels that are required to prevent 
inadvertent platelet activation during circulation. Interestingly mitochondrial number within 
platelets, thought to be pre-determined in the megakaryocyte, is increased in patients with 
cancer (Wang et al. 2015; Zharikov and Shiva 2013) and separate to their role in cellular 
metabolism have also been shown to be released upon activation as microparticles 
(Boudreau et al. 2014). 
 
A differential gene expression analysis identified 51 unique transcripts that were upregulated 
in bone marrow megakaryocytes compared with cultured megakaryocytes and 470 transcripts 
that were downregulated. Interestingly, GO analysis of the genes downregulated in bone 
marrow megakaryocytes showed a functional bias towards translation, protein targeting, 
platelet degranulation and cell cycle. In terms of platelet activation, a number of genes were 
downregulated including PLEK, PPBP, CD63 (a surface marker of platelet activation), 
RAP1B, TMSB4X, ACTB, CAPZA2, F13A1 (coagulation factor XIII), the platelet and 
endothelial cell adhesion molecule, PECAM1 and the transcription factor GATA1, known to 
promote megakaryopoiesis. This may in part be due to recent differentiation of cultured 
megakaryocytes from CD34+ cells, having recently been exposed to high concentrations of 
TPO, which may not be in the same levels at in bone marrow. However, it should be noted 
here that while they are described as downregulated, these genes were expressed at high 
levels also in bone marrow megakaryocytes. 
 
Only 51 genes were found to be significantly upregulated in bone marrow compared with 
cultured megakaryocytes with significance levels much higher than the downregulated genes 
(p>1x10-39, compared with p>1x10-4 respectively). These included genes involved in the 
defense response which reflects the terms enriched in GO analyses: defense response, 
response to bacterium, response to fungus, cell killing, leukocyte chemotaxis, immune 
response, inflammatory response.  
 
It is known that bacteria can induce platelet activation both directly and indirectly (Fitzgerald, 
Foster, and Cox 2006). However, there is a body of evidence now emerging that platelets 
play an important role in immunity (Morrell et al. 2014). They are able to release microbicidal 
proteins termed collectively as platelet microbicidal proteins (PMPs), they express Toll-like 
receptors that detect pathogens (Aslam et al. 2006), also expressed on megakaryocytes 
(Beaulieu et al. 2011), and they are able to internalise bacteria and viruses (Youssefian et al. 
2002). Platelets participate in the inflammatory response by recruitment of leukocytes and 
have influence over their maturation and activation (Gear and Camerini 2010), and contribute 
to antimicrobial neutrophil extracellular trap formation (Brinkmann et al. 2004). There is 
growing evidence to also support their role in adaptive immunity including the expression of 
CD40L on their surface which stimulates antigen presenting cells (Kroczek et al. 1998) and 
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the expression of MHC class I complexes for antigen presentation (Chapman et al. 2012) 
amongst others. 
 
Of the upregulated genes were the defensins DEFA3 and DEFA4. They encode proteins 
involved in the host defense against bacteria and fungus where they insert into cell 
membranes and lead to cell permeability (Aslam et al. 2006). They are found in neutrophil 
granules as well as epithelial surfaces but not previously identified in platelets. Another 
defensin DEFB1 has more recently been found in the alpha granule of the platelet (Kraemer 
et al. 2011) as a class of PMPs. The genes S100A8, S100A9 and S100A12 that encode 
calcium binding proteins are also highly upregulated in bone marrow megakaryocytes. They 
have been observed at protein level within the platelet (Genecards.org). They play an 
important role in the inflammatory response and are involved in neutrophil chemotaxis and 
adhesion, which occurs in platelet. Other genes differentially expressed in bone marrow 
megakaryocytes are thought to be specific to neutrophils such as the cell surface receptor: 
peptidoglycan recognition protein 1 (PGLYRP1) which is a pattern receptor recognising and 
killing bacteria and neutrophil granular proteins: AZU1, LTF, MPO. They have not previously 
been identified megakaryocytes or platelets. A final set of 9 upregulated genes in bone 
marrow megakaryocytes encoded constant and variable regions of IgG, IgA, IgK (Ig Kappa), 
IgL (Ig Lambda) light and heavy chains some of which were highly significant. There is no 
current literature discussing the possible functionality of immunoglobulin transcripts or protein 
in megakaryocytes. Out of the 7 genes, IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, IGLC2, 
IGLC3, IGKC, IGKV1-5, the encoded protein is seen in proteomic studies in platelets with the 
exception of IGKV1-5 (Genecards.org). Platelet transcript has been seen at moderate levels 
for all but IGKV1-5, IGHG2, IGHG4 (Rowley et al. 2011). There are also moderate levels of 
transcription in cultured megakaryocytes of IGHG1, IGHG2, IGLC3, IGKC (Novershtern et al. 
2011).  
 
Taken together, it would appear that the transcriptional profile of megakaryocytes cultured in 
vitro, derived from CD34+ cells and ex-vivo primary human bone marrow megakaryocytes are 
comparable. Genes significantly upregulated in bone marrow megakaryocytes which are 
represented at lower levels in cultured megakaryocytes are those pertaining to the immune 
and inflammatory response. The high levels at which genes involved in innate immunity and 
well as those encoding for immunoglobulins are expressed in ex-vivo megakaryocytes 
suggest an important role for them in the immune response therefore adding further to the 
repertoire of circulating platelet functionality. This finding supports recent evidence that 
megakaryocytes may themselves play a role in immunity where genes related to innate 
immunity and inflammation have been shown to be upregulated in ex-vivo lung 
megakaryocytes in mice compared with those found in the bone marrow (Lefrançais et al. 
2017). Transcription of these genes may also be related to megakaryocyte interactions within 
the osteoclastic or vascular bone marrow niche.  
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Given that the gene expression in megakaryocytes in vitro and bone marrow megakaryocytes 
was relatively comparable, it is interesting that there is a discrepancy between platelets 
produced in vitro and in vivo. Proplatelets can be formed in suspension from megakaryocytes 
derived from either CD34+ cells (Choi et al. 1995; Miyazaki et al. 2000; Thon et al. 2010) or 
indeed iPSCs (Moreau et al. 2016; Feng et al. 2014; Nakamura et al. 2014). However, the 
efficiency remains poor with the numbers on average 1000-fold lower that in vivo (Moreau et 
al. 2016). This suggests that there remains insufficient understanding of the trigger required 
for platelet production. It is likely to be related to the complex interactions of megakaryocytes 
in the vascular niche whereby proplatelets are released into the sinusoidal space. The lack of 
difference in gene expression between cultured and bone marrow megakaryocytes may also 
be explained by the relative heterogeneity of the bone marrow megakaryocytes compared 
with cultured megakaryocytes, with cells at different stages of maturation and ploidy. 
Therefore, further investigation was then focused on the possibility of transcriptional variation 
between ploidy populations. 
 
Megakaryocytes collected as 20 cell pools and single cells and distinguished according to 
ploidy level (2N to 32N) were sequenced for transcriptome analysis to gain insights into 
modulation of gene expression according to ploidy. Firstly the 100 most highly expressed 
genes were analysed for each ploidy group and shared expression by gene list and functional 
annotation using GO between ploidy groups. All groups expressed high levels of genes 
mapping to the mitochondria and those related to cellular metabolism (28 genes, 20 enriched 
GO biological processes shared between all ploidy groups) however both in terms of gene 
lists and over-represented GO categories there was seen to be a dichotomy with more 
overlap between ploidy classes 2N, 4N, 8N (particularly 4N and 8N) and then separately 16N 
and 32N.  
 
The lower ploidy levels expressed increasing numbers of genes involved in platelet function 
within the 100 highly expressed genes, up to 8N. Very few platelet function associated genes 
featured in the top 100 gene lists for 16N or 32N ploidy groups, only genes encoding for 
structural proteins: actin, TMSB4X (an actin polymerisation regulator) and SRGN (a collagen 
binding proteoglycan released by platelets). Alternatively, 16N and 32N megakaryocytes 
demonstrated high expression of genes associated with mRNA disassembly, all parts of 
translation, protein packaging or targeting, localisation to organelle, membrane or 
endoplasmic reticulum. This GO categories were most significant in the 32N megakaryocytes. 
The differential expression analysis that was performed between 32N and 4N as well as the 
ploidy signature seen in the limited single cell analysis that was performed showed a similar 
pattern and therefore added a further degree of confidence to the data.  
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The differential expression analysis between 32N megakaryocytes and 4N megakaryocytes 
revealed 373 transcripts that were upregulated with increased ploidy and 571 transcripts that 
were downregulated with increased ploidy. Functional enrichment analysis indicated that 
while there were 373 upregulated transcripts increasing ploidy was associated with a limited 
number of biological functions. These included translational initiation, elongation and 
termination, protein localisation, protein complex disassembly and inflammatory response. 
The downregulated genes, again showed significant ontological bias to a limited number of 
biological processes. These were all related to coagulation, platelet degranulation, 
haemostasis and wound healing. This was reflected in the single cell analysis. Here only 28 
genes were upregulated with increasing ploidy, the vast majority of these were ribosomal 
transcripts meaning that the main upregulated biological processes were the same and in the 
multicellular pools. However, interestingly there were some genes relating to platelet function 
that were also found to be upregulated. These included the cell membrane protein RAP1B 
and structural proteins: TMSB4X and TUBA4A. The 300 downregulated genes again showed 
significant ontological bias towards  the same GO terms mentioned above (platelet activation, 
wound healing, coagulation and haemostasis). 
 
It should be noted here that the multicellular pools differential expression analysis was 
performed between 32N and 4N to compare high with low ploidy classes. However, the single 
cell analysis was a differential expression analysis was performed to identify genes that were 
consistently upregulated with increasing levels of ploidy from 2N cells up to 32N cells, so 
genes that were consistently differentially expressed. This may account for the upregulation 
of genes that are involved in platelet activation which on the basis on the previous data 
presented could be differentially expressed due to increasing expression levels in 
intermediate ploidy groups for example 2N up to 8N. The next step in data analysis which will 
help to better understand some of this uncertainty will be pairwise comparisons between all 
ploidy groups in multicellular pools with corroboration from the single cell data.  
 
Up until now the purpose of polyploidy in megakaryocytes and its association with platelet 
release remains unclear. There is evidence to support low levels of platelet production from 
low ploidy megakaryocytes both in vitro (Mattia et al. 2002; Miyazaki et al. 2000) and in vivo 
in myelodysplastic syndromes (Wong and Chan 2008) and it has been suggested that 
platelets released from different ploidy levels have different functionality (Martin et al. 2012; 
Hancock, Martin, and Lelchuk 1993). It has been suggested that polyploidisation is required 
to meet the requirement for large quantities of mRNA and protein to be packaged into 
platelets without energy used for mitosis and cytokinesis (Zimmet and Ravid 2000), however 
relationship between polyploidisation to achieve high nuclear content and terminal 
megakaryocyte differentiation related to efficient platelet release and whether these are linked 
or independent processes is still debated.  
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The aim of transcriptome analysis of different megakaryocyte ploidy classes was to better 
understand the processes occurring at different ploidy levels and how they relate to 
megakaryocyte maturity and platelet release. The data presented here suggests that at lower 
levels of megakaryocyte ploidy, a large number of platelet specific genes are transcribed. 
However, as ploidy level increases the transcription of platelet function associated genes is 
downregulated with and increase in transcription of ribosomal genes and genes encoding 
proteins involved directly in translation and protein packaging and targeting to membrane. It is 
reasonable to hypothesise, therefore, that ploidy level is in fact related to megakaryocyte 
maturity. While platelet function associated transcription occurs at lower ploidy levels, with 
increasing rounds of endomitosis or megakaryocyte maturity, these transcripts are then 
translated to proteins and packaged ready for platelet release. Therefore, with increasing 
ploidy there is an upregulation of transcripts related to translation and protein targeting. At 
high levels of ploidy where there is a high demand for protein synthesis it is entirely 
appropriate to significantly increase transcription of ribosomal subunits.   
 
This fits with previous studies of megakaryocyte ultrastructure through different stages of 
maturity where the 4 stages of megakaryocyte maturation have been described (Bessis 1956, 
1973) as: stage 1: megakaryoblasts; stage 2: basophilic megakaryocyte (2N/4N); stage 3: 
granular megakaryocyte (8N, 16N, 32N); stage 4: thrombocytogenic megakaryocyte. By 
electron microscopy, in stage 2 megakaryocytes the nucleus and cytoplasm develop 
synchronously with a number of large mitochondria, free ribosomes and smooth endoplasmic 
reticulum seen within the cytoplasm. Very few alpha or dense granules are seen (Kosaki and 
Kambayashi 2011; Ru et al. 2015). The ploidy transcriptome data presented in this chapter 
indicates an upregulation of transcription of platelet function genes at this stage. It also shows 
that in the next stage there is preferential upregulation of transcription of genes involved in 
translation, formation of ribosomal subunits and protein packaging which is in keeping with 
the electron microscopic appearances observed. Here, there are increased numbers of rough 
endoplasmic reticulum (large numbers of ribosomes now attached), mitochondria, Golgi and 
formed granules are seen within the cytoplasm (Kosaki and Kambayashi 2011; Ru et al. 
2015). The demarcation membrane system is also seen at this stage which has been shown 
to be made in part by extension on rough endoplasmic reticulum and golgi apparatus (Ru et 
al. 2016). In keeping with some of the GO terms seen to be enriched in the higher ploidy 
megakaryocytes the ultrastructural appearance of the nucleus in stage 3 indicates a shutting-
down of transcription in the maturing cell with an increase in the proportion of 
heterochromatin, and smaller nucleoli (Tanum and Engeset 1983). The megakaryocyte is 
then ready for the final stage where the cytoplasm shows global fragmentation into individual 
platelets via the demarcation membrane system and  for platelet release (Kosaki and 
Kambayashi 2011; Ru et al. 2015). Therefore, the transcriptome data presented in this 
chapter shows that with megakaryocyte maturity there is an increase in translation related 
transcription which supports existing evidence from electron microscopy.   
	 183
 
The only possible comparative transcriptome data that has been published is a study in which 
megakaryocytes where cultured from human CD34+ cells were sorted on the basis of ploidy 
level with the transcriptome compared between 2N/4N cells and 8N/16N cells (which due to 
small numbers were collected from a number of biological replicates). This data showed a 
number of upregulated and downregulated features with the overall pattern showing an 
upregulation of genes involved with platelet, coagulation and haemostatic pathways and a 
downregulation of cell cycle associated genes (Raslova et al. 2007). This is in direct contrast 
with the results presented in this chapter. This may at least in part be due to the fact that the 
cultured cells were all in the same conditions receiving the same extracellular cues from TPO 
and IL1B and the cell suspension media whereas the megakaryocytes in the bone marrow 
receive different external cues and signalling at different times in their development reflecting 
a complexity of the bone marrow niche form the osteoclastic niche to the vascular sinusoid. 
The fact that cultured megakaryocytes are unable to consistently produce functional platelets 
and certainly not in physiological numbers suggests that the extracellular growth environment 
in culture compared to in vivo is still very different and may account for the clear 
transcriptional difference between higher ploidy megakaryocytes grown in culture compared 
to their ex-vivo counterparts.  
 
In order to investigate the extracellular signals that might be triggers for physiological platelet 
release in mature megakaryocytes 78 of the upregulated genes in higher ploidy 
megakaryocytes localising to the plasma membrane were characterised further by structure 
and function. It was envisaged that differentially expressed genes in higher ploidy 
megakaryocytes would encoding transmembrane receptors that might transduce the signals 
required for changes in functionality leading to platelet production from the surrounding 
extracellular environment. These include movement from the osteoclastic niche in which 
megakaryocytes are in close proximity with HSCs where the most abundant component is 
collagen 1 (Reddi et al. 1977) to the vascular niche polyploid megakaryocytes localise to 
where the later stages of megakaryocyte maturation and platelet release into vascular 
sinusoids can occur (Tavassoli and Aoki 1989; Avecilla et al. 2004). In this environment there 
may be a number of cues from the extracellular matrix made up of collagen IV, fibrinogen, 
fibronectin and VWF. Therefore, it is possible that signalling through the receptors that are 
seen to be upregulated with ploidy could be important in this migration of megakaryocytes or 
lead to important modifications in function and initiate release of platelets. It is also interesting 
that out of 373 genes that were upregulated in higher ploidy 55 remain unannotated with 
unknown functionality, which could provide an avenue for further investigation. 
 
Of the 78 upregulated genes that localised to the plasma membrane 6 were found to encode 
G-protein coupled receptors. These included the transcript encoding the PGE2 receptor, 
known to be present on the platelet membrane. This can be either stimulatory by potentiating 
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responses to ADP and collagen or inhibitory to platelet aggregation. Its activity is mediated by 
stimulation of adenylate cyclase via G-proteins (Fabre et al. 2001). PGE2 is known to be 
important in regulation of the HSC expansion and function (North et al. 2007) and is therefore 
present in the bone marrow stem cell niche suggesting it could have a regulatory role in 
modulating megakaryocyte maturity and platelet production. Furthermore, PGE2 has been 
shown to specifically promote megakaryocyte lineage recovery after radiation injury in mouse 
(Niswander et al. 2015). Another of the G-protein coupled receptors is the pyrimidine 
nucleotide receptor P2Y6, whose transcript is upregulated in higher ploidy megakaryocytes. It 
comes from the same family as the P2Y12 ADP receptor but is not known to be present in 
transcript form or protein form in the platelet (Rowley et al. 2011; Genecards.org). It binds 
UDP and it is proposed that it mediates the inflammatory response. 
 
Transcripts for a number of cytokine receptors are also upregulated with increasing ploidy, 
two from the TNF receptor superfamily TNFRSF1B. This is known to be present on the 
platelet membrane and enhance platelet response to collagen (Pignatelli et al. 2005). 
However, TNF binding can also suppress apoptosis so may have an important role within the 
stem cell niche as megakaryocytes mature. Moreover TNF alpha has recently been shown to 
induce megakaryopoiesis in haematopoietic progenitors which could in part account for 
increased platelet mass in inflammation (Haas et al. 2015). Transcripts encoding for other 
cytokine receptors include RELT, another TNF superfamily receptor, the anti-inflammatory 
IL13RA1, IL15RA as well as the complement receptor CR1.  
 
Only 1 of the upregulated transcripts encoded a leucine rich repeat receptor, LRRC37B. This 
has no known function. A number of receptors from this family are found on the platelet 
surface including the GPIb-IX-V and toll-like receptors. Other transmembrane proteins that 
are known to be expressed on the surface of platelets with transcripts upregulated with ploidy 
are: PPAP2A, CD63 a tetraspanin known as an activation marker for platelets and SEMA6A.  
 
The increasing and decreasing ploidy signatures from the most robust dataset (multicellular 
pools) were then superimposed on the Monocle plot clustering the single cell HSCs from 
Chapter 3 according to differentiation trajectories (Figure 4.26). The expression of these 
ploidy associated gene signatures was observed in the different HSC clusters. HSC clusters 1 
and 4 were hypothesised to be megakaryocyte-biased by comparison to previously published 
data. Both increasing and decreasing ploidy signatures were highly expressed in cluster 1 
HSCs. There were low levels of expression of these gene signatures in all other HSC 
clusters. The MEP gene signature was also seen in cluster 1 and therefore in Chapter 3 
cluster 1 was proposed as the HSC cluster that might produce megakaryocytes in steady 
state thrombopoiesis. While cluster 4 was the HSC cluster which might be recruited in the 
setting of accelerated thrombopoiesis. The observation that both increasing and decreasing 
ploidy gene signature if the HSC cluster hypothesis were to be true would suggest that 
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transcriptional modulation according to ploidy is not associated with the switch from steady 
state to accelerated thrombopoiesis in states of haemostatic demand. Whether 
megakaryocyte gene signatures from a clinical setting with anticipated accelerated 
thrombopoiesis might show increased expression in cluster 4 is investigated in the next 
chapter.  
 
Limitations of the methods and relevance to the results presented in this chapter would 
include those relating to single cell and low input sequencing as described in the previous 
chapter. Technical dropouts or “zeros” lead to false negatives which are often transcripts that 
are expressed at low levels. Therefore, transcripts that play a role in regulating differentiation 
and cell fate decisions which exhibit burst expression (Suter et al. 2011) and perhaps at low 
levels may be missed. This may be compounded by a PCR amplification bias towards highly 
expressed genes and may lead to false similarity between cells states when assessing 
differential gene expression. The limitations involved in the comparisons between bulk and 
low input RNA-seq comparing cultured megakaryocytes and bone marrow megakaryocytes 
are highlighted above. The first section of this Chapter focuses on the technical challenges of 
working with this particular cell type, many of which were overcome, however the quality of 
the resulting single cell sequencing data was poorer than the HSC data and therefore only 
used for corroboration. 
 
The data presented in this chapter represents the first interrogation of ex-vivo primary bone 
marrow megakaryocytes at the transcript level both as a whole population as well as 
separated by ploidy group. It demonstrates that gene expression is regulated by ploidy level 
reflecting the processes occurring within the cell and may reveal putative drivers in the 
understanding of in-vivo megakaryopoiesis. It also proposes 2 transcriptional states in the 
maturation of megakaryocytes; the first focused on transcription of genes associated with 
platelet function with a transition towards transcription of protein synthesis associated genes 








Platelet turnover in acute coronary thrombosis is thought to be similar to that in states of 
increased haemostatic demand. It has been shown that patients with acute coronary 
syndromes have higher mean platelet volume (MPV), both historically (Martin et al. 1983; 
Cameron et al. 1983; Kishk, Trowbridge, and Martin 1985) and in the era of P2Y12 receptor 
antagonists (Ranjith et al. 2009; Lippi et al. 2009; S. G. Chu et al. 2010; H. Chu et al. 2011; 
Sansanayudh et al. 2014). MPV is increased in stable coronary artery disease (Guthikonda et 
al. 2008; A. Yang, Pizzulli, and Lüderitz 2006) and is shown to change with age, gender, 
ethnicity, obesity, changes in lipid levels and presence of diabetes (Bain 1996; Segal and 
Moliterno 2006; Saxena et al. 1987; Biino et al. 2011; Santimone et al. 2011; Muscari et al. 
2008), factors that modulate risk of atherosclerosis and coronary thrombosis. MPV has been 
correlated with platelet function and increased expression of platelet activation markers in 
patients with AMI (Milner and Martin 1985; Kristensen, Bath, and Martin 1990; Giles, Smith, 
and Martin 1994) and has been shown to be a strong predictor of outcome (Huczek et al. 
2005; Taglieri et al. 2011; Aksu et al. 2009; Azab et al. 2011; Goncalves et al. 2011) 
suggesting its pathological significance. Moreover, there is evidence to show increases in 
numbers of reticulated platelets in AMI and in the setting of in-stent thrombosis (Guthikonda 
et al. 2008; Cesari et al. 2008; Würtz et al. 2010) as well as increases in circulating TPO 
levels (Senaran et al. 2001). This suggests that there may be fundamental differences in 
megakaryocyte activity, platelet production and platelet function in patients with ACS. 
However, megakaryocytes from patients with acute coronary thrombosis have not been 
studied and compared with the healthy population yet. 
 
In this chapter platelets and megakaryocytes are characterised in terms of function and 
phenotype in order to further explore the relationship between platelet phenotype and 
megakaryocyte activity in both the steady state and the pathological state of platelet 
thrombosis. Comparisons are made between patients with recent AMI and severe coronary 
artery disease, undergoing coronary artery bypass grafting and a control group undergoing 
non-coronary cardiac surgery.  
 
In the pathological setting of thrombosis, there is an alteration in platelet activity thought to be 
modulated at the point of thrombopoiesis (Martin et al. 2012). Characterising the 
megakaryocyte and platelet transcriptomes in the setting of thrombosis may guide further 




5.2 Results: Megakaryocyte and platelet phenotype 
 
5.2.1 Patient characteristics 
 
Platelets and megakaryocytes were collected from 46 individuals undergoing cardiac surgery: 
27 from the control group and 19 patients with recent AMI. Of these 39 were paired samples 
with platelets and megakaryocytes from the same individuals (Controls: n=22, AMI n=17). In 3 
individuals only blood samples were collected (platelet data only) and in 4 individuals only 
bone marrow samples were taken (megakaryocyte data only). The study design and sample 
use are shown in Appendix 1 and 2 respectively.  
 
Table 5.1 shows the baseline characteristics of each study population and the differences 
found between them. The AMI group had a higher proportion of males compared with control 
(p=0.013). There was also a higher incidence of smoking (p=0.0009), hypertension 
(p=0.0156) and statin use (p=0.0156) in the AMI group, all coronary risk factors. Interestingly 
there was no difference in the incidence of diabetes between the 2 groups.  
 
The level of residual antiplatelet activity at the time of surgery was higher for the AMI group 
with increased use of aspirin within 48 hours (n=19) and P2Y12 inhibitor within 5 days (n=9), 
(p value for both <0.0001). Pre-operative platelet count taken 1-14 days prior to surgery was 
significantly higher in patients with AMI compared to controls despite dual antiplatelet use. 
Samples were taken from patients in the AMI group a mean of 38 days post-infarction (range: 
5 - 117 days). There was no correlation between time from infarct and pre-operative platelet 




Table 5.1 Baseline patient characteristics 
  
Controls    
n=27 




Gender M 12 16 0.013* 
Age (mean±SD) 65.1 ± 14.83 65.4 ± 8.79 0.9278 
Hypertension 17 18 0.0156* 
Statins 11 15 0.0156* 
Diabetes 6 8 0.1988 
Smoking 0 7 0.0009* 
Aspirin within last 48 hours 4 19 <0.0001* 
ADP antagonist within last 5 days 0 9 <0.0001* 
Left ventricular dysfunction 7 8 0.3412 
Coronary disease on angiography - 19 - 
History of AMI within 6 months - 19 - 
Time from infarction (days, mean±SD) - 37.7 ± 33.61 - 
Aortic valve surgery 16 2 0.0017* 
Mitral valve surgery 12 0 0.0005* 
Pre-operative Hb (mean±SD) 13.01 ± 1.95 12.64 ± 1.73 0.5118 
Pre-operative WC (mean±SD) 7.53 ± 2.21 8.12 ± 2.89 0.4399 
Pre-operative Plt (mean±SD) 222.3 ± 46.0 264.0 ± 70.8 0.0195* 
    
Baseline data from patients with myocardial infarction and severe coronary disease (AMI) and 




5.2.2 Platelet volume and count 
 
Platelet volume is known to be increased in patients with AMI compared to controls a 
parameter which is increased within 12 hours post-infarction (Martin, Bath, and Burr 1991). 
This has also been shown with the routine use of dual antiplatelet agents (Sansanayudh et al. 
2014). In order to assess basic circulating blood cell parameters in the AMI and control 
groups blood was collected in EDTA just prior to bone marrow sampling and analysed on a 
Sysmex-5000 instrument. Platelets collected in EDTA are have been shown to swell with time 
in a predictable manner (Bath 1993). As demonstrated in Figure 5.1, all blood samples were 
analysed at a similar time interval from collection, allowing the groups to remain comparable 
(overall mean 153.5 ± 26.8 min) with no correlation between MPV and time from collection to 
analysis (r=0.09).   
 
No difference was observed in MPV between the AMI and control group (11.06 ± 0.85fL, 
11.16 ± 0.91fL respectively, Figure 5.2a). This observation, whilst conflicting with the known 
evidence base, could in part be explained by the use of younger healthier individuals as 
controls in previous studies as aging has been associated with increases in MPV (Santimone 
et al. 2011). In this dataset controls are age-matched and despite having no evidence of 
coronary disease, have severe aortic/mitral valve disease, which has also been shown to be 
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associated with elevated MPV albeit in small studies (Varol et al. 2011; Bilen et al. 2012; 
Yavuz et al. 2009). It has also been suggested that in the acute infarct population two groups 
may exist, one with normal platelet volume and count and one with increased MPV 
(Trowbridge and Martin 1987). This observation may also reflect the use of newer generation 
P2Y12 receptor antagonists such as ticagrelor. However, platelet counts were higher in the 
AMI group (235.6 ± 65.1 x109/L) compared to controls (198 ± 49.7 x109/L, p=0.0396; t-test; 
Figure 5.2b). Consequently, plateletcrit or platelet mass (product of platelet count and MPV) 
was also higher in the AMI group compared to controls (0.26 ± 0.06%, 0.22 ± 0.05% 
respectively, p=0.0206; t-test; Figure 4.2c). There is limited evidence for increase in platelet 
counts post-infarction, but it has been shown to correlate with poor prognosis (Ly et al. 2006). 
Despite no difference in MPV, patients with AMI exhibited an increased overall circulating 
platelet mass, suggesting an upregulation of platelet production. This would support the 
hypothesis of platelet consumption and increased haemostatic demand in AMI (Martin et al. 
2012). A constant circulating platelet mass is physiologically maintained by an inverse 
relationship between MPV and platelet count. By plotting MPV against platelet count for each 
individual patient, this relationship is shown to be maintained in both control and AMI groups 
(Figure 5.3). This suggests that the same mechanisms controlling platelet homeostasis in 
normal physiology may also lead to the changes seen in AMI.  
 
MPV has been shown to be elevated within 12 hours of AMI and remain elevated up to 4 
months thereafter (Kishk, Trowbridge, and Martin 1985; López-Cuenca et al. 2012; Ranjith et 
al. 2009; Lippi et al. 2009; H. Chu et al. 2011). To establish whether time from infarction to 
sample collection might account for the observed between group differences in platelet 
parameters, time from infarction in the AMI group was plotted against MPV or platelet count 
for the same individual. No overall trend in MPV or platelet count was demonstrated over time 
(p=ns; Figure 5.4). Furthermore, use of aspirin or P2Y12 receptor antagonists within 48hours 







Figure 5.1 Time from blood collection to analysis on Sysmex-5000 instrument. 
A. Time from blood collection to analysis in control and AMI groups (mean ±SEM shown); B. 
Spearman rank correlation between MPV and time from blood collection to analysis in the full 







Figure 5.2 Platelet parameters 
A. MPV in control and AMI groups; B. Platelet count in control and AMI groups (p=0.0396); C. 
Plateletcrit in control and AMI groups (p=0.0206). Mean ± SEM shown, * indicates p<0.05. 
































































































Figure 5.3 Inverse relationship between MPV and platelet count 
Spearman rank correlations between MPV and platelet count for A. all individuals (r=-0.45, 
p=0.0032); B. Control group (r=-0.23, p=0.28), C. AMI group (r=-0.67, p=0.0023). 
 
 
Figure 5.4 Platelet parameters according to time of sample post-infarction 
A. Spearman rank correlation between MPV and time from infarction (p=ns); B. Spearman 
























































































Figure 5.5 MPV according to antiplatelet usage 
A. MPV in patients with aspirin use within 48 hours compared to without; B. MPV in patients 
with P2Y12 antagonist use within 5 days compared to without. Mean ± SEM shown. 48 hours 
and 5 days were used for aspirin and P2Y12 antagonists respectively according to 





































5.2.3 Platelet activity 
 
For platelet activity the 2 groups were compared to a group of anonymised healthy volunteers 
(n=20); see Chapter 2. These were individuals with no co-morbidities (see Section 2.1.2). 
 
5.2.3.1 Platelet activation 
 
Activation in resting or unstimulated platelets was assessed by measuring baseline P-selectin 
expression using flow cytometry. P-selectin is an α granule membrane glycoprotein in the 
resting platelet, it becomes externalised to the plasma membrane upon activation with various 
agonists. It is the most highly expressed surface marker of platelet degranulation (Ruf and 
Patscheke 1995). The proportion of platelets expressing P-selectin on the plasma membrane 
has been used as a measure of baseline platelet activation. P-selectin may be a useful 
marker of clinical outcome (Hollander et al. 1999; Itoh et al. 1995). In order to measure 
baseline platelet activity, resting levels of P-selectin was measured on the surface of platelets 
after blood collection into citrate tubes. All flow cytometry measurements were taken at 
exactly 4 hours from sampling to allow for results to be comparable between patients. Resting 
surface expression of P-selectin was increased in the AMI group (52.1 ± 7.23%), when 
compared to the control group (46.8 ± 7.36%, p=0.044) and to the healthy group (40.4 ± 
7.19%, p<0.0001; t-test). The control group also showed increased resting activation level 
compared to the healthy group (p=0.0088; t-test; Figure 5.6a). Therefore, despite high levels 
of dual antiplatelet therapy, patients with AMI showed elevated resting platelet activation. This 
supports evidence that show increased surface expression of P-selectin in AMI compared 
with controls in previous studies (Ault et al. 1999; Shimomura et al. 1998; Michelson 2004).  
To investigate whether patients with larger platelets also had increased resting surface 
expression of P-selectin, correlation between these two markers was plotted and no 






Figure 5.6 Resting platelet surface P-selectin expression  
A. Proportion of platelets positive for surface P-selectin by flow cytometry in healthy, control 
and AMI groups (mean ± SEM shown, *indicates p<0.05, ** indicates p<0.01, ***indicates 
p<0.001, ****indicates p<0.0001); Spearman rank correlation between P-selectin expression 




































































5.2.3.2 Platelet function 
 
Platelet function or reactivity in the AMI and control group were assessed by flow cytometry 
and compared to the healthy group, measuring change in platelet aggregatory response 
(fibrinogen binding) and platelet degranulation (P-selectin expression) after stimulation with 
the following agonists: adenosine diphosphate (ADP; P2Y12 receptor agonist), cross linked 
collagen related peptide (CRP-XL; GPVI receptor agonist) and thrombin receptor activating 
peptide (TRAP; PAR-1 receptor agonist). As described above, blood samples were collected 
in citrate and all flow cytometry measurements were taken in whole blood at exactly 4hours 
from sampling to allow for results to be comparable between individuals. 
 
The AMI group showed a lower ADP mediated response as measured by fibrinogen binding 
(26.0 ± 21.92%) than the control (47.7 ± 16.1%, p=0.0019; t-test) or healthy (64.2 ± 17.2%, 
p<0.0001; t-test) groups (Figure 5.7a). In order to ascertain whether this was due to residual 
activity of P2Y12 inhibition, fibrinogen binding in response to ADP stimulation was plotted 
separately for patients in the AMI group who has received P2Y12 antagonist within the last 5 
days compared to those that had not (Figure 5.7b). This revealed significant P2Y12 
antagonist inhibition of ADP mediated fibrinogen binding (11.7 ± 11.6%) compared to the 
subgroup of AMI patients in which P2Y12 antagonists were stopped more than 5 days before 
surgery (38.3 ± 20.3%, p=0.013; t-test). This subgroup showed a similar platelet response to 
the control group. A similar pattern was observed when platelet degranulation was measured 
by P-selectin in response to ADP. Again, patients in the AMI group showed lower ADP 
mediated response than the control group (28.5 ± 12.5% compared with 36.0 ± 10.8%, 
p=0.06; t-test) and the healthy group (49.7 ±6.7, p<0.0001; t-test; Figure 5.8a). This was 
largely due to recent P2Y12 inhibition (Figure 5.8b), although the difference in ADP mediated 
P-selectin expression between AMI patients with and without recent P2Y12 antagonist use 
did not reach significance. 
 
There were no significant differences between groups in CRP-XL mediated platelet activation 
both in terms of fibrinogen binding or expression of P-selectin (Figure 5.7c, 5.8c) although 
patients with recent use of P2Y12 antagonist showed a trend towards reduced 
responsiveness (Figure 5.7d, 5.8d). Similarly to ADP stimulation, fibrinogen binding mediated 
by TRAP-6 was lower in the AMI group (3.3 ± 3.8%) than healthy (12.1 ± 12.8%, p=0.013; t-
test; Figure 4.7e) largely caused by inhibition of platelet aggregatory response by recent 
P2Y12 use (5.1 ± 3.2% compared with 1.0 ± 1.1%, p=0.0101; t-test; Figure 5.7f). 
 
The relationship between MPV and markers of platelet reactivity was then studied (Figure 5.9, 




Figure 5.7 Platelet function measured by change in fibinogen binding 
Fibrinogen binding response measured as % positive platelets in whole blood to 5uM ADP 
(A,B); 3ug/ml CRP-XL (C,D); 8uM TRAP-6 (E,F). Difference in response between healthy, 
control and AMI groups (A,C,E); Difference in response between patients with P2Y12 
antagonist use within 5 days and without (B,D,F). Mean ± SEM shown. *indicates p<0.05, ** 































































































































Figure 5.8 Platelet function measured by change in P-selectin expression 
P-selectin expression response measured as % positive platelets in whole blood to 5uM ADP 
(A,B); 3ug/ml CRP-XL (C,D); 8uM TRAP-6 (E,F). Difference in response between healthy, 
control and AMI groups (A,C,E); Difference in response between patients with P2Y12 
antagonist use within 5 days and without (B,D,F). Mean ± SEM shown. *indicates p<0.05, ** 





























































































































Figure 5.9 Relationship between MPV and platelet function measured by change in 
fibrinogen binding 
Spearman rank correlations between MPV and fibrinogen binding platelet response after 
stimulation with 5uM ADP (A,B,C); 3ug/ml CRP-XL (D,E,F); 8uM TRAP-6 (E,F,G). Healthy 
group (A,D,G); Control group (B,E,H); AMI group (C,F,I). No significant relationship was found 
between MPV and platelet function in any of the groups. Pooling all groups together also 


































































































































































































Figure 5.10 Relationship between MPV and platelet function measured by change in P-
selectin expression 
Spearman rank correlations between MPV and P-selectin platelet response after stimulation 
with 5uM ADP (A,B,C); 3ug/ml CRP-XL (D,E,F); 8uM TRAP-6 (E,F,G). Healthy group 
(A,D,G); Control group (B,E,H); AMI group (C,F,I). No significant relationship was found 
between MPV and platelet function in any of the groups. Pooling all groups together also 











































































































































































































5.2.4 Megakaryocyte activity 
 
5.2.4.1 Platelet production 
 
Platelet production and megakaryocyte activity were indirectly measured by the reticulated 
platelet fraction or “immature platelet fraction” in whole blood collected in EDTA by Sysmex. 
As previously described, this is the proportion of platelets that contain mRNA which is found 
in newly formed platelets and degrades with age. It has been used as a measure of 
thrombopoiesis and platelet turnover. As the technology is limited in terms of the amount of 
RNA that can be measured (Briggs et al. 2009) it has been suggested above that although 
newly formed platelets can be of any size, only large platelets contain enough RNA to enable 
quantification. Therefore, the reticulated platelet fraction gives an indication of number of 
newly formed large platelets. This explains elevated levels of reticulated platelets in increased 
thrombopoiesis (Briggs et al. 2004). Reticulated platelet fraction has also been shown to be 
increased in AMI indicating increased platelet turnover, correlated to increases in MPV 
(Guthikonda et al. 2008; Cesari et al. 2008) and associated with outcome in this setting 
(Cesari et al. 2013). Figure 5.11a demonstrates no significant difference in reticulated platelet 
fraction between the AMI group (3.24 ± 2.1%) and the control group (3.49 ± 2.3%, p=ns; t 
test). This was also the case when the AMI group was divided according to the use of P2Y12 
antagonist use within 5 days (data not shown). Reticulated platelet fraction and MPV are 
shown to be highly correlated in this dataset (r=0.76, p<0.0001; Spearman Rank correlation; 
Figure 5.11b) as well as when divided into control group (r=0.59, p=0.0031) and AMI group 




Figure 5.11 Reticulated platelet fraction (Immature platelet fraction) 
A. Reticulated platelet fraction in control and AMI groups, mean ± SEM shown; B. Spearman 





































5.2.4.2 Megakaryocyte frequency and ploidy 
 
No direct measurements of megakaryocyte ploidy have been made in AMI patients although 
there are data from few small studies in normal healthy controls and altered platelet counts 
(ref). These have shown a shift to higher ploidy levels in patients with low platelet counts and 
raised MPV, which is hypothesised to be the case in AMI if this state is associated with 
increased or altered haemostasis. MPV and reticulated platelet fraction were not found to be 
raised in the AMI group, although platelet count and overall platelet mass was significantly 
increased compared to controls (see above). Figure 5.13a shows that there was no significant 
difference in overall megakaryocyte fraction of nucleated bone marrow cells in the AMI group 
(0.1 ± 0.05%) compared with the control group (0.09 ± 0.05%, p=ns; t-test). 
 
Ploidy levels were measured as proportion of cells with 4N, 8N, 16N, 32N genomic DNA 
content. 2N levels were not measured, as there were some questions as to whether this 
population was made up of purely megakaryocytes or that it could be contaminated with any 
other 2N bone marrow cell with megakaryocyte fragments or platelets stuck on the surface. 
Megakaryocytes above 32N were also not quantified as detection of these cells by flow was 
inconsistent suggesting that either these cells were fragmenting at some point either during 
staining or FACS sorting. The ploidy distribution observed in all individuals reflected previous 
studies with a mean ploidy of 16N and a normal distribution around this point (Figure 5.12d, 
5.13b). Although there was a trend towards a ploidy shift to higher ploidy levels in the AMI 
group this did not reach statistical significance (p=ns) (Figure 5.13b), and it was also not 
affected by use of antiplatelet drugs (data not shown). 
 
Furthermore, when investigating the relationship between fraction of 32N megakaryocytes 
and either MPV or platelet counts in the same individuals, no significant correlation was found 
(p=ns) (Figure 5.13c, 5.13d). This was also true if patients were subdivided by group, or 
comparisons were made with fraction of megakaryocytes in the nucleated bone marrow 
compartment, 4N, 8N or 16N cells (data not shown). Fraction of high ploidy megakaryocytes 
(32N or sum of 16N and 32N) was also not seen to correlate with resting platelet activation 
marker P-selectin or platelet reactivity as stimulated by ADP, CRP-XL or TRAP-6 (data not 
shown). 
 
It is possible that this lack of difference in megakaryocyte phenotype between the AMI group 
and controls may be related to experimental limitations, due to the difficulty of working with 
megakaryocytes. This provided further rationale for study of both megakaryocyte and platelet 





Figure 5.13 Megakaryocyte ploidy 
A. Fraction of megakaryocytes within the nucleated bone marrow compartment in control and 
AMI groups, mean ± SEM shown; B. Megakaryocyte ploidy distribution in control and AMI 
groups, mean ± SEM shown; Spearman rank correlation between 32N ploidy fraction and C. 

















































































5.3 Results: Disease associated transcriptional signatures 
 
5.3.1 Disease associated megakaryocyte transcriptional signatures 
 
5.3.1.1 Patient characteristics 
 
Megakaryocyte pooled samples (multicellular pools) consisting of 20-100cells were collected 
from 15 individuals undergoing cardiac surgery, including 8 from the control group and 7 
patients from with recent AMI (Appendix 1). Table 5.2 shows the baseline characteristics, 
platelet parameters and function for each study group, including differences between the 
groups. 
 
5.3.1.2 RNA-seq library preparation: sample selection 
 
Multicellular pools were collected for 3 patients as 20 megakaryocytes by ploidy: 2N, 4N, 8N, 
16N, 32N (AMI: Patient ID 318, Control: Patients ID 0DX, 1FP). These were sequenced 
without qPCR based filtering or cell selection (as explained in Section 4.2.1.5). For the 
purposes of RNA-seq analysis the data from these ploidy multicellular pools was combined 
per patient ID. 
 
For the remaining 12 patients: Control group n=6, AMI group n=6, multicellular pools were 
FACS sorted as 50-100 cells per well irrespective of megakaryocyte ploidy. Here Taqman 
real-time PCR assays for the presence of MT-RNR2 and PPBP in cDNA of multicellular 
pools. This allowed the detection of multicellular pools with a ∆CT between PPBP and MT-
RNR2 of less than 7. As previously explained, the aim was to avoid overwhelming 
representation of mitochondrial transcripts in the resulting RNA-seq data. Figure 5.14 
demonstrates the ∆CT levels for all multicellular pools for 6 individuals from the control group 
and 6 patients from the AMI group. A total of 156 multicell pools went on to be sequenced 
based on these criteria. To validate the use of these criteria in the identification of high quality 
samples for RNA-seq, Taqman real-time qPCR for the presence of B2M was used in 8/12 
patients and correlated with ∆CT PPBP – MT-RNR2. Figure 5.15 demonstrates a correlation 
between these 2 measurements (r2=0.1026). 
 
For the selected 156 multicellular pools, 125bp paired-end sequencing was performed at an 
average sequencing depth of approximately 50 million reads/sample. However, it was felt that 
increasing the sequencing depth might improve quality of RNA-seq data. Therefore 3 multicell 
pools with the lowest ∆CT PPBP – MT-RNR2 were selected from each of the 12 patients to 
take forward for deeper 125bp paired-end sequencing at a depth of approximately 500 million 
reads/sample (Figure 5.16). Although these were selected as the best performing samples 
from each individual, it is evident from the table that the average ∆CT PPBP – MT-RNR2 
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varied widely between samples. The multicellular pools collected by ploidy for the remaining 3 
patients were also sequenced at this depth. In terms of batch effects, Table 5.3 shows each 
sample plate ID and corresponding sequencing lane ID, whereas Table 5.4 outlines the 
batches in which samples were collected, cDNA reverse transcribed/amplified, and Nextera 
libraries prepared and sequenced. Note is made that RNA-seq analysis also included RNA-
seq from previously discussed lanes SLX-10208/10482 for the 15 individuals.  
 
 
Table 5.2 Baseline patient characteristics 
  
Controls        
n=8 
AMI            
n=7       
p value 
Gender M 4 6 ns 
Age (mean±SD) 60.9±18.6 67.6±5.10 ns 
Hypertension 5 7 ns 
Statins 2 6 0.0406* 
Diabetes 1 3 ns 
Smoking 0 3 ns 
Aspirin within last 48 hours 3 7 0.0256* 
Left ventricular dysfunction 3 2 ns 
Coronary disease on angiography - 7 - 
History of AMI within 6 months - 7 - 
Time from infarction (mean±SD)  - 49.7±41.4  - 
Aortic valve surgery 5 1 ns 
Mitral valve surgery 3 0 0.0083** 
Pre-operative Hb (mean±SD) 13.6±1.18 12.5±1.63 ns 
Pre-operative WC (mean±SD) 6.94±1.65 8.81±3.72 ns 
Pre-operative Plt (mean±SD) 245±35.0 260±62.6 ns 
Time to sysmex, min (mean±SD) 152.8±10.0 160.6±33.8 ns 
PLT, x109/L  (mean±SD) 214.5±55.5 228.1±74.0 ns 
MPV, fL  (mean±SD) 10.89±0.84 10.97±0.88 ns 
Plateletcrit, %  (mean±SD) 0.23±0.056 0.26±0.060 ns 
IPF, %  (mean±SD) 3.13±2.88 3.30±2.46 ns 
MK fraction , %  (mean±SD) 0.074±0.050 0.085±0.038 ns 
MK 4N frequency, %  (mean±SD) 12.2±7.57 10.2±3.93 ns 
MK 8N frequency, %  (mean±SD) 20.3±9.12 18.0±5.47 ns 
MK 16N frequency, %  (mean±SD) 45.1±8.26 49.4±7.64 ns 
MK 32N frequency, %  (mean±SD) 22.4±10.4 22.4±4.40 ns 
Resting P-selectin expression, %  (mean±SD) 48.9±7.01 49.9±8.89 ns 
Platelet activation: 
Fibrinogen binding, % with ADP (mean±SD)  42.9±15.6 36.6±17.9 ns 
Fibrinogen binding, % with CRP-XL (mean±SD)  40.8±18.4 36.0±11.9 ns 
Fibrinogen binding, % with TRAP-6 (mean±SD)  4.35±5.32 4.52±2.93 ns 
P-selectin expression, % with ADP (mean±SD) 36.6±7.96 34.8±5.98 ns 
P-selectin expression, % with CRP-XL (mean±SD) 44.2±7.95 41.5±8.04 ns 




Figure 5.14 Sample selection based on ∆CT PPBP – MT-RNR2.  
Taqman real-time PCR was used to investigate the expression of PPBP and MT-RNR2 
transcripts in cDNA from multicellular megakaryocyte pools of 50-100cells each from 12 
individuals (Control group n=6, AMI group n=6). ∆CT PPBP – MT-RNR2 was calculated for 
each sample. ∆CT PPBP – MT-RNR2 <7 was the criteria used to identify samples for RNA-




Figure 5.15 Relationship between ∆CT PPBP – MT-RNR2 and expression of B2M.  
Correlation between ∆CT PPBP – MT-RNR2 by Taqman real-time qPCR and expression of 
B2M by Taqman probe in cDNA for corresponding multicellular megakaryocyte samples, 
r2=0.103. 
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Figure 5.16 ∆CT PPBP – MT-RNR2 for prospectively identified for deep RNA-seq. 
Multicell pools of 50-100 megakaryocytes each from 12 patients (Control group n=6, AMI 
group n=6). 
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Plate ID Sequencing Lane ID 
3XI  SLX-10208, SLX-10546, SLX-11601, SLX-11609 
DSP SLX-10208, SLX-10546, SLX-11602 
ATZ SLX-10208, SLX-10546, SLX-11603 
H4K SLX-10208, SLX-10546, SLX-11604, SLX-11606 
M8T SLX-10482, SLX-11605 
Q6H SLX-10546, SLX-11605 
CEK SLX-10546, SLX-10598 
P4P SLX-10547, SLX-11601 
4J5 SLX-10546, SLX-11602 
EMX SLX-10547, SLX-10598 
EH6 SLX-10547, SLX-11603 
FVB SLX-10546, SLX-11604 




Table 5.3 Patient and plate ID on each sequencing lane 
 
 
Sample collection Amplification Nextera Library prep / RNA-seq 
1 1 1 
  0DX    318   SLX-10208 
2 2 2 
  1FP   H4K   SLX-10482 
3   ATZ 3 
  318 3   SLX-10546 
4   3XI   SLX-10547 
  3XI   DSP 4 
5   4   SLX-10598 
  4J5   M8T 5 
6 5   SLX-11601 
  ATZ   0DX   SLX-11602 
7 6   SLX-11603 
  CEK   FVB   SLX-11604 
8   EMX   SLX-11605 
  DSP   EH6   SLX-11606 
9   7   SLX-11607 
  EH6   CEK   SLX-11608 
10   P4P   SLX-11609 
  EMX   Q6H  
11 8  
  FVB   4J5  
12 9  
  H4K   1FP  
13   3XI  
  M8T   
14   
  P4P   
15   
  Q6H   
 
Table 5.4 Megakaryocyte collection, amplification, library preparation/RNA-seq batches 
 
 
5.3.1.3 RNA sequencing data: Quality measures 
 
Figure 5.17 shows metrics per sequencing lane for total read count, alignment to the 
reference transcriptome (GRCh37), proportion of reads mapped to external spike-in ERCCs 
compared to endogenous transcripts, no of genes called, proportion of reads mapping to 



















Figure 5.17 Quality control metrics/sequencing lane. A. Total reads; B. Rate of alignment 
to transcriptome; C. Ratio of reads mapping to ERCCs; D. No. genes called; E. Ratio of 
exonic reads to exonic+intronic; F. Ratio of reads mapping to mitochondrial genes.  
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5.3.1.4 Gene expression analysis 
 
The top 100 highly expressed genes for the megakaryocytes in AMI group and in the control 
group are shown in Table 5.5. Both highly expressed gene lists showed similarities with 73 
genes commonly seen between the groups (Figure 5.18). Similarly, megakaryocytes from the 
AMI and control groups highly expressed a number of megakaryocyte/platelet lineage genes. 
These included PPBP, PF4, TMSB4X, PLEK and its binding protein SDPR and ACTB and 
CAPZA1, both involved in cytoskeletal change. The most abundantly expressed gene list for 
the AMI group also contained THBS1 and its receptor CD47. In keeping with the 
transcriptomes presented in Chapter 4, megakaryocytes from both groups highly expressed 
mitochondrial transcripts and genes involved in cellular ATP synthesis as well as translational 
machinery. There was also high expression of gene involved in the defense response 
including a host of immunoglobulin domains previously described in Chapter 4. These were 
represented in megakaryocytes from both groups.  Genes in both lists were grouped together 
by function using GO analysis. This demonstrated similar enriched biological processes for 
megakaryocytes from both AMI and control groups. There was a strong over-representation 
of GO categories describing cellular metabolism, followed by coagulation, haemostasis, 
platelet degranulation and wound healing as well as translation and protein localisation. The 
GO results are in word cloud format in Figure 5.19 and Appendix 5, Tables S5.1, S5.2. 
 
A differential expression analysis was then performed between the AMI and control groups to 
identify significantly upregulated megakaryocytes transcripts related to arterial thrombosis. In 
total 810 unique transcripts were differentially expressed between megakaryocytes from the 
AMI group and megakaryocytes from the control group. Of these 140 transcripts were shown 
to be significantly upregulated in recent AMI compared with control. The top 50 transcripts are 
shown in Table 5.6 (full list in Appendix 5, Table S5.3). Interestingly three of the significantly 
upregulated genes were related to platelet activation: PPBP, THBS1 and RAP1B. There were 
also a number of genes encoding transmembrane proteins: BCAM (basal cell adhesion 
molecule), TSPAN10, TMEM130, TMEFF2, FITMB (fat storage-inducing transmembrane 
protein 2). No enriched GO categories were found in genes upregulated in megakaryocytes 
from the AMI group, those that did not reach significance may be found in Appendix 5, Table 
S5.5. However, there were 11 upregulated genes encoding constant and variable 
immunoglobulin domains. Also represented were a number of genes involved in immunity and 
translation. 35 of the 140 transcripts (25%) were those that are as yet unannotated.  
 
670 transcripts were downregulated in megakaryocytes from patients with recent AMI 
compared with controls (Top 50 genes in Table 5.7, Full list in Appendix 5, Table S5.4). The 
main functional categories that were enriched were translation and multi-organism processes 
including the immune response. The significantly downregulated GO terms are shown in 
Figure 5.20 and the full list is in Appendix 5, Table S5.6. 
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No 
Megakaryocytes from AMI group Megakaryocytes from control group 
HGNC_symb
ol Gene_name HGNC_symbol Gene_name 
1 MT-RNR2 MT-RNR2 MT-RNR2 MT-RNR2 
2 ND4 NADH dehydrogenase, subunit 4 (complex I)(ND4) COX1 cytochrome c oxidase subunit I(COX1) 
3 COX1 cytochrome c oxidase subunit I(COX1) MT-RNR1 MT-RNR1 
4 MT-RNR1 MT-RNR1 ND4 
NADH dehydrogenase, subunit 4 (complex 
I)(ND4) 
5 COX2 cytochrome c oxidase subunit II(COX2) COX2 cytochrome c oxidase subunit II(COX2) 
6 CYTB cytochrome b(CYTB) ATP6 ATP synthase F0 subunit 6(ATP6) 
7 COX3 cytochrome c oxidase III(COX3) CYTB cytochrome b(CYTB) 
8 ATP6 ATP synthase F0 subunit 6(ATP6) COX3 cytochrome c oxidase III(COX3) 
9 ND1 NADH dehydrogenase, subunit 1 (complex I)(ND1) ND1 
NADH dehydrogenase, subunit 1 (complex 
I)(ND1) 
10 ND2 MTND2(ND2) ND2 MTND2(ND2) 
11 HBB hemoglobin subunit beta(HBB) HBB hemoglobin subunit beta(HBB) 
12 ND5 NADH dehydrogenase, subunit 5 (complex I)(ND5) ND5 
NADH dehydrogenase, subunit 5 (complex 
I)(ND5) 
13 ERCC-00074  ERCC-00074  
14 ND4L 
NADH dehydrogenase, subunit 4L (complex 
I)(ND4L) ERCC-00046  
15 ND3 NADH dehydrogenase, subunit 3 (complex I)(ND3) ND4L 
NADH dehydrogenase, subunit 4L (complex 
I)(ND4L) 
16 MALAT1 
metastasis associated lung adenocarcinoma 
transcript 1 (MALAT1) S100A8 S100 calcium binding protein A8(S100A8) 
17 S100A8 S100 calcium binding protein A8(S100A8) ND3 
NADH dehydrogenase, subunit 3 (complex 
I)(ND3) 
18 PPBP pro-platelet basic protein(PPBP) S100A9 S100 calcium binding protein A9(S100A9) 
19 S100A9 S100 calcium binding protein A9(S100A9) MALAT1 
metastasis associated lung adenocarcinoma 
transcript 1(MALAT1) 
20 MTCO1P12 MTCO1P12 MTATP6P1 MTATP6P1 
21 B2M beta-2-microglobulin(B2M) ND6 
NADH dehydrogenase, subunit 6 (complex 
I)(ND6) 
22 ERCC-00046  B2M beta-2-microglobulin(B2M) 
23 HBA2 hemoglobin subunit alpha 2(HBA2) TMSB4X thymosin beta 4, X-linked(TMSB4X) 
24 MTATP6P1 MTATP6P1 HBD hemoglobin subunit delta(HBD) 
25 TMSB4X thymosin beta 4, X-linked(TMSB4X) ERCC-00002  
26 PF4 platelet factor 4(PF4) IGHG2 IGHG2 
27 ATP8 ATP synthase F0 subunit 8(ATP8) ACTB actin beta(ACTB) 
28 PPP1CB 
protein phosphatase 1 catalytic subunit 
beta(PPP1CB) PPBP pro-platelet basic protein(PPBP) 
29 MTCO1P12 MTCO1P12 MTCO1P12 MTCO1P12 
30 DEFA3 defensin alpha 3(DEFA3) HBA2 hemoglobin subunit alpha 2(HBA2) 
31 IGLC2 IGLC2 ERCC-00004  
32 ND6 NADH dehydrogenase, subunit 6 (complex I)(ND6) ERCC-00130  
33 ACTB actin beta(ACTB) ERCC-00096  
34 HNRNPH1 
heterogeneous nuclear ribonucleoprotein H1 
(H)(HNRNPH1) PF4 platelet factor 4(PF4) 
35 SRGN serglycin(SRGN) JCHAIN joining chain of multimeric IgA and IgM(JCHAIN) 
36 GNG11 G protein subunit gamma 11(GNG11) FTL ferritin light chain(FTL) 
37 CALM2 calmodulin 2(CALM2) DEFA3 defensin alpha 3(DEFA3) 
38 RAP1B RAP1B, member of RAS oncogene family(RAP1B) MTCO1P12 MTCO1P12 
39 ERCC-00004  IGHA1 IGHA1 
40 TLK1 tousled like kinase 1(TLK1) NEAT1 
nuclear paraspeckle assembly transcript 1 (non-
protein coding)(NEAT1) 
41 ERCC-00002  ATP8 ATP synthase F0 subunit 8(ATP8) 
42 HBD hemoglobin subunit delta(HBD) CLC Charcot-Leyden crystal galectin(CLC) 
43 LIMS1 LIM zinc finger domain containing 1(LIMS1) SRGN serglycin(SRGN) 
44 S100A12 S100 calcium binding protein A12(S100A12) HSP90AA1 
heat shock protein 90 alpha family class A 
member 1(HSP90AA1) 
45 NEAT1 
nuclear paraspeckle assembly transcript 1 (non-
protein coding)(NEAT1) ACTG1 actin gamma 1(ACTG1) 
46 DAAM1 
dishevelled associated activator of morphogenesis 
1(DAAM1) IGLC2 IGLC2 
47 FTL ferritin light chain(FTL) SDPR serum deprivation response(SDPR) 
48 CAPZA1 
capping actin protein of muscle Z-line alpha subunit 
1(CAPZA1) MTND2P28 MTND2P28 
49 YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta(YWHAZ) H2AFZ H2A histone family member Z(H2AFZ) 
50 ERCC-00096  LYZ lysozyme(LYZ) 
51 JCHAIN joining chain of multimeric IgA and IgM(JCHAIN) PRG3 
proteoglycan 3, pro eosinophil major basic protein 
2(PRG3) 
52 SRF3 serine and arginine rich splicing factor 3(SRSF3) LOC105376575 uncharacterized LOC105376575(LOC105376575) 
53 ERCC-00130  RPL21 ribosomal protein L21(RPL21) 
54 IGLV3-21 IGLV3-21 CALM2 calmodulin 2(CALM2) 
55 SAR1A 
secretion associated Ras related GTPase 
1A(SAR1A) LTF lactotransferrin(LTF) 
56 MNDA myeloid cell nuclear differentiation antigen(MNDA) EEF1A1 
eukaryotic translation elongation factor 1 alpha 
1(EEF1A1) 
57 HMGB1 high mobility group box 1(HMGB1) PPP1CB 
protein phosphatase 1 catalytic subunit 
beta(PPP1CB) 
58 IGHG2 IGHG2 HMGB1 high mobility group box 1(HMGB1) 
59 MIR1244-1 microRNA 1244-1(MIR1244-1) CAMP cathelicidin antimicrobial peptide(CAMP) 
60 ACTG1 actin gamma 1(ACTG1) RPLP1 ribosomal protein lateral stalk subunit P1(RPLP1) 
61 NAP1L1 nucleosome assembly protein 1 like 1(NAP1L1) ERCC-00113  
62 IGKC IGKC GNG11 G protein subunit gamma 11(GNG11) 
63 H2AFZ H2A histone family member Z(H2AFZ) MTND1P23 MTND1P23 
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64 MT-TF MT-TF SAR1A 
secretion associated Ras related GTPase 
1A(SAR1A) 
65 CDC42 cell division cycle 42(CDC42) LIMS1 LIM zinc finger domain containing 1(LIMS1) 
66 LYZ lysozyme(LYZ) ITM2B integral membrane protein 2B(ITM2B) 
67 TPT1 tumor protein, translationally-controlled 1(TPT1) ERCC-00136  
68 IGHA1 IGHA1 MIR1244-1 microRNA 1244-1(MIR1244-1) 
69 SAT1 spermidine/spermine N1-acetyltransferase 1(SAT1) S100A12 S100 calcium binding protein A12(S100A12) 
70 PLEK pleckstrin(PLEK) RPL9 ribosomal protein L9(RPL9) 
71 HSP90AA1 
heat shock protein 90 alpha family class A member 
1(HSP90AA1) SRF3 serine and arginine rich splicing factor 3(SRSF3) 
72 ARPC5 actin related protein 2/3 complex subunit 5(ARPC5) RPS13 ribosomal protein S13(RPS13) 
73 RPL1 ribosomal protein lateral stalk subunit P1(RPLP1) HLA-E 
major histocompatibility complex, class I, E(HLA-
E) 
74 SRSF6 serine and arginine rich splicing factor 6(SRSF6) MNDA myeloid cell nuclear differentiation antigen(MNDA) 
75 CTTN cortactin(CTTN) SAT1 
spermidine/spermine N1-acetyltransferase 
1(SAT1) 
76 WTAP Wilms tumor 1 associated protein(WTAP) PLEK pleckstrin(PLEK) 
77 CAMP cathelicidin antimicrobial peptide(CAMP) CTTN cortactin(CTTN) 
78 STOM stomatin(STOM) CAPZA1 
capping actin protein of muscle Z-line alpha 
subunit 1(CAPZA1) 
79 THBS1 thrombospondin 1(THBS1) STOM stomatin(STOM) 
80 HNRNPA2B1 
heterogeneous nuclear ribonucleoprotein 
A2/B1(HNRNPA2B1) ITGA2B integrin subunit alpha 2b(ITGA2B) 
81 UBE2D3 ubiquitin conjugating enzyme E2 D3(UBE2D3) RPS27A ribosomal protein S27a(RPS27A) 
82 MIR4738 microRNA 4738(MIR4738) SNPRE 
small nuclear ribonucleoprotein polypeptide 
E(SNRPE) 
83 RPL21 ribosomal protein L21(RPL21) RAP1B 
RAP1B, member of RAS oncogene 
family(RAP1B) 
84 GNAQ G protein subunit alpha q(GNAQ) MYL6 myosin light chain 6(MYL6) 
85 MTATP6P1 MTATP6P1 NAP1L1 nucleosome assembly protein 1 like 1(NAP1L1) 
86 DEFA4 defensin alpha 4(DEFA4) MIR4738 microRNA 4738(MIR4738) 
87 SDCBP syndecan binding protein(SDCBP) ERCC-00042  
88 MYL12A myosin light chain 12A(MYL12A) IGHV3-53 IGHV3-53 
89 MYL6 myosin light chain 6(MYL6) DAAM1 
dishevelled associated activator of 
morphogenesis 1(DAAM1) 
90 RPL9 ribosomal protein L9(RPL9) PNRC2 
proline rich nuclear receptor coactivator 
2(PNRC2) 
91 SDPR serum deprivation response(SDPR) RPS20 ribosomal protein S20(RPS20) 
92 RPS13 ribosomal protein S13(RPS13) SUB1 SUB1 homolog, transcriptional regulator(SUB1) 
93 HLA-E major histocompatibility complex, class I, E(HLA-E) RPL5 ribosomal protein L5(RPL5) 
94 ITM2B integral membrane protein 2B(ITM2B) WTAP Wilms tumor 1 associated protein(WTAP) 
95 PIP4K2A 
phosphatidylinositol-5-phosphate 4-kinase type 2 
alpha(PIP4K2A) RNASE2 ribonuclease A family member 2(RNASE2) 
96 CD47 CD47 molecule(CD47) SSR4 signal sequence receptor subunit 4(SSR4) 
97 IGKV1-5 IGKV1-5 TPT1 tumor protein, translationally-controlled 1(TPT1) 
98 NT5C3A 5'-nucleotidase, cytosolic IIIA(NT5C3A) HNRNPA2B1 
heterogeneous nuclear ribonucleoprotein 
A2/B1(HNRNPA2B1) 
99 EEF1A1 
eukaryotic translation elongation factor 1 alpha 
1(EEF1A1) CDC42 cell division cycle 42(CDC42) 
100 RPL5 ribosomal protein L5(RPL5) ERCC-00003  
Table 5.5 The 100 most highly expressed transcripts in megakaryocytes from patients with 
AMI compared to control 
 
 
Megakaryocytes from patients with AMI  Megakaryocytes from control group 
 
 
Figure 5.18 Venn diagram to show common expression of abundantly expressed genes in 








































AMI group          Control group 
 
 
Figure 5.19 Over-represented gene ontologies in most highly expressed megakaryocyte genes from AMI and control groups 
The full GO analysis may be found in Appendix 5, Table S5.1, Table S5.2. The word cloud is a visual representation of the over-represented GO biological 
processes with their size an indicator of significance for most abundant genes in megakaryocytes from AMI and control groups. 
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ENSG00000210184 MT-TS2 mitochondrially encoded tRNA serine 2 (AGU/C) [7498] 2.847334232 1.56E-24 
ENSG00000269028 MTRNR2L12 MT-RNR2-like 12 [37169] 1.461315639 1.66E-14 
ENSG00000210144 MT-TY mitochondrially encoded tRNA tyrosine [7502] 1.761370411 2.03E-09 
ENSG00000210077 MT-TV mitochondrially encoded tRNA valine [7500] 1.606536821 2.28E-08 
ENSG00000243264 IGKV2D-29 immunoglobulin kappa variable 2D-29 [5800] 6.397659303 4.13E-08 
ENSG00000198744 ENSG00000198744 0.764145271 3.67E-06 
ENSG00000210195 MT-TT mitochondrially encoded tRNA threonine [7499] 1.857850981 4.78E-06 
ENSG00000210112 MT-TM mitochondrially encoded tRNA methionine [7492] 1.19984291 8.22E-06 
ENSG00000211949 IGHV3-23 immunoglobulin heavy variable 3-23 [5588] 4.042359855 2.00E-05 
ENSG00000211679 IGLC3 
immunoglobulin lambda constant 3 (Kern-Oz+ marker) 
[5857] 2.591235725 2.60E-05 
ENSG00000251546 IGKV1D-39 immunoglobulin kappa variable 1D-39 [5756] 4.155514756 2.96E-05 
ENSG00000211659 IGLV3-25 immunoglobulin lambda variable 3-25 [5908] 4.492515864 4.37E-05 
ENSG00000210154 MT-TD mitochondrially encoded tRNA aspartic acid [7478] 1.731186971 6.68E-05 
ENSG00000210174 MT-TR mitochondrially encoded tRNA arginine [7496] 1.369858066 1.91E-04 
ENSG00000280334 ENSG00000280334 4.551573876 2.25E-04 
ENSG00000261654 ENSG00000261654 3.112157925 4.71E-04 
ENSG00000211898 IGHD immunoglobulin heavy constant delta [5480] 4.544680756 5.43E-04 
ENSG00000148357 HMCN2 hemicentin 2 [21293] 2.898573868 7.00E-04 
ENSG00000134463 ECHDC3 enoyl CoA hydratase domain containing 3 [23489] 3.953027839 8.73E-04 
ENSG00000221995 TIAF1 TGFB1-induced anti-apoptotic factor 1 [11803] 4.11849775 9.35E-04 
ENSG00000163736 PPBP 
pro-platelet basic protein (chemokine (C-X-C motif) ligand 
7) [9240] 1.513084446 9.72E-04 
ENSG00000203875 SNHG5 small nucleolar RNA host gene 5 [21026] 1.625652587 1.09E-03 
ENSG00000210100 MT-TI mitochondrially encoded tRNA isoleucine [7488] 1.226486024 1.78E-03 
ENSG00000142609 CFAP74 cilia and flagella associated protein 74 [29368] 2.922822246 2.09E-03 
ENSG00000240382 IGKV1-17 immunoglobulin kappa variable 1-17 [5733] 4.412594197 2.36E-03 
ENSG00000224650 IGHV3-74 immunoglobulin heavy variable 3-74 [5624] 4.087073797 2.36E-03 
ENSG00000210194 MT-TE mitochondrially encoded tRNA glutamic acid [7479] 1.124514457 2.57E-03 
ENSG00000210196 MT-TP mitochondrially encoded tRNA proline [7494] 0.821292279 3.01E-03 
ENSG00000205622 ENSG00000205622 4.357099261 3.60E-03 
ENSG00000020577 SAMD4A sterile alpha motif domain containing 4A [23023] 2.966890395 3.87E-03 
ENSG00000188783 PRELP proline/arginine-rich end leucine-rich repeat protein [9357] 3.965613306 4.14E-03 
ENSG00000185585 OLFML2A olfactomedin-like 2A [27270] 2.927602289 4.54E-03 
ENSG00000260293 ENSG00000260293 3.930519326 5.54E-03 
ENSG00000203387 ENSG00000203387 4.245687526 5.73E-03 
ENSG00000187244 BCAM basal cell adhesion molecule (Lutheran blood group) [6722] 3.268477088 5.78E-03 
ENSG00000144339 TMEFF2 
transmembrane protein with EGF-like and two follistatin-like 
domains 2 [11867] 3.078674541 5.84E-03 
ENSG00000268549 ENSG00000268549 3.33779745 6.25E-03 
ENSG00000270986 ENSG00000270986 3.538589966 6.47E-03 
ENSG00000211598 IGKV4-1 immunoglobulin kappa variable 4-1 [5834] 2.93182172 6.84E-03 
ENSG00000211638 IGLV8-61 immunoglobulin lambda variable 8-61 [5931] 3.597917664 6.91E-03 
ENSG00000127920 GNG11 
guanine nucleotide binding protein (G protein), gamma 11 
[4403] 1.73948149 7.13E-03 
ENSG00000213753 CENPBD1P1 
CENPB DNA-binding domains containing 1 pseudogene 1 
[28421] 3.235478948 7.65E-03 
ENSG00000211662 IGLV3-21 immunoglobulin lambda variable 3-21 [5905] 2.586296177 8.33E-03 
ENSG00000229753 ENSG00000229753 5.304411343 8.65E-03 
ENSG00000258741 ENSG00000258741 2.945056862 9.06E-03 
ENSG00000140279 DUOX2 dual oxidase 2 [13273] 2.741809501 9.14E-03 
ENSG00000197296 FITM2 fat storage-inducing transmembrane protein 2 [16135] 2.813817846 9.65E-03 
ENSG00000152939 MARVELD2 MARVEL domain containing 2 [26401] 2.597888809 9.65E-03 
ENSG00000116745 RPE65 retinal pigment epithelium-specific protein 65kDa [10294] 4.336426816 9.99E-03 
ENSG00000232398 TMPRSS11CP transmembrane protease, serine 11C, pseudogene [31934] 3.629439205 1.02E-02 









ENSG00000225972 MTND1P23 MT-ND1 pseudogene 23 [42092] -6.887850524 4.94E-109 
ENSG00000198804 MT-CO1 mitochondrially encoded cytochrome c oxidase I [7419] -1.212678956 2.77E-38 
ENSG00000198786 MT-ND5 mitochondrially encoded NADH dehydrogenase 5 [7461] -1.189259734 3.02E-27 
ENSG00000211459 MT-RNR1 mitochondrially encoded 12S RNA [7470] -0.864392322 1.06E-16 
ENSG00000256618 MTRNR2L1 MT-RNR2-like 1 [37155] -2.299632211 1.17E-11 
ENSG00000198695 MT-ND6 mitochondrially encoded NADH dehydrogenase 6 [7462] -0.581178597 4.21E-09 
ENSG00000211666 IGLV2-14 immunoglobulin lambda variable 2-14 [5888] -5.623089436 2.76E-08 
ENSG00000125691 RPL23 ribosomal protein L23 [10316] -2.095471862 3.06E-08 
ENSG00000225630 MTND2P28 MT-ND2 pseudogene 28 [42129] -1.210734612 4.13E-08 
ENSG00000198763 MT-ND2 mitochondrially encoded NADH dehydrogenase 2 [7456] -0.513826979 7.89E-08 
ENSG00000136167 LCP1 lymphocyte cytosolic protein 1 (L-plastin) [6528] -2.317792127 2.50E-06 
ENSG00000232177 MTND4P24 MT-ND4 pseudogene 24 [42220] -2.857699359 2.61E-06 
ENSG00000166012 TAF1D 
TATA box binding protein (TBP)-associated factor, RNA 
polymerase I, D, 41kDa [28759] -3.035159937 3.99E-06 
ENSG00000118181 RPS25 ribosomal protein S25 [10413] -1.747228133 6.70E-06 
ENSG00000070081 NUCB2 nucleobindin 2 [8044] -2.332301955 6.87E-06 
ENSG00000026025 VIM vimentin [12692] -2.127970766 1.61E-05 
ENSG00000170802 FOXN2 forkhead box N2 [5281] -2.559844929 2.96E-05 
ENSG00000110203 FOLR3 folate receptor 3 (gamma) [3795] -3.81752763 3.38E-05 
ENSG00000156508 EEF1A1 eukaryotic translation elongation factor 1 alpha 1 [3189] -1.614829991 3.46E-05 
ENSG00000163682 RPL9 ribosomal protein L9 [10369] -1.553754602 4.51E-05 
ENSG00000187325 TAF9B 
TAF9B RNA polymerase II, TATA box binding protein 
(TBP)-associated factor, 31kDa [17306] -4.270522086 4.51E-05 
ENSG00000140199 SLC12A6 
solute carrier family 12 (potassium/chloride transporter), 
member 6 [10914] -2.594290773 5.23E-05 
ENSG00000122862 SRGN serglycin [9361] -1.934077687 5.57E-05 
ENSG00000119314 PTBP3 polypyrimidine tract binding protein 3 [10253] -2.245101726 6.78E-05 
ENSG00000168461 RAB31 RAB31, member RAS oncogene family [9771] -2.303785535 7.09E-05 
ENSG00000100241 SBF1 SET binding factor 1 [10542] -3.587127679 7.09E-05 
ENSG00000122026 RPL21 ribosomal protein L21 [10313] -1.428659958 1.32E-04 
ENSG00000272211 ENSG00000272211 -3.89338801 1.39E-04 
ENSG00000137076 TLN1 talin 1 [11845] -1.96740421 1.48E-04 
ENSG00000115457 IGFBP2 insulin-like growth factor binding protein 2, 36kDa [5471] -4.554655775 1.60E-04 
ENSG00000145425 RPS3A ribosomal protein S3A [10421] -1.586498056 1.65E-04 
ENSG00000249119 MTND6P4 MT-ND6 pseudogene 4 [39467] -1.387081985 1.78E-04 
ENSG00000163428 LRRC58 leucine rich repeat containing 58 [26968] -2.811236399 1.81E-04 
ENSG00000127603 MACF1 microtubule-actin crosslinking factor 1 [13664] -1.719927507 2.03E-04 
ENSG00000138185 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 [3363] -2.423431939 2.25E-04 
ENSG00000008086 CDKL5 cyclin-dependent kinase-like 5 [11411] -3.016263468 3.01E-04 
ENSG00000081237 PTPRC protein tyrosine phosphatase, receptor type, C [9666] -1.855896932 3.16E-04 
ENSG00000119335 SET SET nuclear proto-oncogene [10760] -1.753945952 3.64E-04 
ENSG00000021355 SERPINB1 
serpin peptidase inhibitor, clade B (ovalbumin), member 1 
[3311] -1.846181192 4.04E-04 
ENSG00000139218 SCAF11 SR-related CTD-associated factor 11 [10784] -1.860512301 4.36E-04 
ENSG00000008988 RPS20 ribosomal protein S20 [10405] -1.497491206 5.24E-04 
ENSG00000007944 MYLIP myosin regulatory light chain interacting protein [21155] -3.391709804 5.24E-04 
ENSG00000168876 ANKRD49 ankyrin repeat domain 49 [25970] -3.688781913 5.24E-04 
ENSG00000108599 AKAP10 A kinase (PRKA) anchor protein 10 [368] -2.534354621 5.51E-04 
ENSG00000198830 HMGN2 high mobility group nucleosomal binding domain 2 [4986] -1.779902529 5.86E-04 
ENSG00000087086 FTL ferritin, light polypeptide [3999] -1.200532107 6.48E-04 
ENSG00000173193 PARP14 poly (ADP-ribose) polymerase family, member 14 [29232] -2.734470718 6.55E-04 
ENSG00000159322 ADPGK ADP-dependent glucokinase [25250] -2.792167824 6.58E-04 
ENSG00000110435 PDHX pyruvate dehydrogenase complex, component X [21350] -3.633520422 6.58E-04 
ENSG00000047410 TPR 
translocated promoter region, nuclear basket protein 
[12017] -2.07250317 7.00E-04 






Figure 5.20 Over-represented gene ontologies in downregulated genes megakaryocytes from 
the AMI compared with control group. 
The full GO analysis may be found in Appendix 5, Table S5.5. The word cloud is a visual 
representation of the over-represented GO biological processes with their size an indicator of 
significance for downregulated genes in megakaryocytes from the AMI group. There were no 




5.3.1.5 Expression of megakaryocyte disease signatures in HSC clusters 
 
To assess the expression of the megakaryocyte gene signatures associated with AMI 
(disease) and control within the clustered single cell HSCs from Chapter 3, the expression of 
the genes upregulated in increasing and those upregulated in decreasing ploidy was overlaid 
onto the Monocle 2 plot from Figure 3.16. The expression of both gene signatures from the 
AMI group and the control group were mainly restricted to cluster 1. There was little or no 
expression of ploidy associated gene signatures in cluster 4 which was thought to be another 
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Figure 5.21 Single cell HSC differentiation trajectories using Monocle 2 showing expression of megakaryocyte disease signatures. 
Individual HSCs are connected by a minimum spanning tree with branch points (thin lines), representing the differentiation trajectory and clusters are differentiated 





5.3.2 Disease associated platelet transcriptional signatures 
 
5.3.2.1 Patient characteristics 
 
Platelets were isolated from the peripheral blood of 29 individuals undergoing cardiac surgery 
for the purposes of RNA-seq. This included 15 non-coronary artery disease control individuals 
and 14 patients with AMI in the past 6 months. Table 5.8 demonstrates the baseline 
characteristics, platelet parameters and function for each study group, including differences 
between the groups. 
 
5.3.2.2 RNA-seq library preparation 
 
RNA was extracted from platelets isolated from peripheral blood using Trizol reagent as 
described in Section 2.3.6. A head to head comparison between RNA-seq library preparation 
using the RiboErase protocol (Kapa) or the Smart-seq2 protocol was made by preparing 
libraries for 3 samples (60Z, 6SP, 6VA) using both methods (Figure 5.22). This comparison 
showed that the RiboErase libraries had higher read counts and higher numbers of reads 
mapping to the transcriptome (Figure 5.22a, b). There was a high correlation in terms of gene 
expression between the two methods (r=0.82-0.84) but the RiboErase kit was able to identify 
expression of greater numbers of protein-coding genes (Figure 5.22c). Furthermore, the 
overall ratio of mitochondrial RNA was significantly lower in the libraries prepared using the 
RiboErase kit compared with SmartSeq2 (p=0.0019; t-test) shown in Figure 5.22d. Therefore, 
all platelet RNA-seq libraries were prepared using the RiboErase kit if enough material was 
available (minimum total RNA input quantity: 50ng).  
 
In terms of batch effects Table 5.6 shows each sample ID and corresponding sequencing 
lane ID whereas Table 5.7 outlines the batches in which samples were collected, and libraries 




Table 5.8 Baseline patient characteristics 
  
Controls        
n=15 
AMI            
n=14      
p value 
Gender M 6 12 0.0183* 
Age (mean±SD) 63.5±17.7 65.4±8.40 ns 
Hypertension 8 13 0.0352* 
Statins 5 11 0.0253* 
Diabetes 2 7 ns 
Smoking 0 5 0.0169* 
Aspirin within last 48 hours 1 14 <0.0001*** 
Left ventricular dysfunction 3 5 ns 
Coronary disease on angiography - 14 - 
History of AMI within 6 months - 14 - 
Time from infarction (mean±SD)  - 33.4±31.9  - 
Aortic valve surgery 7 1 0.0372* 
Mitral valve surgery 9 0 0.0007*** 
Pre-operative Hb (mean±SD) 12.75±2.14 12.52±1.68 ns 
Pre-operative WC (mean±SD) 7.52±2.62 8.14±3.10 ns 
Pre-operative Plt (mean±SD) 230±47.2 274±74.0 ns 
Time to sysmex, min (mean±SD) 173.9±70.9 147.6±31.2 ns 
PLT, x109/L  (mean±SD) 197.5±50.0 242.4±70.6 ns 
MPV, fL  (mean±SD) 11.2±0.78 11.0±0.92 ns 
Plateletcrit, %  (mean±SD) 0.22±0.049 0.26±0.058 ns 
IPF, %  (mean±SD) 3.38±2.09 3.12±2.06 ns 
MK fraction , %  (mean±SD) 0.089±0.046 0.106±0.046 ns 
MK 4N frequency, %  (mean±SD) 10.1±5.52 8.26±3.44 ns 
MK 8N frequency, %  (mean±SD) 20.0±6.54 17.0±5.82 ns 
MK 16N frequency, %  (mean±SD) 48.8±7.29 50.2±5.44 ns 
MK 32N frequency, %  (mean±SD) 21.2±7.52 24.6±7.03 ns 
Resting P-selectin expression, %  (mean±SD) 47.9±7.98 51.4±7.43 ns 
Platelet activation: 
Fibrinogen binding, % with ADP (mean±SD)  45.8±15.6 29.6±21.0 ns 
Fibrinogen binding, % with CRP-XL (mean±SD)  37.9±15.4 31.6±11.1 ns 
Fibrinogen binding, % with TRAP-6 (mean±SD)  9.74±12.0 3.65±3.34 ns 
P-selectin expression, % with ADP (mean±SD) 35.7±8.87 31.2±10.7 ns 
P-selectin expression, % with CRP-XL (mean±SD) 43.2±8.47 41.2±6.41 ns 









Figure 5.22 Direct comparison of RiboErase (Kapa) and Smart-seq2 protocols for platelet RNA-seq library preparation. RNA extracted from peripheral 
blood of 3 non-coronary disease controls (60Z, 6SP, 6VA); RNA-seq libraries were prepared using both the RiboErase kit and Smart-seq2. A. Total read counts; B. 
Alignment rate to transcriptome and genome; C. Spearman rank correlations between gene expression by RiboErase vs Smart-seq2 methods for samples 60Z, 
















































































Table 5.10 Platelet collection and library preparation/RNA-seq batches 
 
 
5.3.2.3 RNA sequencing data: Quality measures 
 
Figure 5.23 shows metrics per sequencing lane for total read count, alignment to the 
reference transcriptome (GRCh37), no of genes called, proportion of reads mapping to 
annotated exonic regions and the proportion of reads mapping to the mitochondrial genome. 
One of the lanes SLX10591, appears to have lower alignment rate and lower exon ratio than 
other lanes, however, otherwise performs comparably with the other lanes. 
 
 







318   60Z, 6SP, 6VA   SLX-10486  
46V 2 2 
4J5   DM0, G6K, FVB, P4P   SLX-10591  
5Q0   R7B, GC8, ATZ, FBE   SLX-10592  
60Z   CST, M8T, CUP, CEK   SLX-10593  
6SP   CDM, 318, H4K, EH6   SLX-10594  
6VA   4J5, CYH, 0DX, F7M   SLX-10595  
ATZ 3 3 
CDM, CEK   F5Q, 5Q0, EFA   SLX-10599  
CST, CUP, CYH   46V, W4Y, WBK   SLX-10600  
DM0   
EFA   
EH6   
F5Q       
F7M   
FBE   
FVB   
G6K   
GC8   
H4K   
M8T   
P4P   
R7B   
W4Y   
WBK   
   
Patient ID Sequencing Lane ID 
 
60Z, 6VA, 6SP  
 
SLX-10486 (SLX-10488 Smart-seq2) 
DM0, G6K, FVB, P4P SLX-10591 
R7B, GC8, ATZ, FBE SLX-10592 
CST, M8T, CUP, CEK SLX-10593 
CDM, 318, H4K, EH6 SLX-10594 
4J5, CYH, 0DX, F7M SLX-10595 
F5Q, 5Q0, EFA SLX-10599 

















Figure 5.23 Quality control metrics/sequencing lane. A. Total reads; B. Rate of 
alignment to transcriptome; C. No. genes called; D. Ratio of exonic reads to exonic+intronic; 
E. Ratio of reads mapping to mitochondrial genes. 
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5.3.2.4 Gene expression analysis 
 
The 100 most abundantly expressed genes in platelets from patients with recent AMI and the 
control group are shown in Table 5.11. There is a marked overlap in the top 100 platelet 
genes expressed in each group with 97 being common to both groups (Figure 5.24).  
Functional annotation of the gene list that is common to both groups using a GO analysis 
demonstrates a strong ontological bias towards platelet degranulation/activation, wound 
healing, coagulation and haemostasis as well as cellular metabolism; Figure 5.25 (full GO 
analysis Appendix 5, Table S5.7). Both sets of platelets contain many transcripts known to be 
highly expressed in platelets from previous datasets (Rowley et al. 2011) including PPBP, 
PF4, SDPR, TMSB4X, TUBB, GRAP2, ITGA2B, ITG1B, MYL9, TPM4, CXCL5. PTGS1, the 
gene that encodes the cyclooxygenase 1 enzyme that is the target for aspirin is also highly 
transcribed in both datasets. 
 
To better understand differences in platelet transcriptome between the AMI and control 
groups hierarchical clustering was performed between samples (Figure 5.26a). Although 
some of the control samples appeared to cluster together there was no clear pattern 
separating the two groups. Similarly, the two groups did not separate according to any of the 
most important variance principal components in gene expression in the dataset (Figure 
5.26b). To investigate if there was a correlation between gene expression and other clinical 
data, rather than disease group, further analysis of the clustering with categorical clinical data 
such as smoking, presence of diabetes and aspirin use was performed. These showed no 
clear effect on clustering (Figure 5.27).  
 
A differential gene expression analysis identified 16 differentially expressed genes. Of these 
10 were significantly upregulated in patients with recent AMI (Figure 5.28). 4 of the 
upregulated genes were Y-linked and therefore gender specific: TMSN4Y, EIF1AY, KDM5D, 
DDX3Y. The majority of the patients with recent AMI were male with the control group being 
more heterogeneous which is likely to have accounted for this differential expression. The 
other genes upregulated included IGHA2 that encodes for the constant region of the IgA 
heavy chain, RPS17L encoding for the ribosomal S17 protein, part of the 40S subunit, RHD 
the Rh blood group D antigen and LOXL3 which encodes lysyl oxidase like 3, that plays a role 
in crosslinking collagen and elastin. Of the remaining upregulated genes 1 was an RNA gene 







Platelets from AMI group Platelets from control group 
HGNC_symbol Gene_name HGNC_symbol Gene_name 
1 ND1 NADH dehydrogenase, subunit 1 (complex I) ND1 NADH dehydrogenase, subunit 1 (complex I) 
2 ND5 NADH dehydrogenase, subunit 5 (complex I) ND5 NADH dehydrogenase, subunit 5 (complex I) 
3 ND4 NADH dehydrogenase, subunit 4 (complex I) MT-RNR2 Mitochondrially Encoded 16S RNA 
4 TMSB4X thymosin beta 4, X-linked(TMSB4X) ND4 NADH dehydrogenase, subunit 4 (complex I) 
5 MT-RNR2 Mitochondrially Encoded 16S RNA TMSB4X thymosin beta 4, X-linked(TMSB4X) 
6 MTND2 MTND2(ND2) COX1 cytochrome c oxidase subunit I(COX1) 
7 COX1 cytochrome c oxidase subunit I(COX1) ND2 MTND2(ND2) 
8 CYTB cytochrome b(CYTB) CYTB cytochrome b(CYTB) 
9 COX3 cytochrome c oxidase III(COX3) COX3 cytochrome c oxidase III(COX3) 
10 B2M beta-2-microglobulin(B2M) B2M beta-2-microglobulin(B2M) 
11 PPBP pro-platelet basic protein(PPBP) PPBP pro-platelet basic protein(PPBP) 
12 ACTB actin beta(ACTB) COX2 cytochrome c oxidase subunit II(COX2) 
13 NRGN neurogranin(NRGN) ND6 NADH dehydrogenase, subunit 6 (complex I) 
14 PF4 platelet factor 4(PF4) ATP6 ATP synthase F0 subunit 6(ATP6) 
15 ATP6 ATP synthase F0 subunit 6(ATP6) NRGN neurogranin(NRGN) 
16 COX2 cytochrome c oxidase subunit II(COX2) MT-RNR1 Mitochondrially Encoded 12S RNA 
17 ND6 NADH dehydrogenase, subunit 6 (complex I) PF4 platelet factor 4(PF4) 
18 MT-RNR1 Mitochondrially Encoded 12S RNA ACTB actin beta(ACTB) 
19 FLNA filamin A(FLNA) SDPR serum deprivation response(SDPR) 
20 TLN1 Talin 1 FLNA filamin A(FLNA) 
21 SDPR serum deprivation response(SDPR) TUBB1 tubulin beta 1 class VI(TUBB1) 
22 TUBB1 tubulin beta 1 class VI(TUBB1) TLN1 Talin 1 
23 F13A1 coagulation factor XIII A chain(F13A1) F13A1 coagulation factor XIII A chain(F13A1) 
24 MYH9 myosin heavy chain 9(MYH9) TAGLN2 transgelin 2(TAGLN2) 
25 TAGLN2 transgelin 2(TAGLN2) ND3 NADH dehydrogenase, subunit 3 (complex I) 
26 HLA-E major histocompatibility complex, class I, E MAP3K7CL MAP3K7 C-terminal like(MAP3K7CL) 
27 SPARC secreted protein acidic and cysteine rich MYH9 myosin heavy chain 9(MYH9) 
28 ND3 NADH dehydrogenase, subunit 3 (complex I) SPARC secreted protein acidic and cysteine rich 
29 VCL vinculin(VCL) FTH1 ferritin heavy chain 1(FTH1) 
30 FTH1 ferritin heavy chain 1(FTH1) HLA-E major histocompatibility complex, class I, E 
31 MAP3K7CL MAP3K7 C-terminal like(MAP3K7CL) MIR1244-1 microRNA 1244-1(MIR1244-1) 
32 MIR1244-1 microRNA 1244-1(MIR1244-1) HBA2 hemoglobin subunit alpha 2(HBA2) 
33 YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta VCL vinculin(VCL) 
34 ITGA2B integrin subunit alpha 2b(ITGA2B) RGS18 regulator of G-protein signaling 18 
35 NAP1L1 nucleosome assembly protein 1 like 1 YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta 
36 MTPN myotrophin(MTPN) NAP1L1 nucleosome assembly protein 1 like 1 
37 CLU Clusterin MTPN myotrophin(MTPN) 
38 RGS18 regulator of G-protein signaling 18(RGS18) KIF2A kinesin family member 2A(KIF2A) 
39 KIF2A kinesin family member 2A(KIF2A) GNAS GNAS complex locus(GNAS) 
40 GNAS GNAS complex locus(GNAS) GRAP2 GRB2-related adaptor protein 2(GRAP2) 
41 HBA2 hemoglobin subunit alpha 2(HBA2) CLU Clusterin 
42 GRAP2 GRB2-related adaptor protein 2(GRAP2) PTGS1 prostaglandin-endoperoxide synthase 1 
43 PTGS1 prostaglandin-endoperoxide synthase 1 ITGA2B integrin subunit alpha 2b(ITGA2B) 
44 PRKAR2B 
protein kinase cAMP-dependent type II 
regulatory subunit beta PRKAR2B 
protein kinase cAMP-dependent type II regulatory 
subunit beta(PRKAR2B) 
45 PKM pyruvate kinase, muscle(PKM) TSC22D1 TSC22 domain family member 1 
46 PF4V1 platelet factor 4 variant 1(PF4V1) RN7SK RNA, 7SK small nuclear(RN7SK) 
47 MYL9 myosin light chain 9(MYL9) SOD2 Superoxide Dismutase 2 
48 TGFB1 transforming growth factor beta 1(TGFB1) TGFB1 transforming growth factor beta 1(TGFB1) 
49 SOD2 Superoxide Dismutase 2 PKM pyruvate kinase, muscle(PKM) 
50 C6orf25 chromosome 6 open reading frame 25 OST4 
oligosaccharyltransferase complex subunit 4, non-
catalytic(OST4) 
51 RN7SK RNA, 7SK small nuclear(RN7SK) ND4L NADH dehydrogenase, subunit 4L (complex I) 
52 LIMS1 LIM zinc finger domain containing 1 LIMS1 LIM zinc finger domain containing 1 
53 ITM2B integral membrane protein 2B(ITM2B) HIST1H2AC 
histone cluster 1 H2A family member 
c(HIST1H2AC) 
54 SH3BGRL3 
SH3 domain binding glutamate rich protein 
like 3 ITM2B integral membrane protein 2B(ITM2B) 
55 MBNL1 muscleblind like splicing regulator 1 MBNL1 muscleblind like splicing regulator 1 
56 HIST1H2AC 
histone cluster 1 H2A family member 
c(HIST1H2AC) EIF1 eukaryotic translation initiation factor 1 
57 THBS1 thrombospondin 1(THBS1) PF4V1 platelet factor 4 variant 1(PF4V1) 
58 OST4 
oligosaccharyltransferase complex subunit 4, 
non-catalytic(OST4) FTL ferritin light chain(FTL) 
59 TSC22D1 TSC22 domain family member 1 MYL9 myosin light chain 9(MYL9) 
60 SH3BGRL2 
SH3 domain binding glutamate rich protein 
like 2(SH3BGRL2) SH3BGRL3 SH3 domain binding glutamate rich protein like 3 
61 ITGB1 integrin subunit beta 1(ITGB1) RANGRF RAN guanine nucleotide release factor 
62 TPM4 tropomyosin 4(TPM4) RAB11A RAB11A, member RAS oncogene family 
63 SNN stannin(SNN) SNN stannin(SNN) 
64 WIPF1 
WAS/WASL interacting protein family 
member 1(WIPF1) C6orf25 chromosome 6 open reading frame 25 
65 EIF1 eukaryotic translation initiation factor 1 SH3BGRL 
SH3 domain binding glutamate rich protein 
like(SH3BGRL) 
66 ND4L 
NADH dehydrogenase, subunit 4L (complex 
I)(ND4L) GPX1 glutathione peroxidase 1(GPX1) 
67 GPX1 glutathione peroxidase 1(GPX1) MAX MYC associated factor X(MAX) 
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68 CALM3 calmodulin 3(CALM3) CALM3 calmodulin 3(CALM3) 
69 FTL ferritin light chain(FTL) CA2 carbonic anhydrase 2(CA2) 
70 ACTG1 actin gamma 1(ACTG1) SH3BGRL2 SH3 domain binding glutamate rich protein like 2 
71 MAX MYC associated factor X(MAX) WIPF1 WAS/WASL interacting protein family member 1 
72 LOC101928834 uncharacterized LOC101928834 ITGB1 integrin subunit beta 1(ITGB1) 
73 RUFY1 RUN and FYVE domain containing 1 RAP1B RAP1B, member of RAS oncogene family 
74 RSU1 Ras suppressor protein 1(RSU1) RUFY1 RUN and FYVE domain containing 1 
75 SH3BGRL 
SH3 domain binding glutamate rich protein 
like(SH3BGRL) C2orf88 chromosome 2 open reading frame 88 
76 RANGRF RAN guanine nucleotide release factor RSU1 Ras suppressor protein 1(RSU1) 
77 ACTN1 actinin alpha 1(ACTN1) THBS1 thrombospondin 1(THBS1) 
78 RAB11A RAB11A, member RAS oncogene family H3F3A H3 histone family member 3A(H3F3A) 
79 C2orf88 chromosome 2 open reading frame 88 MTURN 
maturin, neural progenitor differentiation regulator 
homolog 
80 PTPRJ 
protein tyrosine phosphatase, receptor type 
J TPM4 tropomyosin 4(TPM4) 
81 MTURN 
maturin, neural progenitor differentiation 
regulator homolog(MTURN) ACTN1 actinin alpha 1(ACTN1) 
82 RAP1B RAP1B, member of RAS oncogene family 
ENSG0000023
3968 uncharacterized LOC101928834 
83 HLA-C major histocompatibility complex, class I, C ACTG1 actin gamma 1(ACTG1) 
84 H3F3A H3 histone family member 3A(H3F3A) PIP4K2A 
phosphatidylinositol-5-phosphate 4-kinase type 2 
alpha 
85 ANO6 anoctamin 6(ANO6) ARHGDIB Rho GDP dissociation inhibitor beta 
86 ARHGDIB Rho GDP dissociation inhibitor beta PTPRJ protein tyrosine phosphatase, receptor type J 
87 OAZ1 ornithine decarboxylase antizyme 1(OAZ1) HLA-C major histocompatibility complex, class I, C 
88 CA2 carbonic anhydrase 2(CA2) RNF11 ring finger protein 11(RNF11) 
89 RNF11 ring finger protein 11(RNF11) OAZ1 ornithine decarboxylase antizyme 1(OAZ1) 
90 CD226 CD226 molecule(CD226) PGRMC1 progesterone receptor membrane component 1 
91 CXCL5 C-X-C motif chemokine ligand 5(CXCL5) PCGF5 polycomb group ring finger 5(PCGF5) 
92 HIST2H2BE 
histone cluster 2 H2B family member 
e(HIST2H2BE) CD226 CD226 molecule(CD226) 
93 GNG11 G protein subunit gamma 11(GNG11) GNG11 G protein subunit gamma 11(GNG11) 
94 WDR1 WD repeat domain 1(WDR1) HIST2H2BE 
histone cluster 2 H2B family member 
e(HIST2H2BE) 
95 FERMT3 fermitin family member 3(FERMT3) PTPN18 
Protein Tyrosine Phosphatase, Non-Receptor 
Type 18 
96 PGRMC1 
progesterone receptor membrane 
component 1 ANO6 anoctamin 6(ANO6) 
97 CD99 CD99 molecule(CD99) CXCL5 C-X-C motif chemokine ligand 5(CXCL5) 
98 PCGF5 polycomb group ring finger 5(PCGF5) YWHAE 
Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein Epsilon 
99 PIP4K2A 
phosphatidylinositol-5-phosphate 4-kinase 
type 2 alpha WDR1 WD repeat domain 1(WDR1) 
100 CTSA cathepsin A(CTSA) YPEL5 Yippee Like 5 








Figure 5.24 Venn diagram to show common expression of abundantly expressed genes in platelets 















Figure 5.25 Over-represented gene ontologies for abundantly expressed genes in platelets 
from AMI and control groups that have common expression. 
The full GO analysis may be found in Appendix 5, Table S5.7. The word cloud is a visual 





Figure 5.26 Clustering of platelet transcriptome data by gene expression 
A. Heatmap showing hierarchical clustering of gene expression correlation between samples (mean-centred normalized and corrected log-expression values). 
Dendrograms are formed by hierarchical clustering on the Euclidean distances between genes. Coloured bars on both axes indicates whether the sample is from 
the AMI or control group (CABG denotes the AMI group: recent infarct with severe coronary disease requiring coronary artery bypass grafting – CABG; VR denotes 
the control group who has valve replacement cardiac surgery – VR). B. PCA plot constructed from normalized log-expression values of correlated highly variable 
genes, where each point represents a sample (labelled with patient ID and group: CABG: AMI group; VR: control group). First and second principal components 





Figure 5.27 Clustering of platelet transcriptome data by gene expression, association with 
patient factors. 
A. Heatmap showing hierarchical clustering of gene expression correlation between samples (mean-
centred normalized and corrected log-expression values). Dendrograms are formed by hierarchical 
clustering on the Euclidean distances between genes. Coloured bars on top axis indicates 
categorical clinical data pertaining to individual patients: Aspirin within last 48 hours; smoking history; 
DM: diabetes; disease: AR: aortic regurgitation, AS: aortic stenosis, CAD: coronary artery disease, 
MR: mitral regurgitation, MS: mitral stenosis; procedure: AVR: aortic vave replacement, ARR: aortic 
root replacement, CABG: coronary artery bypass grafting, MVR: mitral valve replacement. In terms of 
group: CABG denotes the AMI group: recent infarct with severe coronary disease requiring coronary 





Figure 5.28 Differential gene expression between platelets from patients with recent AMI and control group 
Heatmap of mean-centred normalized and corrected log-expression values for differentially expressed genes between the AMI and control groups. Columns are 
individual samples with column colours representing group and gender. Rows are differentially expressed genes with HGNC ID and row colours represent 
chromosome name. CABG denotes the AMI group: recent infarct with severe coronary disease requiring coronary artery bypass grafting (CABG), VR denotes the 




The aim of this chapter was to investigate platelet and megakaryocyte phenotype and 
transcriptomes in the setting of recent acute coronary thrombosis causing AMI. The most 
common pathophysiology is acute atherosclerotic plaque rupture combined with platelet 
hyperactivity. This occurs on the background of a chronic inflammatory process of 
atherosclerosis that is characterised by abnormal lipid metabolism, endothelial cell 
dysfunction and inflammatory cell activation. The final common pathway of platelet 
thrombosis is the target of the acute management of AMI with antiplatelet agents: COX1 
inhibition using aspirin, P2Y12 inhibition using clopidogrel, prasugrel or ticagrelor, GP2b/3a 
inhibition using antagonists such as eptifibatide, abciximab or tirofiban and reperfusion with 
pPCI. There is now accumulating clinical observational data to show that in the acute phase 
MPV as well as platelet turnover measured by reticulated platelet count (IPF) are increased 
despite the use of contemporary antiplatelet agents (Sansanayudh et al. 2014). It is unclear if 
this observation is a cause or consequence of the acute event, however it has been linked to 
prognosis thereafter (re-infarction and mortality).  
 
Whether MPV itself is related to the development of coronary artery disease or AMI at the 
population level has recently been challenged in an imputational GWAS analysis of 173,480 
individuals (Astle et al. 2016). However, the implication of the clinical observation in the acute 
phase of infarct, whether cause or consequence, is that there is a pathological cycle of 
production of more reactive platelets or accelerated thrombopoiesis, the control of which if 
better understood could offer further therapeutic opportunities including novel agents or 
information that may guide choice and dosing strategy of current agents (Funck-Jensen et al. 
2013; Armstrong et al. 2017; Bernlochner et al. 2015).  
 
Based on this clinical observation, the setting of acute coronary thrombosis was used as a 
model for accelerated thrombopoiesis with the aim to gain further insight into drivers of 
megakaryopoiesis and platelet production, as well as the pathways that might be upregulated 
in this disease group. To do this, the phenotype and transcriptome of platelets and 
megakaryocytes was analysed in patients with severe coronary disease with recent acute 
coronary thrombosis and a control group without coronary artery disease.  
 
The primary objective of the study was to measure megakaryocyte data which required bone 
marrow sampling. Therefore, the clinical study was designed around this primary aim. The 
disease population (AMI group) were patients who had a recent AMI and required coronary 
artery bypass grafting for severe coronary disease. The control population were also 
undergoing cardiac surgery (aortic or mitral valve replacement) but had no evidence of 
coronary artery disease on coronary angiography. Megakaryocytes were isolated from bone 
marrow taken as a scraping at the time of median sternotomy and blood samples for platelet 
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parameters, function and transcriptome analysis was taken on the day of surgery. Blood and 
bone marrow was sampled from 46 individuals for megakaryocyte and platelet phenotype 
data. Megakaryocyte transcriptomes were sequenced from 15 individuals and platelet 
transcriptomes sequenced from 29 individuals. As expected, there were significantly more 
males in the AMI group (p=0.013), with a significantly higher incidence of hypertension 
(p=0.01560), statin use (p=0.0156) and smoking (p=0.0009). There was also a significantly 
higher level of residual antiplatelet activity in the AMI group at the time of sampling. 
Interestingly, there was also a significantly lower platelet count in the control group. 
 
In this study, no significant difference was found between MPV in the AMI group compared to 
control, in keeping with this there was also no difference in the reticulated platelet population 
between the groups. These two parameters were shown to be highly correlated in line with 
previous studies (Grove, Hvas, and Kristensen 2008). Despite this, overall platelet count at 
the time of sampling was significantly increased in the AMI group with a correspondingly 
greater circulating platelet mass; another platelet marker that has been shown to be 
increased in AMI and have prognostic value (Ergelen and Uyarel 2014). These findings 
suggest that there is a difference in platelet production between the two groups. Furthermore, 
when resting P-selectin levels were measured as a marker of baseline platelet activation, 
there was a significantly higher surface expression in platelets from the AMI group compared 
with the controls and a healthy volunteer cohort. This is a finding that corroborates previous 
evidence to show increased P-selectin expression on platelets after AMI compared with 
controls (Ault et al. 1999; Shimomura et al. 1998; Michelson 2004). In platelet function testing 
however, platelets from the AMI group showed significantly lower responses to ADP shown to 
be due to residual P2Y12 inhibitor activity in the patients who had taken these drugs in the 
last 5 days. There were no other significant differences between the AMI and control group in 
terms of platelet function.   
 
One explanation for finding no difference in MPV is the possibility of chronically lower platelet 
count and increased MPV in patients with valve disease which could have ameliorated any 
difference seen between the two groups. The pre-operative platelet counts in the controls 
(taken approximately 2 weeks prior to planned surgery) were seen to be significantly lower 
than the AMI group, which could have led to a higher than expected MPV. The length of time 
prior to sampling that this platelet count was recorded may reflect chronicity. Increased MPV 
has been reported in a number of small studies in mitral valve prolapse (Icli et al. 2013), mitral 
stenosis (Varol et al. 2009) and aortic stenosis (Varol et al. 2011). Another explanation for this 
observation could be length of time after AMI that the samples were taken. The need for bone 
marrow at the same time as blood samples meant that the time of sampling was at best in the 
sub-acute phase. These were patients who had been admitted with AMI some of whom had 
been stented acutely and were scheduled to undergo either inpatient or early outpatient 
coronary artery bypass grafting. The mean number of days from infarction was 39 days. It is 
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plausible that if indeed raised MPV is a consequence to acute systemic inflammation at the 
time of acute thrombosis, it may have reached its peak and started to decline. However, there 
is evidence to show that MPV remains elevated for up to 4 months post AMI (Martin et al. 
1983; Cameron et al. 1983; Kishk, Trowbridge, and Martin 1985). Furthermore, patients in the 
AMI group all had significant atherosclerotic disease burden to warrant coronary bypass 
surgery and raised MPV and reticulated platelet population has also been demonstrated in 
this cohort of patients (Guthikonda et al. 2008; Cesari et al. 2008).  
 
No differences in terms of frequency or level of polyploidisation were found between 
megakaryocytes of patients with AMI compared with control. Assessment of megakaryocyte 
ploidy has previously been made in healthy individuals and in patients with chronic 
thrombocytopaenia (Mazur et al. 1988; Tomer et al. 1989). While in healthy bone marrow the 
mean megakaryocyte ploidy is 16N, in accelerated thrombopoietic states where there is either 
acute or chronic platelet need, MPV is seen to increase as well as an increase in mean 
megakaryocyte ploidy to 32N. The hypothesis at the beginning of this project was that acute 
myocardial infarction may be analogous these states of increased haemostatic demand as 
the reticulated platelet population is known to be increased, which is the only clinically 
feasible marker of megakaryocyte activity. Therefore, it was hypothesised that the escalation 
in platelet production is related to a transition in megakaryocyte phenotype which might be an 
increase in ploidy, which was found not to be the case. Megakaryocytes from both the AMI 
and control groups were found have a mean ploidy of 16N as has been shown previously in 
healthy individuals. 
 
In order to assess if changes in megakaryocyte activity and platelet production were due to 
changes in gene expression, transcriptome analysis of megakaryocytes from the AMI and 
control groups was performed. The most highly expressed genes in megakaryocytes from 
patients with AMI were highly comparable with those from the control group with an overlap of 
73 genes. Similar to the results in Chapter 4, the over-represented GO categories were 
cellular metabolism with a high concentration of mitochondrial reads, coagulation, 
haemostasis, defense and translation. There were a number of platelet function related 
transcripts highly expressed in both groups. THBS1, the gene encoding thrombospondin 1 
and CD47 for which thrombospondin is a ligand were highly expressed in megakaryocytes 
from the AMI group but not seen in the most highly expressed gene in the control group. 
S100A9 that encodes the S100 calcium binding protein A9 (MRP14) is a gene that has been 
found to be differentially expressed in platelet transcriptomes of patients with STEMI 
compared with controls (Healy et al. 2006). Here in megakaryocytes it was found to be 
expressed at very high levels in both AMI and control groups. 
 
A differential expression analysis between megakaryocytes from AMI and control group 
revealed 810 transcripts, demonstrating considerable differences in megakaryocytes from 
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these groups at the transcript level. 670 of these transcripts were significantly downregulated 
in patients with AMI with the major ontological bias being related to translational processes, 
protein localisation and immune response. 140 transcripts were upregulated in the AMI group. 
Although there were no GO biological processes that were significantly enriched, 11 out of 
the 140 genes encoded for immunoglobulin domains. In comparison, only four 
immunoglobulin domains were significantly downregulated despite a number of 
downregulated immune system and defense GO categories. Immunoglobulin domains have 
been seen to be expressed throughout the bone marrow megakaryocyte sequencing although 
the implications are unclear. There are also 36 unannotated transcripts that are significantly 
upregulated. 
 
Interestingly of the upregulated genes there are three that are directly involved in platelet 
function.  PPBP is significantly upregulated in megakaryocytes from AMI patients. It is highly 
specific to the megakaryocyte/platelet lineage and is located on chromosome 4. It encodes a 
platelet-derived growth factor also known as CXCL7. It is packaged in the alpha granule and 
released on platelet activation with its main role as a chemoattractant for neutrophils although 
it also stimulates various other cellular processes including mitosis, glycolysis, prostaglandin 
E2 secretion, and secretion of plasminogen activator by synovial cells.  
 
THBS1 which was seen in the most highly expressed gene list for AMI patients is also 
significantly upregulated in this group. It encodes thrombospondin 1 which is a glycoprotein 
involved in cell-cell and cell-matrix interactions. It is located on chromosome 15 and like 
PPBP is released from the platelet alpha granule upon activation. It binds to a number of 
surface receptors including CD47 which was also highly expressed in the AMI group. It also 
binds fibrinogen, fibronectin, laminin, type V collagen and CD36. Through its binding to CD47 
and CD36, it is known to be a critical regulator of angiogenesis (Isenberg et al. 2006; 
Isenberg et al. 2007). It may also have a regulatory role in terms of a negative feedback 
mechanism on megakaryopoiesis via its CD36 receptor through which it can lead to 
megakaryocyte apoptosis when platelet need has been met (M. Yang et al. 2003, 2016). 
Thrombospondin and its CD47 receptor have also been linked to cardiovascular disease and 
is known to be upregulated in endothelial cells in atherosclerosis (Rogers et al. 2014). In fact, 
polymorphism in THBS1 has been linked with premature AMI (Topol et al. 2001).  
 
The upregulation of both PPBP and THSB1 in the megakaryocytes of patients with recent 
AMI compared with controls suggests an increased protein expression within the platelets in 
line with increased platelet activity and consequently pathogenicity. 
 
RAP1B is another gene significantly upregulated in megakaryocytes from AMI patients. It is 
located on chromosome 12 and encodes a small GTPase from the RAS family involved in a 
common critical step in platelet activation through a number of pathways. RAP1B is 
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stimulated downstream through both collagen binding to GP6 (Gilio et al. 2009) and ADP 
binding to P2Y12 receptors (Larson et al. 2003). In turn, it is then plays a critical role in 
regulating GPIIb/IIIa activation and its affinity state (Crittenden et al. 2004; Bernardi et al. 
2006). It is essential to normal platelet function and RAP1B deficiency in animal models leads 
to a mild bleeding disorder, with RAP1B knockout mice exhibiting a more dramatic bleeding 
phenotype but are protected from thrombosis (Chrzanowska-Wodnicka et al. 2005). Since 
RAP1B is involved in a number of platelet activation pathways it has been proposed a novel 
therapeutic target for antiplatelet agents (Steinhubl et al. 2008). The fact that in the 
megakaryocyte transcriptome of patients post AMI, RAP1B is significantly upregulated 
despite some residual P2Y12 inhibition suggests that it may have a pathological role in this 
setting. 
 
Other upregulated genes in megakaryocytes from AMI patients include a number of 
transmembrane proteins. One of these is GRIA1, located on chromosome 5 encodes an 
AMPA glutamate receptor that is known to be transcribed in platelets and megakaryocytes 
(Morrell et al. 2008). Glutamate is released from platelet dense granules and plasma levels 
are increased in cerebral thrombosis (Mallolas et al. 2006) and have also been linked to 
coronary atherosclerosis and myocardial ischaemia (Djekic et al. 2015; Liu et al. 2010). 
Antagonism of glutamate signalling through the AMPA receptor leads to resistance to 
thrombosis in vitro (Morrell et al. 2008) and glutamate NMDA receptor antagonism in 
megakaryocyte cell lines has shown defective megakaryopoiesis (Genever et al. 1999). This 
suggests that upregulation of glutamate signalling through the GRIA1 receptor in 
megakaryocytes in the setting of AMI may stimulate megakaryopoiesis and lead to 
accelerated platelet production. Enhanced thrombopoiesis by stimulation of megakaryocyte 
maturation has recently been described in the setting of atherosclerosis. Pathogen-
associated molecular patterns released by the atherosclerotic plaque stimulate TLR2 on the 
megakaryocyte surface leading to enhanced megakaryopoiesis (Beaulieu et al. 2011). 
Defective cholesterol efflux that occurs in atherosclerosis is also thought to enhance 
megakaryopoiesis via the cholesterol transporter ABCG4 as its deficiency leads to enhanced 
TPO signalling and platelet production in an animal model (Murphy et al. 2013, 2014). 
Probably the most compelling evidence to suggest that enhanced megakaryopoiesis may be 
an important pathogenic driver in the setting of atherosclerosis and myocardial infarction is 
from the positive results of the recent CANTOS trial (Ridker et al. 2017). IL1B is known to be 
increased in the setting of athersclerosis (Hayashi et al. 2010) and is also an important driver 
of megakaryopoiesis both in vitro and in vivo (Kimura et al. 1990; Jiang et al. 1994; Beaulieu 
et al. 2014) as well as playing a regulatory role in HSCs (Espín-Palazón et al. 2014). The 
CANTOS trial demonstrated an improvement in cardiovascular outcome in patients with 
previous myocardial infarction through the administeration of Canakinumab, a therapeutic 
monoclonal antibody targeting IL1B. While the data in this chapter does not show differential 
expression of IL1B or its receptors in patients with AMI compared to control, it could be 
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argued that the trial result may be in part related to modulation of megakaryopoiesis and 
thereby thrombopoiesis. The upregulation of GRIA1 encoding the AMPA glutamate receptor 
seen in the AMI group could be another mechanism through which megakaryopoiesis is 
enhanced which may be a causal factor in acute coronary thrombosis.  
 
The megakaryocyte gene signatures from the AMI group and from the control group were 
then superimposed on the Monocle plot clustering the single cell HSCs from Chapter 3 
according to differentiation trajectories (Figure 5.21). While both HSC clusters 1 and 4 were 
hypothesised to be megakaryocyte-biased based on their similarity with gene signatures from 
previously published cultured megakaryocyte data, cluster 1 was hypothesised to lead to 
megakaryopoiesis in the steady state while cluster 4 was hypothesised to be mobilised 
towards the megakaryocyte lineage in states of accelerated thrombopoiesis. In this chapter 
the aim was to use the setting of acute coronary thrombosis as a model for accelerated 
thrombosis. Superimposing the megakaryocyte transcriptome data on the Monocle 2 plot 
showed that both disease and control gene signatures were highly expressed in cluster 1 
HSCs with low levels of expression in all other HSC clusters. This finding would fit with the 
discussion above that the setting of AMI may not be an ideal model for increased haemostatic 
demand and stress megakaryopoiesis. However, there are a number of limitations of this 
study to bear in mind. Firstly, as discussed above the patient groups may not optimal to 
address the specific aims here. Due to need for bone marrow sampling the AMI group were 
patients with AMI mean of 39 days prior to recruitment so it could be argued this was not the 
acute phase. Furthermore, the control group did not consist of healthy volunteers rather 
patients with chronic valve disease and often impaired ventricular function. Secondly, due to 
technical challenges relating to overwhelming mitochondrial transcripts within the 
megakaryocyte RNA-seq libraries, samples were selected for sequencing on the basis of 
expression of MT-RNR2 and PPBP using qPCR. This may well have introduced additional 
biases in the resulting transcriptome data.  
 
In contrast with the megakaryocyte transcriptome data, analysis of the platelet transcriptome, 
showed only 10 differentially upregulated genes in the AMI compared to the controls. Many of 
these were Y-linked and therefore a likely result of the significantly higher numbers of males 
in the AMI group. In the top 100 abundantly expressed genes in both groups there was an 
overlap of 95 demonstrating a marked similarity in transcriptome between the two groups. To 
add confidence to this observation no pattern was identified on unsupervised clustering of 
samples even with other clinical parameters accounted for. This is in contrast to previously 
described gene expression data in coronary disease vs control cohorts. 54 transcripts were 
found to be differentially expressed in a comparison between STEMI patient and controls in 
an early study using microarrays (Healy et al. 2006). This study identified CD69 and S100A9 
as important markers of disease. While both of these genes were switched on in our dataset 
there was no significant difference between the two groups. In another expression array study 
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GP1BA encoding for the VWF receptor was differentially expressed in platelets from NSTEMI 
patients compared to controls (Colombo et al. 2011). Again, while GP1BA was highly 
expressed in both the AMI and control group there was no significant differential expression 
found. In a GWAS analysis COMMD7 and LRRFIP1 were identified as being associated with 
the development of myocardial infarction (Goodall et al. 2010). Both of these genes were 
found equally expressed in both the AMI and control cohorts. Recently, platelet transcriptome 
data has been reported comparing STEMI and NSTEMI patients. Similarly, no significant 
differences were shown between these two clinical groups. This data corroborated by the 
finding presented in this thesis questions the significance of the platelet transcriptome despite 
evidence that platelets do possess translational machinery to form proteins. While acute 
coronary thrombosis is shown to be related to megakaryocyte transcriptional changes, 
platelet transcriptome in the setting of thrombosis and control show no differences. Therefore, 
it is possible that upregulation of specific megakaryocyte transcripts would lead to their 
translation within the megakaryocyte and thereby upregulation in the platelet proteome rather 
than effecting change within the platelet transcriptome.  
 
This study found that while there were phenotypic differences in platelets from patients with 
recent AMI, namely increased platelet mass and resting platelet P-selectin levels, the widely 
reported difference in MPV levels were not reproduced. Furthermore, megakaryocyte ploidy 
was similar in both groups. Platelet transcriptome data from patients with recent AMI 
compared with controls demonstrated no significant differences. However, at the 
megakaryocyte level a number of genes that are directly associated with platelet activation 
were significantly upregulated. Importantly, RAP1B was found to be significantly upregulated, 
encoding a small GTPase that is vital in GPIIb/IIIa activation and has been implicated as a 
target for novel antiplatelet therapeutics. Furthermore, GRIA1 encoding the AMPA receptor 
for glutamate was also upregulated. Systemic thrombosis has been shown to increase 
plasma glutamate levels and which have been previously shown to have an additional 
regulatory role in megakaryopoiesis. Therefore, it could be hypothesised that myocardial 
thrombosis and ischaemia through this AMPA receptor can affect megakaryopoiesis, 
promoting increased platelet development, which would warrant further investigation. 
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CHAPTER 6  
Conclusions 
 
In this chapter the main findings from my thesis have been summarised and future work 
based on these findings is discussed. 
 
The novel findings presented in this thesis are: 
1. One of the first demonstrations of transcriptionally distinct subpopulations within the 
human bone marrow HSC compartment, using single cell RNA-seq. Two megakaryocyte-
biased subsets within the human bone marrow HSC compartment, with potentially differing 
functional relevance. 
2. The first interrogation of the human bone marrow megakaryocyte transcriptome 
demonstrating regulation of gene expression according to ploidy level. Increasing 
megakaryocyte ploidy is transcriptionally associated with the downregulation of platelet 
specific genetic programs and the upregulation of translation and protein localisation as 
well as expression of a number of transmembrane receptors which might have functional 
relevance. 
3. The first comparison of megakaryocyte transcriptome data in patients with AMI and severe 
coronary disease compared with a control group. There was an upregulation of platelet 
activation related gene expression in megakaryocytes isolated from patients with AMI and 
severe coronary artery disease. 
 
 
6.1 The first demonstration of transcriptionally distinct subpopulations within the 
human bone marrow HSC compartment, using single cell RNA-seq.  
 
The concept of functional heterogeneity within the HSC compartment has existed for over 50 
years (Siminovitch, McCulloch, and Till 1963; Till, McCulloch, and Siminovitch 1964). My PhD 
work represents one of the first times single cell RNA-seq has been used to identify 
transcriptionally distinct cell populations within the human bone marrow HSC population. 
Based on gene expression, single HSCs clustered into 5 discrete subpopulations, using two 
independent clustering methods. Two of these subpopulations, Cluster 1 and Cluster 4 which 
accounted for 56 of 119 single HSCs, were identified as megakaryocyte-biased. This is on the 
basis of marker genes expressed by each cluster that distinguish these two clusters from 
each other and from the other three HSC clusters. HSCs in these two clusters differentially 
expressed genes that have been shown to be expressed highly in the megakaryocyte-platelet 
lineage according to previous expression array and transcriptome studies of platelets and 
CD34+ derived megakaryocytes.  
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Many of the HSC Cluster 1 marker genes encoded proteins relating to HSC function and 
megakaryopoiesis, with fewer directly related to platelet function. Furthermore, Cluster 1 also 
included genes previously shown to be expressed HSC, MPP, CMP, GMP and MEP (L. Chen 
et al. 2014). This suggests that cluster 1 HSCs are primed to produce megakaryocytes 
through the classical megakaryocyte lineage differentiation pathway. Interestingly, out of 313 
marker genes identified for cluster 1, 77 were related to ribosomal subunits and GO functional 
enrichment analysis shows that translation and protein localisation have an important 
functional role in megakaryopoiesis from the HSC. By comparison, the majority of cluster 4 
marker genes encoded proteins directly related to platelet activation. Moreover, the genes 
expressed were more specific to the megakaryocyte lineage than cluster 1 marker genes, 
with little expression of these genes observed in previous datasets in the megakaryocyte 
progenitors. This observation suggests that while Cluster 1 may represent HSCs that 
differentiate along the classical pathway, Cluster 4 represents HSCs with direct 
megakaryocyte lineage potential, independent of intermediate progenitors. Furthermore, 
HSCs in cluster 4 have already turned on genetic programs that are required for platelet 
function required post thrombopoiesis from the terminally differentiated megakaryocyte and 
are therefore primed for thrombopoiesis. Based on this, I hypothesise that while 
megakaryocytes originating from cluster 1 HSCs are those produced during steady state 
haematopoiesis (Figure 1.7), megakaryocytes originating from cluster 4 HSCs are those that 
are released in accelerated thrombopoiesis or stress thrombopoiesis which occurs in states of 
either physiological or pathological increased haemostatic demand where emergency platelet 
production is required (Martin et al. 2012; Haas et al. 2015). 
 
The cells sorted and defined as HSCs for transcriptome analysis were functionally validated 
to be HSCs by engraftment and multilineage repopulation when transplanted into sub-lethally 
irradiated NSG mice. Further functional validation is required to investigate the lineage biases 
of clusters 1 and 4 using either in vitro clonal assays or transplant-based tracking of their 
reconstitution activity. This however, is reliant on prospective identification of cells belonging 
to these HSC clusters on the basis of surface marker expression. This could either be using a 
combination of the surface marker used to identify HSCs or with addition cell surface markers. 
Sorting greater numbers of cells for further transcriptome analysis would also give additional 
statistical power to the observations made thus far. 
 
 
6.2 The first interrogation of the human bone marrow megakaryocyte transcriptome 
demonstrating regulation of gene expression according to ploidy level. 
 
The transcriptome of human bone marrow megakaryocytes has not previously been profiled. 
This important in gaining further understanding into platelet production as well as into the 
origin of both thrombotic and bleeding disorders. There remains a lack of understanding of the 
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process of megakaryocyte maturation, its association with polyploidisation and platelet 
production which means that the number of platelets produced per megakaryocyte in vitro is 
>1000-fold lower than in vivo (Moreau et al. 2016; Feng et al. 2014; Nakamura et al. 2014; Y. 
Liu et al. 2015).   
 
In this study, I have successfully obtained transcriptome data from human bone marrow 
megakaryocytes for the first time. Amongst the most abundantly expressed genes were those 
encoding for mitochondrial proteins and other proteins involved in cellular metabolism. This 
observation is indicative of the high levels of energy required to maintain polyploid cells with a 
large mature cytoplasm to support thrombopoiesis. When comparison was made with cultured 
megakaryocytes, ex-vivo bone marrow megakaryocytes also showed similar high levels of 
expression of megakaryocyte and platelet lineage genes. However, this was a limited 
comparison due to the inconsistencies of experimental procedures. 
 
The ability to perform low input and single cell RNA-seq on human bone marrow 
megakaryocytes allowed for the investigation of changes in gene expression with increasing 
ploidy class. This study has for the first time shown that with increasing ploidy up to 32N there 
is a downregulation of genetic programs that are related to platelet functionality although 
these transcripts are still switched on and remain expressed at high levels within the higher 
ploidy megakaryocytes. Instead there is a marked upregulation of transcripts with increasing 
ploidy level encoding ribosomal subunits, and those associated with translation and protein 
localisation. Not only does this show that gene expression is indeed regulated with increasing 
ploidy and maturation, it reveals a clear transcriptional difference between the higher ploidy 
megakaryocytes which are most abundant in vivo and those grown in vitro. While high levels 
of platelet specific gene transcription occur in the lower ploidy classes as further 
polyploidisation occurs enough transcript has been generated and the focus is redirected to 
translation of mRNA to protein at the ribosome and appropriate localisation of the newly 
generated proteins in preparation for thrombopoiesis. The high translational requirement of 
bone marrow megakaryocytes, particularly those of higher ploidy was one of the most 
important observations, highlighting a focus on platelet protein production and packaging into 
alpha granules, dense granules and other vesicles, ready for thrombopoiesis and platelet 
activation. It also explains the high levels of mitochondrial and other transcripts involved in 
cellular metabolism since the production of ribosomes consumes large amounts of energy 
(Lane and Martin 2010). Further work would include differential expression analysis between 
individual pairs of ploidy classes to identify marker genes for each ploidy group, at the level of 
both multicellular pools and single cells. Deeper sequencing of megakaryocytes of different 
ploidy would also support the lowput/single cell data presented here but would rely on larger 
numbers of isolated cells or pooling samples from a number of individuals. 
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A number of genes upregulated with increasing ploidy were identified as transmembrane 
receptors, which upon binding to their ligands, might modulate functional effects such as 
megakaryocyte chemotactic migration from the osteoclastic niche to the sinusoidal space or 
indeed initiate platelet production. Future work on these transmembrane receptors and testing 
appropriate ligands to investigate their role in megakaryocyte maturation might ultimately help 
to improve in vitro platelet production by simulating the bone marrow niche.  
 
 
6.3 The first comparison of megakaryocyte transcriptome data in patients with AMI and 
severe coronary disease compared with a control group. 
 
In order to assess if there are transcriptional differences in megakaryocytes and platelets in 
accelerated and steady state thrombopoiesis, the clinical setting of AMI was used as a model, 
as acute changes in platelet parameters have been widely documented which may be cause 
or effect of acute platelet thrombosis (Martin et al. 2012). While there was no difference in 
platelet and megakaryocytes physical traits between patients with AMI and control there were 
significant megakaryocyte transcriptional differences. A number of genes upregulated in 
patients with acute myocardial infarction were directly related to platelet activation and 
proteins released by the alpha granule. The observation that RAP1B was upregulated in 
megakaryocytes in patients with AMI is interesting. RAP1B encodes a protein which is 
involved in a number of platelet activation pathways, it is stimulated by collagen binding to 
GP6 and ADP binding to P2Y12 and plays a critical role in modulating the affinity state of 
GP2b/3a (Crittenden et al. 2004; Bernardi et al. 2006). Importantly it has also been identified 
as a potential therapeutic target in AMI (Steinhubl et al. 2008). Another important finding was 
that the gene encoding the AMPA glutamate receptor, GRIA1, is also upregulated in 
megakaryocytes from patients with AMI. As glutamate serum levels are increased in 
thrombosis (Djekic et al. 2015; Z. Liu et al. 2010) and interruption of glutamate binding to the 
NMDA glutamate receptor in megakaryocyte cell lines has impaired megakaryopoiesis 
(Genever et al. 1999), this observation raises the possibility of a positive feedback 
mechanism of glutamate signalling leading to increased platelet production perpetuating a 
prothrombotic state.  
 
No significant difference in platelet transcriptome were observed between patients with AMI 
compared with control, despite differences in megakaryocyte transcriptome. I therefore 
postulated that translation of differentially expressed megakaryocyte transcripts occurs within 
the megakaryocyte itself with abundance of protein production depending on transcript 
expression. Accordingly, proteins would already be packaged within the megakaryocyte, 
ready for platelet activation before the onset of platelet release, which would explain finding 
no significant transcriptional differences in patients with platelet thrombosis compared to 
controls. It is however possible that the transcripts found within the platelets may play a role in 
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post-translational protein modification. Further study of platelet proteomics in the two clinical 
groups would be required to investigate this hypothesis. 
 
Ploidy and AMI megakaryocyte signatures are overlaid onto the monocle differentiation 
trajectories showing HSC clusters 1-5. Both upregulated and downregulated megakaryocyte 
signatures for ploidy and AMI were expressed highly in cluster 1 HSCs. This would suggest 
that the bone marrow megakaryocytes that were sequenced were all generated via the 
classical megakaryocyte lineage commitment pathway. None of the megakaryocyte genes 
regulated by ploidy or disease aligned to cluster 4 HSCs. This was proposed to be the HSC 
subpopulation that was primed for emergency or stress megakaryopoiesis and platelet 
production. It is not clear from the bone marrow megakaryocyte transcriptome data presented 
here what the functional relevance of this HSC is. Future work would include HSC 
transcriptome analysis in the setting of AMI or accelerated thrombopoiesis to ascertain if 
cluster 4 HSCs are indeed expanded. It is also reasonable to suggest that a different clinical 
setting may be a better model for accelerated thrombopoiesis or increased haemostatic 
demand such as immune thrombocytopaenia where increased megakaryocyte ploidy has 
been shown with increased MPV and IPF, or immediately following cardiopulmonary bypass. 
 
 
6.4 Summary of future work 
 
1. Prospective identification of HSC clusters 1 and 4 for functional validation (in vitro clonal 
assays and xenotransplantation) and further transcriptome analysis to increase statistical 
power. 
2. Pair-wise differential expression analysis of megakaryocytes of different ploidy classes to 
identify transcriptional signatures for individual ploidy classes.  
3. Functional work on transmembrane receptors upregulated in high ploidy megakaryocytes 
to further understand their role in megakaryocyte maturation and platelet production.  
4. Functional work on megakaryocyte genes upregulated in the setting of AMI to further 
understand their role in megakaryocyte maturation and platelet production.  
5. Proteomic study of platelets in the setting of AMI with the assumption that this is more 
reflective of platelet prothrombotic potential than platelet transcriptome. 
6. HSC single cell transcriptome analysis in setting of AMI to compare transcriptionally 
distinct subpopulations between AMI and controls. 
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Figure S1.1 Study design 
BM: bone marrow, HSC: haematopoietic stem cell, MK: megakaryocyte, Plt: platelet, SC: single cell, 
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15 S011FP 13/01/15 14/01/15 Ctrl         1   MC:ploidy SC 1 1   
18 S01318 20/01/15 21/01/15 AMI         1   MC:ploidy SC 1 1 1 
19 S013XI 27/01/15 28/01/15 Ctrl         1 MC:bulk MC:ploidy SC 1 1 1 
20 S0146V 03/02/15 04/02/15 Ctrl         1 MC:bulk       1 1 
21 S014J5 10/02/15 11/02/15 AMI         1 MC:bulk     1 1 1 
22 S01CST 10/02/15 18/05/15 Ctrl         1 MC:bulk   SC 1 1 1 
23 S015Q0 09/03/15 10/03/15 AMI         1     SC   1 1 
25 S015Y8 10/03/15 11/03/15 AMI         1     SC   1 1 
26 S0160Z 10/03/15 11/03/15 Ctrl     HSC 1 1     SC 1 1 1 
27 S0165P 15/03/15 16/03/15 Ctrl         1     SC   1 1 
28 S016VA 22/03/15 23/03/15 Ctrl         1     SC   1 1 
29 S017SC 30/03/15 31/03/15 Ctrl         1     SC   1   
30 S017TA 31/03/15 01/04/15 Ctrl         1     SC 1 1   
31 S01ATZ 05/05/15 06/05/15 Ctrl         1 MC:bulk     1 1 1 
32 S01CEK 13/05/15 14/05/15 AMI         1 MC:bulk   SC 1 1 1 
33 S01CDM 13/05/15 14/05/15 Ctrl         1     SC   1 1 
34 S01CUP 17/05/15 18/05/15 Ctrl         1     SC 1 1 1 
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35 S01CYH 17/05/15 18/05/15 Ctrl         1     SC 1 1 1 
36 S01DFE 26/05/15 27/05/15 AMI         1     SC   1 1 
37 S01DGC 26/05/15 27/05/15 Ctrl         1     SC   1   
39 S01DM0 31/05/15 01/06/15 Ctrl         1     SC   1 1 
40 S01DSP 02/06/15 03/06/15 Ctrl         1 MC:bulk   SC 1 1 1 
41 S01EFA 14/06/15 15/06/15 Ctrl         1     SC   1 1 
43 S01EH6 16/06/15 17/06/15 AMI         1 MC:bulk   SC 1 1 1 
44 S01EMX 21/06/15 22/06/15 AMI         1 MC:bulk   SC 1 1 1 
45 S01F4S 23/06/15 24/06/15 AMI         1     SC   1 1 
46 S01F5Q 28/06/15 29/06/15 AMI         1 MC:bulk   SC   1 1 
47 S01F7M 29/06/15 30/06/15 AMI         1     SC   1 1 
49 S01FBE 02/07/15 03/07/15 AMI         1 MC:bulk   SC   1 1 
50 S01FVB 06/07/15 07/07/15 AMI         1 MC:bulk   SC 1 1 1 
52 S01FX7 09/07/15 10/07/15 Ctrl     HSC 1 1         1   
53 S01G0W 12/07/15 13/07/15 AMI         1         1   
54 S01G1U 13/07/15 14/07/15 Ctrl   1 HSC 1 1             
55 S01G6K 16/07/15 17/07/15 AMI         1     SC   1 1 
56 S01GBA 19/07/15 20/07/15 Ctrl   1 HSC 1 1             
57 S01GC8 20/07/15 21/07/15 AMI         1         1 1 
58 S01GNN 27/07/15 28/07/15 Ctrl   1     1             
59 S01GPJ 27/07/15 28/07/15 Ctrl   1 HSC 1 1             
60 S01H4K 02/08/15 03/08/15 Ctrl         1 MC:bulk MC:ploidy   1 1 1 
61 S01M8T 26/08/15 27/08/15 Ctrl         1 MC:bulk MC:ploidy   1 1 1 
62 S01P4P 06/10/15 07/10/15 AMI         1 MC:bulk     1 1 1 
63 S01Q6H 12/10/15 13/10/15 Ctrl         1 MC:bulk     1 1 1 
64 S01R7B 22/10/15 23/10/15 Ctrl 1                 1 1 
65 S01W4Y 01/02/16 02/02/16 AMI 1                 1 1 
66 S01WBK 14/02/16 15/02/16 AMI 1                 1 1 
 
Table S2.1 Log of patients recruited and sample use 
BP ID: Blueprint ID (anonymised ID), BM: bone marrow, HSC: haematopoietic stem cell, MK: megakaryocyte, Plt: platelet, SC: single cell, MC: multicell, AMI: acute 
myocardial infarction, Ctrl: control. 
